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Male anabolic androgenic steroid-users: A mixed-
methods study: The voice of the AAS-user 
Orlanda Anita Harvey 
Abstract 
Anabolic androgenic steroids (AAS) are increasingly used by the general 
population, particularly male gym users, for their muscle-building and aesthetic 
effects. AAS can have a detrimental impact on physical and emotional wellbeing. 
The motivations for use are wide ranging and include a desire for a muscular 
physique. There is a shortage of research exploring AAS-users’ experiences, their 
perceptions of risks of AAS or how the complexity of motivations for use effects 
support needs.  
The mixed-methods scoping review in this integrated thesis revealed (a) AAS-
users access a range of sources to obtain information on how to inject, side-
effects, risk management and types of substance; and (b) a paucity of data on the 
types of information and support users want.  
This shaped the questions for the primary research namely to explore the 
experiences of recreational AAS-users and ascertain their needs and wants on 
information and support. A two-phase process via quantitative questionnaires and 
semi-structured interviews was followed. Descriptive statistical analysis was used 
for quantitative data and thematic analysis for the qualitative data.  
This study found complex and interlinked motivations for AAS use by participants 
that could change over time including the use of unprescribed AAS as 
Testosterone Replacement Therapy. This study suggests that the internalisation of 
socially constructed ideal perceptions of masculinity could be a reason for using 
AAS and may impact on users’ health seeking behaviours. Most AAS-users were 
seeking evidence-based information but did not seek professional support due to 
stigma and lack of faith in the knowledge of professionals. 
It is recommended that a person-centred approach should be taken to supporting 
AAS-users. Professionals should explore with users their history of AAS use and 
their concerns, so that support can be tailored to individual needs. One-to-one 
 
 
4 
 
and group support should include discussions around beliefs linked to masculinity 
and negative self-talk. Services for AAS-users should be separated from those 
serving other illicit drug users.  
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 Introduction Chapter 1
1.1 Chapter overview 
The aim of this study is to explore both individuals’ experiences of using AAS 
(Anabolic Androgenic Steroids) and their experiences accessing information and 
support. This is important because in the UK the number of people using AAS is on 
the increase and the few support services provided are typically those provided 
for people with ‘traditional’ illicit substance use dependencies or services around 
harm reduction linked to spreading and acquiring blood borne viruses (BBVs).  
1.2 Definitions 
Image and Performance Enhancing Drugs (IPED) include substances that allow 
longer, harder physical training, promote weight loss and build muscle (Brennan 
et al. 2017). IPED in this thesis refers to oral and injectable AAS and injectable 
ancillary drugs that are often taken in combination with AAS (e.g. human growth 
hormone, insulin) (Christiansen et al. 2016). AAS are one of the six human 
enhancement drugs used to enhance the structure and function of muscle 
(McVeigh et al. 2012). This study does not include using prescribed AAS. The 
author acknowledges that a person’s use of a substance does not define them and 
would not use the phrase ‘AAS-user’ in everyday practice, instead using the 
phrase ‘people who use non-prescribed AAS’. However, for the purposes of 
brevity and clarity in this thesis the phrase ‘AAS-user’ will be used. In the UK, 
policy and guidance documents use the term Needle and Syringe Programmes 
(NSPs), also known as Needle Exchanges (NEs), to refer to services for intravenous 
substance users. 
1.3 The author’s research journey 
My rationale for undertaking this study came from my curiosity about the impact 
of using AAS, after working with AAS-users at a NE. Anecdotal information from 
Poole Addiction Community Team’s Harm Minimisation Lead indicated that AAS-
users do not see themselves as ‘stereotypical’ substance users despite regular 
intramuscular injections of AAS, and distance themselves from them, a stance 
supported in the literature (e.g. Evans-Brown et al. (2012)). Some frequent AAS-
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users came not just for needles, but to discuss the impact of AAS use on their 
moods. AAS use was not covered on the Bournemouth University (BU) Social 
Work Masters, and there is scant information on it in the social work literature 
(Harvey and Parrish 2019). However, there was a wealth of public health literature 
on this subject but little that addressed support needs. There could be a number 
of reasons for the lack of information in the social work sphere including: that it is 
only in recent years that AAS-users have started to access NEs, that it is not 
necessarily recognised as being harmful to others or that it does not impact on an 
individual’s ability to live their daily life, for example, AAS use rarely presents as 
emergency services (Kanayama and Pope 2018). Furthermore, AAS use is often 
overlooked due to the late onset for starting use and the public perception that it 
is only used in professional sporting environments (Kanayama and Pope 2018).  
During the 1980s people started using AAS for recreational (non-competitive) 
purposes (Kanayama and Pope 2018). There are both potential physical and 
emotional harms that can come from AAS use, and there is the potential to 
become dependent (Kanayama, Brower, et al. 2009). Although my interest came 
from being in a social work role within the area of substance misuse, in the 
current climate it is often frontline staff in charities or the NHS who are 
supporting people with the whole range of substance use problems. This led to 
my Social Work MA dissertation on the motivations for and risks of using AAS 
focussing on ‘recreational use’. Moreover, the UK IPED Survey (Bates and McVeigh 
2016) concluded that it would be useful to investigate ways of better engaging 
AAS-users with health services to gain a better understanding of this sub group of 
IPED users. Therefore, the focus of my primary research will be on understanding 
the type of support that people who use AAS would find useful, not just with the 
intention of adding to the social work literature but also wider substance use 
literature.  
Generations of women have been impacted by society’s views of what it is to be 
female (Worell 2012) including how they should look. This has led many women 
to diet and undergo surgery to change their appearance in order to live up to 
some sort of feminine ideal (Sharp et al. 2014) and in some instances such 
pressures have led to problems such as drive for thinness and disordered eating 
(Krahé and Krause 2010, Fernandez and Pritchard 2012, Hefner et al. 2014) . 
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Women’s views of themselves are heavily influenced by the portrayal of women 
in the media and the internalisation of body image ideals, giving them a negative 
perspective of their own body image (Borg and Fredriksson 2015). In recent years, 
boys have become exposed to the same type of ‘ideal body’ stereotypes (Barlett 
et al. 2008). There is in an increase in people using AAS and users are accessing 
NSPs for support in many western countries (McVeigh et al. 2016, Wicks 2017). 
Kanayama and Pope (2018) suggest that the increase in use for recreational 
purposes could be influenced by the increase in the prevalence of the ideal 
muscle image being represented in the Media from GI Joe through to Rambo. 
They point out that this mesomorphic shape is a predominant representation for 
masculinity in social media, and this is highlighted in a qualitative study where one 
AAS-user stated that only strong muscular men get to play the action heroes 
(Smith et al. 2009).  
Professionals working with people who use substances should acknowledge that 
service users are experts of their own situations (McCarthy and Galvani 2010) and 
explore with them the beliefs of their sub cultures and how their beliefs and 
values fit within this context to help ensure the service user is safe from harm 
(Teater 2014). Moreover, it is important to recognise the unique nature of people 
who use human enhancement drugs, “their motives for use and associated risk 
perceptions and behaviours” (Brennan, Van Hout, et al. 2013, p.219). 
Consequently, an acceptance of these perspectives suggests that any support 
offered to people who use AAS should take into consideration motivations for 
use.  
1.4 Background 
AAS are synthetic drugs which mimic male sex hormones especially testosterone 
(Nutt 2012), and are typically used in six to twelve week cycles to build muscle 
(Philowitz 2014) and come in both oral and injectable forms. Bhasin et al. (1996) 
confirmed that AAS use is beneficial for muscle gain and testosterone enhances 
the effects of resistance training to increase muscle. The use of AAS has historical 
roots in enhancing performance in sports, however recently they are increasingly 
used by the general population (particularly male gym users) for their anabolic 
effects (Bojsen-Møller and Christiansen 2010, Nutt 2012). Users often take supra-
physiological doses (that is a dose that is larger or more potent than would occur 
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naturally) to increase lean body mass, muscle size and strength (Parkinson and 
Evans 2006) and AAS are more often than not used in conjunction with other 
substances such as growth hormone and anti-inflammatory drugs (Bates and 
McVeigh 2016), often with the intention to enhance the effects of the steroids or 
mitigate its side-effects.  
A meta-analysis of AAS use indicates a global lifetime prevalence of 3.3% (men: 
6.4%, women: 1.6%) (Sagoe, Molde, et al. 2014). Whilst users still represent a 
minority of the UK substance using population, just under 61,000 16-59 year-olds 
had used AAS in 2017/2018 (increasing over the decade from 0.1 to 0.2 % of the 
national representative population surveyed); 17000 of these were  16-24yr-olds 
(UK Home Office 2018). Moreover, the National Crime Survey of 34,440 
households (71% response rate) found the lifetime use of AAS among 16-59 years 
old as 0.9% (UK Home Office 2018), however, these figures are likely to be under-
reported (Advisory Council on the Misuse of Drugs (ACMD) 2010). It has been 
suggested that this increase in use could be ‘indicative of the public’s appetite for a  
short  cut’ for aesthetic gain (Brennan, Van Hout, et al. 2013, p.219) or because of 
the availability of AAS online.  
Legal factors further complicate estimating steroid use. In the UK, AAS are 
classified as Class C substances and supplying AAS, even via the Internet from 
outside the UK, sharing them or giving them away free, is unlawful and can lead to 
a 14-year jail sentence, which is similar in Canada. However, it is legal to possess 
AAS for personal use and to purchase steroids in other countries where they are 
legal and bring them back into the UK, but it is illegal to import steroids using 
postal services (Misuse of Drugs Act, 1971). In the USA steroids are classed as 
Schedule III controlled substances and use and supply is illegal, and non-
prescribed steroid use is also illegal in countries such as Australia, France and 
Germany. However, AAS use is legal in other parts of the world such as Hong 
Kong, Egypt, Mexico. Such factors make the law around purchase and supply 
complex and this could also be linked to under reporting. Some suppliers and 
users are confused about the legality of using, purchasing and supplying steroids 
in the UK due to the complexity of the law (Antonopoulos and Hall 2016). 
AAS use is less prevalent in the general population than in certain subpopul ations 
(recreational sports people, athletes, injecting drug users, sexual and gender 
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minorities); there is also a lower prevalence among women (Sagoe and Pallesen 
2018). AAS is now more likely to be used recreationally; for example a survey of 
500 AAS-users found 78% (n=392) were non-competitive bodybuilders and non-
athletes (Parkinson and Evans 2006). Recent studies have shown an increase in 
the number of AAS-users accessing NSPs (Chantal et al. 2009, McVeigh and Begley 
2016) with recent figures from the north of England evidencing that in twelve out 
of fourteen areas, IPED use was reported by more than half of people using NSPs 
(Kimergård and McVeigh 2014a). The ACMD (2010) raised particular concerns for 
the potential negative impact on the normal physiological and behavioural 
development of young people and in a recent survey 13% of people using 
injectable IPEDs started to use in their teenage years (Begley et al. 2017).  
1.5 Philosophical worldview proposed in the study – 
Rationale 
Evidence-based practice (EBP) is central to social work practice (Lishman 2015) 
and social work takes the perspective that the service user is at the heart of social 
work practice, and is therefore the expert of their substance use experiences 
(Galvani 2012). Social work’s value base of respect for the individual’s expertise 
(Banks 2001) contributes to the study’s premise that practice could be enhanced 
through asking AAS-users about their experiences and motives for using 
(Petersson et al. 2010). Consequently, this study takes a humanist approach, 
seeing the person as a unique individual rather than defining them by their 
substance use. The aim is that such an approach may help the identification of 
more person-centred strategies to support AAS-users more effectively. Taking a 
humanist approach to the data collection, which is congruent with the social work 
value of respect for the individual (Banks 2001) may help identify strategies for 
those working with AAS-users to support them more effectively.  
1.6 Outline of the thesis 
This integrated thesis is divided into ten chapters, including one published paper, 
one accepted paper and one submitted paper. Chapter 2, an overview of AAS use. 
In Chapter 3 the literature review is a mixed-methods scoping review undertaken 
in a systematic manner. The results of the scoping review helped inform the study 
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design by providing data on the types of support and information AAS-users 
access and their views on what would constitute ideal support. As this review was 
published the chapter also includes an introduction that covers additional key 
points that were not included in the publication due to word limits. Chapter 4 
outlines the methodology, the rationale for a mixed-methods approach, the 
overall study design, data collection methods and analysis. Chapter 5 presents the 
findings, which are split into three parts: a synthesis of the qualitative and 
quantitative findings relating to key themes identified; the qualitative findings 
from the interviews related to ideal support wanted and the in-depth findings 
from the mixed-methods study on AAS-users use in relation to the effects on 
libido and sex-drive. Chapter 6 presents a theme of the findings in the form of a 
published paper, and Chapter 7, a subset of a theme in the form of a submitted 
paper. Chapter 8 is split into four sections; the first two explore the themes 
identified under two areas: management of use and identity, more specifically 
section 2 discusses the notions of masculinity as part of identity and uses Erikson’s 
development theory as a lens through which to consider AAS use. Section 3 
identifies the strengths and limitations of this study and section 4 discusses 
reflections on the use of typologies and need for person-centred practice and the 
author’s personal reflections on the study. Chapter 9 concludes the thesis and 
Chapter 10 summarises the key recommendations of this study.  
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 Overview of AAS use Chapter 2
2.1 Chapter overview 
This chapter sets the context for AAS use and gives an overview of the potential 
risks of AAS use. It then explores the motivations for AAS use, as identified in the 
literature from recent research and introduces current thinking on typologies of 
AAS-user. It considers the underlying factors for starting and continuing use. The 
chapter concludes with the aims and objectives of the study.  
2.2 Risk of AAS use 
Research over the last thirty years has demonstrated that the use of AAS can be 
detrimental to a person’s physical and emotional wellbeing (Pope and Kanayama 
2012). The short and long-term negative physical health effects include: 
hypogonadism, testicular atrophy (Coward et al. 2013, Kanayama et al. 2015), 
cardiovascular abnormalities, cardiovascular toxicity (Kasikcioglu et al. 2009, 
Lusetti et al. 2015, Baggish et al. 2017, Barbosa Neto et al. 2018) increased blood 
pressure, higher aortic stiffness, coronary disease (Hartgens et al. 2004, 
Rasmussen et al. 2018), cardiac arrest (Lichtenfeld et al. 2016), ruptured tendons, 
infertility, baldness, acne, sleep abnormalities, neurochemical abnormalities 
(Chyka 2003, de Souza and Hallak 2011, Jones et al. 2011), reproductive system 
effects (Christou et al. 2017), arterial hypertension (Solakovic et al. 2015) hepatic 
and renal injury, and hepatotoxicity (Kafrouni et al. 2007, Robles-Diaz et al. 2015, 
Bond et al. 2016, Hansma et al. 2016, Niedfeldt 2018). Pilot studies have shown 
that lifetime AAS use may impact on some cognitive processes and the structural 
features of the brain (Kaufman et al. 2015, Bjørnebekk et al. 2017, 2019, Seitz et 
al. 2017, Westlye et al. 2017, Hauger et al. 2019). If used in adolescence, AAS use 
can alter the normal pattern of brain development and neurotransmitter function 
and may lead to heightened vigilance in response to social encounters 
(Cunningham et al. 2013) and one study found that adolescents who had used 
AAS were more likely to have attempted suicide in the last 12 months (Ganson 
and Cadet 2018). AAS-users are at greater risk than non-users of psychological 
risks such as: rage, mania and delusions (Chyka 2003), aggressive behaviours, 
depression and anxiety (Piacentino et al. 2015). Other effects of AAS use include 
the potential to impact on pre-existing conditions such as increased 
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symptomology of Tourette’s (Leckman and Scahill 1990) and tics (Rashid 2000). It 
appears linked to the development of dementia (Kaufman et al. 2019), a higher 
mortality rate and more hospital admissions than non-AAS-using counterparts 
(Horwitz et al. 2018) and injuries due to poor injection techniques (Hope et al. 
2015). One study found over 99% of AAS-users surveyed injected AAS and 13% 
admitted to unsafe injecting practices (Parkinson and Evans 2006). Other risks can 
include contracting and spreading BBVs through sharing vials or engaging in risky 
sexual behaviours (Larance et al. 2008, Ip et al. 2016). Further risks include 
physical and psychological harm from combining AAS use with other licit and illicit 
substances (Parkinson and Evans 2006, Hope et al. 2015, Sagoe et al. 2015). 
With most people who use IPEDs, some form of polypharmacy is unavoidable as 
AAS-users take a variety of substances to work with the AAS to enhance 
performance or to mitigate the side-effects (Sagoe et al. 2015, Grönbladh et al. 
2016), and they frequently vary the type/brand of AAS (Bloor et al. 1998) to help 
ensure their body does not build up a resistance. Studies into the effects of using 
supra-physiological doses of AAS are challenging as it is unethical to give people 
such high doses as part of any trial, and testing people who use AAS is complex as 
they often use in combination with a range of other substance (Cheung and 
Grossmann 2016), including Human Growth Hormone (HGH) (Bloor et al. 1998, 
Parkinson and Evans 2006, van Hout and Kean 2015, Bates and McVeigh 2016, 
Brennan et al. 2017). Another potential risk to health comes when AAS-users end 
a cycle and are no longer using AAS, as many choose to enter a phase of post-
cycle therapy (PCT), using a variety of substances to help with the effects of 
stopping use (El Osta et al. 2016, Griffiths, Henshaw, et al. 2016), which can 
include loss of libido and depression (Kanayama and Pope 2018). Worryingly, 
there is growing evidence that some AAS-users are not ‘cycling’ and are 
continuing AAS use without a break (Hanley Santos and Coomber 2017), which 
does not allow the body to recover and could impact on the side effects that 
would otherwise occur only temporarily when AAS are used.  
In assessing risk around substance use, people who are diagnosed with substance 
dependence could potentially be considered at greatest risk of harm. The ICD-10 
(World Health Organisation 2010) lists AAS as non-dependence producing 
substances whereas the Diagnostic and Statistical Manual of Mental Disorders 
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(DSM)-5 (American Psychiatric Association 2013 (APA)) categorises AAS under 
other substances but does not explicitly state non-dependent and instead has 
criteria for substance use disorders (e.g. mild anabolic steroid use disorder)  
(Harvey and Parrish 2019). Kanayama et al.’s (2009) analysis concluded on the 
basis of seven studies that 30% of AAS-users develop dependence based on DSM 
IV criteria and therefore it is a valid diagnostic entity. Kanayama and colleagues 
(2009, 2009) put forward a suggested mechanism for dependence with three 
pathways to dependence: body image (fear of losing muscle size), androgenic 
effects (loss of sexual function, fatigue, depression: negative reinforcements), and 
hedonic effects (classical addiction pathways may reinforce psychoactive effects 
such as increased aggressiveness or self-confidence).  
Hildebrandt et al. (2011) highlight the challenges with diagnosis for the focus has 
been on dependency on AAS yet the use of polypharmacy evidences a need to 
seek to further understand the impact that stacking and cycling (i.e. what 
combination of substances are used over what length of time), different types of 
drugs have and whether it is possible to pinpoint a dependency on AAS or 
whether the dependency is on IPED use, or even something more psychological 
such as developing a mesomorphic body shape. One recent study found 
substantial evidence for AAS dependence and a 30% likely prevalence amongst 
AAS-users (Grönbladh et al. 2016). A recent study found there were structural 
brain differences with dependent AAS-users having “a significantly thinner cortex 
in frontal, temporal, parietal, occipital and prefrontal regions” when compared 
with non-dependent users (Hauger et al. 2019 , p.7) and suggested more research 
is needed, as the impact of combined use of AAS with other illicit substances 
could not be ruled out. Moreover, one study found that greater social physique 
anxiety was associated with more severe symptoms of AAS dependence (Griffiths 
et al. 2018).  
In addition to other supplements, AAS-users have been found to use a mix of 
substances such as cocaine and cannabis, and alcohol (Begley et al. 2017, Salinas 
et al. 2019). A number of risks come from AAS-associated polypharmacy including 
the associations with violent and criminal behaviour, and types of pathology, 
using substances in combinations may cause unknown/unintended/adverse 
psychological or physiological effects (Sagoe et al. 2015). In the USA, a survey 
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found that 50% of AAS-users bought their supplies from underground bootleg 
laboratories (Parkinson and Evans 2006). The UK legislation potentially puts 
people at risk as it may lead them to enter an unregulated black market, which 
includes the use of underground laboratories (Advisory Council on the Misuse of 
Drugs 2010, Kimergård and McVeigh 2014b), and there is evidence that the 
products can be of variable strength (Nutt 2012), adulterated (van Hout and Kean 
2015), mislabelled (Abbate et al. 2015) or counterfeit (Coomber et al. 2014, Cho et 
al. 2015). AAS use often results in joining a community, often secretive (i.e. kept 
secret from family and friends) (Hildebrandt et al. 2006, Walker and Joubert 2011) 
and information is often accessed from fellow users or via websites (Larance et al. 
2008), which evidence suggests is not always trustworthy or accurate (Brennan, 
Kanayama, et al. 2013).  
 Benefits of use  2.2.1
The main benefit from AAS use is increased strength and endurance (Larance et 
al. 2005). There are also psychological benefits including increased confidence and 
elevated mood (Vassallo and Olrich 2010, Mey et al. 2018). For many AAS-users 
the benefits outweighed the risk of side-effects (Alsaeed and Alabkal 2015, 
Kimergård 2015). Risks might be normalised within IPED communities and AAS-
users may “disassociate from the potential harms” (Brennan et al. 2017). The 
internet is full of articles on busting the myths of steroid use by addressing each 
‘lie’ from their perspective, for example, Ten Big Fat Lies about Steroids (Harris 
2017) or to comments on articles such as ‘from Mr Average to Superman’ 
(Davidson 2008), which showcased both the benefits and ‘hellish’ side effects of 
use. This comment from a forum about Davidson’s article typifies how such 
stories are perceived by the community:  
‘he's attention seeking. There's no way he got ALL those side effects i.e. 
the neanderthal type ridge-skull! Gets his book promoted ;) Still, good 
results and well written. Lol (sic)’ (MuscleTalk 2008)  
Andreasson and Johansson (2016) suggested that online fora support the 
transformational process of learning in which the acceptance of certain types of 
behaviours that are out with social norms such as high risk taking behaviours and 
use of illicit substances is developed. This could be true of AAS-user fora (often 
subgroups of internet bodybuilding communities), as although risks of using IPEDs 
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are discussed, posts are dominated by the benefits of use (Andreasson and 
Johansson 2016). AAS-users exist in a culture and narrative which takes use for 
granted and in which AAS use represents a relatively innocuous practice for 
people who wished to develop muscles (Monaghan 2002).  
 Risks of harm to others 2.2.2
When considering risks of substance use, the risk of harm to others must be 
considered (Heanue and Lawton 2012). From a UK public health perspective, the 
focus on harm is through transmission of BBVs such as Hep C (Seear et al. 2015, 
Rowe et al. 2017) which is contrary to the evidence that suggests that this is not a 
high risk population when it comes to sharing of needles or vials when compared 
to people who inject illicit substances such as heroin (Ip et al. 2016). Moreover, 
the prevalence of BBV among people using AAS is not as high as among other 
injectors, although it is higher than the general population (Iversen et al. 2013). A 
study of 395 injecting IPED users found HIV prevalence was similar to that among 
injectors of psychoactive drugs (Hope et al. 2013) and another study found AAS-
users more likely to engage in high-risk sexual behaviours and have more multiple 
partners than the general population (Ip et al. 2016). There are potential risks of 
increased aggressive behaviours particularly when associated with alcohol use 
(van Amsterdam et al. 2010), potential risks to children from storing substances 
and needles in the home (Nutt 2012), and of potential physical or psychological 
harm from children experiencing violent behaviour (Collis 2013).  
Within the literature there is some qualitative evidence and case studies where 
people using AAS self-reported an increase in aggression or willingness to fight as 
a result of using AAS (Bahrke 2005, Skårberg et al. 2008, Bates and McVeigh 2016, 
Amaral and Cruz 2017, Bahri et al. 2017, Hanley Santos and Coomber 2017). Two 
reviews of AAS use and aggressive behaviour in humans could not find a clear 
conclusion that AAS causes aggression (Bahrke 2005, Tomlinson et al. 2016), but 
there is evidence to show that effect within other species such as rats and 
hamsters (Onakomaiya and Henderson 2016, Tomlinson et al. 2016). In their 
review, Trenton and Currier (2005) concluded that aggression was linked to AAS 
use but only in a small subset of users. Studies have found that AAS use could 
cause an increase in manic symptoms but these were confounded by personality 
disorder traits for antisocial, borderline and histrionic personality disorders (Pope 
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Jr. et al. 2000, Perry et al. 2003). A case study also linked AAS to manic symptoms, 
but in this case there was a pre-existing health condition (Kouvelas et al. 2007) 
and in a study of twins high levels of aggressiveness, hostility, anxiety and 
paranoid ideation in the twin who used AAS (Pagonis et al. 2006). Midgely et al. 
(2001) found self-reported levels of aggression amongst AAS-users, but this was 
more linked to irritability and feelings rather than acts of physical violence and the 
link to increased hostility and verbal aggression was also found by Hildebrandt et 
al. (2014).  
In a study of 23 AAS-users and twelve non-AAS-users, AAS-users not only reported 
more aggressive behaviour towards others whilst on cycle but also reported 
specific incidents related to aggression towards their partners (Choi and Pope Jr. 
1994). This gives some support to the concept of ‘roid rage’ (the colloquial term 
for aggressive behaviour caused by using high doses of AAS (Thiblin et al. 1997)) 
and that partners could be at risk, but the evidence is anecdotal and self-reported. 
One study found that adolescents who had used AAS were at greater odds of 
having engaged in teen dating violence (Ganson and Cadet 2018), but the lines 
between cause and effect with AAS use and violence are blurred (Dunn 2015, 
Lundholm et al. 2015). Moreover, Cheung and Grossmann (2016) suggest that the 
variety of information in the literature concerning the effects on AAS and mood, 
behaviour and cognition could be down to the dose used, the drug metabolism 
and pharmacokinetics. Pope Jr. and Katz (1990) offer three case studies that 
highlight homicide and near-homicide by men that link to their AAS use. A more 
recent case study considered a man who killed and dismembered his wife; he also 
had a complex mental health history, and it had been a controlling relationship. 
His alcohol-related problems were reported to have become more aggressive 
after starting to use AAS, and within ten weeks of starting use he killed his wife. 
Such rage was previously out of character (Seppänen and Eronen 2016). There 
have been studies that link AAS use to violent crime (Klötz et al. 2007) and reports 
that people use AAS in preparation for racially motivated atrocities, with such 
examples as: Anders Breivik and Omar Mateen (Melle 2013, Wilber 2016). There 
is also one case of child-sexual-abuse-related to AAS reported in the literature 
(Driessen et al. 1996), where a man using AAS forced a child to masturbate him 
and links this to the possible increase in sex drive pertaining as a result of AAS use. 
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Although these examples highlight possible risks the case studies are limited by 
their very nature. 
The risks relating to harm to others from violent behaviour are still up for debate, 
and AAS use does not increase aggressiveness in all users. However, there is 
mounting evidence that a subset of users, namely people who already have 
violent predispositions, those with pre-existing mental health conditions and 
those who use other substances such as opiates or alcohol, may be more 
susceptible to AAS use negatively impacting on their mood.  
2.3 Motivations to use AAS 
Understanding the motivations for using substances is essential to effective social 
work, with people misusing substances (Galvani 2015) and there is a need to 
understand the beliefs around efficacy of use and understand the all ure of using 
AAS to build muscle (Murray et al. 2016). An interest in motivation for use may 
help identify ways to prevent people from starting use, ways to inform and 
educate people about the long-term harms and help identify those who might be 
susceptible and how to influence them.  
The most prominent motivations are to enhance physical appearance and/or 
improve physical performance (Cohen et al. 2007, Begley et al. 2017, Hanley 
Santos and Coomber 2017). Sagoe et al.’s (2014) systematic review of qualitative 
literature in the English language encompassing 44 studies, from eleven western 
countries, found noteworthy psychosocial elements for the initial use of AAS 
(Sagoe, Andreassen, et al. 2014). The motivations for AAS use identified were: 
occupational, improved appearance, aggression, enhanced muscle or strength, 
personal security, psychological well-being (including boosting self-esteem or 
confidence) or satisfaction, sexual attraction, physiological recovery or injury 
prevention, overcoming depression, curiosity, trainers’ approval, family influence, 
media influence, peer influence, use of AAS as a sport or social norm and for 
sporting or competitive activities (Sagoe, Andreassen, et al. 2014). However, the 
review does not explain what is meant by aggression being a motivator. Other 
studies have found additional motivations including preparation for crime, 
concealing concomitant substance use, becoming brave (Petersson et al. 2010), 
bring in income (Boardley et al. 2014), achieve goals, build confidence (Nøkleby 
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and Skårderud 2013), increase sex drive, lose fat (Bates and McVeigh 2016), and 
an ethnographic online study of IPED users found that another motivation for use 
was that users could maintain a social life whilst still increasing their muscle 
(Underwood 2017). Petrocelli et al. (2008) interviewed thirty-seven recreational 
AAS-users and concluded that frustration was a motivator, as people turned to 
AAS when they did not achieve the desired results from exercise. Another study 
suggested that motivations for non-athletes to start using AAS included having 
reached a plateau in muscle development, frustration as others were over-taking 
them in size and curiosity about the efficacy of AAS (Smith et al. 2009). This raises 
concerns for peoples’ perceptions of AAS use as a short cut to achieve a desired 
physique, which fits into society’s current culture with the use of human 
enhancement drugs being “indicative of the public’s appetite for a short cut” 
(Brennan, Van Hout, et al. 2013).  
Nøkleby and Skårderud (2013) found that some people turned from the illicit 
drugs to steroids as part of a healthier lifestyle and a healthy body was equated 
with a muscular body (not healthy heart), and were looking to gain the  masculine 
body ideal. AAS use is often seen as a tool to improve oneself, for example some 
people recovering from heroin dependency will take AAS as a quick fix in order to 
look healthy quickly (Cornford et al. 2014). Consequently, heroin use could be 
seen as a gateway drug for AAS use, especially as heroin users have few qualms 
around injecting substances.  
It is worth considering that motivations may differ depending on the type of use 
and there is a need to assess and distinguish between performance and image 
based motivations (Murray et al. 2016). Those wishing to compete in sport at the 
highest level may be using AAS to further these goals and therefore may be more 
likely to be influenced by other professionals who compete. However, those using 
recreationally, who start using for appearance may have been more influenced by 
social media and cultural influences. Smith et al. (2009) suggest that professionals 
need to understand what motivations drive people to use AAS as a matter of 
urgency, as these motivations may be complex and individual; focussing on 
messages related to the morality of use or the health problems may not be 
successful when compared with the positive reinforcement users get from the 
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AAS-users’ subcultures. Moreover, the positive reinforcement is further enhanced 
as often the positive results of AAS match the users’ pre -use expectations.  
Concerns have been raised by the UK Medicines watchdog that programmes such 
as ‘Love Island’ are influencing men to use AAS to increase their muscle size 
(O’Neill 2018). The social media platforms such as Instagram, where people post 
selfies, to get likes, as a form of social capital could become a new motivation to 
start using AAS (Richardson et al. 2019). If motivation for use and the user 
experiences is changing then this may impact on the types of information people 
need and want. In a study looking at media influences on the drive for muscularity 
in young people (undergraduates), watching television was related to an increase 
in the drive for muscularity in men as was reading men’s health magazines 
(Cramblitt and Pritchard 2013).  
 Risk factors for starting use 2.3.1
One of the considerations regarding any type of substance use that could cause 
harm is to consider risk factors and protective factors that may make some people 
more vulnerable to starting use than others (Stone et al. 2012). Early identification 
or prevention, so substance use does not become problematic (Galvani et al. 
2014) and talking about the use would maximise the chance of identifying hidden 
problems. Body image concerns have already been discussed as a potential risk 
factor. The literature highlights a range of risk factors that could lead to a 
vulnerability to starting AAS use, including childhood and adolescent conduct 
disorder, criminal activity (including rape), bullying, truancy, cheating at exams, 
contact with support services, poor school adjustment (Kanayama, Brower, et al. 
2009, Pope Jr. et al. 2012, Hallgren et al. 2015). Other potential factors that could 
be considered are that AAS use might be associated with a personality that 
exhibits risk-taking behaviour (van Amsterdam et al. 2010, Alsaeed and Alabkal 
2015). Mental health problems are another factor for predicting AAS use, 
including psychological disorders such as depression (Sagoe, Andreassen, et al. 
2014), as is scoring high on aggression for adolescents (Jenssen and Johannessen 
2015, Sagoe et al. 2016). A range of childhood problems have been overly 
represented among AAS-users including: poor relationship with parents, history of 
mental or physical abuse, problems at school (Skårberg and Engstrom 2007). 
There have been associations found between body dysmorphic disorder, bulimia 
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and child maltreatment including child sexual abuse (Murray and Waller 2002, van 
Gerko et al. 2005, Didie et al. 2006). While a link between AAS use and low levels 
of education compared to non-users has been found (Hakansson et al. 2012, de 
Siqueira Nogueira et al. 2014, Melki et al. 2015), this may not be conclusive. 
Alsaeed and Alabkal (2015) found no significant difference in education levels 
between users and non-us. Bates et al. (2019) note that the relationship is 
complex especially since AAS-users are more likely to be in paid employment than 
other illicit substance users, and that education levels within AAS-using 
populations have been comparable or above average (Cohen et al. 2007, Bates, 
Tod, et al. 2019). Consequently, as there is a generally positive relationship 
between education, health literacy and health outcomes (Van Der Heide et al. 
2013, Yamashita and Brown 2017),  this researcher suggests that in the absence of  
direct studies on the health literacy of AAS users, AAS users are likely to (above) 
average levels of health literacy.  
Other predictive factors for AAS use include participation in sports (Sagoe, 
Andreassen, et al. 2014). AAS is normally used in conjunction with an exercise 
regime (Skårberg et al. 2008, Hakansson et al. 2012). Users tend to exercise more 
than non-users (Onakomaiya and Henderson 2016) and students who exercised 
daily increased the odds of lifetime AAS use (Kokkevi et al. 2008). However, this is 
challenged by two studies, one that found AAS-users were only slightly more 
active gym goers than non-AAS-users (Melki et al. 2015) and another that found 
only a small fraction of dual users (i.e. AAS and another substance) were gym 
customers (Gårevik and Rane 2010). However, a recent study found that people 
using protein supplements were positively correlated with intention to use AAS 
(Parent 2016). Having low self-esteem could be considered another potential 
predictor as Kindlundh et al. (2001) conclude that high self-esteem is a protective 
factor in terms of young people being less likely to initiate AAS use. There is the 
possibility that having been bullied could be a risk factor as childhood bullying 
victimisation and MD are associated with low self-esteem (Wolke and Sapouna 
2008) and one study found that AAS-users perceived that there was less likelihood 
of being bullied if they were more muscular (Smith et al. 2009). There was 
minimal information in the literature on protective factors other than high self-
esteem. 
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Another potentially vulnerable group are gay men. A large percentage of gay men 
are using AAS (Seear et al. 2015) and sexual minority adolescent boys were at an 
increased odds to report a lifetime prevalence of AAS compared with 
heterosexual boys (Blashill and Safren 2014, Blashill et al. 2017). Also their 
motivation is more likely to be one of appearance and they are also more likely to 
use alongside other illicit drugs (Dillon et al. 1999). A study of 772 gay men found 
that 15% had used AAS and found some HIV positive men were using AAS 
therapeutically. A drive for muscularity in a study of 326 gay men was related 
positively with intention to use AAS (Brewster et al. 2017). The risks of use might 
be increased for gay men as they are more likely to share multiple partners than 
heterosexual men (Brooks et al. 2008, Rhodes et al. 2009), putting them at a 
higher risk of BBV and STDs. One study found that gay men were also less likely to 
access injecting equipment from NSPs (Larance et al. 2008), another identified 
sexual minorities in the UK experience health inequalities (Booker et al. 2017, 
Bourne et al. 2017) and a third noted they experience discrimination from health 
professionals (Guasp 2013).  
2.4 Typologies of AAS-user 
Christiansen et al. (2016) developed a typology for the different types of AAS use 
that have come to the fore in recent years aligned to motivation, this typology 
consists of four types: (1) You Only Live Once (YOLO); (2) Expert; (3) Athlete and 
(4) Wellbeing types. These have been used to consider if certain types are more at 
risk due to the way they use AAS. They identify the YOLOs as a high-risk subset of 
users as they are most likely to initiate AAS use early. Cluster analysis of 614 users 
identified four clusters of users (Zahnow et al. 2018) (Appendix 1). Cluster one, 
had on average younger users (26.9 years), who predominantly tended to take 
AAS orally and report higher levels of alcohol use than other clusters. This group 
sourced AAS predominantly through friends and align to the YOLO typography 
(Zahnow et al. 2018). Cluster two characteristics included: an average age of 36, 
they are unlikely to use other IPEDs in conjunction with AAS, they inject, and 
source AAS through friends (Wellbeing Type). Cluster three (average age 32.2), 
used peptides and other IPEDs in conjunction with AAS, used oral and injectable 
AAS, used more psychoactive drugs and experienced more side effects than other 
clusters. They also acquired IPEDs from multiple sources (Athlete). Cluster four 
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(average age 30.6) do not binge drink, had less alcohol use overall and less 
psychoactive drugs. They acquire their AAS through multiple sources (Expert) .  
2.5 Aims and objectives 
With noted academics in the field calling for more innovative approaches to harm 
reduction (Glass et al. 2019) and the need to be aware of the negative impact that 
the narrative of harm within the public domain can cause in relation to engaging 
this population (Mulrooney et al. 2019), it seems timely to gain a perspective from 
the AAS-user. Moreover, as not only could the range of motivations for use but 
also AAS-users’ understandings of the risks and harms of using AAS impact on the 
types of information and support users’ access and desire, this study will seek to 
explore motivations for use. Understanding user experience is vital and their 
voices should be heard in research (Richardson et al. 2019), therefore this study 
will also investigate AAS-users experiences of their use, of information and 
support services and gain an understanding of what support they feel they need 
with a view to answering the question: 
 How can professionals effectively support people who use AAS? 
Table 2.1 outlines the aims and objectives and related research methods needed 
to answer this question. 
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Table 2-1 Thesis Aims and objectives (version 1) 
Aims Objectives Methodology 
1. To gain insight into 
male users’ perspectives of their 
experiences of their using AAS 
for predominantly recreational 
purposes 
1a. To explore whether there are any 
generic factors/risk factors contribute 
to the onset of recreational AAS use. 
Qualitative 
study 
1b. To explore with AAS-users whether 
they have experienced their use 
contributing to specific mood changes 
or behavioural problems. 
Literature 
review & 
Quantitative & 
qualitative 
studies 
1c. To explore the experiences of 
those who use AAS from a user’s 
perspective with particular emphasis 
on experiences of AAS use and 
managing the positive and negative 
effects of AAS use. 
Qualitative 
Study 
2. To il l icit what AAS-users 
perceive as the barriers to and 
opportunities for accessing 
support services and identify 
effective pathways to share 
information on the risks 
associated with using AAS, 
especially amongst young 
people and recreational users. 
To gain users’ perspectives into the 
sharing of information on AAS and the 
perceived barriers and opportunities 
for accessing support.  
Literature 
review and 
Qualitative 
study  
3. To consider the practice 
implications for social work and 
related inter-professional teams 
working with services that offer 
support to people using AAS or 
to those working with people 
who may start or are already 
using AAS 
3a. To provide recommendations on 
effective methods for communication 
to help people make educated 
decisions about their substance-use 
and choices which ultimately could 
reduce the number of people who are 
using AAS.  
Literature 
review, 
Quantitative & 
qualitative 
studies 
3b. To provide information for Social 
Workers and other professionals 
working with AAS-users. 
 
2.6 Summary 
There are a wide range of factors which have been identified for initiating and 
maintaining AAS use. There are also a complex range of motivations for choosing 
to start using AAS. AAS use comes with a wide range of associated risks, based on 
the user’s perception that benefits outweigh risks, and potential pathways to 
dependence have been identified. Considering the risks, it is necessary to consider 
what information and support is available and also what support users want.  
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 Literature review Chapter 3
3.1 Chapter overview 
This chapter provides an overview of the current literature on AAS use in relation 
to the information and support that AAS-users access and want. The main section 
of this chapter is in the form of a Scoping Review published as part of this study 
(Harvey et al. 2019), which includes the PRISMA diagram, inclusion and exclusion 
criteria and databases searched (Section 2). However, due to word limitations of 
the published paper there are several relevant elements relating to the review 
process that are addressed in this preamble. The chapter ends with a redefining of 
the aims and objectives of this thesis based on the findings of the literature  
(Section 3).  
Chapter 3  Section 1  
3.2 Introduction 
The word restrictions for the published paper did not allow for detailed 
information on either the research strategy or data extraction. These are included 
later in this section. This chapter begins by addressing a key challenge faced by 
the researcher when searching the literature, that of inconsistencies in the 
terminology.  
3.3 The search strategy 
 Inconsistencies in terminology  3.3.1
Inconsistency of terminology was a challenge when trying to identify literature 
relevant to this study. This first came to light through a review of the search 
strategies of a number of recent literature reviews. Several recent reviews 
covering different aspects of AAS use (2011 to 2018) did not give details of the 
search terms used. Those that did focussed on a small number of key words e.g. 
‘anabolic steroid’, ‘performance enhancing drug’/“anabol*”, “steroid*,” and 
“doping” (Sagoe, Andreassen, et al. 2014, Sagoe, Molde, et al. 2014), whereas 
other reviews used a narrower lens e.g. Anabolic Androgenic Steroid (Frati et al. 
2015) or ‘anabolic OR androgenic OR AAS’ (Christou et al. 2017). Other authors 
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included brand names (Brennan et al. 2017) and others a completely different set 
of terms e.g. ‘prohormones’, ‘designer steroids’, ‘testosterone boosters’, and 
‘legal steroids’ (Rahnema et al. 2015). The terminology also differed by country, 
for example, Australia uses PIEDS, the UK, IPEDs. Table 3-1 highlights some of the 
numerous different terms (and acronyms) that could include non-prescribed use 
of AAS in the literature. 
Table 3-1  Terminology to describe steroid use 
Terminology Associated 
acronyms 
Appearance or image enhancing drugs or substances APEDs 
Performance or muscle enhancing drugs or substances PEDs, PESs 
Performance and image/appearance enhancing 
drugs\agents 
IPEDs, PIEDs, PEAs 
Anabolic steroids, Androgenic Anabolic Steroids, 
Androgenic-Anabolic Steroids 
AS, AAS 
Ergogenic aids/substances/drugs, UES, EDs 
Synthetic testosterone, testosterone boosters, synthetic 
steroids 
 
Muscle developing drugs or substances   
Designer drugs, prohormones  
Doping (agents)  
Black market steroid  
Non-prescription steroid use, non-medical steroid use  
Brand names e.g. Trenbolone  
 
Terms such as IPED (Brennan et al. 2017), PES (Karazsia et al. 2013), PIEDs 
(Griffiths et al. 2017) and APEDs (Nieuwoudt et al. 2015) are a ‘catch all’ to 
encompass all types of drugs that act on performance enhancement and can 
include HGH, nutritional supplements and AAS. The word ‘doping’ proves 
challenging as this word is normally associated with drug use in competitive 
sports; however, it appears to be used for studies that include recreational AAS 
use e.g. Sagoe and colleagues (2014, 2015) reviews. Additionally, the terms 
‘drugs’ and ‘substances’ are often used interchangeably, and the terms 
‘supplements’ or ‘agents’ are also widely used in the literature. The wide variation 
of terms used to describe this type of substance use means that searching the 
literature for the specifics of AAS use is fraught and could lead to confusion 
regarding motivations, effects and even risks of use. This could in part be due to 
the nature of the research as the people who use these substances do take a 
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range and combination of substances, which may make it a challenge for 
researchers to get a clear picture of used substances.  
 Development of the search strategy 3.3.2
The search strategy is briefly outlined in the following paper but again word 
limitations meant that some process details were not reported, so are addressed 
here for completeness. The search strategy followed an adapted PICO (Fineout-
Overholt and Johnston 2005), as comparison was not relevant to the questions 
(Appendix 2). The wide variation of terms to describe AAS could have led to key 
studies being omitted, as the term ‘IPED’ is often used when covering a wider 
variety of substances than just steroids such as HGH and creatine. Therefore, in 
order to develop an effective search strategy, key words and number of word 
groupings were tested (Appendix 3) with expert support from Bournemouth 
University library staff to select articles on AAS. These terms were drawn together 
from the terms used in the recent reviews and publications in the UK public health 
arena. This was followed by an analysis of key words contained in the title, 
abstract and the index terms used to describe the article in order to broaden 
search terms. Searches of terms such as ‘anabolic androgenic steroids’, ‘image 
and performance enhancing drugs’ and associated acronyms (not including the 
brand names of specific AAS) were combined with the terms ‘support’ and 
‘information’, and associated synonyms (Appendix 2). To try to minimise the risks 
of missing out key literature, several variations of search terms were trialled using 
a Boolean search strategy and checked through inverse searching to try to throw 
the net as wide as possible. Initially, the word ‘doping’ had been excluded as it is 
normally associated with drug use in competitive sports however, it was 
reincorporated on the basis of Sagoe and colleagues (2014, 2014) reviews (section 
1.31). Due to the number of articles selected, articles were excluded in the search 
strategy using NOT “animal* OR mice OR rats OR "guinea pig*" OR spectrometry 
OR bovine” to exclude non-relevant topic areas. The initial literature search was 
carried out in July 2017 to inform the development of the questionnaire and 
updated in June 2018. 
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3.4 Data extraction 
The data extraction process is reported in the following paper, however, it should 
be noted that customised data extraction forms were designed (Appendix 4) to 
extract key data on information on support and advice, population, substance use, 
study aims, recruitment methods, methodology and demographics. To help 
ensure the quality and consistency of the data extraction process, the data 
extraction sheet was piloted and the supervisory team reviewed a proportion of 
articles (Chapter 3, 2).  
Data extraction also posed several challenges. It was difficult to ascertain which 
studies included AAS-users who were using for purely recreational purposes, as 
bodybuilding can be done competitively but is also a term used for working out to 
increase muscle size. Terms such as bodybuilding were often used indiscriminately 
to refer to either competitive or recreational motivations. The lack of granularity 
when related to types of AAS-user added to the lack of clarity as, although some 
studies included only competitors or athletes, others used the term athletes, yet 
also incorporated recreational use and others did not report type of use.  
3.5 Quality assessment 
Due to the different types of source articles, three quality assessment tools were 
used. The critical appraisal skills tool checklist (Public Health Resource Unit 2006) 
was applied to the qualitative articles. For the quantitative studies, which were a 
mix of methodologies, a tool was adapted from Davids and Roman (2014): 
Quantitative Review Methodology (Appendix 5). To assess the quality of the 
report, the quantitative and qualitative elements were individually assessed using 
the chosen assessment tools, then the criteria from the mixed-methods section of 
the Mixed-Methods Appraisal Tool (Pluye et al. 2011) was used, to assign an 
overall quality score. Only studies scoring ** or above were included (Appendix 6). 
No studies were excluded based on quality.  
3.6 Literature review 
The next section is the scoping literature view exploring information and support 
accessed and wanted, and is in the form of a published paper (Harvey et al. 2019).  
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Chapter 3  Section 2 Research Article 
 
 
Support for people who use Anabolic Androgenic 
Steroids: A Systematic Scoping Review into what 
they want and what they access 
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Support for people who use Anabolic 
Androgenic Steroids: A Systematic 
Scoping Review into what they want 
and what  they access 
Orlanda Harvey1* , Steve Keen1, Margarete Parrish1 and Edwin van Teijlingen2 
    Abstract 
Backgrou nd: Since there is a paucity of research on support for people using Anaboli c Androgen i c Steroids (AAS), we aimed to 
identify and synthesis e the availabl e evidence in this field. Gaining an underst andi ng of the support both accessed and wanted by 
recreational AAS users will be of use to professionals who provide services to intravenous substance users and also to those working in the 
fields of public health and social care, with the aim to increase engagement of those using AAS. 
Methods: A systematic scoping review of the literature to explore and identify the nature and scope of information and support both accessed 
and wanted by non-prescri bed AAS users. Any support services or information designed to help people who use AAS were considered. 
Results: We identified 23 papers and one report for review, which indicated that AAS users access a range of sources of information on: how to 
inject, substance effectiveness , dosages and side effects, suggesting this is the type of information users want. AAS users sought support from a 
range of sources including medical professionals, needle and syringe programmes, friends, dealers, and via the internet, suggesting that, 
different sources were used dependent on the information or support sought. 
Discussion: AAS users tended to prefer peer advice and support over that of professionals, and access information online via specialist forums, 
reflecting the stigma that is experienced by AAS users. These tendencies can act as barriers to accessing services provided by professionals. 
Conclusions: Support needs to be specific and targeted towards AAS users. Sensitivity to their perceptions of their drug- use and the 
associated stigma of being classified in the same sub-set as other illicit drug users is relevant to facilitating successful engagement. 
Keywords: Androgenic anabolic steroids (AAS), Image and performance enhancing drugs (IPED), Support, Harm minimisation, Advice, 
Information, Needle and syringe Programmes (NSPs) 
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 Background 
In the UK, just under 54,000 16–59 year-olds reported 
having used Anabolic Androgenic Steroids (AAS) in 2015/ 
2016 [1]. Although representing only a small minority of all 
substance users, this is probably underreported due to the 
illegality of supply and the use of self-reported data. A 
simultaneous increase in the use of needle and syringe 
programmes (NSPs) by people using Image and Perform- 
ance Enhancing Drugs (IPED) (including AAS) has also been 
noted [2]. NSPs provide harm minimisation services to 
people who inject substances, which includes handing out 
injecting paraphernalia, offering advice on safe injecting and 
harm minimisation and sometimes screening for Blood Borne 
Viruses (BBVs) [3]. Since the late 1980s NSP support has 
become an established service for AAS users [4], in one 
study of 500 users [5] 99.2% reported using injectable AAS 
or a combination of injectable and oral sub- stances and a 
recent UK survey of 684 AAS users, 85% of users injected 
IPED, and steroids were the most commonly used IPED [6]. 
AAS use is linked with negative physical health effects, 
such as testicular atrophy, liver toxicity, dermal scarring, 
cognitive problems, gynaecomastia, muscle damage, myo- 
cardial injuries, infertility [7], and BBVs [8]. AAS users are at 
greater risk than non-users of psychological risks such as: 
mania, delusions, aggressive behaviours, depression, suicide 
and anxiety [9–14]. Pilot studies have shown that lifetime 
AAS use may impact on some cognitive processes and the 
structural features of the brain [15–17]. 
Further risks include harm from using AAS in combin- 
ation with illicit substances [18], self-medication [19] and 
becoming AAS dependent [20]. Importantly, not all AAS 
users will experience these. Reasons for starting use vary, the 
most prominent being to gain  muscle/strength  [21, 22] and 
historically this has been associated with sport. However, 
recently a wider range of motivations has been identified 
including improved appearance, aggression, personal security, 
psychological well-being (including boosting self-esteem or 
confidence) or satisfaction, sexual attraction, overcoming 
depression, curiosity, influence of family, peers and media 
[23]. People who use substances are the experts in their own 
use [24], therefore, given the wide range of risks, a variety of 
motivations (many not mutually exclusive) and the potential 
for people to be- come dependent it is important to 
understand what sup- port people who use AAS wish to 
receive. Getting their perspectives on ideal support may lead 
to more effective engagement with services. Additionally, 
people working with substance users need knowledge of the 
types of sup- port available, to make changes relevant to their 
needs and to reduce the risk of harm to self and others [25]. 
Consequently, this systematic scoping review explores the 
nature and scope of the information and support accessed and 
wanted, by investigating two questions: 
• What support and information do people using non- 
prescriptive AAS recreationally  access? 
• What support and information do these recreational 
AAS users say they want? 
 
 Methods 
Scoping reviews can be helpful in providing one source of 
information for professionals to develop Practice Guidance 
[26]. A scoping review follows a systematic process but 
allows for flexibility, incorporating changes as part of the 
iterative process [27], and allows for the inclusion of grey 
literature. To ensure the process was transparent, robust and 
replicable, the authors followed the Preferred Report ing 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [28]. Our protocol is registered in PROSPERO 
[29]. 
 
Search strategy 
The wide variation of terms to describe AAS means that 
searching the  literature  is  fraught  with  difficulty  and could 
lead to key studies  being  left  out,  as  the  term ‘IPED’ is often 
used when covering a wider variety of substances than just 
steroids such as Human Growth Hormone [30]. Variations on  
the acronyms  included:  PIED, PES, PED, APED, NMASS 
(non-medical Anabolic Androgenic Steroid), and terms such as 
‘doping’, ‘testosterone boosters’, ‘prohormones’, ‘ergogenic aids’ 
‘designer steroids’ and brand names. The first author tested key 
words and word groupings, drawn from recent UK Public Health 
literature. 
In June 2018 a search was carried out in EBSCO (Table 
1), searching 141 databases. Papers were found in 52 
databases (see Additional file 1). Some databases proved 
irrelevant, but it was useful to take a multi- disciplinary 
approach as it was difficult to predict where the most 
pertinent studies might come up. Separate searches on 
SCOPUS, Google Scholar and reference lists of included 
articles were also undertaken, as electronic databases may not 
throw up all available literature [31]. 
Inclusion and exclusion criteria (Table 2) were applied 
initially through a title, abstract and full paper screening. 
Publications were limited to those in English (due to lack of 
resources for translation), without geographical restrictions. 
Irrespective of the study design, articles that met inclusion 
criteria were reviewed, i.e. populations such as recreational 
users and non-competitive AAS- using bodybuilders were 
eligible; there were no age or gender restrictions. The first 
author screened and reviewed all articles. To validate the 
search strategy the second author reviewed 10% of articles 
screened out by title and 20% screened out by abstract. The 
second, third and fourth authors checked 10% each of articles 
in the full review. 
Harvey et al. BMC Public Health (2019) 
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Table 1 Systematic review search strategy - search terms 
Search algorithms 
 
anabolic androgenic OR designer N3 steroid* OR recreat* steroid* OR anabolic steroid* OR anabolic drug* OR Synthe* testoste rone OR “Synthe* 
testoster one” OR “non prescrip t*” steroid* OR non-pre scr ipt*  steroid* OR “non -m edic *” steroid* OR “non presc ri*” N2 steroid* OR non-pr esc ri* 
N2 steroid* OR “non medic *” N2 steroid* OR non-me dic* N2 steroid* OR perform a nce N3 enhanc*  drug* or image N3 enhanc* drug* or 
appearance N3 enhanc* drug* or muscle N3 enhanc* drug* OR muscle N3 develop* drug* or performance N3 develop*drug* OR doping N3 
steroid* 
NOT animal* OR mice OR rats OR “guinea pig*” OR spectrometry OR bovine 
AND Support  or advice or help or aid or barrier* or information or guidance or intervention* or “needle exchange* or program*” 
Literature search 
Our search found several papers relating to question 1, but 
few relating to question 2, therefore the search strategy was 
revised for question 2. Scoping reviews do not necessarily 
have to rate the quality of the papers [27], however the 
authors concluded that due to the complexity of identifying 
participants, such a quality review was of value. Therefore, 
for question 1, only peer-reviewed documents were included 
to ensure a level of quality, and this proved fruitful when 
considering support accessed. However, for question 2, only 
nine papers gave limited information on support wanted, 
therefore the authors searched the references of the included 
articles for grey literature (non-peer reviewed) that might 
include qualitative data on ‘ideal support’. One report that 
specifically sought information relating to ideal support 
wanted was identified [33]. Acknowledging this report was 
not peer reviewed, the authors felt the information 
contained was of value and relevant to the second question. 
Figure 1 outlines the search strategy. 
 
Data extraction and analysis 
Information regarding support and advice, population, 
substance use, study aims, recruitment methods, meth- 
odology and demographics was extracted by the first author 
and 30% of data extraction forms were crossed checked by 
co-authors. Reviewer agreement on inclusion and exclusion 
criteria was 100%. Both qualitative and quantitative data 
were included. Due to the  different  types of articles, three 
quality assessment tools were used: The CASP Checklist 
[35] for qualitative articles (Table 3). 
For the quantitative studies the Quantitative Review 
Methodology tool by Davids and Roman [46] was adapted. 
To assess the quality of the grey literature, the quantitative 
and qualitative elements were individually
Table 2 Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Studie s including populations such as recrea tion al AAS users, non-
competitive AAS-using bodybuilders and weightlifters and, AAS 
users accessing drug servic es. 
Studie s involving partic ipants who compete professionally and any study that  
focuses on competitive sports/athletes or high school athletes 
Peer-R evie wed Papers^ Studies on wider drugs prevention interventions or strategies 
Qualita tive and Quantitative data Studie s that made passing  refere nce s to participa nts seeking inform a tio n but did 
not clarify the type of support or information including studies which 
showed an increase in people using NSPs but did 
not share exactly what they were using them for 
Studies where participants were asked about where they access support, 
advice and information to help them manage their substance use 
and that identified the types of support and information they were 
seeking. 
Studie s that include d data collec ted on any support (inform a tion, 
advice, servic e or intervention) designed to support people who use 
IPED 
Specific medical interventions i.e. efficacy of treatments for side effects 
 
Studie s that focusse d on prevention of AAS use and effic ac y of such 
interventions 
Studies that referenced participants attitudes to who they trusted around 
inform ation but did not specifica lly state the types of inform ation or support 
Studie s that were solely based on recom m enda tions of professionals as to what 
support and informa tion was needed but where the voice of the AAS user was 
absent 
Articles not in English 
Studies before the predominance of the internet as a source of information 
i.e. pre 2001. In 2001 the numbe r of interne t users went over 500 million 
worldwide [32] 
 
 
^ due to the limited number of articles found to answer the second question, inclusion criteria were modified to include relevant grey literature from references
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assessed using the aforementioned assessment tools, then the 
Mixed Methods Appraisal Tool [47] was used, to as- sign an 
overall quality score. Studies scoring ** or above (*** 67–
100% & **34–66% score) were included (Table 4) and no 
studies were excluded on the basis of quality. 
There have been several challenges when identifying and 
reviewing the literature. The number of different terms that 
cover AAS is inconsistent (Table 1). Identifying purely 
recreational users was difficult due to a lack of granularity 
when studies consider AAS/IPED use e.g. terms such as 
bodybuilder, weightlifter and athlete were utilised both for 
competitive and recreational use. Not all studies identified 
whether participants used solely AAS or in combination with 
other IPED. Due to the heterogeneous nature of the data this 
review takes a narrative approach. Moreover, unless clearly 
stated as AAS use within the study, the generic term IPED 
will be used. 
Analysis was mixed method as scoping reviews can incorp- 
orate numerical summaries alongside thematic analysis of 
qualitative data [56]. Initially tabulations were used for the 
quantitative data, which led to the identification of specific 
categories such as BBV checks and acquisition of injecting 
equipment. Thematic analysis was conducted in an inductive way, 
each article was read to identify types of information and support 
and then categorised into type 1 (information or sup- port 
accessed) or type 2 (information or support wanted).  The research 
team met frequently to discuss the emerging themes, which led to 
the identification of three overarching themes: harm minimisation, 
research and information and support for health concerns. Then 
sub categories were identified based on the type of information or 
support. It was challenging to identify the type of information 
participants were searching for and in these instances the authors 
coded this data as ‘seeking of general information on IPED use’. 
 
  Results 
For question 1, twenty-three papers: eleven quantitative 
articles (nine studies) and twelve qualitative  articles (nine 
studies) were included as for several papers the same data set 
was used to explore different questions related to the use of 
AAS (Fig. 1). For question 2, nine studies were included and 
one report. 
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Table 3 Summary of papers included: Qualitative studies 
First author, year & 
refere nce 
Country Participants defined, (age 
range/mean), gender 
No. of participa nts Type of data # Sources potential bias & 
limitations 
Quality 
review~ 
Maycoc k (2005) 
[36] 
Australia Used or had used AAS and 
dealer s, men 
42 AAS users, 22 
dealer s 
#Qualitative: Participant 
observation (147), interviews 
include longitudinal (10 over 3 
years) 
Purposive sampling ** 
Grogan (2006) [37] UK Use(d) AAS, 5 men, 6 
wome n 
11 #Qualitative: interviews Small sample *** 
Skårberg  (2008) 
[38] 
Sweden Addiction clinic patients 
who use(d) AAS, 4 men, 2 
women 
6 Qualitative interviews: case- 
study 
Sought help for AAS use. 
Small sample 
** 
Kimer går d (2014) 
[39] 
England 
& Wales 
AAS users and harm 
reduction service providers 
(mean = 34), men 
24 Qualitative: semi-structured 
interviews 
Bias towards those 
showing positive health 
behaviours 
*** 
Kimer går d (2014) 
[3] 
England 
& Wales 
Used or had used AAS, men 24 #Qualitative: semi-structured 
interviews 
same study as above *** 
Kimer går d (2015) 
[22] 
England 
& Wales 
AAS users, men 24 #Qualitative: semi-structured 
interviews 
same study as above *** 
Van Hout (2015) 
[40] 
UK IPED users, men 20 #Qualitative: in-depth 
interviews 
Privileged access 
recruitment^ 
*** 
Dunn (2016) [41] Australia Used or had used AAS, 19 
men and 2 women 
21 #Qualitative: semi-structured 
interviews 
Voucher for taking part; 
one region (non-r ura l), 
length of interviews 
varied 
*** 
Griffiths (2016) 
[42] 
Australia Used or had used AAS, 24 
men 2 women 
26 #Qualitative: semi-structured 
interviews 
– same study as above *** 
Hanley Santos 
(2017) [43] 
UK AAS users, 21 men 1 woman 22 Qualitative: semi-structured 
interviews 
Bias towards those 
showing positive health 
behaviours - £10 given 
*** 
T ighe (2017) [44] Australia Specialist forum users, 
(none), unknown 
450 unique 
avatar s 
Qualita tive : threa ds from 3 
Online forums: 134 threads: 1716 
posts 
Austr alian sites yet people 
from other countries on 
forum s 
*** 
Gree nwa y (2018) 
[45] 
UK AAS Users, male 8 Qualitative: interviews Sample bias, one NSP *** 
~ Quality Review: Qualitative studies: CASP Checklist for Qualitative Research [34] was used: *** 90% boxes checked as yes, evident, ** if equal to or greater 
than 70% checked. ^The authors acknowledged that one interviewer had privileged access, here that is likely to be an insider within this sub-community [49] 
#where practicable data analysed from studies which included dealers or professional services providers, only findings from AAS users have been included 
 
Sample sizes for IPED-using participants ranged from six 
to 1955. All studies incorporated data on information or 
support accessed and the majority were self-reported. Ten 
studies featured only male AAS-using participants. In the 
seven studies where gender was recorded there were only 
twenty women, and one study of 253 men, and 59 women, 
did not report the gender split after participants who reported 
no adverse effects were excluded, leaving a mixed-gender 
sample of 195. One study included women but only as non 
AAS-users [49]. Two studies: one on an anti-doping hotline 
[50] and another on online forum posts [44] had incomplete 
demographic data and one did not record discreet visits of 
NSP services [51]. 
 
Informati on and support sought 
IPED users sought different types of information and support 
from a range of potentially overlapping sources: NSPs, 
pharmacies, doctors, sexual health clinics, other medical 
professionals, peers, coaches/trainers, friends, 
dealers, family, the internet, specialist online fora, experi- 
enced users, steroid guides in gyms, underground books, 
online videos and addiction clinics (Table 5). 
 
Harm minimisation and advice 
Ten studies evidenced IPED users obtaining injecting equipment 
from NSPs. However, five studies recruited from harm reduction 
services [19, 43, 51, 53, 54] and one had predominantly NSP 
clients [3, 22, 42]. This could explain the prevalence of NSPs as 
places to access injecting equipment. Hanley Santos and 
Coomber [43] noted that some reported no difficulties using 
NSPs, found services easy to access, anonymous, discreet and 
they valued the advice. However, they also reported users 
collecting supplies on be- half of friends who were afraid of 
being recognised. Elsewhere 44% of IPED users obtained 
needles on behalf of others and 27% acquired needles from 
friends [54]. In one study of 1716 internet forum posts, it was 
evident, although not explicitly stated, that NSPs and anti-aging 
clinics were
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Table 4 Summary of papers included: Quantitative and mixed methods studies 
First author, year 
& refer enc e 
Country     Participa nts defined, (age 
range/mean), gender 
No. of participants   Type of data # Sources, potential 
bias & limitations 
Quality 
review~ 
Parkinson (2006) 
[5] 
USA AAS users, 494 men 6 
wome n 
500 Quantitative: web-based 
questionnaire 
Web-based, self-
 *
* selected , self- 
report 
Cohen (2007) [48]  US AAS users (Non-m edical), 
men 
1955 Quantitative: web-based survey Online population *** 
Laranc e (2008) 
[49] 
Austr alia  IPED users, men 60 #Quantitative: cross -sectional 
structured Intervie ws 
Self-selecting 
sample, purposive 
recruitment 
strategies, self- 
reports 
*** 
Al-Falasi (2009) 
[50] 
 
 
Bojsen-Møller 
(2010) [51] 
UAE AAS users (34 male) and 
non-AAS users (129 male & 
female), age range not 
specific 
Denmark General public (incl AAS 
users), (not given for AAS 
queries subset), 284 men, 40 
women 
154 Quantitative: Self-administer ed 
questionnaire 
 
 
374 Quantitative: Anti-Doping Hotline En- 
quires: web and phone queries (sub- set 
AAS use) 
Self-report, small
 *
* sample size, 
selective bias 
 
Self-sele cte d,
 *
* missing data for 
AAS users’ subset 
Hope (2013) [52] England 
& Wales 
(UK) 
Injectors of IPED (NSP s), 
(n = 347 mean = 28 [not all 
gave age]), men 
395 Quantita tiv e: unlinke d -a nonym ous 
cross-sectional biobeha vioural survey 
(oral fluid sample) 
NSPs as settings *** 
Hope (2013) [19] England 
& Wales 
(UK) 
Injectors of IPED (NSPs), (n 
= 319, mean: 28 [not all 
gave age]), men 
366 Quantita tiv e: unlinke d -a nonym ous 
cross-sectional biobeha vioural survey 
(oral fluid sample) 
same study as 
above 
*** 
van Beek (2015) 
[53] 
Australia Injectors of IPED (NSPs), 
(mean = 32.6), men 
103 Quantitative: Self-administered survey Recruited from 2 
public healthcare 
providers 
*** 
Jacka (2017) [54] Austr alia Injector s of IPED, (median 
27), men 
100000 occasions  Quee nsla nd NSP Minimum dataset NSPs as settings *** 
Rowe (2017) [8] Austr alia Injectors of IPED, (mea n = 
28.8), men 
605 Quantitative: Self-administer ed 
questionnaire 
NSPs as settings *** 
Zahnow (2017) 
[55] 
Global AAS users, 253 men & 59 
wome n (no exact No. after 
exclusion criteria applie d) 
195 AAS users 
with adverse 
effects 
Quantitative: Sub-se ction of global 
drug survey – online 
Self- nomin ating,
 *
* online only 
Dennington 
(2008) 
[34] 
Australia IPED users, 61 men, 1 
woman, 7 trans, 24, key 
informants 
69 (+ 24) #Mixed Methods: semi-structured inter- 
views collecting quantitative and quali- 
tative data 
Report: not peer ** 
reviewed. Data sets 
not integrated 
 
 
~ Quality Review: Davids and Roman’s [47] Quantitative Review Methodology. Appraisal Score: *** 67–100% & **34–66% 
score. #where practicable data analysed from studies which included dealers or professional services providers, only findings  from 
AAS users have been included 
 
being used since experienced IPED users advised inexperi- 
enced users to access such services [44]. 
Table 5 shows that some IPED users did access HiV tests 
and/or vaccinations for BBVs; although take up was not high. 
Those who had discussed their AAS use with a doctor were 
more likely to have undertaken a test for Hep B or C, or HiV 
[8] and one study found that people screened for  Hep B or C 
and HiV were more likely than those who did not to rate their 
overall experience with the doctor as good [56]. AAS users also 
sought advice on safer injecting. 
 
Research and information seeking 
 
As Table 6 highlights IPED users’ general information about 
IPED use was sought from a range of sources particularly 
internet sites and subject specific fora. Only  four studies 
 evidenced AAS users seeking information from medical 
professionals [36, 49, 52, 57]. Rowe et al. [8] found that NSP 
staff were perceived as the most reliable source of 
information relating to IPED followed by nurses and doctors, 
however others found doctors’ knowledge limited [36, 38, 
58]. For more specific information around cycling and 
stacking (i.e. what combination of substances are used over 
what length of time), dealers, fellow users and online fora 
were utilised. Maycock and Howat [36] found that 
experienced users and dealers were seen as a credible source 
of information. This is not without risk as substances may 
affect individuals differently, dependent on physiological 
make-up and patterns of use. One study found that over 60% 
of AAS users reported getting incorrect information about 
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Table 5 Data by type of information or support - Harm minimisation 
Type of information / support Support  sought from (if given) Article reference 
 
Acquisition of injecting equipment Dealer (s) [36, 40, 43] 
NSPs [19, 22, 39–41, 43, 51–54] 
Chemist/Pharm acy [40, 41, 43, 52, 54] 
Doctor(s) [39, 52, 54] 
Friends(s)/Peer (s)/S ocial Network [41, 43, 52, 54] 
Steroid Clinic(s) [22, 39] 
Gym/Outre ach services in Gyms [39, 54] 
Online/W ebsites [40, 54] 
Anti-A ging clinic (s) [41] 
Outreach service/O ther [22, 52] 
Guida nce on how to inject and safer Dealer(s)/Supplier(s) [8, 36, 40, 43] 
injection practic es Friend(s)/Peer(s)/Experienced Gym mate(s)/ Other 
AAS user(s)/F am ily 
[8, 38–40, 46, 53] 
Self-ta ught [52] 
NSPs [51] 
Online/W ebsites [8, 43] 
Leaflets/Other sources [8, 43] 
Personal trainer (s) [8] 
Doctor (s)/Nurse(s) [8, 52, 55] 
Blood Borne Virus screening~ Hep B and Hep C [8, 55] 
Hep B (20%), Hep C (18%) [19] 
Hep C (64%) [55] 
Hep B (23%), Hep C (22%) [53] 
HiV testing~ HiV [8, 55] 
HiV (31%) [53] 
HiV (64%) [54] 
HiV (28%) [19] 
Any data given about access of services that is not linked to AAS/IPED use has not been included in this table. ~Percentage of participants where given  
 
adverse side-effects from credible sources [36] and some 
AAS users acknowledged that not all information from 
dealers was reliable [43]. Additionally, one study highlighted 
self-experimentation as a key method for working out the 
most efficacious doses [3]. 
 
Support for health issues 
Some studies referenced IPED users ensuring that they got 
their ‘bloods’ checked, and other tests done regularly by a 
medical professional (Table 7) however, not all had told their 
doctor about their IPED use [8, 19, 52, 58]. In some 
countries, IPED users were able to access prescription 
medicines [42, 59]. IPED users sought help from Accident 
and Emergency departments and NSPs and self- medicated 
for AAS-related health issues [19] but it is un- clear which, if 
any information sources they accessed on how to self-treat. 
Help was sought from experienced users [38] often through 
online fora [41]. All six AAS users in Skårberg et al.’s study 
[38] were using an addiction clinic 
to help manage their AAS use/dependency specifically to 
support psychological problems. Differences were found in 
the type of support or information sought dependent on the 
type of participant and type of support offered. Women were 
more likely to access health services than men, and older men 
were more likely to access these than younger men [55]. 
 
Ideal support 
Figure 2 lists the kind of support that IPED users wanted. 
One study found that people who were thinking about 
using AAS sought out detailed information to make in- 
formed choices [36]. Requests were posted on internet fora 
for information on side-effects and the most effective ways to 
achieve results [44]. According to Dennington et al. [33] 
users wanted to know the optimum way to use IPED, where 
to acquire high quality substances, effective nutrition and 
exercise regimes, safer injecting techniques, 
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Table 6 Data by type of information or support - Research and information seeking 
Type of information / support Support   sought  from (if given) Article reference 
Seekin g of genera l inform a tio n on IPED use: including 
effectivene ss, dosage, the effects, how to use, types of 
Friend(s)/Experienced user(s)/Training 
partners/Peers/O the r user(s)/Fa mily 
[1, 2, 4, 8, 12, 13, 15, 16] 
substances/br and 
Online forum s* [3, 8, 17] 
Underground books/Magazines [1, 8, 13, 16, 18] 
Doctor (s)/M edical practitioner(s)/Nurse (s) [1, 4, 12, 15] 
Gym contact(s)/Gym trainer (s)/P ersonal trainers [1, 4, 12, 15, 19] 
Dealer (s)/Supplie r(s) [1–3, 11, 12, 15] 
Question s to anti-doping hotline/Online servic e on 
AAS 
[20] 
Internet/S pecialis t websites* [2–4, 12, 13, 15, 16, 18] 
Medic al journals [1] 
NSP(s) [2, 4, 12, 15] 
Steroid guides in gyms/Othe r source s [12, 15, 18] 
Resear ch into cycling, stacking  and types of substa nce s Peers/F ellow users [2, 13] 
Websites [16] 
Deale rs [2] 
Online forums [17] 
Self-expe rimentation [16] 
Resear ch into side effects and risk manage m ent People with ‘hands -on ’ experie nce of use/ Steroid 
guides in gyms/ Undergrou nd books/D edica ted 
websites 
Question s to anti-doping hotline/Online service on 
adverse side-effects/ Health risks 
Doping tests Question s to anti-doping hotline/Online service on 
obtaining positive doping test and penalties 
[18] 
 
 
[20] 
 
[20] 
 
Any data given about access of services that is not linked to AAS/IPED use has not been included in this table. *It could be that when AAS users refer to websites        
they might also mean specialist forums 
safe ways to combine substances for effectiveness and when 
to consult a doctor. Grogan et al. [37] reported that women 
found much of the online information and steroid bibles
male-centric and wanted more information on side-effects for 
females. 
In one study 66% of participants were willing to seek 
medical supervision for their AAS use [58], and 91.6% of 
users wished to use AAS legally under direct supervision of a 
knowledgeable doctor [5]. Some AAS users were frustrated 
by the limited health options available and were willing to 
buy drugs from their doctor [41]. Users expressed a desire for 
treatment for IPED-related physical problems, e.g. abscesses 
and the need for specific services such as blood screening 
[33, 39]. Griffiths et al. [42] found that AAS users wanted 
post-cycle therapy (PCT) to stay healthy, minimise harms 
and to prevent losing the gains acquired from use. 
Furthermore, a few users suggested that IPED should be legal 
and medically prescribed [33]. Some users wanted specialist 
IPED services where drugs could be tested for purity and to 
know how to avoid counterfeit drugs [33, 36]. The ideal sup- 
port sought was focused on managing health risks [5, 
41]. Moreover, participants were also specific about how that  
support should be delivered, wanting: 1. a place to obtain 
credible advice and information that was non-judgemental 
and balanced and 2. medical support by knowledgeable 
professionals. 
 
  Discussion 
In summary, it is clear a large number of AAS users seek out 
information and support, predominantly from online fora and 
from experienced AAS users. Professionals are trying to 
tailor support to AAS users where resources allow but few 
studies have explicitly asked users what type of support they 
need. There is potentially a large number of AAS users who 
have not been surveyed  as they are not accessing local 
substance use services or choose not to complete surveys for 
fear of being classified as junkies [60]. 
One key purpose of a review is to identify gaps in the 
literature [61] and IPED users seemed to reject the medical 
model that doctors are the experts as they give credibility to 
advice from people who have used [33] stating that doctors 
lacked credibility as they did not 
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Table 7 Data by type of information or support – Support for health issues 
Type of inform ation/support Support  sought from (if given) Artic le refer enc e 
Regular medical check -ups / Unspecified laboratory/Medical tests 
including blood-tests 
Not stated 
Not stated but bloodwork obtained 
Doctor(s) 
Doctors (Liver function test, ECG, Diabetes tests) 
[21] 
[22] 
[4] [12] [9] 
[14] 
Steroid Clin ic (servic e provider inform a tion) [11] 
Anti-a ging clinics [9] 
Consultation on specific AAS – relate d health issues Doctor 
Doctor (includes discussion on mood) 
Doctor (for PCT advice) 
[21] [6] [5] [9] 
[14] 
[23] 
Specialised addiction clinic (psychological problems) [13] 
Sexua l health clinic s [5] 
NSPs 
NSPs (including < 1% interve ntio ns – drug treatme nt refer ra ls) 
[6] [5] 
[7] 
Accide nt & Emergenc y/walk -in [5] [6] 
Anti-a ging clinics [9] 
Self-tr ea tm ent and other [6] 
Online websites/F orum s [9] 
Prescribed substances relating to AAS use Not stated [6] 
Any data given about access of services that is not linked to AAS/IPED use has not been included in this table 
 
have personal experience [36]. This perspective is more 
aligned to a social care perspective with the substance user 
being the expert in their own use, hence the trust in 
experienced users. One reason given for this lack of 
credibility was that IPED users felt that the advice from 
professionals was not balanced and focused on health harms 
whilst ignoring the benefits [33]. Many argue for 
professionals to be better informed [53, 55] so as to be 
able to challenge the doses in steroid bibles [37]. In a 
society where men are affected by images of the idealised 
male body image [62 64], and negative messages from 
others, it is unsurprising that men adopt a range of strategies 
to become more muscular [65 67]. Many of the short-term 
effects of AAS use are reversible and not as life-threatening 
as the long-term effects and the severity  of side-effects could 
be reduced with early access to 
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health services [55]. Consequently, having the appropriate 
support in place for AAS users is vital and some rec- 
ommend that peers could have a positive role in harm 
minimisation [68]. 
The literature was sparse on the support that women 
access and want; this was not unexpected as the majority of 
AAS users are male [69]. Dennington et al’s. report was 
the only one to include transgender people.  This is a 
population that has not traditionally been identified within the 
research, but one small study found that transgender youth 
had 26.6 times greater odds of AAS use without a 
prescription than cisgender male respondents [70]. It is worth 
considering that this group may be using AAS as part of the 
transition from female to male [71], but this is not necessarily 
the case and there- fore more research on support for women 
and the trans- gendering population would be useful, 
particularly aligned to support needs. 
 
Online information 
Many users sought AAS information from the internet, but the 
majority of online material presents a pro-use position [72], 
can be incorrect or even  dangerous [73] and sites may sell 
steroids [74], which could put users at risk and could 
perpetuate the impetus to use. Andreasson and Johansson [75] 
suggest that the online community with its openness and 
acceptance of AAS use is part of a culture of learning and 
education for novices. They believe such communities can be 
seen to normalise AAS use, the idea of obtaining an ‘ideal 
masculine body’ with- out using AAS becoming a fantasy. 
 
Support services 
Most support from professionals has a harm minimisation 
focus. AAS users are already less likely than traditional 
injecting substance users to engage in risky injection 
practices [76] which could explain the low uptake for BBV 
tests. However, AAS use does increase sex drive [77] so this 
could increase sexual risk taking and may explain why HIV 
tests uptake was higher  than BBVs. Users also sought help 
from sexual health clinics [53]. If, however, IPED users do 
not perceive this as a risk, they may not be engaging with 
services, and might be accessing NSPs simply because the 
needles are free. Three studies evidenced that guidance on 
injecting came from AAS dealers [8, 40, 43]. This is 
concerning as dealers often trivialised potential risks [37]. A 
good harm minimisation strategy could be for gyms to 
provide  a safer injecting service [78] and this outreach 
service has been provided in some UK gyms [39]. However, 
gyms are often reluctant to provide anything that would 
suggest that their clientele may be using AAS [79]. For 
people who wish to access PCT there are few services 
available. Hence the need to reconsider PCT support 
due to the perceived needs linked to mental and physical health 
[42]. 
Only two studies [38, 55] showed that AAS users seek 
support for potential mood changes or underlying psycho- 
logical issues. Kanayama et al. [69] concluded on the basis of 
seven studies that 30% of illicit AAS users develop de- 
pendence based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) IV criteria and therefore it is a valid 
diagnostic entity. The DSM 5 [80] states that some 
individuals with muscle dysmorphia (MD), a form of body 
image disturbance, use AAS. Moreover, one study found that 
men using AAS for image-related reasons reported higher 
levels of MD and eating disorder symptomology [79, 81] 
suggesting there is a need for more awareness raising and that 
people showing such symptoms should be supported through 
appropriate gender specific interventions [82]. No study 
evidenced a need for support aligned to stopping AAS use. 
Traditionally, UK substance misuse support services offer 
talking treatments, and group and one-to-one sessions for 
people dependent on substances, yet there was no evidence in 
the UK studies of AAS users accessing these services. 
Previous studies have advocated that specialist steroid 
services, created with input from AAS users are needed [39]. 
There are comparatively few specialised support services for 
people who use AAS and those few dedicated Steroid 
Clinics, often publicly-funded harm reduction initiatives, are 
subject to the ‘whims’ of local funding and resourcing. It 
would be useful to investigate ways of engaging AAS users 
with health services [6]. A useful strategy could be through 
health professionals engaging with online fora as a 
mechanism for harm reduction providing the language used is  
that  of  the  forum and not of health professionals [44]. This 
would need to include strategies to overcome the lack of trust 
AAS users have in professionals. This review echoes these 
recommendations and suggests that there is a case to consider 
AAS users as a different population to traditional substance 
users. The AAS users accessing NSPs are more likely to be 
those who are injecting AAS and not those who take AAS 
orally. People who only use oral AAS are therefore 
potentially an even harder to reach population who are 
nevertheless putting themselves at risk. Dennington et al.’s 
[33] report examining current users’ views on the information 
and support provision found opposing views on types of 
support offered de- pending on the individual perspective of 
the user. Recent studies have identified distinct types of AAS 
user, each with different motivations for use [59, 83]. 
Differing motivations could be one reason why AAS users 
have differing opinions on the support offered. Consequently, 
offering information and support through a range of services 
and mediums and targeted at the different types of AAS use 
could be beneficial. 
Harvey et al. BMC Public Health (2019) 
19:1024 
Page 50 of 13 
 
50 
 
 
 
 
Barriers to accessing support 
This review did not explore why people may not access the 
information and support that is currently available to them. 
However, several studies highlighted reasons as to why AAS 
users chose not to access specific services. When it came to 
accessing NSPs, pharmacies, and doctors, AAS users spoke of a 
fear of stigma or embarrassment [33, 39, 41, 43, 55],  and there 
were several other reasons given for not accessing professional 
services [33, 36, 37, 41, 42, 55, 58]: 
 
• perceived lack of trust or lack of knowledge from 
professionals 
• fear of judgemental reactions 
• inability to obtain drugs wanted for PCT 
• the need for private health insurance 
• cost and difficulty of booking advance appointments 
• not wanting to be identified as ‘drug’ users or as 
visiting such support services 
 
Generally, AAS users do not see themselves as “typ ical” 
drug users [33, 43]. Consequently, a key barrier for accessing 
NSPs [33] was the presence of other types of substance users. 
Another consideration could be the link between AAS use 
and MD [84, 85] as research suggests that people with MD 
may be in denial of this as a problem [86] and may not link it 
to their use of AAS. A lack of recognition of an underlying 
psychological problem would mean AAS users would not 
naturally seek any type of psychological support. 
Using AAS requires more preparation, research and 
planning than other illicit drug use, and users take a strategic 
approach looking to minimise harm and maxi- mise results 
[58]. This could explain why AAS users justify their use as 
being different from other types of people who use illicit 
substances. Whilst many felt a stigma in attending NSPs, 
others felt these offered a discreet service [41]. This area of 
barriers to accessing ser- vices requires further investigation. 
 
Weaknesses and strengths 
As the search was limited to English language papers, this 
could have excluded some studies. In studies where 
participants were recruited from NSPs, the authors have 
presumed that AAS users were accessing those services, 
predominantly to obtain injecting equipment. Another 
limitation is that data came from different countries, which 
influences information and support available and willingness 
to take part in surveys, e.g. AAS use in Australia and 
America is illegal, whereas in the UK, it is legal for personal 
use, but it is illegal to supply. A further challenge has been to 
identify the types of substances used within the literature and 
exactly what information and support is related to which 
substance. However, as it is likely that people who use AAS 
are also using these in combination with a number of other 
substances to either achieve their aims or mitigate side 
effects, it is plausible that the support and information they 
seek is similar. To our knowledge, this is the first scoping 
review on the types of support accessed, and support wanted. 
 
   
Conclusion 
AAS users access a wide range of sources to obtain in- 
formation on: injecting, effectiveness of substances, dos- 
ages to use, side effects, cycling and stacking, and risk 
management, which suggests that this is the type of in- 
formation users want. AAS users seek out support from 
medical professionals and NSPs for health issues, blood tests, 
prescription substances, and equipment, suggesting these 
types of support are wanted by AAS users. However, AAS 
users do not state or potentially recognise a need for 
psychological support, or support to stop  using. 
Consideration of the barriers faced by users for accessing 
services identified a need for services to take a non- 
judgmental approach and have credible knowledge around 
use. There is a need for AAS support to be specific and 
targeted, with further research required to understand their 
experiences around drug-use and their support needs. More 
research into the experiences of female and transgender AAS 
users and the stigma all AAS users experience would be 
beneficial to ensure a less ‘one size fits all’ service 
provision. Providers of services need to have an in-depth 
knowledge of benefits, harms and range of drugs available 
and benefits of PCT. This review echoes previous studies 
regarding the need to gain a deeper understanding of 
methods that would encourage AAS users to seek support. 
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Additional file 1 – Database Search 
EBSCO Search of 114 databases and Scopus 
54 of the databases searched (without any exclusion inclusion criteria) returned data –  plus separate 
Scopus search: June 2018.  Total: 6384 
All Providers  No.  All Providers No. 
InfoTrac Newsstand  1,191 HeinOnline  12 
Academic Search Complete  901 
Library, Information Science & 
Technology Abstracts  10 
MEDLINE Complete  699 eBook Collection (EBSCOhost)  9 
Complementary Index  627 
eBook Academic Collection 
(EBSCOhost)  9 
SPORTDiscus with Full Text  508 PsycARTICLES  7 
Supplemental Index  430 Communication Source  6 
PsycINFO  354 British Library EThOS  6 
CINAHL Complete  284 J-STAGE  5 
ScienceDirect  224 
Cochrane Database of Systematic 
Reviews  5 
SocINDEX with Full Text  215 JSTOR Journals  5 
Regional Business News  211 Credo Reference: Academic Core  5 
Education Source  113 Hospitality & Tourism Complete  4 
Business Source Complete  110 GreenFILE  3 
Directory of Open Access Journals  56 Art & Architecture Complete  3 
Newswires  51 Government Publishing Office Catalog  3 
NewsBank  41 Communication Abstracts  2 
Networked Digital Library of Theses & Dissertations  34 
Bournemouth University Library 
Catalogue  2 
LexisNexis Academic: Law Reviews  32 Informit Literature & Culture Collection  2 
ERIC  31 IEEE Xplore Digital Library  2 
Environment Complete  28 PsycBOOKS  1 
SciELO  25 arXiv  1 
Harvard Library Bibliographic Dataset  24 Informit Health Collection  1 
Teacher Reference Center  21 Hoover's Company Profiles  1 
SwePub  18 Alexander Street Press  1 
British Library Document Supply Centre Inside 
Serials & Conference Proceedings 18 
Digital Access to Scholarship at 
Harvard (DASH)  1 
OpenDissertations  18   
NewsBank - Archives  12 Scopus (searched separately) 1687 
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Chapter 3  Section 3 Revision of aims and objectives 
3.7 Introduction 
This section reports on the reflections following the publishing of the literature 
review and the development of the overall study objectives as a result of the 
review findings. 
3.8 Reflections on the review 
The scoping review publication was initially intended to be a Systematic Literature 
Review and proposed as such (Harvey et al. 2017) (Appendix 7), and the methods 
followed the PRISMA guidelines for such (Moher et al. 2009). However, peer 
review feedback was mixed; some reviewers did not question the methods, 
whereas others suggested the methods used were not compatible with the 
reporting process. Consequently, the review was reworked as a scoping review. 
However, to maintain rigour, it was decided to keep the quality assessment (3.5).  
3.9 Refining the aims and objectives  
Several changes were made to the aims and objectives as a result of the literature 
review (3.6). Although not reported as part of the paper, exploring the literature 
evidenced a range of motivations for use across differing age groups and as it is 
possible that types of support needed may differ dependent on motivation, 
objective 1a was amended to reflect this (Table 3-2). Objective 1c was revised for 
clarity. The review highlighted that there was a range of information and support 
for people who use AAS, which differed across countries dependent on resources 
and Government policies. Few studies were found which had asked AAS-users 
what information and support they wanted. Consequently, a further objective was 
added (2b) to ascertain users’ views on support and identify AAS-users’ thoughts 
on what type of information and support they wanted. The third aim was 
reworded to reduce the focus on social work, as it was clear from the literature 
review that there was no mention of social workers amongst the professionals 
mentioned. The objective was also amended to be less generic as it was clear 
from the literature review that there were barriers to accessing support.  
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Table 3-2 Thesis aims and objectives 
Aims* Objectives* Methodology 
1. To gain insight into 
male users perspectives of 
their use of AAS for 
predominantly recreational 
purposes 
1a. To explore the experiences of 
those who use AAS from a user’s 
perspective with particular 
emphasis on underlying 
motivations for initiation of use 
and motivations across the 
lifespan 
Qualitative study 
1b. To explore with AAS-users 
whether they have experienced 
their use contributing to specific 
mood changes or behavioural 
problems 
Literature Review & 
Quantitative & 
Qualitative study 
1c. To explore how AAS-users 
manage the positive and negative 
effects of AAS use 
Qualitative study 
2. To establish 
barriers to and 
opportunities for accessing 
support services and 
identify effective pathways 
to share information on the 
risks associated with using 
AAS, especially amongst 
young people and 
recreational users  
2a. To gain users’ perspectives into 
the sharing of information on AAS 
and the perceived barriers and 
opportunities for accessing support 
Literature Review 
and Qualitative study  
2b. To gain users’ current views of 
information and support and 
discover what types of 
information and support AAS-
users say they want 
Quantitative & 
Qualitative study 
3. To consider the 
practice implications for 
inter-professional teams 
working with services that 
offer support to people 
using AAS or to those 
working with people who 
may start or are already 
using AAS 
3a. To provide recommendations 
on effective methods for 
communication to help people 
make educated decisions about 
their substance-use and choices 
which ultimately could reduce the 
harms of using AAS. 
Literature Review, 
Quantitative & 
Qualitative study 
3b. To provide recommendations 
for the types of information and 
services that AAS-users might 
choose to access 
Quantitative & 
Qualitative study 
*(changes highlighted in bold) 
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 Methodology and methods Chapter 4
4.1 Introduction 
This chapter outlines the methodological approach and assumptions underlying 
this study and explores the ethical considerations of researching this sub-
community. It describes the methodology, research design and methods used 
including dissemination of the questionnaire and data collection and analysis.  
4.2 Methodological approach and assumptions  
A methodology identifies the philosophy of the approach and describes the 
worldview adhered to by the researcher which guides and informs the research 
(Creswell 1998). When considering the methodological approaches to exploring 
this subject there are a variety of options, several of which were considered as 
potential options for this study. One option considered was Grounded Theory, 
developed in the 1960’s (Glaser and Strauss 1967), and is a way of systematically 
coding emerging data which is collected with the aim of developing an inductively 
derived theory about a phenomenon (Corbin and Strauss 1990). This study seeks 
to answer specific questions relating to a sub-community and does not seek to 
explain this phenomenon through the development of a specific theory,  a key 
element of Grounded Theory. In Grounded Theory it is recommended not to 
engage with the literature prior to the data analysis (Corbin and Strauss 2015) 
however, the researcher had already explored some of the literature as part of a 
Master’s dissertation. Furthermore, as this study aimed to explore the 
experiences of AAS use from user perspectives in order to offer recommendations 
to enhance support services and one way of understanding people’s current 
experiences through comparison with those in the literature, this necessitated an 
approach that included familiarisation with the literature. Therefore, a Grounded 
Theory approach was not suitable.  
Ethnography and Interpretive Phenomenological Analysis (IPA) were both also 
considered. AAS-users are a hard-to-reach population (Smith et al. 2009, Ravn and 
Coffey 2016, Richardson and Antonopoulos 2019) and one way of exploring 
motivations and support sought would be to have taken an ethnographical 
approach. This approach is situated in the realm of social constructivism with the 
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researcher immersed in the real-life environment, as participant observation is 
integral to this approach (Reeves et al. 2008). The real-world environment for this 
population was likely to be hard-core muscle gyms, and it was unlikely that a 
female researcher (non-bodybuilder) would be welcomed and able to gain trust in 
such an environment and gender may also have precluded her from entering such 
areas as the male locker rooms. Therefore, ethnography was also not suitable. 
IPA is concerned with how people experience/make meaning of an event, and 
make sense of their world (Smith and Osborn 2003). Although IPA would have 
allowed for a very detailed exploration of individual’s experiences, it would not 
have met the study’s objectives and enabled the exploration of the range of 
motivations as this requires a larger number of participants than would 
traditionally be used for such a phenomenologically based method. Moreover, IPA 
did not allow for the investigation of a preconceived hypothesis (due to the 
experiential nature of its approach), and therefore did not support an approach 
which sought to answer several questions in order to support the practical 
application of the knowledge.  
Current practice in the field of support for those who use AAS is driven by public 
health issues around contraction of BBVs (Underwood 2019) and takes a ‘one-size 
fits all’ approach with regards to support for people who use  AAS, treating AAS-
users as illicit substance users. Support is often provided through NSPs or not at 
all (dependent on the country of residence of the user)  and does not necessarily 
reach the desired population (McVeigh 2019). Furthermore, by its very nature, the 
one-size fits all approach does not consider the varied range of motivations AAS-
users have for wanting to modify their appearance and using AAS to enable this. 
The limited specialist support that is available in a few areas of the UK has been 
predominantly delivered by professionals from a harm minimisation focus and not 
necessarily developed, or utilising an approach, based on the potentially broader 
needs of the AAS-users (Bates et al. 2013). This researcher does not conform to 
the idea that the support provided for traditional illicit substance users would 
necessarily work for people who choose to use AAS, as both the user group 
demographics and reasons to use may differ; that is, it is unclear if the 
motivations for use are similar across both groups. Consequently, this researcher 
sought to find out from the AAS-user group what types of support (if any) they 
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would value and how if at all, they may be linked to their motivations for, and 
experiences of, AAS use. The intention of this research process was to propose 
concrete recommendations based on the users stated needs as an outcome, and 
this influenced considerations of the approach utilised. 
Consequently, this researcher’s methodological standpoint is rooted in 
Pragmatism. 
 Pragmatism 4.2.1
Pragmatism originated in the USA in the 19th century, and aims to contribute 
practical solutions to a problem to inform future practices (Saunders and Bristow 
2015). Pragmatism uses a concrete way of viewing the world, and values both 
objective and subjective knowledge (James 1908) allowing both quantitative and 
qualitative research methods in a study. It does not adhere to metaphysical 
concepts such as truth and reality (Creswell and Plano Clark 2011) and 
pragmatists believe that the world can be interpreted in a vast range of ways and 
no one perspective gives a complete picture (Saunders and Bristow 2015).  
A pragmatist’s philosophical standpoint sees the research question as more 
important than the underlying paradigm of the method (Punch 2013). The focus 
being on using what is needed to answer the research question (Tashakkori and 
Teddlie 2003) with a defining process of inquiry (Morgan 2014). A pragmatic 
approach understands and values the epistemological differences of quantitative 
and qualitative data but does not see them as irreconcilable (Bishop 2015). It is a 
solution focused philosophy, and looks to seek an answer to a problem with a 
view to providing socially useful knowledge whilst not being concerned with the 
methods chosen, providing they are fit for purpose (Feilzer 2010, Saunders and 
Bristow 2015).  
This research project aimed to ensure that the voice of the AAS-user is heard, 
specifically in relation to questions on their motivations for use  and experiences 
of use and how these relate to the support wanted. Situated at the heart of the 
project is the question: what specific support do AAS-users feel they need? A 
variety of motivations have been identified for AAS use and a range of side-effects 
experienced. It could be helpful to identify if people with certain types of 
motivation seek certain types of support or if there is a relationship between 
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types of side-effects experienced and support wanted. Given the complex nature 
of the varied motivations driving the use of AAS across a broad demographic 
group, the most effective way of answering the research questions on support 
and motivation, was a mixed-methods approach. There is an assumption that the 
views of AAS-users, on a number of issues, such as whether or not AAS is 
dependence-inducing, could vary dependent upon demographic information such 
as gender, age, or their motivation for use. Again, this may impact on their 
perceptions of which information and support might be desired. A quantitative 
approach would enable the comparison of such attributes. Moreover, quantitative 
data collection would seek to test out AAS-user perspectives aligned to what was 
already stated in the literature. However, as Feilzer (2010) evidenced, quantitative 
data alone may lead to some answers being selected for different reasons, but 
provide no way of knowing what those underlying reasons are, so there was need 
for a deeper understanding of the individual’s underlying motivations which could 
influence their need for support. With questions posed by social and health 
science researchers, the use of one type of data collection is often “inadequate to 
address the complexity” (Creswell 2009, p.203) of a subject. Qualitative data is a 
way of exploring the richness and complexity of a phenomenon (Burns and Grove 
1999), which can lead to a deeper understanding. In the context of its application 
to this study, this approach should lead to greater insight into individuals’ 
perceptions and experiences of AAS use and associated support services.  
Research should be blended in a way that gives the optimal opportunities for 
achieving the research aims (Johnson and Onwuegbuzie 2004). A mixed-methods 
approach uses quantitative and qualitative data collection in parallel and 
sequentially (Tashakkori and Teddlie 2003) with each type of data collection 
allowing for the exploration of different aspects of phenomena (Creswell 2009), 
which can allow for a greater variety of divergent views (Tashakkori and Teddlie 
2003). A mixed-methods approach is helpful when looking for practical 
implications as it can help to enhance the interpretation of the results (Bergh et 
al. 2017) and can help to bridge the gap between the micro and macro levels 
(Bryman 1995). Consequently, this study employed a mixed-method research 
design and aimed to collect, analyse and combine both quantitative and 
qualitative data. This approach aligned to this researcher’s values as a social 
worker, bringing the voice of the AAS-user to the fore aligning to the concept that 
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the substance user is the expert in their own experiences of substance use 
(Galvani 2012).  
4.3 Methods 
 Overview of mixed-methods approach  4.3.1
The three methods utilised for this study are: 
 
1. literature review of quantitative and qualitative literature on information and 
support (Chapter 3); 
2.  quantitative and qualitative questionnaire; 
3. semi-structured interview. 
 
An analysis of the information gained from the literature review provided the 
basis for the development of the questionnaire. The questionnaire combined a 
mix of both quantitative questions, to give an overall picture of the participants, 
and included a range of free-text questions to give participants’ freedom to share 
their experiences. The questionnaire provided the opportunity for participants to 
consent to a follow-up interview. The interview questions further explored 
participants’ experiences of AAS use and support.   
 Overview of the study phases 4.3.1.1
Phase 1: A review of recent literature on the risks, motivations and psychosocial 
consequences of using AAS (Chapter 2) and a scoping literature review (Chapter 3) 
focussing on the information and support for AAS-users. Gaps identified helped 
shape the questions for the subsequent primary research.  
Phase 2: Development and distribution of a questionnaire to seek the following 
information about current AAS-users’ experiences on: 
 
 reasons for use 
 the physical and psychological effects of using AAS  
 accessing information and support 
 the type support wanted 
 the risks of AAS use 
 
The questionnaire was also the sampling frame for recruiting participants to 
phase 3.  
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Phase 3: Interviews with people who use AAS to further explore the motivations 
behind their use and gain a deeper understanding of ideal support needs.  
 Piloting the tools 4.3.1.2
Pilot studies are an important part of the research design process as they can help 
test the adequacy of the research instruments, including: assessment of the likely 
success of research approaches, identification of any logistical problems and train 
a researcher in the data collection process. More specifically, when used with 
questionnaires and interviews they can assist in understanding the length of time 
it takes to carry out the process, identifying any ambiguous or unnecessary 
questions, assessing the clarity of the questions and re-wording any as necessary 
(van Teijlingen and Hundley 2001). Therefore, phases two and three were piloted.  
 Analysis 4.3.1.3
The main analysis was focussed on the data collection from the questionnaires 
and interviews (quantitative analysis using SPSS and qualitative analysis using 
NVivo). This was an explanatory design with the qualitative data being used to 
explain the results of the quantitative data (Creswell 2010). It sought to identify 
themes, using a thematic analysis approach (Darlington and Scott 2002, Braun and 
Clarke 2012) that emerged from the questionnaire data and conversations with 
the participants. 
 Population 4.3.1.4
This project entailed working with adults (18+) who are using non-prescribed AAS. 
The participants for Phase 2 consisted of: Self-identified AAS-users from NSPs and 
the public who choose to access the online questionnaire. Because of the written 
component, adequate English language comprehension levels were necessary. 
Participants for Phase 3 consisted of: Self-identified AAS-users who on completion 
of the questionnaire had ticked a box stating an interest in taking part in the 
interview phase.  
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There is a range of different ways to sample a population (Mason 2002) and it is 
important to consider whether the population sampling was convenient or 
random (Ryan et al. 2001). As this study aimed to research a notoriously hard-to-
reach population (4.6.1), the researcher used several different sampling methods: 
opportunity/convenience, self-selected (Rees 2011, Patton 2013), time-location 
space and snowballing, which is useful in sensitive areas of research (Shaghaghi et 
al. 2011). As the questionnaire was online, it was open to an international 
audience. This could be potentially limiting as geographically controlling the 
location of the respondents would be difficult. There could also be a cultural 
context and options for support and information may be impacted by location, 
both in terms of laws and policies on provisions of service. However, evidence 
suggests that the AAS using community spends a lot of its time online, in fora 
accessible across the world, and studies in populations across the US, Australia 
and Europe have shown similar motivations (Sagoe, Andreassen, et al. 2014). 
Consequently, it was decided not to exclude participants based on nationality, but 
only age and AAS use. The majority of AAS-users are men due to the motivation to 
increase muscle size (Kanayama, Hudson, et al. 2009) and female AAS-users are 
more likely to be competitive bodybuilders rather than recreational users (Ip et al. 
2010). Most studies are overwhelmingly focussed on male populations; 
consequently, with the intention of gaining further insight from the little 
understood female AAS-user, this study was open to all genders to see if any 
women were willing to share their views, however the hypothesis was that there 
would be significantly fewer female respondents.  
4.4 Ethical considerations 
Ethical approval was sought and obtained from the University (Appendix 8 BU 
ethical approval). There were a number of ethical considerations for this study. 
Key considerations were vulnerability of participants, legality of use and 
anonymity and confidentiality.  
 Vulnerability 4.4.1
A seemingly simple question incorporated as part of the University Ethics 
application for a research project asked: ‘are your participants considered 
vulnerable’? An important question as a label of vulnerability may have 
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ramifications in terms of research participation (Crabtree 2013). When exploring 
the experiences of adults who use un-prescribed AAS the ramifications could link 
to the legality and stigma around using AAS and the potential emotional harm of 
participating in research. This straight-forward question turned out to be more 
complex on reflection and in research, vulnerable individuals are those ‘especially 
prone to harm or exploitation’ (Lange et al. 2013). PhD students are expected to 
comply with ethical requirements of their University’s ethical process and e thics 
committees will refer to relevant legislation for the safeguarding of vulnerable 
people (Crabtree 2013). However, if potentially vulnerable groups are listed 
simply as part of research ethics there is a risk of stereotyping (Rogers and Meek 
Lange 2013). Therefore, to determine if this group of users were vulnerable there 
was a need to consider the definitions of vulnerability within the literature and 
legislation. This exploration led to a published paper (Appendix 9) which 
concluded that AAS-users should not be automatically considered vulnerable 
(Harvey 2019).  
The university’s ethical guidance on vulnerability did not give people who use 
substances as an example of a vulnerable population but did explicitly list people 
who receive a local authority service with being vulnerable. This is in line with 
another legal definition as; Section 59 of the Safeguarding Vulnerable Groups Act 
2006 defines adults who are the subject to regulated activity as vulnerable. It 
could be argued that NSPs, which are used by AAS-users, function as a service, 
however, using an NSP to obtain needles is not necessarily a regulated activity nor 
does it suggest an inability to care for oneself. As NSPs are part of a harm 
reduction strategy (Stimson et al. 1990, Bates et al. 2013), users don’t have 
allocated workers, visit voluntarily and often remain anonymous, so attendance 
could indicate a clear capacity to manage risks. From a research perspective, 
people who use AAS, although at risk of harm from using AAS, are unlikely to 
experience an increased risk of harm from taking part in research about their 
experiences and taking part would not impact on their ability to access a service. 
Consequently, they would not be a vulnerable population on the basis of AAS use 
alone; however, there is always the possibility (as with any research) that some 
participants may be vulnerable for other unidentified reasons and consequently 
web links to relevant support services were added to the end of the questionnaire 
(Appendix 10).  
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 Legal issues 4.4.2
The legality of AAS is complex in the UK and differs across the globe (1.4). 
Consequently, complex ethical concerns necessarily arise when surveying and 
interviewing people engaged in AAS use particularly in a global context. In this 
study, questionnaire administration focused on western nations; while, the legal 
status of Anabolic steroid use differs across the world, in some countries e.g. the 
US, Norway, Sweden steroid use is illegal. In other countries such as the UK, use 
comes under drug legislation but sits in a legal grey area as a class C substance 
under the Misuse of Drugs Act 1971; thus they are illegal to sell or deal unless 
they are prescribed by a doctor for medical reasons, but it is not against the law to 
buy the drug as long as it is for personal use. In other countries e.g. Canada and 
Spain, use is prohibited but not punishable and in others e.g. Slovakia, the local 
law only states that giving steroids to minors (under 18) is criminal offense, but it 
is not legal to buy AAS without prescription. Consequently, it is possible that the 
differing legal status of AAS use in differing countries may have impacted both on 
participants willingness to undertake a survey albeit anonymous, their 
perceptions of use and access to support.  
The BU Ethics Committee raised the legality issue of disclosure and requested 
reassurance that questions would not be asked around purchase and supply of 
the AAS as this could lead to an issue of whether criminal activity needed to be 
reported. Hence sources of AAS were not asked. Due to the complexity around 
the legality of AAS use, and that use can be stigmatised (Sagoe 2015), AAS-users’ 
anonymity was protected through the use of pseudonyms and anonymous 
questionnaires. This was crucial as researchers must be vigilant when dealing with 
substances users’ confidentiality (Tirone et al. 2014) and AAS-users are often 
concerned about confidentiality (Cohen et al. 2007). For the interviews a range of 
communications channels were offered to allow participants to choose whether 
to protect their identity from being made available to others without explicit 
knowledge and consent.  
Several services were happy to support the study; only requiring confirmation of 
the approval by the BU Ethics Committee, others required a confirmation from 
their Local Authority but no additional paperwork, e.g. Bournemouth and Poole 
Local Councils. However, three UK charities wanted more detailed ethics 
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submissions, so three additional ethical applications were made to Turning Point, 
Change Grow Live and the Westminster Drug Project (WDP). The researcher also 
approached services based overseas in high income nations who advertised 
support services online. Again, many of the services contacted agreed to support 
needing only the confirmation of BU Ethics approval, however two organisations: 
ACON (NSW Australian LGBT Charity) and Ottawa Public Health required 
additional paperwork to be submitted.  
4.5 Development of the questionnaire 
 Questionnaire content 4.5.1
The questionnaire included a range of questions; including demographic data, AAS 
use patterns, positive and negative effects, support services used, sources of 
information sought and user’s views on the support wanted (Appendix 10). The 
questionnaire was informed by the literature review (Chapter 3), conversations 
with local NSP staff who worked with AAS-users, a conversation with an academic 
who had designed questionnaires for this population (Prof. J McVeigh) and a 
recent study (Ager 2015). The design strategy was to develop questions aligned to 
the motivations for use, effects of use and support required as identified in the 
literature (individual question references in Appendix 11) and to see if AAS-users 
had experienced these. However, there was a potential limitation with this 
strategy. Advice received from Prof. McVeigh, suggested the need to be wary that 
people may attribute their health conditions to AAS use, if suggestions are given 
an attribution that it is not possible to verify. This was difficult to overcome, as 
part of the basis for the questionnaire was to ascertain if findings that had been 
identified across the literature matched the current users’ experiences; so, the 
limitation was noted and considered as part of the analysis. However, Oppenheim 
(1966) recommends starting with open questions to avoid unintended influencing 
of the participants. Therefore, free-text options were included to give participants 
the opportunity to share their subjective experiences. Furthermore, the question 
on harms was redesigned as an open question, and the open question on 
behavioural changes was re-positioned prior to the quantitative questions with 
the intent of lessening this effect. Oppenheim (1966) also suggests that richness 
of the data can be lost with open questions when clarifying answers as part of the 
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data analysis, but they do give respondents freedom to respond, be spontaneous 
and use their own language. This freedom to respond is important for exploring 
the experiences of AAS-users, particularly in relation to their experiences of 
seeking support. Therefore, despite the challenges this added to the analysis, the 
need to understand individual user experiences, framed in the context of their 
world perspective and language, was considered to be of more importance. 
Closed questions, although less nuanced in their approach give more concrete 
data (Oppenheim 1966), so several were incorporated such as recreational or 
competitive user as they could be directly compared to such questions as type of 
support wanted or views on dependency. Two questions were taken from a 
previous study (Ager 2015); one on how to define user type (with an aim to add 
consistency of terminology/category) and one adapted from a question on ‘the 
impact that AAS use has had on quality of life ’. A question on ‘risk of AAS use to 
others’ was also included as a potential negative unintended consequence of use 
could be risk to others, a concept which has not been explored in-depth in the 
literature (Harvey and Parrish 2019).  
  Gender and sexuality 4.5.1.1
When designing questionnaires, researchers need to think more widely about 
how they ask questions on gender and sexuality (Eisenberg et al. 2017) and this 
was considered as AAS use is found within both homosexual and heterosexual 
communities (Ip et al. 2015, 2017). For this questionnaire, views were sought 
from a nurse practitioner from a local lesbian, gay, bisexual, transsexual, queer 
(LGBTQ) sexual health clinic and a LGBTQ researcher on how to phrase questions 
on gender and sexuality. This led to the inclusion of a self -describe question on 
gender and a two-option question on sexual orientation with a self-describe 
option, as this is a more empowering and inclusive practice (Stonewall 2016). The 
use of ‘self-describe’ also added to the clarity of the question for the participant, 
as not everyone is familiar with the new definitions around gender and this is 
considered a less oppressive approach as labelling people can also be 
disempowering (Eisenberg et al. 2017).  
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 Anonymity 4.5.1.2
Anonymity for this type of questionnaire is an important consideration as people 
may not agree to participate if there is a chance this may be violated (Shaghaghi 
et al. 2011). Therefore, to help with participants’ confidence, questions at the end 
of the questionnaire that requested contact information in case the participant 
wished for a summary of the study were optional, and the use of anonymity was 
clearly stated in the introduction to the questionnaire.  
 Questionnaire structure 4.5.2
 Length  4.5.2.1
Consideration was given to the length of the questionnaire, as people are more 
likely to complete questionnaires of a shorter length (Rolstad et al. 2011, 
Markstedt and Vernersdotter 2013). However, Markstedt and Vernersdotter 
(2013) found it impossible to separate the impact of content from length; 
therefore, the decision on the length of this questionnaire was based on the 
objectives of the study. 
 Question order 4.5.2.2
The ordering of questions in web-based questionnaires is important, as precedent 
questions can affect how people consider subsequent questions (Fan and Yan 
2010). The item placement was based on guidelines by Siniscalco et al. (2005). 
Items of major interest to the participant such as questions about how they use 
AAS were placed early on, as completing topic-related questions may encourage 
participants to be more open about more generic personal questions (Regmi et al. 
2017). Questions on behaviour and demographic questions were placed towards 
the end as behavioural change could be a sensitive subject with AAS-users, due to 
the perceptions relating to ‘roid rage’, and sensitive questions can provoke 
resentment or influence responses to other questions (Siniscalco et al. 2005). A 
further reason for placing demographic questions at the end is that they can seem 
boring to the reader and cause the reader to disengage (Stone 1993). Similar 
topics were grouped together; funnelling (broader questions leading to more 
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specific ones) was used within the topics and section titles incorporated. The 
participant introduction sheet at the start of the questionnaire included the 
purpose of the study, confidentiality and importance of the study to the intended 
participants (Siniscalco et al. 2005) (Appendix 10). The questionnaire structure 
was designed so that key questions on support were placed in the middle of the 
questionnaire, aiming to reduce the number of non-answers from questionnaire 
fatigue.  
 Mandatory questions 4.5.2.3
An advantage of a web-based questionnaire is that it can be designed so that 
participants have to give an answer before moving on and consideration was 
given to including such mandatory questions. However, mandating questions can 
put up a barrier with the respondent, particularly when dealing with a sensitive 
subject, and may lead the participant to leave the questionnaire  (Stieger et al. 
2007). Denying choice also goes against this researcher’s values, so the majority of 
questions were optional, bar those about consent and use of steroids (the 
eligibility questions), and those on support, where a lack of data would limit the 
potential of the questionnaire to address the primary study question. 
 Piloting the questionnaire 4.5.3
The draft questionnaire was critiqued through supervision, by an NSP Harm 
Minimisation Team leader, and a number of professionals who had knowledge of 
AAS-users, social work, statistics and visual questionnaire design. This scrutiny 
proved invaluable. The questionnaire was revised on the basis of the feedback 
gained, as expert reviews can identify question problems, which could impact on 
the gathering of meaningful quality data (Olson 2010) and visual presentation can 
strengthen response rates (Dillman 2007). The feedback from testing the 
questionnaire prior to the pilot elicited the need for the design style to be 
aesthetically pleasing, the answer format to be consistent, the use of language to 
be less academic, less formal and more concise. There was some specific feedback 
around the question format including discussion on use of ‘other’ and using 
‘please describe’ over ’please explain’. This led to changes in layout to improve 
usability and flow, fixing errors in the online questionnaire design, changing words 
 
 
70 
 
to simplify language, improve clarity and ensure the questionnaire was pitched 
correctly. Advice from a mental health practitioner led to the removal of clinical 
terms when describing psychological effects and this critique also identified that 
the researcher had missed a potential support group. The BU Ethics Committee 
suggested minor amendments to the participant information sheet to highlight 
any risks to the participant in taking part, how long any data would be held and a 
change in contact information but did not ask for any amendments to the 
questionnaire (Appendix 8 BU ethical approval).  
It is vital to pilot the questionnaire as a whole as this can help identify if questions 
are understandable (Oppenheim 1966, Stone 1993, Kelley et al. 2003). Originally, 
the idea had been to run a pilot with service users from a local NE, however, the 
service was re-commissioned, and the key gatekeeper had left the organisation. 
The gatekeeper had built up strong relationships with service users and the 
researcher had been relying on this relationship for the recruitment of pilot 
participants. Consequently, there was no possibility, in the short-term, of gaining 
access to pilot participants through the NE; therefore, it was necessary to explore 
other options. A colleague put the researcher in touch with a contact who was a 
martial artist and fitness expert, who in turn shared the paper-based version of 
the questionnaire with a few people they knew who used AAS. This influenced the 
potential demographic of the AAS-users but did mean that the sample would not 
be contaminated. Consequently, the questionnaire was piloted with a group of 3 
current users and 1 ex-user: all male, white, British. An unintended consequence 
of piloting in this way meant that the pilot included an ex-user (who had not used 
for a number of years). This turned out to be particularly useful as they were 
willing to meet with the researcher and discuss their thoughts on ways to 
distribute the questionnaire. Piloting questionnaires does not guarantee that 
every potential flaw will be identified. An initial analysis of the data collected via 
the pilot questionnaire did not show any problems with the format or structure of 
the questions. The participants did not appear to have difficulty answering the 
questions and when the data was added into the online version (using the Bristol 
Online Questionnaire Tool), all the information transferred correctly, and the data 
exported accurately. The questionnaires were all completed and no amendments 
were made to the questionnaire as a result.  
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4.6 Distribution of the questionnaire 
 Sampling frame 4.6.1
With the need to seek out a different population than the one initially intended 
(4.5.3), it became clear that it would be impossible to construct a sampling frame 
as there is no pre-existing records of AAS users. Moreover, constructing a 
sampling frame from for example online fore and gyms is not feasible as there is 
no way of knowing who takes AAS for recreational use compared to use for 
competitive sports. This meant utilising non-probability sampling methods 
(Fielding et al. 2012).  
 Challenges of accessing this hard-to-reach population 4.6.2
AAS-users are acknowledged as a hard-to-reach population (Smith et al. 2009). 
Moreover, the differing legal status across the world (1.4 and 4.4.2), and the fact 
that this community have experienced stigma (Maycock and Howat 2005, Yu et al. 
2015) makes them more likely to be secretive about use (Thorlton et al. 2012, 
Settanni et al. 2018). Settanni et al. (2018) suggest in times of data privacy 
infractions, that people might be put off participating in online surveys around 
steroid use for fear of being outed. The literature review evidenced that NSPs and 
gyms were key recruitment targets however more recent studies, had used online 
forums. Consequently, this researcher pursued a range of approaches in an 
attempt to reach populations that do not use NSPs or necessarily train in hard-
core gyms. The internet can be a valuable resource for recruiting participants, 
particularly those from hard-to reach populations (Rodham and Gavin 2006) and 
as the questionnaire asked for personal information, the anonymity of cyberspace 
could help encourage people to participate (Rodham and Gavin 2006). Therefore, 
a large part of the questionnaire distribution was done online  to attract as diverse 
a sub-population as possible. AAS use has been linked to the idea of masculinity 
within Western cultures (Kanayama et al. 2012), therefore some targeting of 
western high income countries via social media and online muscle fora was part of 
the questionnaire distribution. Although targeted at people who use AAS, it is 
acknowledged that this is still an opportunistic sampling method.  
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 Recruitment strategies 4.6.3
There is a range of different ways to sample a population (Mason 2002) and it is 
important to consider whether the population sampling was convenient or 
random (Ryan et al. 2001). As this study aimed to research a notoriously hard-to-
reach population, the researcher used several different non-random sampling 
methods: opportunity, self-selected (Rees 2011, Patton 2013), time-location space 
and snowballing, which is useful in sensitive areas of research (Shaghaghi et al. 
2011). Here the term snowballing refers to the method of having a gatekeeper 
share the questionnaire within the community (Biernacki and Waldorf 1981).  
Table 4-1 Recruitment Strategies 
Strategy Description Strengths Limitations 
Opportunity Uses the knowledge of 
the researcher to 
identify potential 
participants (Jupp 
2006) 
Useful for hard to 
reach populations 
such as drug users 
(Goode 1999) and 
allows the researcher 
to define who and 
where to study (Jupp 
2006) e.g. focussing 
on non-NHS services 
Perceived from a 
positive perspective 
as weak data as it is 
unlikely to produce a 
representative 
sample of the 
population  (Jupp 
2006) 
Self-selected Participants self-select 
as to whether or not 
undertake the survey 
e.g. via web-based 
questionnaire 
(Lavrakas 2008) 
Useful to reach 
secretive populations 
such as drug-users 
(Lavrakas 2008) 
Introduces self-
selection bias which 
limits the data being 
generalisable to the 
whole population 
(Lavrakas 2008).  
Time-location 
space 
Identifiable locations 
which the intended 
population frequent  
(Karon and Wejnert 
2014) e.g. NSPs (Hope 
et al. 2013), muscle 
gyms and AAS-user 
forums online 
Useful for data 
collection from hard-
to-reach populations 
(Karon and Wejnert 
2014) 
Can be difficult to 
validate. There is a 
bias towards those 
who attend venues, 
leaves out those who 
do not attend 
(Raymond et al. 
2007).  
Snowballing  The method of having 
a gatekeeper share the 
questionnaire within 
the community 
(Biernacki and Waldorf 
1981). Used when 
desired sample 
characteristic is rare 
(Fielding et al. 2012). 
Useful to access 
participant 
characteristics are 
rare and when there 
are sensitivities 
involved.  (Shaghaghi 
et al. 2011). 
Snowballing can lead 
to a more 
homogenous set of 
participants (Zahnow 
et al. 2018) as it 
relies on referrals 
from initial 
respondents to their 
network  (Fielding et 
al. 2012). 
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The intention was that by using a variety of media to get the questionnaire out 
into the community that it would reach someone who would share it amongst 
their peers, although it would be difficult to know if this had happened. As 
snowballing can lead to a more homogenous set of participants (Table 4-1), 
therefore in an attempt to reduce this homogeneity the researcher also targeted 
a variety of services (NSPs, muscle gyms, supplement shops), online fora, personal 
social networks and used social media. The summary of distribution methods is at  
Table 4-2. 
Table 4-2 Summary of distribution methods for questionnaire 
Distribution Channel Type of Medium 
UK NSPs and substance Use service 
providers (non-NHS) 
Request to share paper-based questionnaire, display a 
poster and/or promote online questionnaire l ink. 
Overseas substance use services: Canada, 
Australia, America, Ireland, Jersey 
Request to promote/share online questionnaire l ink. 
Work colleagues Request to put up posters and share questionnaire l ink. 
Pro-muscle gyms  Request to display a poster or promote questionnaire l ink 
Friends Request to put up posters and share questionnaire l ink. 
Local health food shops & other businesses 
e.g. l ibrary, cafes 
Request to display flyers 
Twitter Pinned tweet and direct tweets to people who used the 
hashtag #steroids and substance use services.  
Online muscle and bodybuilding fora  Contacted administrators to ask to create a post with 
questionnaire l ink  
LinkedIn contacts Request to promote/share online questionnaire l ink. 
Facebook (FB) Post of online questionnaire l ink and request to share in 
selected relevant groups 
Instagram Post and promoted link alongside pictures of AAS relevant 
material, used relevant hashtags  
Reddit webpage Posted questionnaire l ink  
YouTube Video presentation with l ink to questionnaire: 
https://www.youtube.com/watch?v=iOsX1us3-O8 
Appendices 12 and 13 give examples of above channels and methods  
 
As the questionnaire was online, it was open to an international audience. This 
could be potentially limiting as geographically controlling the location of the 
respondents would be difficult. There could also be a cultural context and options 
for support and information may be impacted by location, both in terms of laws 
and policies on provisions of service. However, evidence suggests that the AAS 
using community spends a lot of its time online, in fora accessible across the 
world, and studies in populations across the US, Australia and Europe have shown 
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similar motivations (Sagoe, Andreassen, et al. 2014). Consequently, it was decided 
not to exclude participants based on nationality, but only age and AAS use.  
 Non-internet distribution routes 4.6.3.1
 UK NSPs and substance use service providers (non-NHS) 4.6.3.1.1
Facility-based targeting, that is recruiting participants from services they access 
(Shaghaghi et al. 2011), was used, approaching professionals working with AAS-
users. It was a challenge to identify UK services as they are run by many different 
types of agencies. The FRANK website has 157 pages of possible support services 
(FRANK 2018), therefore this information was hand-searched to identify NSPs and 
a list of potential support services created. Websites for these services were then 
researched for contact information. Not having NHS ethics meant that the 
questionnaire could not be shared with any service run by, or commissioned by, 
the NHS. Depending on the contact details available, services were emailed or 
telephoned to ask if they would share the following with service users: a paper-
based version of the questionnaire or a business card or a poster with the online 
link and quick response (QR) code for easy phone scanning. Services were also 
provided with a project brief. In total 76 services were contacted and 26 agreed to 
share the questionnaire in some format i.e. handing out business cards, displaying 
posters, sharing paper-versions, listing the study on their website or promoting 
via social media.  
One reason for targeting such services, is that previous studies have sought 
participants via this method and there has been an increase in recent years in 
AAS-users accessing NSPs (ACMD 2010). Additionally, two gatekeepers, one within 
the AAS using community and one professional felt their personal/professional 
relationship with the AAS-users was key to getting them to engage with the 
questionnaire. One of the issues with handing out questionnaires via an official 
service provider is the power imbalance in relationships with service users. This 
was a potential concern, when considering distribution via NSPs, however the 
questionnaire was anonymous and service users were not being asked to 
complete it as part of the service provided. Three service providers invited the 
researcher to their organisation, either to talk to them or their frontline staff 
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about AAS use. This opportunity was taken up, as Clark (2011) argues, it can 
sometimes be hard to gain the cooperation of gatekeepers and often offe ring 
benefits in return, such as staff training, can help to build the relationship as the 
organisation will see a clear benefit to partaking in the research. Another example 
where an organisation wanted clear benefits was WDP, a charity who hold a 
number of NSP contracts, who asked to promote the study and link to the 
University on their website. Moreover, in an attempt to encourage organisations 
to take part, they were offered a summary of the research findings. Further NSPs 
were found via an academic who had sought participants via NSPs in the past. 
They were also an advocate for the researcher to join a Google group of people 
working in the area of AAS use and allowed the researcher to use their name in 
the emails, with the hope that a personal connection would improve the 
likelihood of a response. Often from NSPs the likelihood of the response was 
heightened if the person working in the NSP had a particular interest in 
supporting people who used AAS. A full list of services that agreed to share the 
questionnaire is in Appendix 12.  
 Overseas substance use services 4.6.3.1.2
To find services overseas (in this instance {due to translation issues} focussing on 
English-speaking countries: USA, Canada, Ireland, Australia and New Zealand that 
may potentially support AAS-users), a similar approach was taken to that in the 
UK, initially seeking out a central website that listed substance use services with 
NSPs. This did not prove as fruitful as the UK search, with only four organisations 
agreeing to share the questionnaire (Appendix 12).  
 Local businesses 4.6.3.1.3
The researcher visited the two local shops selling supplements and both agreed to 
display business card flyers. Posters were also put up around the BU and in the 
local town library (appendix 13).  
 Pro-muscle gyms 4.6.3.1.4
The researcher undertook a Google search of phrases such as: ‘hard-core’ ‘power’ 
and ‘muscle’ gym to identify potential gyms to target. They reviewed the websites 
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and contacted a number of UK gyms that focussed on strength and conditioning 
to request if they would share the link. Several friends asked gyms to put up 
posters in their local areas. 
 Online distribution 4.6.3.1.5
There is a need to understand this sub-group in a wide range of situations and not 
just limited to those who access NSPs (Hope et al. 2015). Therefore, part of the 
distribution strategy was to seek other avenues such as online and personal 
contacts. Due to the immediacy and transient nature of social media, the 
distribution was an ongoing process and steps were taken to re-share the 
questionnaire over a range of social media fora for the period that the 
questionnaire was open. A summary (to maintain confidentiality) of online 
distribution and engagement is in Appendix 12 and a snapshot of the social media 
communication and impressions is in Appendix 13. 
 Use of personal social networks and wider social media channels 4.6.3.1.6
Users often keep their AAS use secret with the exception of within their own sub-
culture networks; therefore, it was difficult to know who within this researcher’s 
social network had contact with people who used AAS. Consequently, working on 
the assumption that even if they did not know someone personally they might 
share the questionnaire link via their social media, the researcher’s LinkedIn (a 
professional networking site) and FB contacts were direct messaged to ask if they 
would share the questionnaire link on their social networks. This met with a mixed 
response. The link was also posted on the researcher’s own FB feed and LinkedIn 
profile.  
 Twitter, Instagram, Youtube, Reddit 4.6.3.1.7
The researcher developed the following strategy to promote the questionnaire via 
Twitter (Table 4-3).  
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Table 4-3  Promotion strategy 
Pinned a tweet of the questionnaire link to her own Twitter profile, and regularly 
tweeted AAS related material using hashtags  
Searched for terms such as ‘steroids’ and ‘roids’ to find people on Twitter who 
were interested in AAS and then directly tweet to ask them to retweet the 
questionnaire.  
Targeted the following relevant individuals and organisations to ask them to share 
the post: 
o Substance use agencies, charities and academics in related fields,  
o People who promoted bodybuilding, 
o Celebrities with a significant number of followers (only one person of 
any celebrity status retweeted – an engineering academic: 
@markmiodownik, 
o Her Twitter followers with a large followership  
Tweeted the questionnaire link using a number of hashtags relevant to the topic 
in English and in other languages focussed on western countries (e.g. #muscle).  
Utilised a range of specialist interest hashtags to increase to recognition (e.g. 
#ripped). 
Translated the phrase ‘Anabolic Androgenic Steroids’ into a number of different 
languages using Google translate (due to lack of resources), searched for that on 
Twitter and then directly tweeted people who had used the phrase in their feeds 
asking them to share the post.  
 
The researcher was advised by an NSP worker to use Instagram. Therefore, the 
researcher set up an account and promoted the questionnaire by regularly adding 
relevant IPED related stories to the feed, using hashtags to draw people to the 
posts.  
The researcher created a video on AAS use and harm reduction, which included 
information about the questionnaire and posted this on a specially created 
channel on YouTube. Additionally, the researcher regularly searched for the most 
recent posts on YouTube about AAS and where possible shared the questionnaire 
link in the comment sections. The questionnaire was posted online on Reddit 
under the PhD academic study forum, in line with Reddit’s guidelines.  
 Online fora and Facebook groups 4.6.3.1.8
The researcher contacted moderators (also known as Forum Admin) of online 
muscle fora to ask for permission to post (Appendix 13) as this is in line with 
ethical research practice (Rodham and Gavin 2006). This is a variation of time-
location space sampling, which looks at targeting people from a population at a 
place or time where they might gather (Shaghaghi et al. 2011). Previous studies 
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have used special interest online discussion fora to seek participants as often 
these spaces have whole discussion boards devoted to questions on AAS. Initially, 
the fora mentioned in previous research were targeted on basis of 
recommendations from the literature e.g. UK-muscle and MesoRX.com 
(Papangelis et al. 2016). A Google search was undertaken to seek out other pro-
muscle fora. One of the concerns about using fora is that there is potentially a 
negative attitude towards researchers, perceiving them as opportunistic 
outsiders, treating AAS-users in the same way as street drug users and invading 
their safe space (Papangelis et al. 2016). Therefore, seeking permission from 
moderators was important to help ensure that privacy was not invaded, and the 
post was framed as a request focussing on seeking opinions and getting the voice 
heard. Several FB groups relating to AAS use (found via a search of the term 
steroids within FB) were directly messaged. Two FB groups (Testosterone and 
Anabolic Steroid Harm Reduction) agreed to share the post within their closed 
group and allowed the researcher to join the groups.  
4.7 Design and development of interviews  
Interviewing is a useful method for gaining an understanding of an individual’s 
current or past experiences (Darlington and Scott 2002) and this was why the 
researcher chose to use follow-up interviews to collect qualitative data. This was 
backed up by advice from two different professionals: 1. an experienced NSP 
worker who shared that his service users liked to tell their stories; and 2. an 
academic who investigated Muscle Dysmorphia (MD) and had found this 
approach allowed people to open up more. A wide range of methods for 
undertaking the interview was offered to the participants. This included 
traditional methods as face-to-face and telephone interviews as in today’s digital 
age telephones should not be considered a lesser option to face to face interviews 
(Sturges and Hanrahan 2004, Holt 2010). As it is possible to be able to engage in 
real-time conversations via the internet (Rodham and Gavin 2006), mediums as 
Messenger, FB, Skype, and WhatsApp, which includes ‘live’ real-time typing, audio 
and video were also offered. Moreover, by offering a choice of method the 
researcher was hopeful that this would encourage people to participate as it 
allowed them control over the level of anonymity i.e. total anonymity by using 
tools such as a FB chat where they use a pseudonym and typed answers or a 
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phone call, which are more anonymous tools than video via Skype or face-to-face 
interviews as they cannot be seen.  
 Interview pilot 4.7.1
Prior to the first interview, a pilot interview was carried out with a current AAS-
user recruited through an academic contact. The pilot participant completed the 
questionnaire and gave feedback on the interview process. The interviewee was 
surprised that the researcher did not ask a question regarding the details of all the 
types and doses of the drugs taken. This was discussed and agreement was 
reached that although this is interesting, due to the research question and time 
limitations it was decided not to include these. The feedback from the interviewee 
was that the Skype format had worked and that the interview style was relaxed. 
No changes were made to the structure of the interview based on the pilot. 
Undertaking a pilot interview allowed the researcher to practice and hone thei r 
interviewing skills, and this was vital as interviewer skill may affect data accuracy 
when collecting self-report data (Del Boca and Noll 2000).  
 Interviews 4.7.2
The researcher contacted all those who agreed to be interviewed in the 
questionnaire, and those still willing to participate were emailed an invitation to 
take part (Appendix 14). The interviews all had a standard opening which could be 
adapted to meet the medium by which the interview was taking place. The 
interviews were semi-structured, asking specific questions about participant’s 
experiences of using AAS aligned to three areas drawn from the objectives (3.9) 
and consisted of nine main questions (Appendix 15) with follow-up questions 
based on the interviewees’ answers. The interview schedule included a specific 
question on why the participants decided to start using AAS was included as when 
considering why someone may wish to use AAS to achieve such goals as change 
appearance, become stronger or build confidence it is worth considering if there 
are underlying motivations for wanting these changes. All interviews were 
conducted by the current researcher and audio-recorded without interruption. 
Permission for recording was gained with participants providing consent either by 
signing in person, using an e-signature or confirming on tape at the start of the 
audio-recording. All data were obtained confidentially, interviewees were also 
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given the option to maintain a level of anonymity for interviews, and some 
participants chose to share their identity with the researcher e.g. personal email 
and ‘video’ chat or face to face interview, however some chose to retain a level of 
anonymity by using impersonal web-based email addresses, pseudonyms and live 
chat or purely audio conversations (Table 4-4). The interviews lasted between 45 
min and 1 hour 50 minutes.  
Table 4-4  Interview Summary 
Participant No *from 
Questionnaire 
Country  Method Chosen Transcript 
Actions**  
Supervisor 
check 
P1 UK Skype video call   A B (Y)  
1  UK In person A  ST 
3 UK Telephone A  EVT 
5 UK Telephone A B (Y) C   
31 UK Telephone A   
36 UK In person A  MiP 
45 UK Telephone A EvT 
75 UK Skype video call  A   
77 UK 
What’s App typed chat 
(Synchronous) 
A   
100 UK Google Hangouts call  A   
119 UK Skype video call  A  MIP 
129 UK In person A   
133 UK Skype call  A   
 Participant No Country Method Chosen Transcript 
Actions 
Supervisor 
check 
28 USA What’s App call  A  B (Y)  
32 USA Skype video call  A   
46 USA Skype video call  A B (Y) EvT 
49 Denmark FB Messenger call  A  B (Y) ST 
54 USA What’s App call  A   
88 USA Google Hangouts call   A B (Y)  
91 
Belgium  
FB Messenger typed 
chat (Synchronous) 
A B (Y)  
93 Canada  Skype call  A ST 
115 Hong 
Kong Skype video call  
A B (Y) C  
120 USA Skype call  A B (Y) C MiP 
* used to maintain confidentiality ** Transcript Actions: A: sent offer email to read B: 
received Y/N reply and sent if said yes to review, C: received comments 
 
The interviews were transcribed by the researcher as the process of transcribing 
can yield important insights (Lapadat and Lindsay 1999) (example transcript in 
Appendix 16). Two rounds of transcription were done, first the entire interview 
was transcribed, including all ums, repetitions and pauses, as what to include can 
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help to make sense or clarify the text (Oliver et al. 2005) and then re-listened to, 
to identify any mistakes, or to clarify, where possible, inaudible text.  As much as 
possible was transcribed, however different regional/international accents and 
interference in recordings meant that some parts of the audio were inaudible, 
signified by XX in transcript. Participants were offered the opportunity to review 
their transcripts and have a copy of their transcript if they desired. Nine of the 
participants asked to review the transcripts (Table 4-4), no revisions were 
requested and if they added information then these transcripts were the ones 
coded in the analysis phase. An example of how the progression from 
questionnaire to interview participant process is at Error! Reference source not 
ound. 
Table 4-5  Progression from questionnaire to interview participant (example) 
Example of progression from questionnaire to interview participant  
Don checked yes to being interviewed in response to the questionnaire. 
Consequently, I contacted Don and asked if he still wished to be interviewed and 
if so, which method would he prefer? When he agreed I sent the time and method 
for interview and a copy of the participant information and agreement forms 
(Appendix 14). I read his questionnaire, made a few notes in prep for interview. I 
then undertook a Skype interview, which including taking a few field notes.  
 
Post interview, I typed up the transcript and contacted Don to see if he wished to 
review the transcript (Appendix 19), and he chose not to. I then re-read the 
transcript, checked back against the questionnaire, and analysed the transcript for 
themes. Don’s transcript was also one which my supervisor coded separately to 
ensure quality.  
 
4.8 Method for data coding and analysis 
 Quantitative data 4.8.1
The quantitative data from the questionnaires was exported from the Bristol 
Online System (4.5.3) and imported into SPSS for analysis. SPSS allows for 
transparency in the analysis process whilst providing a clear audit trail. Data 
cleaning was used to edit the raw research data to identify and clear out any data 
points that could hamper the accuracy of the results (4.8.3). Descriptive analysis 
was undertaken to summarize the data and find patterns and inferential analysis 
to identify any potential multiple relationships between variables specifically 
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looking factors that might influence or indicate types of support desired. Tests to 
identify if the data is parametric or nonparametric were used to ascertain which 
tests need to be used for the inferential analysis. As it had been decided not to 
mandate any questions (4.5.2.3) it was assumed that some people may have 
chosen not to answer a number of questions, therefore the data analysis would 
not be a whole case analysis but the findings would be presented with the ‘n’ 
given when there was missing data.  
For clarity, percentages given in the text have been recorded to the nearest whole 
number. Due to the types of data collected, and the small sample size, in order to 
have confidence in the statistical findings the data will be reported against one of 
three criteria: 
 *** If Significance is <.001 
 ** If Significance is <.01 
 If Significance is >.05 
 Qualitative data 4.8.2
Thematic analysis was the chosen method to analyse and interpret the qualitative 
data. It is an iterative process that is “a method for systematically identifying, 
organising, and offering insight into patterns of meaning (themes) across a data 
set” (Braun and Clarke 2012, p.57). This type of analysis involves the coding of 
data to attach units of meaning to segments of text. It is useful as a tool as it is not 
welded to any particular epistemological position or theoretical framework (Braun 
and Clarke 2006) and can be used “across a wide range of epistemologies and 
research questions” (Nowell et al. 2017, p.2). Thematic analysis does not seek to 
look for unique items within individual data sets but to identify and make sense of 
collective experiences or meanings (Braun and Clarke 2012) relating to 
participants’ lived experiences (Clarke and Braun 2017). This lends itself to the 
specific research questions around both experiences of AAS use and ideas about 
the support wanted.  
As these were semi-structured interviews, coding was both deductive and 
inductive, as the participants’ often added information pertinent to other 
questions at different times and shared their own thoughts and ideas around AAS 
use in general. Therefore, the categories used for the questions: Reasons for 
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starting use, support and information accessed and wanted were used to code 
deductively, and other data was coded inductively.  
Braun and Clarke’s (2006) six steps to thematic analysis were followed. NVivo was 
chosen as the tool for managing the data as it allows for transparency in the 
coding process, allowing the researcher to manage the coding through its 
iterations with a clear audit trail and partially address researcher bias through 
rigour:  
 Initial coding: descriptive: participant-led which are captured as self-defined 
nodes.  
 Secondary coding: the researcher’s knowledge is bought to bare and includes 
the merging and renaming of codes to address the research questions and the 
identification of themes 
 Tertiary coding: includes further distilling of the data, interpretation of data, 
addition of theories from the literature and the conceptual mapping of 
categories 
Table 4-6 summarises the coding process. 
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Table 4-6 Thematic Analysis Coding Process 
 Six Steps  Adapted from Braun and Clarke (2006) Researcher actions 
Samples in Appendices 16,17 
1.  Familiarising 
yourself with 
your data 
Familiarisation with data. Researcher is 
fully immersed and actively engaged in 
data by first transcribing the interactions 
and then re-reading transcripts and/or 
l istening to recordings. Initial ideas  
noted down. This step provides the 
foundation for the subsequent analysis  
Transcribed 21 out of 23 interviews. 
two interviews were conducted via 
l ive chat (and therefore already 
typed). Once transcribed, re-read all  
transcripts in their entirety and initial 
notes written on transcripts  
2.  Generating 
initial codes 
Once familiar with the data, identify 
preliminary codes, which are the 
features of the data that appear 
interesting and meaningful. These codes 
are more numerous and specific than 
themes but provide an indication of the 
context of the conversation 
Each transcript was read and coded 
manually using coloured highlighters: 
initial groups were identified relating 
to questions. On further reading other 
grouping emerged such as othering, 
media perceptions. The groups 
formed an initial coding framework  
3.  Searching for 
themes 
The start of the interpretive analysis of 
the collated codes. Relevant data 
extracts are sorted (combined or split) 
according to overarching themes. The 
researcher’s thought process should 
allude to the relationship between 
codes, subthemes, and themes 
Initial coding framework was entered 
into NVivo software 
A secondary coding framework was 
developed, subdividing some of the 
groups that had been initially 
identified. Each transcript was 
recorded against this framework. This 
process ensured that the transcripts 
that had been coded first were given 
equal weighting and helped ensure 
data was not missed 
4.  Reviewing 
themes 
A deeper review of identified themes 
follows, questioning whether to 
combine, refine, separate, or discard 
initial themes. Data within themes 
should cohere together meaningfully, 
while there should be clear and 
identifiable distinctions between 
themes. Themes checked in relation to 
the coded extracts (phase 1), and then 
for overall  data set (phase 2) 
Qualitative data from the 
questionnaires was coded against the 
identified coding framework at this 
point.  
Stages three, four and five were 
iterative with constant rechecking 
against the original transcripts to 
ensure that meaning was not lost or 
distorted 
5.  Defining and 
naming 
themes 
‘Refining and defining’ themes and 
potential subthemes within data. The 
researcher needs to provide theme 
names and clear working definitions that 
capture the essence of each theme. At 
this point, a unified story of the data 
needs to emerge from the themes 
Further iterations of coding were 
undertaken to refine themes due to 
complexity and interconnectivity of 
data. Some themes were subsumed 
into others and some were discarded 
due to l imited supportive. Themes 
and sub-themes were names/labelled 
6.  Producing the 
report 
Transformation of analysis into an 
interpretable piece of writing by using 
extract examples that relate to themes, 
research questions and literature 
Six overarching themes were 
identified (Figure 5-1) 
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Themes can ”provide a framework for organising and reporting the researcher’s 
analytic observations”(Clarke and Braun 2017, p.297). The interview data was 
analysed in the first instance and a coding framework developed in line with the 
objectives of the study. Reliability in coding is critical when conducting analysis 
(De Wever et al. 2006). Three of the interviews were coded independently by one 
of the supervisory team. Another member of the supervisory team then used the 
secondary coding framework to code three different transcripts to quality assure 
the analysis as such independent coding and collaboration can help to maintain 
the quality and rigour of the analysis (Morrow 2005), no changes were made as a 
result of this. The qualitative data from the questionnaires was then incorporated 
into the data set (Figure 4-1) and was coded deductively using the coding 
framework developed at stage three (Table 4-6) and inductively if data was found 
that did not fit any already identified themes to create a fuller picture as thematic 
analysis allows for large amounts of data from multiple participants to be 
synthesized to create a meaning (Boyatzis 1998).  
 
Figure 4-1 Data capture and analysis process 
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 Data cleansing 4.8.3
In order to effectively carry out statistical analysis on the quantitative data from 
the questionnaires a small amount of data cleansing was required. The data set 
was cleansed, re-categorised and recoded e.g. redefining USA, US and America 
under one heading, amalgamating Europeans under one category and where 
necessary amending erroneous entries in some of the demographic data. The 
decision to re-categorise items such as ethnicity, sexual orientation, education 
and employment status was done in discussion with the supervisory team, as one 
way to show reliability is through being transparent about how data is 
summarised or re-categorised (Dey 1993). The process used is summarised in 
Appendix 18.  
 Participant IDs 4.8.3.1
To ensure the voice of the AAS-user is at the fore, verbatim quotations are used to 
illustrate participant views and ensure authenticity. Consequently, the grammar 
or spelling of the written qualitative data nor the colloquialisms or phraseology of 
the transcriptions has not been amended. Some participants have English as a 
second language so some quotations may be grammatically incorrect to native 
English speakers and due to the number of errors, these have also not been noted 
with [sic] (with the exception of the publications). In line with the researcher’s 
values, each participant was given a unique pseudonym. For clarity quotations will 
be identified as follows:  
 Quote from questionnaire: Questionnaire participant only 
(pseudonym/country of residence/age) for example: (Barak/Greece/44 [q]). 
 
 Quote from questionnaire: Questionnaire and Interview participant 
(pseudonym/country of residence/age [Q]) 
 
 Quote from ‘typed chat’ interview: Questionnaire and Interview 
participant (pseudonym/country of residence/age [TI]) 
 
 Quote from ‘transcribed’ interview: Questionnaire and Interview 
participant (pseudonym/country of residence/age [CI]) 
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 Quality in mixed-methods research 4.8.4
In mixed-methods research, sequential designs can aid in maintaining the integrity 
of the separate methods and help to ensure quality as method specific criteria can 
be used (Bishop 2015) and the rules for controlling validity should be followed 
(Steven 2012). Validity and reliability are central to the quality of both 
quantitative and qualitative research (Golfasni 2003), but qualitative research may 
not use these particular themes. A number of measures have been taken in this 
study to try to ensure the academic rigour and to address the issues of reliability 
and validity throughout the data collection and reporting process.  
 Quality in the quantitative elements of the study 4.8.4.1
For the quantitative analysis a measure of reliability was through the transparent 
redefining of the categories (Appendix 17). Internet questionnaires provide a 
validated method for collecting self-reported data on drug use (Pealer and Weiler 
2003, McCabe 2004) and are consistent with other data collection methods 
(Crawford et al. 2005). Face validity considers how sensible the questionnaire 
appears to be and is also an important measure (Bruce et al. 2018). Therefore, to 
address this, a range of professionals from different specialisms reviewed the 
questionnaire (4.5) with a view to pointing out any errors or anomalies. Content 
validity, how the questions are representative of the construct being measured 
(Ryan et al. 2001) is important in the construction of questionnaires. In this study, 
the questionnaire was reviewed by a professional in the field with knowledge of 
the participant group and piloted with AAS-users (4.5.3) to help ensure the 
content was relevant. Moreover, pilot participants were asked to explicitly 
comment on the questionnaire design. Some questions were taken from other 
questionnaires (Appendix 11), and data used for selected questions was taken 
from papers included in the literature review (Harvey et al. 2019) (3.6) in an 
attempt to address the issue of criterion and construct validity, that is whether 
the questions used actually measure what is sought to be measured and the 
extent to which measure relate outcomes (Ryan et al. 2001). This was further 
addressed through the piloting of the data (4.3.1.2).  
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 Quality in the qualitative elements of the study 4.8.4.2
When it comes to quality assessment of qualitative research, there is a view that 
the role of the researcher and how the data is gathered is vital and that quality 
criteria such as validity and reliability originating from quantitative research need 
not be established (Pope and Mays 2006). However, there are specific criteria that 
can be applied to qualitative research: credibility, transferability, consistency and 
confirmability (Lincoln and Guba 1985). Consistency requires that there is a clear 
pathway between findings and the source and confirmability that there is a clear 
audit trail for this (Ryan et al. 2001). This transparency of coding is maintained 
through use of NVivo (4.8), as demonstrated through Appendices 16 and 17, and 
the findings make use of quotations to illustrate the themes identified. For the 
qualitative data, a way of helping to ensure reliability is to attempt to correct for 
mistakes in categorisation such as overlooking or mis-assigning codes (Dey 1993) 
and therefore the number of transcripts were reviewed by supervision and using 
NVivo to search key words and phrases in the texts. 
Triangulation is a way of helping to add validity and credibility to qualitative 
research data (Pope and Mays 2006), and mixed-methods should increase validity 
of findings (Mckim 2017). Consequently, the use of both questionnaires, with 
free-text answers and semi-structured interviews, a form of sequential 
triangulation, should help to ensure a level of validity. NVivo has helped to ensure 
that the data was analysed in a systematic and rigorous way (4.8) which is crucial 
to avoid flawed research (Ryan et al. 2001). Another way to help ensure quality 
within qualitative research is for their researcher to actively reflect on the 
methodology and their inherent influences (Mason 2002), as it is impossible (if 
not undesirable) for a researcher to remain truly objective (Ryan et al. 2001). This 
researcher has therefore undertaken reflective practice in two ways, first through 
active discussions within supervision, and secondly as part of the thesis narrative 
(9.13). In addition, having more than one researcher analysing the data set can 
also reduce subjectivity (Ryan et al. 2001), due to resource limitations it was not 
possible for the supervisory team to take on the task of coding the whole data set 
but a proportion was also coded by others (detailed in methods in Chapter 6) in 
order to ensure a level of quality.  
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4.9  Summary 
A mixed-methods approach was used in this study. Ethical approval was sought 
and permission granted. Questionnaire and interview questions were developed 
and piloted and consideration was given to key ethical issues, and emphasis put 
on maintaining the confidentially and anonymity of participants. A communication 
strategy was developed for the dissemination of the questionnaire and data from 
these informed the interviews. Thematic analysis was the chosen method for 
analysis of the qualitative data. The findings will be presented in the next chapter.  
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 Findings Chapter 5
5.1 Overview 
This chapter reports the key quantitative and qualitative findings from the 
questionnaires and interviews that contributed to the six themes. The qualitative 
data builds on and illuminates the quantitative information gathered in the 
questionnaires, as quantitative and qualitative data should be integrated for 
mixed-methods findings (Bryman et al. 2008). The findings have been synthesised 
into six themes with associated sub-themes. This chapter set out the demographic 
data and the findings from five of the six themes. Chapter 6 is in the form of a 
published paper (Harvey et al. 2020) and covers the sixth theme. Chapter 7 is a 
submitted paper that explores one of the sub-themes in detail. The findings have 
been laid out in this way as one aim of the study was to bring the voice of the 
AAS-user to the fore and ensure that their experiences were captured and 
reported in the literature. 
5.2 Introduction 
The first section of findings outlines the study population and a description of AAS 
use patterns. The second section then details the findings aligned to the five 
emergent themes.  
 Participants 5.2.1
The questionnaire was accessed by 133 people (summary table of demographics 
in Appendix 19). As the piloting of the paper-based questionnaire led to no 
changes to the online questionnaire, three of the four participants ’ data was 
added to the data set = 136 participants. The fourth pilot participant was excluded 
as he had not been using AAS within the six-month period prior to completing the 
questionnaire. One person was excluded from the data set as they had not 
answered any questions. Two further participants were excluded as they were 
both female, and although they had been eligible to take part in the study it was 
decided that due to the low number of female respondents and the fact that 
neither volunteered to be interviewed to exclude them. Knowledge of female AAS 
use is limited within the literature, and although it would not be viable to include 
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the data from the two women who completed the questionnaire within the 
analysis of the wider data set to ensure that the voices of these female 
participants are not lost, as short summary is provided at the end of the 
discussion (8.8) as it is important to recognise the power of the researcher in the 
research and to ensure that potentially marginalised groups are not 
disempowered e.g. made invisible by excluding data as we have a duty of care to 
those who participate in research (Edwards and Brannelly 2017). 
Three participants self-described their sexual orientation as bi-curious, demi-
sexual and pansexual, two of whom also cited their gender as male and so were 
incorporated into the data set. One, defined their gender as gender-fluid, not 
male, however he was also included in the data set as it was clear from his 
qualitative answers that he was biologically male, and this was confirmed in the 
Skype video interview (Appendix 25 Sketches to illuminate the differing AAS 
use pathway). 
Of those who were contacted to be interviewed, twenty-two people responded in 
the affirmative. Interviews were undertaken, either in person, via Skype or online 
synchronous chat (Table 4-4). All 70 participants checked Yes, to the being happy 
to undertake an interview and 0f these the 68 who gave contact details were 
emailed, 23 replied. As no changes were made to interview questions as a result 
of the pilot, the pilot interview data was incorporated into final analysis. In total 
133 participants (23 interviewed) were included in the data analysis from the 
questionnaires and interviews. 
Whole case analysis could not be completed on the data as there were a few 
questions across the data set that had missing data, but no systematic missing of 
questions. This resulted from having only a limited number of mandated 
questions in the questionnaire (4.5.2.3). The sample was not so large that the 
number of people who did not answer a specific question reduced the power of 
the statistics.  When visualising the data (using histograms and boxplots) it failed 
to meet the assumption of normality which was confirmed by a Shapiro-Wilk test 
(p<.05). As the data was skewed non-parametric tests were used (Smalheiser 
2017).  
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 Participant demographics  5.2.1.1
A summary of participant demographics is in Table 5-1.  
Table 5-1  Summary of Participant demographics 
Demographics Percentage n=*  Participant 
information: AAS use 
Percentage n=* 
Age  Mean: 35.7 
Median: 34  
Range: 18-
65  
SD: 10.9 
130  Age started using AAS Mean: 27.3 
Median: 25 
Range: 14-57 
SD: 9.1 
130 
Employment status  129  Inject AAS  131 
Employed 85.2 110  Yes 97.7 128 
Unemployed, student, 
retired, Other 
14.7 19  No 2.2 3 
Gender  130  AAS use pattern  133 
Male 99.2 129  Cycling 39.8 53 
Other (Gender-fluid) 0.77 1  Continuous 57.8 77 
Ethnicity  133  Other 2.2 3 
White 78.9 105  Number of years using 
AAS 
Mean 7.2 
Range: <1-30  
132 
Other 21.1 28  Has your quality of life 
improved since using 
AAS? 
 128 
Level of education  132  Yes – improved 74.2 95 
Primary or secondary 20.4 27  No – stayed the same 20.31 26 
College or university 79.5 105  No – got worse 5.4 7 
Sexual orientation  133  Take part in 
competitive sports 
 132 
Heterosexual 90.9 121  Yes 21.9 29 
Other 9 12  No 78 103 
Country of residence  133  Use of HGH  133 
UK 43.6 58  Yes 21.8 29 
USA/Canada 25.5 34  No 36.8 49 
Europe 25.5 34  Considering 41.3 55 
Other 5.2 7     
* The only mandated question was ‘are you 18 years or over’, therefore n i s given for each s tatistic 
as  some people chose not to answer every question.   
 
The mean age was 36 years. All 133 participants included were male, 121 selected 
heterosexual, eight gay and four ‘other’. When asked to self-describe their 
gender, 129 used the word male or associated synonyms, and one described 
themselves as gender-fluid. The majority (44% N=58) lived in the UK, 26% (N= 34) 
from USA and Canada, 26% (N=34) from Europe (including one British person who 
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resided in Spain), five from Australia, one from the Philippines and one from Hong 
Kong (a French national). A more detailed summary of the demographics of 
interviewees is provided in Appendix 19 as it is their perspective that forms the 
basis of insights into experiences of use. 
 AAS Use 5.2.1.2
The median average age for starting AAS use reported was 25 (mean 27) . The data 
set contained two modes (ages 21 and 23, each with 10 people starting use) with 
one person reported as starting at 14 years of age and one person at 57 years of 
age. Years using ranged from 0-30, with a mean range of 7, (median 4, mode 1). 
The majority of participants (98%; n=128) injected AAS. Forty percent followed an 
AAS cycling pattern of use, while 58% of participants favoured a continuous use 
pattern, a number of those who used continually describing a ‘blast-and-cruise’ 
pattern in which use is continuous but with changes between high and low doses 
(Sagoe et al. 2015).  
5.3 The six themes 
From the analysis of the data the researcher identified six overarching themes and 
associated sub-themes related to Management of Use and Identity that covered a 
range of aspects of users’ experiences (Figure 5-1).  A key for the qualitative data 
source of the quotations is at 4.8.3.1.
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Figure 5-1 Six themes and associated sub-themes 
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 Theme one: Reasons to use AAS 5.3.1
‘that bigger, faster, stronger mentality’ (Lee/USA/43 [TI]) 
The first theme that emerged from the data was ‘reasons to use AAS’ with  two 
sub-themes: 
I. Reasons for starting use 
II. Reasons for continuing or re-starting use 
 
Participants were asked to select all their reasons for using AAS, a summary of 
motivations is provided in Table 5-2. Notably, the third most selected was the 
‘positive results I have achieved from using AAS’ which aligns to reasons for 
continuing use. The fourth most selected was not a physical, concrete reason but 
an emotional reason: ‘become happier’. It is also worthy of note that family 
influences, coach recommendations and increased aggression were selected by 
less than 1% of cases. Just under one third of participants, gave overcoming 
depression as a reason and interestingly, over one third selected options on 
increased sex drive and/or sexual attractiveness.  
The data do not indicate which of the reasons (Table 5-2) were for starting use 
and which explained continued use, but the number of cases suggests the 
complexity of motivations for using AAS.   
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Table 5-2 Reasons for use 
Top reasons for using AAS N 
Percent of 
cases 
Percent  
Enhance my muscles or strength 116 12.1 87.9 
Improve my appearance 98 10.2 74.2 
Positive results I achieved from using AAS 76 7.9 57.6 
Become happier 70 7.3 53 
Improve fitness 66 6.9 50 
Increase my confidence 60 6.2 45.5 
Increase my sex drive 51 5.3 38.6 
Improve endurance or stamina 49 5.1 37.1 
Additional reasons for using AAS N Percent of cases 
Increase my sexual attractiveness  45 
4-5 
Lose weight 44 
Prevent injury 40 
Positive results that others achieved who used AAS 39 
Overcome depression 28 
2-3 
Curiosity 25 
For competition 22 
Frustration: I've not achieved the desired results from exercise 21 
Other 21 
For personal security 16 
1-2 
Impress my friends 13 
My friends use AAS 12 
Become brave 10 
Increase my aggression 9 
Less than 1 
For my Job 8 
Recommended by my coach/trainer 5 
An elite sportsperson, I respect uses AAS 5 
Help me stop being bullied 4 
A celebrity, I respect uses AAS 4 
A family member uses AAS 4 
My partner uses AAS 1 
 
There were some exceptions as in the qualifying data collected ‘under other 
reasons’; participants self-reported other reasons for starting non-prescribed AAS 
use linked to a number of health-related conditions including: preventing HIV 
wasting, recovery from a car accident, auto immune disease, chronic illness and 
unusually one participant reported managing mental health conditions: 
‘Using 150+ mg test EW helps me to better keep my Asperger and ADHD in 
check’ (Ansgar/Denmark/33 [q]) 
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Another unique motivation involved one participant who had only sought out 
non-prescribed AAS on one occasion and did not have any motivations related to 
building muscle but was self-medicating for the symptoms of low testosterone. He 
turned to accessing AAS illegally when he ran out of his prescription testosterone 
replacement therapy (TRT) medication. This was a one-off, and it was unclear if he 
would return to this as an option if future prescriptions changed:  
‘…because they was giving me a prescription of so many vials, I think like it 
was 10 vials, and that was supposed to last me 14 days, every 2 weeks, 
you take a vial a week, well I was cutting it down to every 10 days... when 
I went to get the prescription… they said no it is not due yet, but I was out 
of vials …that was when I went to black market and picked it up because I 
couldn’t get any more on prescription.’ (Han/UK/42 [TI]) 
 Reflections on starting use 5.3.1.1
The interviews allowed participants to consider the impact that starting use had 
on them. Several participants shared regrets related to starting use, of which four 
types were identified, illustrated in Table 5-3. 
Table 5-3 Reflections on starting use 
Type of regret Reflections on starting use 
Lack of knowledge 
on initiation of use 
‘It's actually quite remarkable how ignorant people are comes to 
doing things like this to your body a bit like i was when i when i first 
started.’ (Peter/UK/24 [TI]) 
Regret starting use 
early, but no 
regrets about 
using AAS per se 
 ‘I started taking too early… If I know if I know what, if I had started 
with my knowledge which I have now then I would wait. I would wait 
probably until 21.’ (Lev/Canada/32  [TI]) 
‘I was a kid so, …in retrospect, dumping that kind of hormone into an 
already hormonal body. It kind of messed up my, my mental state 
…it kind of exacerbated all your natural teenage angst and issues at 
the time... I knew the, the changes in me weren't just all me, they 
couldn’t have been because I was taking out quite quite large doses 
at that time.’ (Lewis/USA/37 [TI]) 
Detrimental 
effects on 
psychological 
development 
‘I do regret sometimes starting using it cause I know it's, some of my 
behaviour completely changed for permanence’ (Lawrie/UK/27  [TI])  
Regret about 
starting to use 
‘If I could go back in time, I wouldn't have started that young. I can 
even say i maybe wouldn't do it at all.’ (Tomaz/Belgium/40  [CI]) 
‘I have regreted the use of AAS/PEDs, for two reasons: The health 
issues and the impact on my social relationships (family, marriage, 
friends, work)’ (Barak/Greece/44 [q]) 
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 Reasons to continue or re-start use 5.3.1.2
From these findings, reasons for use were complex, with people selecting multiple 
options, and further information from the interviews showed that participants 
would give initial reasons for starting use and then unintended/unknown 
consequences of use also then became seen as desirable and added to or 
superseded initial motivations. One participant describes how he felt, and how he 
then became “addicted” as a result: 
‘An injury led me to more seriously get involved, serious motor vehicle 
accident, no lost limbs just large lacerations and abrasions everywhere. 
Started to help heal better and faster. Decided to continue use after 
initially planned 8-12wk cycle due to effect and/or psychological addiction’ 
(Niall/Canada/25 [q]) 
This study set out to only recruit those people who used AAS recreationally; 
however, it became clear that competitive use and recreational use were often 
intertwined. Some participants motivations for use started out as competitive i.e. 
to help them succeed in a specific sport (i.e. to build muscle and strength); others 
started out to enhance their image and then became involved in the bodybuilding 
culture while, others who had started for competitive reasons, continued use 
even after stopping competing for aesthetic or health reasons: 
‘After 42 years became impossible train hard, stay lean and have a decent 
libido -)’ (Matteo/Italy/47 [q]) 
The positive experiences of using AAS, led them either to continue their use, or 
even re-start their use, often in a more measured way, with motivations being less 
about gaining muscle and more to combat the effects of ageing and maintaining 
their wellbeing, although some still did cycle. The anti-ageing element was often 
seen as a way to combat falling testosterone levels and referred to as a form of 
TRT. The concept of self-medication with AAS as a form of TRT is developed 
further in Chapter 7. Anti-ageing was one of several motivations that were more 
explicitly referenced in the interviews, the others being: self-medication (TRT) to 
overcome genetics and self-medication for other medical conditions.  
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Yet, for one participant, continued use was more than self-medication; it was part 
of a healthy lifestyle: 
‘I decided to stay on test year round and introduce other compounds 
periodically, the ‘cruise/blast’ because I used to party a lot and do party 
drugs and was a daily drinker, being on gear motivates me for a more 
healthy lifestyle, I have been clean off of all ‘drugs’ for a year now and I 
love my life’ (Fred/USA/26 [q]) 
Fred is using AAS but does not see his use as ‘drug use’, as he might other 
recreational or ‘party’ drugs. Others also talked about their use in this way:  
‘I wouldn’t classify myself …as a steroid user really, I wouldn’t anymore, 
because I now see it more as like a health aspect, self-medication and 
health, that’s it really’ (Robert/Spain/34) 
Moreover, qualitative answers to the question: Why couldn't you stop using?" 
provide reasons for continuing use as illustrated by the following [TI]g: 
 ‘I will get depressed again, i've tried once before’ (Erik/Sweden/35 [q]) 
 ‘It has a strong effect on my confidence and well being’ (Jerrik/Denmark/35 
[q]) 
 ‘Since the age of 37, I have used continuously as a method of avoiding 
withdrawal/post use experience’ (Isaac/UK/42 [TI])  
 
This is a recognition or acknowledgement that they would find it hard to stop 
using AAS, and it could be argued that this is the language of dependency. 
Figure 5-2 Could you stop using AAS? 
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In the questionnaire 70% of participants felt that it was possible to become 
addicted to AAS use (Figure 5-3) and 27% of participants thought that they could 
not stop using AAS (Figure 5-2). More than two-thirds of the younger participants 
felt it was possible to stop using compared to users over the age of 40 (Just over 
½) and a Chi Square test of independence was conducted between ‘Age (over or 
under 40 years old)’ and ‘belief it is possible to become addicted’. All expected cell 
frequencies were greater than 5. There was a statistically significant association 
between Age (over or under 40 years old) and ‘belief it is possible to become 
addicted’, X2 (1) = Pearson Chi Square 6.072, p = 0.014. The association was 
small/medium (Cohen 1988), Cramers V = .217 (small/medium). Moreover, a 
Mann-Whitney U test was run to determine if there were differences in ’the 
number of years using AAS’ between ‘could you stop using AAS’ (yes [n=96], no 
[n=36]. Distributions of the number of years using for ‘could you stop using AAS’ 
were not similar, as assessed by visual inspection. The number of years using AAS 
was statistically different between Yes (mean rank = 59.43) (median = 3) and No 
(mean rank= 85.35) (median = 76), U = 1049.5, z= -3.491, p = 0.000 (***), using an 
exact sampling distribution for U (Dinneen and Blakesley 1973). This evidences 
that the longer AAS use continues, the less likely the user is to consider stopping 
possible.  
In the interviews, continued use was rarely articulated in terms of dependence or 
addiction but more often as self-medication.  
Figure 5-3 Is it possible to become addicted to AAS? 
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However, some participants did talk about the addictive nature of the positive 
effects of use and wanting to avoid the terrible feelings experienced when they 
stop using: 
‘To go back to the topic of addiction when you try to get clean because 
you are getting to the point to get clean can you start feeling like shit you 
realise actually that, then life is not as beautiful as you think can you again 
need to feel like a normal human and stuff like that, that's the biggest, I 
think addictive point, do you go back to you and to get the feeling again 
and stuff like that.’ (Lawrie/UK/27 [TI]) 
One participant drew a connection between how he felt after an AAS injection 
and how this meant he was most likely dependent on AAS:  
‘The reason why I would categorise this as dependency is within half an 
hour of taking that injection, I immediately feel better. Now the shortest 
acting ester and the blend I am currently using takes around 18 hours to 
get into your system before it clears your body completely of the ester so 
there is no way it is having an effect on me within half an hour but I do 
start to feel better half an hour after taking that… It’s like a functional 
addict who takes the of whiskey in the morning before going to work 
because he can then think straight, and it gets him back to normal. That’s 
…what it feels like to me, I don’t see it as being a particular problem’  
(Isaac/UK/42 [TI]) 
The point Isaac raised about dependency on AAS as an adaptive coping strategy 
was also referenced by another participant: 
‘…it's a little bit of an adaptive coping with the idea of the loss of status 
and the invisibility that comes with ageing as a gay man’. (Hugo/USA/53 
[TI]) 
Further examples of views on “addiction” are included in Appendix 20 as it could 
be important for professionals to understand how users explain the psychological 
drivers to continue to use AAS.  
 Theme two: Effects of AAS use  5.3.2
“…you feel pretty much like a superhero, if you know what you are doing 
a course. It is definitely addicted on that stage” (Lawrie/UK/27 [TI]) 
The second theme to emerge was ‘effects of AAS use’. This consisted of five sub-
themes of which the first three align to personal impact, the fourth to wider social 
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Figure 5-4 Impact on quality of life 
95; 74% 
26; 20% 
7; 6% 
Participants (n:%) 
My quality of life has improved since using AAS
My quality of life has  stayed the same since using AAS
My quality of life has got worse since using AAS
impacts of use and the fifth considers risks to someone else from someone using 
AAS: 
I. Positive effects of using AAS 
a. Physical 
b. Psychological 
II. Side-effects of using AAS 
a. Physical 
b. Psychological 
III. Low testosterone, TRT experiences and views 
IV. Personal, societal and ethical issues 
V. Risks to others  
 
Participants were asked to self-describe the benefits of AAS use and the positive 
and unwanted effects, as well as to select from lists relating to the types of 
positive and psychological or behavioural effects which were drawn from the 
current AAS literature. All effects were chosen by at least one participant. There 
was, however, a marked difference in the total number of responses given 
between the positive and negative ones, with 768 responses for the positive 
effects and 143 for the side-effects. It should be noted that this is self-report data 
and the power of suggestion may have impacted on the responses. Moreover, 
although participants may have felt these effects, they may not have resulted 
from AAS use.  
One key finding from this study was that the overwhelming majority of 
participants (74%) stated that their quality of life had improved since using AAS 
(Figure 5-4), which comes from a combination of positive physical and emotional 
effects of using AAS.  
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The positive effects are reported in two sections: physical and psychological.  
 The positive effects of using AAS: Physical  5.3.2.1
The most referenced physical benefit was strength and power (n =44), followed by 
muscle building (n=42), which aligned to the main motivations for use. A summary 
of benefits is listed in a tally in Figure 5-5 which is a way of quantifying qualitative 
data (Krippendorff 1980) aligned to symptoms experienced. In order to ensure the 
experiences of the AAS-user are not overshadowed, and to highlight the range 
and complexity of the benefits of use a more detailed summary is in Appendix 21.  
Over and above the body transformation, specific perceived health benefits were 
identified, such as faster injury recovery, stabilising wasting syndrome and 
boosting the immune system.  
Moreover, the interviewees also illuminated the complexity and interconnectivity 
of a range of motivations e.g.  
‘I think it stabilised the wasting syndrome. It gave me some energy, it 
made me look more muscular with the workouts. And so, there was a 
medical benefit and there was a cosmetic benefit and what's not to like.’ 
(Hugo/USA/53 [TI])  
 
Figure 5-5 Benefits of use 
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The 'bigger, faster, stronger' concept (5.3.1) was referred to by more than one 
participant, comes from the title of a well-known documentary film (Bigger Faster 
Stronger 2008) about AAS use and was referenced several times to explain the 
benefits that AAS gave people particularly in relation to training in the gym.  
Moreover, these effects often served as a positive reinforcement for use: 
‘I was really happy with the effect, with …how you feel, how your body 
reacts, how your body changes so quickly ...what I was addicted to most, 
as I said the feeling of training…how are you pumped up I look nice, you're 
stronger...Feel better, look better, getting stronger, more focused‘. 
(Lawrie/UK/27 [TI]) 
 Positive effects of using AAS: Psychological 5.3.2.2
Equal to the increase in strength and power, were the positive impacts on mood 
and increase in confidence (n=44) (Figure 5-5). Participants were also asked to 
select which positive emotions they had as a result of using AAS. Interestingly, 
although only 27 people noted it as an unintended side-effect, the greatest 
number of cases 90% (n=118) selected ‘increase in my libido’ for positive 
emotions experienced, with 83% for feeling strong. A large number of participants 
selected increased confidence (n =103, 78% of cases) and feeling happier (n = 101, 
76% of cases), this matches the selected motivations to use AAS and suggests that 
for many the desire of obtaining of a more muscular physique was not just 
physical but also psychological.  
Figure 5-6: Metaphors 
for how it feels to use 
AAS 
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Figure 5-7 Positive feelings from using AAS 
Benefits were often aligned to the motivations for use, but when asked directly 
about the positives aspects of using AAS, participants mentioned the combination 
of effects, feelings of wellness, spoke in hyperbole (Figure 5-6), and described it as 
rejuvenating e.g. 
‘…like a rejuvenating fountain of youth type thing’ (Lewis/USA/37 [TI]) 
There was a clear narrative aligned to the positive psychological impact of using 
AAS. The range of positive emotions noted included feeling younger, increased 
confidence, self-esteem, increased happiness, better moods, increased 
assertiveness, feeling more grounded, more mentally stable, more optimistic, 
calmer, more gregarious, better able to cope with stress and an increased overall 
sense of wellbeing. Several participants noted not just improved mood, but also 
the alleviation of depression and one went as far as to describe it as helping him 
regain his own personality; Del explains that it impacted his whole life:  
 ‘It’s given me a lot more confidence in talking to people. In the past, I was 
kind of always covering myself up not really wanting to talk to anyone, but 
it has kind of opened me up a bit and, I feel a lot more outgoing. …I 
haven’t had a personality transplant I am still the same person but it’s like 
I am slowly changing and becoming more like the person I want to be...It 
means I don’t have to worry about taking my shirt off at the beach, that 
was a big problem for me. I can have photos taken of me at any time, in 
the past I used to delete all the photos of myself, erm, I don’t feel 
embarrassed when I am eating food, because when you are a fat person 
eating food, people think ah you shouldn’t be eating that, you’re fat. ’ 
(Del/UK/35 [TI]) 
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However, not everyone felt the same: 
‘The psychological mumbo jumbo is a big load of bullshit. I don't feel any 
different at all when on steroids or off. Sometime of just go off the steroids 
cold turkey when I feel that I don't have time to put in the hours in the 
gym and I still don't feel any different - sure I loose some musclemass but 
that's it. My mind couldn't care less.’ (Rasmus/Sweden/35 [q]) 
 Side-effects of using AAS: Physical 5.3.2.3
Among participants 84% (n=112) listed one or more physical or psychological side-
effects that they had experienced and only 12 said they had not received any. As 
the side-effects question was free-text, and some people listed one side-effect 
whereas others several the results have been summarised in frequency table 
(Table 5-4). It is noteworthy that the side-effects predominantly focussed on 
physical health issues.  
Table 5-4 Tally of side-effects listed by participants 
Issue N* Issue N 
Skin problems e.g. acne 47 Problems with l iver 5 
Increased blood pressure 24 Cholesterol problems 4 
Mood changes 24 Erectile problems 4 
Gynecomastia 20 Effected appetite 4 
Sweating 15 Hormonal imbalance 3 
Problems with sleep 14 Problems with kidneys 3 
Hair loss 10 Increased libido 3 
Water retention 10 Muscle and joint pain 3 
Reduced libido 9 Injection-related pain / injuries  3 
Testicular problems 8 Digestive issues 2 
Increased red blood cell  count 7 Dyslipidaemia 2 
Cardiac problems 7 Injuries 2 
Body hair 6 Body odour 2 
*Number of participants who wrote this side-effect in the questionnaire 
 
Some participants reported that they experienced few side-effects or saw them as 
little more than an inconvenience e.g. sweating more, whilst others downplayed 
the severity: 
‘The blood pressure and your balls shrink a little bit, so does not really 
matter.’ (Andrew/UK/25 [TI]) 
  
 
 
107 
 
And often the focus was not on the side-effects but on how to manage them: 
‘Whilst on my cruise dose nothing, no side-effects, the only inconvenience 
is the jab itself. When I blast it can be …all sorts really, but I have sort of 
found what works for me, and generally the only side-effects that now are 
not very controllable are the spots...Most things you can dial out with 
other drugs or dosages’ (Robert/Spain/34) 
 
 Side-effects of using AAS: Psychological 5.3.2.4
A variety of emotional side-effects were noted (appendices 22, 23, Figure 5-8, 
Table 5-6). Among participants 45% reported experiencing mood swings as a 
result of using AAS and 55% said that they had experienced behavioural changes 
directly linked to their AAS use. Figure 5-8 details the quantitative responses of 
participants to a list of side-effects (drawn from the literature).  
AAS-related feelings of aggression (noted in 2.2), remain a contested concept in 
the literature. Among participants 49% (n=65) acknowledged having experienced 
negative emotions aligned to becoming more irritated, aggressive, angry, or 
violent, although 83% of participants stated that they had not acted on any 
feelings of aggression from using AAS. Of the 17% who reported having had 
aggressive side-effects, examples included: getting into more fights, using it in 
sports or at the gym, snapping or shouting at someone, getting into an argument, 
FB hacking, road rage. A full list of quotations on the effects relating to AAS use 
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Figure 5-8 Emotional side-effects of using AAS 
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that referred to some type of irritable of aggressive behaviour and management 
are detailed in Appendix 22. One specific brand (Trenbolone) was noted for 
unwanted side-effects, particularly related to aggression, and due to the impact of 
the side-effects of this specific compound, these have been recorded in Appendix 
23.  
 Self- Management of emotional side-effects 5.3.2.4.1
A key finding from this study was the focus on self-management of emotional 
side-effects. Several of the participants, who talked about increased irritability as 
a side-effect, were clear that this was something that could be managed by using 
techniques. The categorization of data can “contribute to identifying-meaning-in-
context” (Dey 1993, p.266), consequently the strategies used to manage 
emotional side-effects have been categorised by technique (Table 5-5).  
However, this ability to self-manage mood changes was not so easy for everyone:  
‘…more tendency to get angry for stupid reasons,...mentally, i say to 
myself that it is due to the use that i feel irritated or less patient but 
sometimes it is not easy to put that feeling beside you’  
(Tomaz/Belgium/40 [CI]) 
And, not everyone felt that AAS caused aggression and one participant, Rasmus, 
who did not believe in psychological effects of AAS use, was adamant that ‘roid 
rage’ was a myth: 
‘This is bullshit, pure and simple. But always since a was a little kid 6 years 
old or so I got cranky if I'm hungry - yeah I'm still human. Mood swings are 
propaganda that's never been proven and I've been around this shit for 
years and I have never seen mod swings aka ‘roid rage’, that's just the bad 
publicity that the newspapers / media keeps feeding us.’ 
(Rasmus/35/Sweden [q]) 
Aggressiveness was not the only psychological side-effect and one participant 
talked about how particular compounds exacerbated existing mental health issues 
and that they could not be avoided:  
‘If I feel sweaty that night, I throw on an extra fan, the nightmares, there 
is nothing I can do about the nightmares …those just suck…I …already 
have some mental health issues, …and I already suffer from night terrors. 
Um. So that that exacerbates like, night terrors. …some of the nightmares 
from Tren are just, they're very lucid.’ (Lewis/USA/37 [TI])  
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Table 5-5 Managing unwanted emotional side-effects of AAS use 
Management 
technique 
Anger and other emotional side-effects 
Self-awareness: 
Avoidance of 
certain 
substances 
‘some of the steroids I tried earlier on did affect my patience and things 
that normally I could have just gone with, you know, it would have kept 
me up all night seething about it and turned into an argument when I 
saw them next, so I stay away well from those ones.’ (Milton/UK/40 [Q]) 
Self-awareness 
– manage 
feelings 
‘I get irritated alot easyer but it's not a problem. I just think about why 
do i get these feelings and how can i avoid Them’ (Aron/Sweden/27  [q]) 
‘I am quite self-aware you see I meditate every day. So I notice things 
about myself very, very easily. So, I'll notice that my patience is a little 
bit more thin.’ (Peter/UK/24 [TI]) 
‘Being mindful of temper helps control it’ (Todd/Australia/34 [q]) 
‘I understand completely that the anger i can feel doesn't focus on 
something that happened... meaning, it's not that SOMETHING 
happened and made me angry, i can get angry while looking on a movie, 
so when this does happen i just remain cool until it goes away. If that 
happens while i am on a conversation i just ask them for a minute to 
calm down and get back to the conversation when that feeling goes 
away.’ (Costa/Greece/32 [q]) 
‘Had a fight with my girlfriend. I was about to slap her when i 
understood what i was about to do and said to myself ‘immediately 
calm the fuck down. you are not THAT type of a faggot person. 
Apologized and asked her a minute to calm down myself before we 
continue the argument.’ (Costa/Greece/32 [q]) 
Support from 
others 
‘With difficulty, sharing with my partner who made me aware of how i 
was being’ (Iain/UK/31 [q]) 
‘I've always told my partner if you ever feel it's affecting my mood or 
aggression, or if I'm treating you any different, just let me know, and I'll 
stop’ (Paul/USA/29 TI]) 
Used other 
substances 
‘get in to argument with my partner over stupid little things with time 
and yeras this become easily contoble drinking lots of melisa and other 
herbal tea to help with my mood swings.’ (Zack/Canada/ UK/32 [q]) 
Meditation  ‘Meditation. Learning to not speak, situations can’t escalate if you don’t 
allow yourself to open your mouth.’ (Niall/Canada/25 [q]) 
‘I meditate and reflect on my frustration.’ (Will/USA/50 [q]) 
‘am quite self-aware you see I meditate every day. So I notice things 
about myself very, very easily. So I'll notice that my patience is a little bit 
more thin. I’ll I notice that I'm more decisive’ (Peter/UK/24  [TI]) 
 
Participants reported a range of effects when stopping AAS use or changing to a 
low dose including losing muscle gain, feeling lethargic, lacking energy, sexual 
dysfunction (physical and psychological), loss of libido and anxiety.  
Participants selected those emotions (if any) they had when they stopped using 
AAS (Figure 5-9); low mood was the most frequently reported, followed by a 
reduction in confidence. Only seven people experienced relief.   
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As these are self-reports, they are based on the participants’ views in relation to 
the link to their AAS use, so it is worth considering that in some cases the negative 
psychological responses may have other causes entirely.  
Some participants self-described the feelings and these contained a wealth of 
negative emotional experiences (examples in Table 5-6).  
Table 5-6 Behavioural side-effects experienced coming off-cycle 
‘Not so good points, The downhill after a big cycle’ (Tomaz/Belgium/40 [CI]) 
‘It was just I feel like I feel like nothing really, …I feel like shit. I really I didn't wanna do 
nothing really I don't want to do any training that's all I didn't fancy any woman nothing 
like it was like below zero trust me’ (Lawrie/UK/27 [TI]) 
‘...worthlessnes’ (Alec/USA/38 [q]) 
‘lack of confidence and moticvation to diet ’ (Scott/UK/34 [q]) 
‘I get panic attacks when going from AAS to starting my own production back up’ 
(Doug/Canada/52 [q]) 
‘If I don't actually take like a aromatase inhibitor my oestrogen does seem to get high and 
I do seem to experience a fair amount of anxiety because of that.’ (Powel/UK/34  [TI]) 
 
Anxiety was experienced by 40 participants and several linked the anxiety 
experienced to specific Post-Cycle Therapy (PCT) substances: 
‘I implemented is PCT protocol… and I noticed that the clomid, had an 
effect on me actually made me feel quite anxious and it made me feel 
quite depressed.’ (Peter/UK/24 [TI]) 
  
Figure 5-9 Emotions experienced when stopping AAS use (off-cycle) 
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For one participant coming off cycle was something that needed to be prepared 
for as there was an expectation that they would feel bad: 
‘…this is my first time ever do a 16-week cycle but the reason I'm doing 
this is because I can't go into post cycle therapy right now because I got 
some stuff I gotta take care of for the next few months. And when I do go 
into post cycle therapy, it's a rough month... you start feeling really bad, 
like you just have no energy, you feel lethargic, you feel weak.’ 
(Joel/USA/34 [TI]) 
For some there was a strong desire to want to start the next cycle: 
‘I seem to be more confident in my appearance on cycle, so when i come 
off I tend to count the days to when I can get back on, anxiously’ 
(Saul/USA/40 [q]) 
For others the experience was so bad psychologically, they chose not to stop 
using: 
‘PCT is horrible to go through, and that will have an effect psychologically, 
and um, it is just something that it is just a pointless exercise’ 
(Robert/Spain/34 [TI]) 
For a few, increased libido was considered both a positive and negative and again 
participants explained their coping mechanisms e.g. 
‘Increased libido managed by more sex with wife, not a negative but a 
positive though.’ (Ray/New Zealand/39 [q]) 
 Low testosterone, TRT experiences and views 5.3.2.4.2
Another concept that emerged related to the participants’ thoughts and feelings 
around low testosterone and testosterone replacement therapy (TRT). This is 
explored in-depth in Chapter 7.  
 Personal, societal and ethical issues 5.3.2.5
Interestingly, the side-effects of use reported also concerned things other than 
benefits and health harms. Three participants reported financial cost and a few 
participants felt the changes had a profound and positive effect on different 
aspects of their lives (Table 5-7), highlighting the individuality of the experiences.  
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Table 5-7 Effects on AAS use on wider aspects of users' lives 
Impact on 
different 
areas of life 
Quotation 
Relationships ‘My wife agrees that the last year, since using steroids, has been a very happy 
and peaceful year of our marriage. This is a positive experience’ (Mitch/USA/XX  
[q]) 
Social capital  ‘It's that gay, middle aged men’s invisibility …I mean, a Bentley or a Rolls Royce 
will do it too but …muscularity will sometimes give you back something that 
aging has taken away …with the idea of the loss of status and the invisibility 
that comes with aging as a gay man.’ (Hugo/USA/53  [TI]) 
Economic 
Benefits 
‘I think what looks like permanent muscle from useage will play a part in 
helping me move my salary up faster in the future to’ (Niall/Canada/25  [q]) 
 
However, there were also specific personal, social and ethical costs that 
participants saw as negative side-effects, including: the cost of buying the 
products e.g. ‘along with my bank account’ (Troy/USA/28), ‘societal stigma’ 
(John/USA/22) and ‘Legal risk’ (Hugo/USA/53) linked to law violation and possible 
incarceration (dependent on the legal status of AAS use in any given country). 
There was also the personal cost of feeling a need to use steroids to achieve the 
results they wanted: 
‘Am I embarrassed that I feel that I have to take steroids to get to where I 
want to be? Yes, it's definitely a knock to my confidence’ (Joel/USA/34 [TI]) 
Another cost was the negative impact on relationships with others which was 
linked to emotional changes: 
 ‘I know then that can have a negative, on my relationship even with my 
missus or even with you know everyone really around me, but to be honest 
after so many years using it I can manage much more the negative 
outcomes, aggression and the rest of it.’ (Lawrie/UK/27 [TI]) 
And from the need to keep their use secret: 
‘lying to my wife because she thinks I am not taking it right now, that is 
another thing, which is bad and I have to admit to that I don't feel 
comfortable with that ...I need to get this sorted so it is not on my soul 
driving me insane every day (laughs).’ (Lev/Canada/32 [TI]) 
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 Risks to others 5.3.2.6
The questionnaire asked participants whether their AAS use put anyone else at 
risk. Only 18 participants replied ‘yes’ and even fewer qualified their answers. 
From the small number of responses there were two types of risks identified 
which are reported in Table 5-8. The risks identified were predominantly those to 
their families linked to inability to provide due to ill health, early death, or 
imprisonment and aggressive behaviours.  
Table 5-8 Risks to others 
Risks to Others Quotation 
Risk to family / 
relationships 
‘Only legal issues because it's illegal to use it in the country I live in. I Can potentially put 
my family in risk if I go to jail, loose my job etc.’ (Elvin/Sweden/39 [q]) 
‘If I did experience health complications as a result of AAS use it would negatively 
impact my son, mother and ex-wife’ (Isaac/UK/42 [Q]) 
‘Dying early and not being able to provide for my family’ (Max/Canada/26  [q]) 
‘My relationship with my spouse.’ (Hank/USA/53  [q]) 
‘Family as I don’t want to pass away to young. Agression and violence behavior only if 
some want harm my family or put my person in danger… I know that I have very calm 
personality but deep inside of something happened is like a ticking bomb’ 
(Lev/Canada/32 [TI]) 
more aggressive, and would suck for my kids if i died (Viggo/Sweden/34 [q]) 
Primarily, legal. Secondarily, if any of the previous issues mentioned lead to a decline in 
health it may lead to a financial or relationship problem which I would categorise as 
risk. (Asi/USA/28 [Q]) 
‘Increased aggression can result in responses inappropriate to the stimulus / trigger, 
leading to strained relationships or even criminal acts.’ (Don/UK/39  [Q]) 
Risks to wider 
network/public 
or as an 
influencer 
‘If I have a heart attack driving a car. Otherwise no.’ (Rod/Australia/39 [q]) 
‘Perhaps because i was a role model for the youth and boys tend to follow the steps of 
their mentor’ (Barak/Greece/44 [q]) 
‘People knowing that I take them seems to make them more likely to take them’ 
(Dale/USA/30 [q]) 
 
There were those that felt there were no risks to others and one participant, the 
same person who felt there were no emotional side-effects, stated that the 
question itself was irrelevant: 
‘If I eat a candybar, does that put others at risks? If I weigh 60kg or 100kg, 
does that put others at risk? This question is stupid. If I was a drug addict 
on heroin, it would put other people at risk but I can't really see how the 
levels of my testosterone low or high could put others at risk.’ 
(Rasmus/Sweden/35 [q]) 
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 Theme three: Risk management 5.3.3
‘…it's a calculated risk If you do it responsibly’ (Johan/Hong Kong/36 [TI]) 
Participants talked about a variety of strategies and/or considerations that they 
used to manage all aspects of their use, and also to support others. Four sub-
themes were identified: 
I. Risks versus benefits 
II. Managing side-effects 
a. Planning and preparation 
b. Developing ethnopharmacological knowledge  
c. Self-knowledge: body and mind 
III. Role as a mentor  
IV. Worries and fears 
a. Reasons to stop using AAS 
 Risks versus benefits 5.3.3.1
The first sub-theme was the notion of giving consideration to the perceived risks 
of use when compared with the perceived gains. Many participants appeared to 
have a clear understanding of the potential risks of using AAS, weighing up the 
risks versus the benefits as part of the decision-making process to use. They 
acknowledged some of these openly and talked in-depth about how they 
managed them. Participants felt they took calculated risks and that they were 
potentially healthier than other people (non-users). For many the positives 
outweighed the negatives, with improvement on quality of life playing a key role 
in the decision-making process and justification to use. However, some were 
aware they might be biased and that they might not be being honest with 
themselves (examples in Table 5-9). 
However, the impact was not the same for everyone and for Don, although, he 
saw physical improvements, he did not feel the same psychological 
improvements: 
 ‘I don’t, I guess you call it a vague positive, I was kind of living under this delusion 
that the things were getting better and I was progressing, and as the weights went 
up, you know my self-esteem was going magically go up as well.’ (Don/UK/39 [TI]) 
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Table 5-9 Risks versus benefits of use linked to quality of life 
‘…when I first started taking the drugs… my quality of life was that… far down the pan it 
didn't really matter because even if I’d shorn five years of my life this might have given me 
another 10-15 of actual years rather than shit years lying about and not feeling good 
about myself’ (Powel/UK/34 [TI])  
‘I am obviously going to be biased because I have had so far err pretty good experiences 
with it… I am also fully aware that there are certain risks involved long term and that… 
ultimately it may…not adding years to my life expectancy... I think it is like with everything 
in life err if you are reasonable about it and do it in moderation most things probably won’t 
kill you... if I was to come off and err you know what levels it could recover to I am not 
willing to make that change to the quality of my life err and that is the reason why I would 
never stop therapeutic use.’ (Alvin/UK/36  [TI]) 
‘I weigh up the pros and cons almost like a retrospective cognitive dissonance. I justify my 
use by asserting to myself I wouldn't be able to do what I do without it - sometimes I 
blatantly lie to myself because I have no evidence that I couldn't function adequately 
without my TRT dose this mitigates the negative feelings of using and injuries caused by 
using’ (Isaac/UK/42 [Q]) 
 Managing side-effects 5.3.3.2
One thing that helped participants to justify the benefits outweighing risks, was 
that they felt they could mitigate for side-effects. Most participants were clear 
that they could manage side-effects using ancillary compounds:  
‘…after 30 years of use I'm not worried about hormone use causing risks. I 
think generally speaking they are overstated or can be overcome with 
ancillaries.’ (Nick/50/USA [q]) 
Some participants managed risks, but were aware that there were some things 
which could not be mitigated for and needed to be put up with or were simply a 
cause for future concern:  
 ‘…honestly, I just suck it up… just deal with it, I mean what else can I do.’ 
(Lewis/USA/37 [TI]) 
 ‘I get quite anxious …if I'm on a cycle this can get really bad and last for 
hours, making me feel sick and worry deeply about something I can't 
explain... Just relax and ride it out. I'm quite head strong, however I can 
imagine that if I suffered badly with this, the AAS would make it 
unbearable. Which again, is why I can be confident in my choice to take 
them. I might have bad days, but they're pretty minor in reality. It's never 
been so bad that I've had to cut a cycle short’ (Clinton/UK/20 [CI]) 
 ‘Most of the risks are preventable with responsible use and ancillary drugs, 
but my concern is heart problems which you cannot do anything to 
prevent’ (Del/UK/35 [TI]) 
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For many, the key to doing this successfully was being able to assess the impact 
on the body. Knowledge of baseline levels for their own bloods, monitoring health 
metrics and getting regular tests was something that people felt was a way to 
minimise harm and this set them apart from other users:  
‘Blood work it's one of those if you are going to you know put this in your 
body you should know what else is happening within your body. and I 
know for a fact that some users do not do that, especially ones that is sort 
of the GymBros that you see’ (Asi/USA/28 [TI]) 
One of the more concerning methods that participants used to help manage the 
side-effects was phlebotomy. However, access to bloodletting was not easy,  and 
depended on location, as one participant explained:  
‘I'm gonna have to go and try and give blood and stuff like that and then 
that's another problem if you tell someone that you take steroids and try 
and give blood they will refuse you to give blood so you are immediately 
running a massive RBC heart attack issue’ (Powel/UK/34 [TI])  
One of the elements of using safely was around the dosage taken and some 
participants noted the importance of moderation. Several participants were clear 
that they considered the amount of AAS when compared to other users, 
describing their usage as ‘moderate’ (Johan/Hong Kong/36 [TI]) and (Asi/USA/28 
[TI]) ‘normal hormone replacement doses’ (Powel/UK/34 [TI]). An example of the 
comparison being: 
‘…they take crazy doses, crazy doses, grams a week, not milligrams 
anymore, you know the big 10ml vials, I know of kids going through one of 
those in a fortnight.’ (Milton/UK/40 [TI]) 
The use of low doses was seen as a way to mitigate the harms and linked to the 
idea of being different from ‘other’ irresponsible users:  
‘I feel like my use is, has been very on the low side compared to a lot of 
people... I respond very well to low doses of things so and my body has 
always been pretty much in line. So, I feel like in the long term now that 
I'm past that heavy type of use it's going to be fine.’ (Lee/USA/43 [TI]) 
As already noted, many participants experienced negative experiences off cycle 
and one tool for managing the side-effects is to undertake PCT, where a range of 
substances are taken to help rebalance the body’s natural testosterone 
production. The participants had differing opinions on the use of PCT or whether 
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you should take AAS for a number of weeks at a time and then undergo PCT, or 
whether you should take continuous low doses and, if desired increase the dose 
for short periods to achieve specific short-term goals (blast-and-cruise). Some had 
started out using PCT but had switched to continuous low-level use after using 
AAS for a while. Many felt returning to a 'therapeutic testosterone dose' was the 
healthier choice, as this led to less muscle loss and did not impact negatively on 
mood or libido.  
To investigate if there was a link between age and use patterns a Kruskal-Wallis H 
test was conducted between ‘use in 8-12 week cycles, with PCT’ (n= 37), ‘continual 
low level use, topping up as desired’ (n= 63) and ‘other’ (n= 30) AAS use pattern 
groups. Distributions of age scores were similar for all groups, as assessed by the 
visual inspection of a boxplot. Median age scores were statically different 
between groups, X²(3) = 6.560, p = .038. Pairwise comparisons were performed 
using multiple Mann-Whitney tests with a Bonferroni correction for multiple 
comparisons. Statistical significance was accepted at the p <0.0166667 level. This 
post hoc analysis revealed statistically significant differences in age scores 
between ‘use in 8-12 week cycles with PCT’ (mean rank = 40.85) and ‘continual 
low level use, topping up as required’ (mean rank = 56.17) (p=.011) (**) AAS use 
pattern, but not any other group combination. Those who were older were more 
likely to have chosen or changed to ‘continual low-level use’. The reasons for such 
choices were explored in the interviews, and explanations often related to not 
wanting to experience the emotional side-effects for example: 
‘I will stay on for the rest of my life, for me therefore it is the right 
decision, and I, it is a roller coaster if you are cycling… there is no other 
way to describe it really and it’s just something I didn’t want to continue 
doing. I would probably sooner stop than continue cycling.’ 
(Robert/Spain/34 [TI]) 
There were several methods that participants used for effective risk management. 
The first of these was to put in the required groundwork before starting use. The 
second was to continue to develop a detailed knowledge of IPEDs and the third, 
alongside knowing about all the substances and their general effects, was 
knowledge of their own physical and psychological selves.  
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 Planning and preparation  5.3.3.3
Participants of all ages reflected that they had often taken time (sometimes 
months or even years) before making the decision to start using and had often 
done significant research. This study time allowed them to justify starting use, 
manage risk and also reduce fear (examples in Table 5-10). 
Table 5-10 Planning to use AAS 
‘I read a lots before using I'm talking like easily 2 or 3 years before using’ (Johan/Hong 
Kong/36 [TI]) 
‘I considered that there were potential health benefits, but I had done almost 2 years of 
research on the safe use of them before I took them’ (Clinton/UK/20  [CI]) 
‘I spent over 2 years researching, talking and investigating what I wanted to do.’ 
(Vincent/UK/32 [q]) 
‘So, I was scared at first, but it took me about two years of reading and Googling stuff 
and trying to find out as much information as I could’ (Joel/USA/34  [TI]) 
 Developing ethnopharmacological knowledge 5.3.3.4
A large number of the interviewees exhibited extensive ethnopharmacological 
knowledge when discussing their experiences of AAS use and how to use safely. 
They educated themselves on the short and long-term harms of the different 
types of substances and how to mitigate for unwanted side-effects. They read 
scientific papers, talked with experienced users and experimented on their own 
bodies: 
‘I would go home and… pour page after page over the internet and 
articles. I mean, I was a biology major in college. So, I was very fascinated 
with the body and the way it worked and what I was doing what was 
happening inside of me. Just how things were interacting like myostatin’  
(Paul/USA/29 [TI]) 
Participants talked about how their knowledge meant that they were better able 
to maximise the benefits on cycle and retain the benefits of using when off cycle. 
It was clear that this in-depth knowledge and focus on research was one of the 
things that users felt not only set them apart from other types of substance user, 
but also from irresponsible AAS-users who were not knowledgeable about long-
term harms.  
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 Self-knowledge: Body and mind 5.3.3.5
Many participants considered self-knowledge as key to managing side-effects and 
an important part of responsible use: 
 ‘Knowing yourself and how you react in different situations will counter 
any issues’ (Ansgar/Denmark/33 [q]) 
Some AAS-users undertook a lot of self-experimentation in order to achieve the 
optimal result aligned to their motivations, for example, to maintain a base level 
of sexual function or to gain muscle and strength. This led to a level of body 
(kinaesthetic) self-awareness, which in turn allowed them to make decisions 
about which substances they should use. Participants stated they had an 
awareness of the hormonal changes within their body and the effects this had on 
their mood:  
‘…two hormones that will make a man especially depressed are low levels 
of testosterone and low levels of thyroid hormone. And my thyroid 
hormone was fine but I would say that just from knowing my own body, 
that my testosterone levels were low ... I’d tell you I can feel my hormone 
levels drop, but whether I can feel my hormone levels drop or not I don’t 
know because ... If I do not keep to my routine for injecting every two 
weeks ...I start to get feelings that, things are starting to go wrong here I 
do not feel as good as I should be’ (Isaac/UK/42 [TI]) 
Some kept meticulous records to help the development of this self -knowledge: 
‘I log absolutely everything, with progress, weights, and any sort of 
comments, like the way I was feeling, side-effects, things like that so at 
least I could always go back and …know ahh that this particular drug did 
this.’ (Robert/Spain/34 [TI]) 
Many felt this self-awareness of the body was vital as each person’s reactions 
would be different and that through planning and trial and error they learned 
from mistakes and could apply this learning to maximise effect whilst minimising 
unwanted side-effects: 
‘You can make a plan, an initial plan by going by other people suggest, but 
you have to try it for yourself and be ready to make the adjustments’ 
(Del/UK/35 [TI]) 
For some AAS-users there was a perception that AAS use was a serious business, 
and there was a need for personal responsibility for those who chose to use AAS:  
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 ‘…use is down to a personal choice, you have to realise if you are able to 
handle all the negative side-effects, some people just shouldn't use period. 
TRT has been one of the most impactful decisions I have made, as long as 
you keep doses reasonable get bloodwork done to monitor what's going 
on in the inside and be able to control aggression, then I am all for AAS 
use’ (Saul/USA/40 [q]) 
 Responsible use 5.3.3.6
Most participants’ decisions to use AAS required careful thought and evidence-
based knowledge in order to be done properly. The phrase 'responsible use' was 
widely used by participants as a way to minimise risk: 
‘…if you want to do this thing, then you need to make sure that you take 
ownership of it and that you do it properly’ (Peter/UK/24 [TI]) 
Although some users talked of carefully planning their use, others acknowledged 
that their initial use had been under-researched and irresponsible, and some felt 
young people today were not necessarily using wisely. This was a major concern. 
Many participants acknowledged an increased risk of harm for adolescents and 
suggested that AAS use required a level of maturity e.g. 
 ‘…these young kids in high school or what, they just don't have the 
mentality or their body is going to be shut down at an early age, …I guess 
mature enough to do enough research, … make a proper decision of how 
it's going to affect your body.’ (Lee/USA/43 [TI]) 
Moreover, they also showed concern for young people using without proper 
support: 
‘Kids should not be taken this shit… They shouldn't be messing with a 
hormonal system that is already out of whack from stuff like puberty… not 
only is it a nightmare for their bodies, I think it's potentially a nightmare 
for their mental health and if they don't have mental health issues, just all 
those extra hormones messing with them and messing with their 
endocrine system, I have a feeling that it could exacerbate or cause 
…issues for them. So, I would love to see youth intervention but truthful 
youth intervention… I would like to see intervention based on truth and 
knowledge as opposed to scare tactics’ (Lewis/USA/37 [TI]) 
 Role as a mentor 5.3.3.7
One element of risk management was not self-management but supporting 
others to manage risks. Seven interviewees expressed the belief that their 
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experiences enabled them to advise and support other AAS-users, seeing this as a 
positive aspect of their own use, a duty and potentially adding to their status. This 
was expressed in subtly different ways, often with a harm reduction message or 
word of caution: 
 ‘I'll never recommend it to somebody that is something I won’t do. That's 
a personal decision. But if somebody is committed to doing it, I feel it's my 
duty to be able to sit down and talk with them about how they're going to 
go about doing it, so they don't mess themselves up. (Lewis/USA/37 [TI]) 
 Worries and fears 5.3.3.8
When considering risks of use some participants spoke of personal concerns 
around their AAS use and considered what might make them consider stopping 
use. Leading on from knowledge of self, some participants, when reflecting on 
their use, openly acknowledged specific worries and fears about the 
consequences of their AAS use. Some specific side-effects concerned them more 
than others including short-term health risks such as acne and long-term risks 
such as permanent baldness, but these were very individual.  
For some these fears were not enough to cause them to stop using: 
‘I worry slightly about infertility and baldness, but I don't get so worried 
that I'm willing to stop using them. There's no guarantee I'll suffer’ 
(Clinton/UK/20 [CI]) 
Again, there was a notion to manage risks and for one person, infertility was such 
an important concern that he had taken precautions: 
‘I've banked viable sperm samples at a cryogenic facility so that children 
can be a possibility in the future.’ (Asi/USA/28 [Q]) 
A worry around the dangers of using fake or poor-quality substances also 
emerged:  
‘I've had the bejesus scared out of me, you know, with HIV, literally the 
threat of death from a medical condition. I'm loath to get near anything 
that threatens my life medically, … I'm buying… anabolic steroids from 
someone, I don't know, online …and I know that there's a risk there, I don't 
know that what I use is, is effective necessarily, I don't know that it's pure.’ 
(Hugo/USA/53 [TI]) 
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Again, some users had ways to mitigate getting such poor-quality substances: 
‘There's a website that you donate to that, anonymously. That buys drugs 
from certain popular places and tests them. Then posts the tests, so I go 
there, and I order from the people that they, they test the most.’ 
(Joel/USA/34 [TI]) 
There were fears around the potential to become dependent,  
‘Becoming dependant of injectable testosterone’ (Sander/The 
Netherlands/21 [q]).  
Perhaps the biggest concern was premature death.  This often related to media 
stories that had linked AAS use to sudden death, for example, people like Dallas 
Carver, Rich Piana and Lyle Alzado, but were still not enough of a concern to cause 
individuals to stop use: 
‘…he died, they posted it online, you’ll find it as soon as you put in Dallas 
McCarver autopsy, every single organ was something like 3 times the size 
it was meant to be, err, and that just kinda scares you a little bit.’ 
(Andrew/UK/25 [TI]) 
Yet conversely, there were also concerns not focussed on the physical harms of 
using but on what would happen if they were forced to stop. These worries 
included the possible loss of self-identity, as illustrated by the examples in Table 
5-11. 
Table 5-11 Concerns over loss of identity 
‘A potential risk that if the ever supply dried up …I could find myself in serious 
psychological trouble …that is the one thing that worries me about it.’ (Isaac/UK/42  [TI]) 
‘At this point I've been been steadily on them for so long including big doses on and off 
that I am a little afraid that I won’t feel like the man I do now.’ (Lewis/USA/37  [TI]) 
‘Do I want to be on testosterone for the rest of my life I don't think so. I don't like the idea 
of it only because I'm afraid of not being able to get it like what you know what if I'm 60 
and I got to just I don't know… I don't like the idea of having to be on it forever but …they 
say that… once you started you're going to be on it forever.’ (Joel/USA/34  [TI]) 
 Reasons to stop using 5.3.3.8.1
The majority of participants (73% )(Figure 5-2) thought that they could stop using 
AAS. Some already had periods in their life where they had stopped using. 
Reasons for this included: entering a relationship and the partner not being 
supportive; wanting children; being in prison; an injury; mental health problems, 
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no longer able to access a supply. All bar three interview participants who had 
stopped for a period had already reinitiated use. One person was seriously 
considering starting again and another was hoping to find a way to access a new 
supply. The third acknowledged that he had recently achieved his goal (which had 
been curiosity) so had decided to stop. However, he was clear from the beginning, 
that this was purely an experiment. Nonetheless, he had run a couple of extra 
cycles than originally planned, again attesting to the potential allure of the effects 
of using: 
‘I did like the results so maybe my, my perception did change slightly, …I 
probably stayed on it longer than I originally anticipated because of that… 
I always set out for it to be an experiment, …it's made it easier for me to 
come off them because I had set out, I had a plan set out to do what I was 
going to do’ (Harry/UK/52 [TI]) 
Despite, nearly three quarters of questionnaire participants stating they could 
stop using AAS, from the interviews it was clear that few participants were 
considering stopping use. Some of the participants did talk about circumstances 
that would lead them to stop using AAS, which included: no longer wanting to 
gain mass; starting a family; serious health concerns; and worries about the 
impact on those close to them. Some participants could see themselves stopping 
the blast-and-cruise cycles but were unable to envisage a future without TRT. The 
long-term health effects and pressure from hiding the use from his wife, had one 
participant already planning to stop using within the next few months; however, 
the discussion about the plan was punctuated with phrases that meant that this 
would be a challenging commitment:  
‘It will be difficult for a while, …other people survive without it and I used 
to ...I'm just worrying too, …not to be in a queue for a liver transplantation 
in the next few years, …so I think that's a good reason to believe it is 
possible to survive without it, so yes ...to be honest I had a friend which 
they didn't wake up in the morning. …he wasn’t looking as good as he 
wanted to for his competition so increased dosage ...his heart just popped 
out overnight and his wife woke up next to him and he was dead he was 
36, he looked amazing’ (Lawrie/UK/27 [TI]) 
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 Theme four: Perceptions on and perceptions of AAS use and 5.3.4
society 
‘an image of a steroid user, …like public consciousness, …everyone thinks 
that it’s this …gym monkey that has nothing really important to say and 
no thoughts of their own and all they want to do is get bigger, stronger.’ 
(Alvin/UK/36 [TI]) 
The benefit of using open questions was that it allowed questionnaire participants 
to comment on different aspects of their experiences and use and some 
referenced how society impacted on their use. Semi-structured interviews 
allowed for a deeper exploration through a wider discussion of this issue. This can 
be helpful as people are influenced by society and also the groups within which 
they socialise. This theme brings together participants’ thoughts on their own sub-
culture on AAS use, how they view other illicit drug users, how AAS use is seen by 
society in general and how they felt this impacted on them in relation to 
stereotypes and stigma. It is sub-divided into the following five sub-themes: 
1) Different to 'other' illicit drug users  
2) Childhood experiences and influences 
3) The myth of the 'meathead' and other misrepresentations  
a. Influences: personal and societal  
4) Stigma  
5) AAS-using community  
 Different to ‘other’ illicit drug users 5.3.4.1
When it came to discussing drug use in social contexts many participants were 
clear to disassociate themselves from people who used other illicit drugs and this  
disassociation was represented in a variety of ways: 
 Indignation when professional services treated them in the same way as 
heroin users, as they did not see AAS as impairing them in the same way or 
putting anyone else at risk. 
 Being clear (within the UK) that they were not using harmful Class A 
drugs. 
 Using disparaging language for people who use other substances 'junkie', 
'crack addict' and associating them with anti-social behaviours. 
 Willingness to pay for services such as needles. 
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 Differing legal status of AAS use globally. 
 
Table 5-12 gives examples of how these views were expressed. 
Table 5-12 Disassociation from other types of substance user 
‘…it is not addictive in the sense that you are trying to feed your habit like you were a crack 
addict, who robs from old grannies for example so it is not really seen as an issue is it’ 
(Andrew/UK/25 [TI]) 
‘…like, listen if you are willing to go and spend £200 a quid on a 10 week cycle, to make 
yourself look better, stop going and sitting with junkies and go and pay £10 to have you 
know, to buy it yourself’ (Robert/Spain/34 [TI]) 
‘We shouldnt be looked upon as drug addicts, these are legal in most of the world and 
there is no possible way to become addicted.’ (Kian/Sweden/22  [q]) 
 
Participants were clear as to how they were different from other types of illicit 
drug users. They argued that AAS use was not unhealthy as evidenced through the 
non-drinking/smoking references and saw their ethnopharmacological 
knowledge, planned use and independence as a way of distancing themselves. 
This ‘othering’ was not just from other recreational drug users, but interviewees 
also described how their use was different compared to other types of AAS-user 
who were less knowledgeable and less prepared: 
‘I still think there's so many people just so ignorant and they just don’t 
know about the long-term repercussions.’ (Peter/UK/24 [TI])  
Participants described such users as being ‘unwise’, 'in a rush’, using irresponsibly, 
taking overly large doses, lacking planning and often referred to them as 
'uneducated' and careless. There was derogatory language used about those who 
were using unwisely or unsafely and used such terms as ‘morons’ and 'idiots’ to 
set themselves apart. Participants suggested that it was this ‘type’ of AAS-user, 
one who used extremely high doses, without any planning that fuelled the 'roid-
rage' and 'steroids will kill you' media myths. Several people made it clear that 
there was a personal responsibility for managing any mood changes and were 
disapproving of those who did not do this. One example of how AAS-users 
outlined their differences to other types of AAS-users was when talking about 
behaviour change and in particular, aggressive behaviour. As previously noted, 
(Appendix 22, 23), there was an acknowledgement that AAS use did impact on 
mood, and many evidenced that it made them more irritable or more assertive. 
However, they also expressed the idea that if you already had an aggressive 
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personality then AAS use might enhance that assertion was made by more than 
one participant. Furthermore, there was also the suggestion that people might 
use AAS use as an excuse for their behaviour: 
‘I have seen people where they have just turned into an absolute idiot on 
them, erm but I think a lot of that is personality wise, just like you would 
with alcohol, there is always that one kind of person you go out with who 
turns into an absolute dick when they have had a drink. It is just the same 
with steroids’ (Andrew/UK/25 [TI]) 
There was indignation that this side-effect of AAS use was being seized on and 
misrepresented in the media and participants used emotive words such as 
'evilness' and ‘demonisation', to describe how the media depicts the use of 
steroids. They accused the media of 'scaremongering', putting out 'false 
information' and focussing on the pervasive myth that steroid use could turn 
someone into a 'monster'. More than one participant related the myth of AAS use 
causing and leading to atrocities:  
‘Chris Benoit0F1, …killed his kids, killed his wife and then killed himself, the 
first thing the media said is but he was on steroids. Now I'm sorry there's 
not a hormone on this fuckin’ planet that will cause you to murder your 
loved ones, if you're going to do something sick and twisted like that, 
that's already in you, that your soul is already dark, there's nothing that 
can push you, like no amount of testosterone or even freakin’ Tren can 
push you into such a state.’ (Lewis/USA/37 [TI]) 
 Childhood experiences and influences 5.3.4.2
This study did not seek to find any quantifiable links between childhood history 
and AAS use but did seek to explore underlying motivations for starting and 
continuing use. Some participants shared their thoughts about what might have 
set them on the path from a young age, and several interviewees described 
adverse childhood experiences including having been homeless, having been 
imprisoned, parents with mental health problems, having a controlling father, 
                                                                 
1 This refers to the case of World wrestling champion Chris Benoit, a known steroid user, 
who killed his wife and 7-year-old son and hung himself at his home gym (Sutton and 
Morehouse 2007).  
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having suffered abuse. They linked their desire to change their body shape to 
these experiences e.g. 
‘I had a terrible childhood. I was homeless, you know I was 14. So, I was 
19, I moved to Texas, my mom lived in Texas and I didn't talk to her for 
about three years and at that was pretty hard for me. I went to jail for like 
11 months which, that really changed my life for the better... I have this 
problem like I get hooked on things... and I think it's the over 
compensation for having my bad parents, like I go to the gym… I'm an 
addict there, I am a workaholic. …I don't want to fail and my parents, I just 
don't want to be like them… So, do I think that affects my steroid use and 
to try to get bigger and bigger and bigger. Yes, I think it does.’ 
(Joel/USA/34 [TI]) 
Two other participants talked about childhood histories of depression, and 
although there is a complexity of issues surrounding initiation of their use, one 
was introduced to testosterone injections by his father and the other initially as a 
way to self-medicate for gynecomastia but found it also alleviated his depression: 
‘…I was put on antidepressants at a very young age and it, to an extent 
almost delayed puberty and had just negative side-effects such as, I had 
teen prepubescent gynecomastia and that was actually how I first began 
researches. I was looking at ways to treat it and …I discovered the other 
side of anabolic steroids.’ (Paul/USA/29 [TI]) 
‘…as a teenager I was always depressed and weak and would sleep all 
day, had no drive, no confidence, sex life was terrible I started taking oral 
steroids only and all those symptoms above became way worse. My father 
introduced me to testosterone injections and that's when my life changed 
for the better.’ (Max/Canada/26 [q]) 
Some participants did not mention any history of trauma but did talk about how 
adolescent experiences were linked to the decision to start using AAS.  
A motivation to train stemmed from an internalisation or desire to achieve a 
mesomorphic ideal, with the hope that they would feel less inferior and prevent 
them from being bullied or judged because of their shape, whether that be too fat 
or too skinny, for example: 
 ‘When I was around 17/18 …I had an inferiority complex of how I looked… I 
was like a really skinny guy and I wanted to be as far away from that guy as 
possible and my life only started to improve when I started going to the gym’ 
(Peter/UK/24 [TI]) 
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 ‘I first went to the gym when I was 14 years old. The reason I started is 
because I was obese and didn't feel comfortable how I looked. You know what 
kids can be like, they say it how it is’ (Clinton/UK/20 [CI]) 
 
 ‘When I was 19 and I was 68 kilos …I was proper skinny, so I did want to look 
like a man really, feel more comfortable’ (Lawrie/UK/27 [TI]) 
 
It is notable here, that Lawrie saw being muscular as linked to his masculine 
identity. 
Others went into deeper explanations of their motivations and the complexities of 
use, often motivations overlapped and were connected to a person’s be liefs (e.g. 
what they felt women wanted), values (e.g. social currency in their community) 
and identity (e.g. not wanting to be seen as a fat person). For participants working 
in the fitness industry there was a feeling that it helped with credibility; yet this 
was not the whole picture. Here Peter explains how important he felt it was to his 
occupation but also to his identity and was influenced by childhood experiences:  
‘I wanted to increase my strength I wanted to look better a lot of it was 
from a professional standpoint as well …the rest of the personal trainers 
are like jacked and ripped and like, if that gives me credibility... I viewed 
steroids as a … sort of hack …my way to improvement… I… had a lot of 
anger issues when I was younger …I had an inferiority complex of how I 
looked, because I was so skinny …and started improving myself the 
person, I was like a really skinny guy and I wanted to be as far away from 
that guy as possible and my life only started to improve when I started 
going to the gym, …I want to get as much out of my training as possible. I 
know how far I've come already …it is like I'd already gone through a 
psychological like transformation of who identified myself was but I felt 
like I needed a physical transformation …to reflect how different I felt 
about myself internally. (Peter/UK/24 [TI]) 
 The myth of the ‘meathead’ and misrepresentation 5.3.4.3
The second sub-theme addresses how users felt there was a misrepresentation of 
AAS-users and use within western society. People who used AAS felt there was a 
stereotypical image of an AAS-user that did not depict reality. Stories such as the 
one noted by Lewis about Crispin Benoit were cited as evidence of this 
misrepresentation, and users argue people who were reported as having ‘roid 
rage’ or dropping dead from use was not the whole truth, which was often more 
complex, with a range of contributing factors.  
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AAS-users were confident that AAS use was more prevalent than the statistics 
reported, was used by ordinary people including professionals, and was 
potentially becoming normalised within certain professions: e.g. 
‘Most military guys do, most cops do, most firemen do …what I learned, 
especially on Facebook, is that it is much more pervasive than people 
admit. …the steroid user next door.’ (Hugo/USA/53 [TI]) 
It was not just the ‘roid rage’ concept that users felt was overplayed, but also that 
there was a general overreaction and hysteria surrounding AAS use . Many noted a 
conflict between scientific fact and perceived societal truths about all AAS-users 
being overly muscular ‘meatheads’ who get ‘roid rage’. They felt that those 
outside the community over-exaggerated the negative effects of using AAS. This 
idea that the public are misinformed was a concept that was shared by 
participants from a number of countries and many felt this led to an emotional 
and unrealistic reaction to the use of AAS. Some felt this over-exaggeration and 
hysteria, created an environment where AAS use was kept secret to avoid 
judgement and wanted reassurance that research did not portray AAS-users in a 
negative light. They felt society’s perceptions had wider implications for research: 
‘You will find the consensus among any experienced steroid users is that 
the general opinion about their dangers is grossly exaggerated… Like 
many others I was hesitant to even participate in this survey because more 
often than not what we say is taken out of context to paint a 
sensationalist and alarmist picture of steroid use as though there is an 
"epidemic" and the hospital morgues were full of steroid users which 
couldn't be further from the truth and the vast majority of us live perfectly 
normal lives on which steroids have little to no effect’ (Conan/UK/28 [q]) 
One person gave an alternative perspective suggesting that the stigma in society 
was reducing and use was becoming more socially accepted even outside of sport. 
They saw the change resulting from a desire for men to have a certain aesthetic:  
‘I think more so 20 years ago than now I think the social aspect of it now 
it's very acceptable in a lot of groups and specially not even just for 
competing... It is okay for guys to do it, to look good at the pool, you 
know.’ (Lee/USA/43 [TI]) 
This concept of using AAS for purely aesthetic reasons was a reoccurring idea and 
users raised concerns about the pressure on young men to need to look a certain 
way.  
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 Influences: personal and societal  5.3.4.3.1
As part of the discussions around society’s perceptions of users, participants 
reflected on their own influences and their perceptions of the influences of media 
stereotypes and masculinity tropes. Some interviewees talked about how they 
had been influenced by society’s perception of masculinity to want to change 
their shape:  
‘…it's not a bad thing I think to have ideals, but so I grew up you know 
with like Predator, Terminator, Commando, all these movies so I always 
was looking for an ideal male body’ (Johan/Hong Kong/36 [TI]) 
One pinpointed a male role model closer to home: 
 ‘My father had a friend who was a bodybuilder. I saw him once with his 
torso naked and i thought 'i also want to look like that'. I was 8 or 9 back 
then but i never forgot the impression it gave me and at 17 i started to 
train myself. It was like a moment i knew immediately what i wanted to do 
when i will be old enough’ (Tomaz/Belgium/40 [CI]) 
The idea that young people could be influenced by the media and role models was 
not an uncommon one. Some felt that social media was normalising and 
encouraging use with the promotion of the idea of the ideal muscular physique 
via film, reality TV shows, and online 'influencers': 
‘…movie stars like Dwayne Johnson and whatnot, that is seen as he looks 
great while they wanna to aspire to be like that but they don’t realise how 
much stuff he is taking, or well they do and that is why they end up taking, 
it is so normalised, that is just that he looks super cool and big and muscly 
and people want to look like that don’t they’ (Andrew/UK/25 [TI])  
Some users felt that the new selfie culture had started a trend for people to use 
AAS purely for the aesthetics to gain the admiration of others and be more 
sexually attractive: 
‘A lot of these guys are posting their big old flex muscles on Instagram and 
all that …a couple of them will show me oh, look how many girls are 
following me… I think a big part of it is cosmetic and sexual appeal... with 
social media it's whoever's more appealing, whoever's bigger, whoever's 
got the bigger biceps whoever can video themselves on Snapchat lifting 
the most weight’ (Lewis/USA/37 [TI]) 
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There were also other references to the fact that a mesomorphic body shape was 
something that would make them more attractive to women and men, as 
illustrated by the following quotations: 
‘A lot of women are attracted to that so I think when you are single and 
you want to look good at the pool or at the lake... that definitely has an 
impact on your thoughts, on what you want to look like’ (Lee/USA/43 [TI]) 
‘Gay men fetishise muscularity …it’s not universal, but it's darn close to it... 
I get more attention from 24-year olds now than when I was 24. I think 
because they're fetishizing the grey hair and the muscularity …so there is a 
social prestige to it’ (Hugo/USA/53 [TI]) 
These, alongside the ease of availability of the substances via the internet, were 
part of the reason why use was on the increase.  
 Stigma 5.3.4.4
Some felt the public perception of AAS use impacted on how their partners, 
friends and family judged them, and this led them to keep their AAS use secret: 
‘I haven't dealt with any stigma because I haven't, I'm not open about it... 
It is 100% the perception of others, I am afraid of what my family and my 
friends would think of me if they knew what I was doing’ (Joel/USA/34 
[TI]) 
For others this wealth of misinformation meant a need to explain their use and 
one participant reported that after such an explanation, people close to them 
were less judgemental:  
‘The only people that would actually know for sure are people that I want 
to know and respect and take the time to actually understand it, and listen 
…take my current girlfriend for example, her initial reaction was just like 
anybody’s, …like you are a junkie …but once I persuaded her to stop 
googling, …and actually listen to me, we didn’t really have any more 
problems’ (Robert/Spain/34 [TI]) 
When it came to talking to professionals there were the same fears and concerns. 
Some were open about their use whereas a number of participants lied to medical 
professional about it, due to such concerns as the potential impact on insurance 
or that everything would be blamed on the AAS use. Again, when it came to 
accessing professional support participants felt that they were different from and 
 
 
132 
 
should be treated differently to people who used other types of illicit substances. 
One participant gave an example of a fellow AAS-user who had applied for a 
mortgage and the insurance was very high, as a doctor's report had labelled him 
as an injecting drug user and therefore high risk. He reported that they were  
indignant: 
‘I am not an injecting drug user in the way that you understand what an 
injecting drug user is. The bank’s response was, it doesn’t matter, you put 
a needle in and that puts you in the high-risk category for XYZ so 
obviously, after that he went into the gym and told everyone about it and 
the next minute everyone was like right don’t go to the doctor.’ 
(Isaac/UK/42 [TI]) 
Isaac shared this story as he felt it summed up not only the reason why there was 
a lack of faith in the medical profession but also how the medical profession was 
adding to the stigmatisation of AAS-users. Such stories can spread within the 
community and these can potentially impact on someone else's decision to seek 
help. Several participants did not disclose their AAS use for fear of it being added 
to their medical records, and as such could lead to the medical professionals not 
being able to support them effectively.  
Some AAS-users felt that the stigma associated with AAS use was unfair and made 
comparisons to how society views people who drink alcohol, smoke or even use 
Botox, particularly in relation to how professionals perceived them when it came 
to accessing support. They felt that harm caused by using AAS were comparable 
to or less harmful than those caused by smoking or drinking alcohol, and 
expressed the opinion that relatively speaking their own lifestyles were healthier 
than that of the average person: 
‘There is usually no such stigma with people who smoke or drink excessive 
amounts of alcohol even though all evidence shows those are actually 
much more of a public health risk than anabolic steroids’. (Jake/UK/29 [q]) 
 AAS-using community 5.3.4.4.1
There was one sub-section of society where understandably participants did not 
feel such stigma. Participants talked about a global AAS-using community, with its 
own language and culture. This was a community that was visible both in certain 
types of hard-core gyms and within online fora. In the online fora, AAS use was 
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discussed openly, with threads devoted to planning and using AAS. However, it 
was clear that even within gyms where AAS use was taking place, the participants 
were not consistent about the openness of discussion around this, as shown by 
the examples in Table 5-13.  
Table 5-13 Talking about AAS use at the gym  
‘…you’ve got this sort of taboo unspoken elephant in the room always whenever you are in 
that sort of gym culture’ (Robert/Spain/34 [TI]) 
‘…most gyms have people that use. It is not really a talked about thing not so much unless 
you are in kinda that atmosphere where you’re in kinda a nitty gritty body building gym’ 
(Andrew/UK/25 [TI]) 
‘I don't discuss steroid usage with people on the gym I keep it clean unless I know for sure 
that it's someone that I trust and is also a AAS-user. It's taboo to discuss it on the gym in 
my contry.’ (Rasmus/Sweden/35 [q]) 
‘I won't just talk to some random guy that comes up and starts talking to me about steroids 
but to a certain degree, I try to be as open as possible and that all revolves around the 
whole idea of the harm reduction.’ (Lewis/USA/37  [TI]) 
 
When it came to people outside the AAS-using community there were differing 
opinions on whether AAS was something to be kept secret; some feeling that you 
should be open and honest about use, while others feeling that the stigma and 
perceptions of others was something they had no wish to experience, and so 
maintaining secrecy was better. For those that were more open, there was a 
sense that there needed to be a level of trust built up before the subject was 
discussed.  
 Theme five: Information and support accessed 5.3.5
‘They are never going to know what the bros know’ (Harry/UK/52 [TI]) 
There were three sub-themes identified under the theme of information and 
support accessed: 
1) Types of information accessed: What, from where and from whom? 
2) Assessment of information  
3) Types of practical support accessed 
a. Injecting paraphernalia and learning to inject 
b. Seeking help for side-effects 
c. Experiences of using medical professionals 
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 Types of Information: What, from where, from whom? 5.3.5.1
The first of the sub-themes brought together all aspects around information 
seeking. A wide range of options of different information sources were included in 
the questionnaire (identified from the literature review Chapter 3) for participants 
to identify if there were differences as to where participants would seek out 
information dependent on the type of information they were looking for. The data 
was re-categorised and recoded for the advice categories to assist in the analysis. 
(The categories were: professional support (NEs, pharmacy, medical 
professionals), support from peers (including gym colleagues, friends, suppliers, 
work colleagues, family) and the internet (including websites, fora and online 
videos). If participants had selected one or more of the groups in each category, 
they were coded Yes). Table 5-14 summarises the top three sources for advice and 
support by category. The results showed that in relation to seeking support and 
advice the internet (AAS use fora) was the highest category in each case.   
Table 5-14 Seeking information and support 
 Question Top 3 Answers N Percent Percent 
of cases 
Who do you discuss your AAS use with AAS-user fora 71 18.2 55.5 
AAS-users 70 17.9 54.7 
Friends 64 16.4 50.0 
Where do you get advice concerning 
cycling and stacking 
AAS-user fora 90 30.4 69.2 
AAS-users 62 20.9 47.7 
Other 35 11.8 26.9 
Concerning the risks of AAS use  AAS-user fora 84 24.2 63.2 
AAS-users 60 17.3 45.1 
Other 39 11.2 29.3 
Concerning the most effective types of 
AAS to use 
 AAS-user fora 94 26.3 71.2 
AAS-users 70 19.6 53.0 
Other 38 10.6 28.8 
 
The interview participants talked about a variety of types of information including 
information on what drugs to use, dosages, injection locations, time on/off cycles, 
stacks, ancillaries, side-effects, long term studies, detrimental side-effects and 
TRT. As with the quantitative data the focus was centred on accessing information 
from the specialised fora and experienced users. It should be noted that the 
highest recourse for accessing professional advice was when seeking information 
on risks. 
 
 
135 
 
 The interviews evidenced that some felt the internet had changed things when it 
came to accessing information:  
’…it's gone from books, and to talking to people and just trial and error to 
…you can get online and look up anything or you can go to chat room or 
you can go to a forum, you can go to people who actually will talk about it 
in the open… It was more secretive then, so you had to sneak around, 
…instead of a nudey magazine you had a steroid handbook underneath 
the bed’ (Milton/UK/40 [TI]) 
Yet this was not true for everyone and books were still used:  
‘…if it is something, I was never really sure of or hadn't been studied I’d 
probably going to look in someone that's half credible, someone like 
Llewellyn.‘ (Powel/UK/34 [TI]) 
For one person, however it was not AAS information but information about TRT 
that mattered, as this was felt to be more reliable:  
‘Internet, but not steroid information but testosterone replacement 
information, which is a lot more medical a lot better, standard of 
knowledge.’ (Del/UK/35 [TI]) 
Moreover, a number of the participants referenced a FB group ‘Testosterone’ 1F2, 
run by a medical professional, as somewhere/someone they trusted. Overall 37 
participants used Youtube or other videos to help ascertain the most effective 
type of AAS to use. Others were accessing vlogs and podcasts online from 
experienced users. Those people involved in sports often relied on information 
from coaches. Two people (both Australian) mentioned harm reduction websites 
and only one person (Canadian) a Government onl ine resource. However, there 
was scepticism about the value of UK Government supported websites and this 
bears out the quantitative data where these were the least preferred sources of 
information and support:  
‘Government support or social support, or whatever if you look at a 
particular website, i.e. TalktoFrank which is supposedly the Government 
website, you get crap you know you just get drivel, it doesn’t actually help 
anybody, so if there was a government support, it would probably be 
rubbish’ (Robert/Spain/34 [TI]) 
  
                                                                 
2
Testosterone is a group focused on the Androgen Receptor and all that it entails, including 
cycling, PCT, and more. 
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 Assessment of information 5.3.5.2
With the aim of seeking to understand how participants chose which information 
to pay attention to, participants were asked about who they trusted to give them 
advice. Overall, 47% trusted the internet, 37% trusted their peers and 16% trusted 
professionals. The interviews gave the opportunity to explore this concept of trust 
in more depth. Similarly, in the interviews, the predominant sources of trusted 
information came from evidence-based research, medical experts who also were 
knowledgeable of AAS, AAS-user fora, books such as the Anabolics’ Handbook 
(Llewellyn 2017) and peers/experienced users. The interviews highlighted that the 
sources people trusted differed by individual.  
Some participants made the point that not all information accessed online was 
trustworthy and found it difficult to know which advice to follow, yet still did not 
access other sources: 
‘Websites are where I get all my information from… It's hard to 
understand what's good and what's bad advice. That's, that's the scary 
thing because there's a lot, lot of bad advice out there.‘ (Joel/USA/34 [TI]) 
Whereas, others were clear that books and experienced users were more reliable: 
‘I started on fora online like most people, however quickly realised that the 
info on there was bogus so I bought a book called 'Anabolics' by an author 
named William Llewellyn... I knew that I couldn't really trust online sources 
as I seemed to see a lot of information which was blatantly made up. I 
instead went to people around me who took them, amongst them were a 
few professional bodybuilders’ (Clinton/UK/20 [CI]) 
The interviews evidenced a perceived need to be wary of any source that also 
supplied AAS. Consistency of the information; a consensus amongst different 
sources, was important as a method to evaluate the quality of the information. 
Evidenced-based information was felt to be particularly useful and, credibility 
given to those who cited research studies. Participants took pride in developing 
their own knowledge: 
‘I make an effort to understand how the drugs work and therefore read 
scientific studies related to the endocrine system in medical journals.’  
(Del/UK/35 [TI]) 
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Some felt the academic journals did not cover everything as they could only go so 
far ethically with research, so broscience (a combination of the words brother and 
science, and relates to user-generated knowledge passed on within the 
community (Bilgrei 2018)) had a place: 
‘…because they’ve used it and they've combined these things, they know 
what works, whereas science is not allowed to do that’ (Harry/UK/52 [TI]) 
‘There's a lot of baloney information on there but there's also a lot of good 
information from guys …who just have a lot of experience with this stuff. 
There is a lot of what I call folk knowledge and, and … some of it’s …very 
legitimate knowledge of just cause and effect experiences.’  (Hugo/USA/53 
[TI]) 
However, although positive about broscience in the main, Hugo felt that it was 
the policies that led to reliance on this:  
‘By having the policies that we do that are not patient friendly, that are 
based in hysteria and not based in science we're leaving the entire 
community of anabolic steroid users largely in the dark. they're relying on 
what they got ‘broscience’, Yo bro. You know we're relying more on folk 
knowledge than on medical knowledge‘ (Hugo/USA/53 [TI]) 
It was acknowledged that, years of using AAS had led some to develop an in-depth 
knowledge of use and there was a clear ‘older and wiser’ narrative from some 
participants. Peter sums up the journey many of the interviewees described 
regarding how they assessed information and how their assessments improved 
over time and with experience you were able to recognise less credible 
information: 
‘I am quite wise to that now whereas before it was Iike oh wow he’a 
fuckin’ massive I’d better listen to him and now …it’s like a bit of a bullshit 
sense… I am very selective with who I get my information from and I'll 
make that decision on who I think is credible and based on you know are 
they referencing studies, have they got sort of testimonials of people that 
they've worked with, are they like an authority in that area, if somebody’s 
name keeps flagging up between other sort of evidence based people then 
…the chances are that that person's got credibility as well and I’ll consume 
their content I’ll listen to podcasts, read their articles. Look at what they're 
referencing and then I’ll formulate my own opinion on what I think is true 
or not.’ (Peter/UK/24 [TI]) 
The idea that the largest guys would also be the most knowledgeable was the 
method used by the one participant who was seeking help for side-effects of an 
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orchidectomy, so had no interest in bodybuilding or the gym, yet still felt that the 
gym was the best place to get information: 
‘I went to the biggest guy in the gym …rather than the doctors went 
straight to the gym and picked this guy and I said I got this trouble. What 
is this stuff? Cos’ I didn’t know nothing about it. and he sat me down and 
went through it and all the rest of it and that is where I found out most of 
the information’ (Han/UK/42 [TI]) 
There was an awareness from one participant that they might be paying attention 
to information that supported their use: 
‘I tend to justify my own bad behaviour by being selective in the 
information that I look at’ (Isaac/UK/42 [TI]) 
 Types of practical support accessed 5.3.5.3
This sub-theme covered three different aspects of support, one concerning 
injecting AAS, one seeking help for the side-effects of use and one on the 
experiences of accessing medical support.  
 Acquisition of injecting paraphernalia and learning how to inject 5.3.5.3.1
Only a minority of participants sought needles from friends, family or doctors, and 
33% sought equipment from pharmacies; 49% purchased needles online and only 
12% from a NE. Within these categories it is possible that when participants 
selected pharmacy, they might have meant online pharmacy. One website 
(Exchange Supplies 2019) was mentioned as a source and this website was 
interesting as it has been purposefully set up to support people who use AAS. If 
AAS-users choose to inject AAS, they have to learn how to inject the substances 
into the muscle. To get a broader picture of how participants were learning how 
to inject the data was re-categorised, recoded and amalgamated for the ‘who 
taught you to inject’ category to assist in the analysis. The categories were: 
professional support (NEs, medical professionals), support from peers (Including 
friends, family, coach) and self-taught (including websites, forum and online 
videos, books). If participants had selected 1 or more of the groups in each 
category, there were coded Yes. After recoding only 9% of participants had used 
professional support, 25% friends or peers and 66% of participants had taught 
themselves to inject by using the internet, or books. However, as this self -taught 
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option was selected by 77% of cases this suggests that people  who sought advice 
from friends or professionals also did their own research. Some participants 
talked about their experiences of learning to inject and in line with the 
questionnaire results, some asked friends and peers to help and some referenced 
websites that had step by step instructions or videos, specialist fora and talked 
about having practised: 
‘…by myself and online, the very very first time (laughs) I used a vitamin 
B12 because I didn't want to waste drugs …I didn't know that the needle I 
bought was a straw (laughs,) so I almost stabbed myself, but yep no, well 
a little bit on the Fora, a little bit on the internet and just experimenting 
with myself but to be honest it's nothing, it's really easy.’  (Johan/Hong 
Kong/36 [TI]) 
In some countries it is possible to acquire needles freely from NSPs: 
 
‘I used needle exchanges and stuff which I found surprisingly easy to, …you 
just walk in the chemist, tell them which pack you want and away you go ’ 
(Harry/UK/52 [TI]) 
However, although one participant was positive in the interview about using the 
NSP to gain needles, his answer to the questionnaire showed there was still room 
for improvement: 
’In terms of benzodiazepine and steroid addiction, yes but the staff at the 
local needle exchange who arranged blood tests knew too little about AAS 
and ancillary drugs. Some of their advice was plain wrong’ (Don/UK/39 
[Q]) 
Some participants were clear this was not really an option for them, as they felt 
they would be judged and seen in the same light as class A drug users. Some also 
evidenced a sense of pride and were clear they did not need handouts:  
’I went to the needle exchange and they basically told me that we are 
going to give you 1 set of needles so that you have to come back every 
week …and you’re sorta waiting in a queue combined with sorta heroin 
users. …it is judgmental for me to say that it is like you categorising me in 
the same sort of category as these people who are using Class A drugs 
which you know quite evidently are really impairing them, and then you 
are punishing me by saying like you want me to come back every single 
week for the needles like that's just pointless.‘ (Peter/UK/24 [TI]) 
‘‘I actually prefer not to go and get free needles from there because, of 
kinda, you look like a drug addict, and I can afford needles’ (Del/UK/35 
[TI]) 
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 Seeking help for side-effects  5.3.5.3.2
Participants self-reported a range of side-effects experienced (Table 5-4). Despite 
116 participants reporting side-effects only 46 participants said they had sought 
help for side-effects. This could be because others had not experienced side-
effects, did not consider side-effects severe, or they had not sought help from 
professionals but may have sought advice from peers and/or self-medicated. 
Participants were asked to note which problems they had specifically sought help 
for (Table 5-15).  
Table 5-15 Conditions that AAS-users sought help for* 
ED Antibiotics 
Diabetes type2, probably from the GH Kidney numbers  
Acne (n=4) Low blood sugar  
Pec rupture Needed to donate blood 
Gyno (n=7) High prolactin 
Lower jaw problem Cycle advice and harm reduction 
Blood pressure (n=5)  Lowering haematocrit 
Enlarged prostate Knee pain 
Raised liver enzymes (alt over 300; fertil ity Advice - nothing serious 
High haemoglobin Infection in site of injecting 
‘Hypertension, arrythmia, polycytemia, 
dislipidemia, abdominal pain’ 
Blood work at end of 1 year experiment to assess 
recovery 
Suppressed testosterone Benzodiazepine dependence 
P.C.T  
*n given if more than 1 respondent 
 
Further statistical analysis using the Mann-Whitney U test was undertaken to 
explore if the number of years using and age made as difference to whether 
people would seek help for side-effects. There was no significant difference found 
in relation to age, however, there were differences in the ’number of years using 
AAS ‘and ‘whether people said they would seek help for side-effects’ (Yes (n 
=46)/No (n=86)). Distributions of the number of years using AAS for people saying 
yes/no to seeking help were similar, as assessed by visual inspection. The number 
of years using AAS was statistically different between Yes (Mdn = 6) (Mean rank = 
79.09) and No (Mdn = 3) (Mean Rank 85.53), U =1399, z= -7.784, p =.005 (***), 
using an exact sampling distribution for U (Dinneen and Blakesley 1973). 
Therefore, length of time using AAS was a factor in whether or not parti cipants 
sought support, those who had been using longer being more likely to seek help 
for side-effects. Those AAS-users who had been using AAS for a longer time (Mdn 
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6) were more likely to seek support than those who had been using for a median 
of 3 years. This is not an unexpected finding as the longer AAS is used the more 
likely someone is to experience potentially more harmful side-effects.  
Side-effects of using AAS are not limited to just the physical there can also be 
emotional side-effects. When it came to beliefs around whether there should be 
support for such emotional side-effects 71% (n=95) of participants answer yes. 
Yet, notably not one of the questionnaire participants put down counselling as a 
type of support accessed related to their AAS use. Two interview participants 
talked about accessing counselling support (talking therapies) related to their use. 
One had experienced a range of therapies to support his mental health and had 
not found them overly helpful. The other described how it was useful and gave 
him a tool for managing his emotions. Further statistical analysis was therefore 
undertaken to determine if there was a link between belief for a need for 
emotional support and a person’s own experiences. A Chi Square test of 
independence was conducted between ‘belief there is a need for emotional 
support’, and ‘have you experienced behavioural changes’ and between ‘belief 
there is a need for emotional support’, and ‘have you experienced mood swings’. 
In both cases all expected cell frequencies were greater than 5 and, in both tests, 
there was a statistically significant association (small/medium) between the two 
parameters (Table 5-16). When considering emotional support needs, there was a 
small association between those who had experienced behavioural changes 
and/or mood swings and the perceived need for emotional support.  
Table 5-16 Chi Square test results: Belief there is a need for emotional 
support 
Parameter Yes/No parameter Sig 
Y/N 
Chi 
Square 
Cramer V (strength – 
effect size) 
Belief there is 
a need for 
emotional 
support 
Experience Behavioural 
Changes 
.008 7.100 .233 (small/medium) 
Experience Mood Swings .002 9.866 .272 (small/medium) 
 
Dependency could also be a factor in people’s willingness to access support. Only 
26 people (21%) selected yes when asked if they would consider seeking 
professional support to help them stop using AAS. A Chi Square test of 
independence was conducted between could you stop using AAS and ‘would you 
seek professional support to stop’. All expected cell frequencies were greater than 
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5. There was a statistically significant association between ‘could you stop using 
AAS’, and ‘would you seek professional support to stop’, X2 (1) = Pearson Chi 
Square 7.699, p = .006. There was a positive association (Cohen 1988) Cramers V = 
.249 (small/medium) with those who stated they could not stop using AAS is they 
chose being more willing to seek professional support to stop.   
 Experiences of using medical professionals 5.3.5.3.3
The quantitative study showed that people did seek help from medical 
professionals regardless of their geographical location but there was a range of 
responses in terms of how helpful this was. Participants received information 
around harm reduction, and received advice on substances to redress 
gynecomastia, lower haemocrit, reduce side-effects, lower blood pressure and 
obtain blood panel tests. Not everyone had a positive experience and two key 
concepts dominated the discussion on access to medical support:  
1) Doctors being judgemental  
2) Doctors lack of knowledge around AAS. 
 
Table 5-17 Perceived limited knowledge of medical professionals 
‘…more educated than lots of actual doctors because we are dealing with stuff that is 
that is not really studied everything in-depth in medical school, that is normal because so 
many stuff they have to cover’ (Johan/Hong Kong/36  [TI]) 
‘Judged me, got angry, told me to just come off and levels would just come back. I did and 
they never came back’ (Max/Canada/26  [q])  
‘I have had general discussions with GPs on AAS use, their knowledge is questionable’ 
(Isaac/UK/42 [TI]) 
‘…so he put me on a trial of testosterone gel, um which er, wasn’t completely successful 
cos the doctors have a very poor understanding of male endocrinology’ (Del/UK/35 [TI]) 
‘Knowledge among doctors i Sweden is rock bottom about this stuff’(Elvin/Sweden/39  
[q]) 
 
AAS-users felt that often they knew more about the compounds and effects than 
the medical professionals due to the specialised nature of the topic (Table 5-17). 
 
How participants felt about the support they received often depended on the 
opinion/open-mindedness of the professional i.e. whether they took a 
preventative or harm reduction approach. Some found those professionals who, 
whilst not necessarily condoning use, did offer support, more helpful: 
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‘…some of them will be hysterical, and say, ‘No, no, no, you know, I'm not 
talking about this. If you if you say that you do this, I'm not talking about 
it. I can't have anything to do with this... They'll get hysterical that way. 
But the more progressive doctors will be like, ‘all right, look, dude, I know 
you're doing this, let's talk about how to do it safely’ (Hugo/USA/53 [TI]) 
One person talked about the GP prescribing a pill for his depression but not really 
understanding the core of the problem which led to self -research and self-
medication:  
‘I was expecting a little bit more support and maybe get sent someone 
that could help me with how I felt rather than get a prescription for a pill… 
the anxiety/ depression symptoms definitely eased of course but it 
affected my everyday life …I became quite apathetic, I have lost any 
interest in er, like I had a completely lost sex drive... was not happy while I 
was on the drug I was just sort of stable, you know, …tried speaking to the 
doctor …I got told was don’t worry about it the loss of the sex drive and 
symptoms like this would go away after a while… eventually stopping that 
all together but I still didn’t feel great after coming off of them, and I think 
this was why I started looking into erm, therapeutic use of testosterone as 
a means of treating depression‘ (Alvin/UK/36 [TI]) 
Many participants referenced that medical professionals would insist that they 
stop using, and they felt this was counterproductive: 
‘…like the person I met who tells me go cold turkey and …just deal with it. 
I'm like okay that's not for I want to hear from the doctor who actually is 
an endocrinologist.’ (Lev/Canada/32 [TI]) 
These negative personal experiences were often shared within the community, 
causing some users to seek help but not be honest about their use and therefore 
may not have been given the necessary support. Overall, many participants said 
they were unlikely to seek any professional medical help, giving a variety of 
reasons that are summarised in (Table 5-18).  
Over and above the negative impressions and experiences users had of medical 
professionals, a lack of acknowledgement of the benefits of AAS use was also 
something that impacted on the credibility of professionals:  
‘I live in the United States and they refuse to even admit that steroids will 
put on muscle mass’ (Paul/USA/29 [TI]) 
There is a wide range of specific types of information and support that AAS-users 
accessed. Interestingly, the predominant UK Public Health harm reduction 
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discourse focuses on the risk of BBVs and need for testing, but few participants 
accessed this type of support.  
Table 5-18  Reasons for not seeking medical support 
Reasons for not 
seeking medical 
support 
Quotations 
Avoid Stigma  ‘…becasue i dont want to tell i used AAS so i dont get ‘right’ 
help’ (Viggo/Sweden/34 [q]) 
 ‘…if I wanted to I probably wouldn’t anyway, I wouldn’t want it 
going on my medical record... in case one day I wanted to apply for life 
insurance or something, that’s going to make things a lot harder for me. 
…Because they won’t want to go anywhere near me if they think I am 
taking steroids or have in the past’. (Del/UK/35  [TI]) 
Lack of trust in 
medical 
professionals 
 ‘Never felt the need. I self-medicate. I dont trust most medical 
professionals to know what to do.’ (Brad/USA/26  [q]) 
Negative stories 
from others -do 
not want to be 
told to stop 
 ‘…it's just something I've heard about. Anyone I know that has 
seeked professional advice has been told to stop their usage 
immediately. We all know that what we do can damage us, but we're 
not going to stop’ (Clinton/UK/20 [CI]) 
 ‘…the experiences my sort of friends and team mates have had, 
with healthcare professionals …I am trying to think if they have been 
entirely, yes they have been entirely negative… I feel like going to a 
healthcare professional with anything you know would be a last resort.‘ 
(Alvin/UK/36 [TI]) 
Blame 
everything on 
AAS use 
 ‘…literally go in with a sore foot, is it cos you have taken 
steroids? (really) you know what I mean, literally, I get a cold it’s cos you 
take too many steroids’ (Powel/UK/34 [TI]) 
 ‘…if you go to the doctor for anything they are going to say, 
they might say ok, well, that is probably to do with the steroids and they 
will brush things aside and not take you seriously.’ (Del/UK/35  [TI]) 
Because they 
can do it 
themselves 
  ‘…never had any issues i couldnt handle my self’ 
(Jerrik/Denmark/35 [q]) 
 ‘…the resources are out there and it seems much easier, and 
hassle free than actually going to see the doctor.’ (Alvin/UK/36  [TI]) 
Because the 
problem was 
unfixable 
 ‘I waited for too long and the gyno effects were permanent 
already’ (Costa/Greece/32 [q]) 
 
There was a clear narrative around the need for the medical profession to not 
judge or stigmatise people who use AAS, as this proved to be a barrier to 
accessing support, as did the perceived lack of knowledge of such professionals.  
 Theme six: Ideal support 5.3.6
This section has reported on five of the six themes. A key objective of the study 
(3.9) was to understand what users say they want, as compared to their thoughts 
on information and support already provided, as the literature review identified 
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this as a key gap in knowledge. The following publication (Harvey et al. 2020), 
based on the findings of this study explores theme six: ideal support.  
There was a further sub-theme on participants continuing to use AAS linked to 
wanting to maintain their libido and this brings something new to the discussion 
around motivation for use. This sub-theme is explored in part three of this chapter 
and takes the form of a submitted paper.  
5.4 Summary 
This chapter has detailed the findings from five of the six themes: 
1. Reasons to use AAS 
2. Side-effects of AAS use 
3. Risk management 
4. Perceptions of and perceptions on AAS use and society 
5. Information and support accessed 
It has described the data aligned to these themes under a number of sub themes 
(Figure 5-1). 
The following two chapters report two further findings. Chapter 6 considers the 
theme of ‘ideal support’ and takes the form of a published paper. Chapter 7 
explores the sub-theme of ‘impact on libido’ and takes the form of a submitted 
paper.  
Chapter 8 uses the concepts of management of use and identity to explore the 
themes from the findings in more depth. Moreover, it considers the strengths and 
limitations of the study and includes reflection on theory and personal reflections 
on the thesis.  
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 Research article Chapter 6
Harvey, O., Parrish, M., Van Teijlingen, E. and Trenoweth, S., 2020. 
Support for non-prescribed Anabolic Androgenic Steroids users: A 
qualitative exploration of their needs. Drugs: Education, Prevention 
and Policy 
 
See: https://eprints.bournemouth.ac.uk/33216/ 
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 Research article - submitted Chapter 7
Harvey, O., Parrish, M., Van Teijlingen, E. and Trenoweth, S., 2020. 
Libido as a reason to use non-prescribed Anabolic Androgenic 
Steroids. Drugs: Education, Prevention and Policy 
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 Discussion  Chapter 8
8.1 Overview  
This chapter is divided into four sections and discusses the two overarching 
themes from the findings in this thesis:  
(1) management of use;  
(2) identity.  
(3) the limitations and strengths of the study.  
(4) The theoretical reflections on the findings linked to practice, suggesting a 
person-centred approach via a Pathway model for exploring a user’s life 
experiences. 
The chapter concludes with researcher’s personal reflections on undertaking this 
study. 
The first section begins with a comparison of the participants’ demographics 
compared with recent studies on this population and an introduction to the 
concepts of identity and management of use. It then explores six themes aligned 
to the concept of management of use, with a comparison and contrast of the 
literature with particular attention paid to addressing objectives 1b and c, 2a and 
b, 3a and b (3.9).  
 Participant demographics comparison 8.1.1
It is useful to compare and contrast the demographics of participants with those 
in recent studies to situate this study in its context. This study found a mean age 
of 35. This is slightly older than recent studies of 684 UK participants (mean age: 
32) (Begley et al. 2017), 180 patients who visited a specialist AAS clinic in the 
Netherlands (mean age: 34) (Smit and de Ronde 2018), and 232 Norwegian AAS-
users (mean age: 31) (Havnes et al. 2019). The mean for number of years using 
(7.2 years) was greater than the four years found by Smit and Ronde (2018) but 
less than the 10.2 years found by Havnes and colleagues (2019). 91% of 
participants who self-identified as heterosexual is comparable with 95% found by 
Begley and colleagues (2017). Comparisons of ethnicity are difficult as this study 
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was globally distributed however, the finding of 79% white is consistent with 
Begley and colleagues (2017), (80% white British). The employment status of 85% 
was slightly higher than recent studies: 67% (Smit and de Ronde 2018), 50% 
(Havnes et al. 2019) and 78% (Begley et al. 2017).  
8.2 Identity at the heart of management of use 
Further synthesis of the themes (Figure 5-1) identified two overarching, 
interconnected concepts: ‘management of use’ and ‘identity’. Identity appeared 
to be at the heart, as information and support seeking behaviours were linked to 
risk management strategies and motivation to use both of which were influenced 
by an individual’s identity (Figure 9-1).  
 
Figure 8-1 Concepts of identity at the heart of management of use 
Identity underpinned many participants’ decisions to use (5.3.4.2.1, 9.4.5) and in 
turn this impacted on how they managed that use. The effects of using also 
influenced decisions over the choice of an AAS use regime, as well as 
consideration for continuing or stopping use. When it came to identity, positive 
effects could reinforce different identities, side-effects of stopping use could 
adversely affect it and this researcher argues that masculine identity could also 
impact help-seeking behaviours (9.4.6, 9.4.7). Responsible use was an important 
part of identity as an “AAS-user” for many (5.3.3.2), as was an identity as a mentor 
(5.3.3.7); advising novice users on harm reduction strategies. Mitigation of risk 
played a key role in managing use including consideration of risks versus benefits, 
developing ethnopharmacological knowledge, self-experimentation and seeking 
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evidence-based knowledge (5.3.3.2). Their perceptions of how society viewed AAS 
impacted on choices about management of use both in information trusted and 
services accessed.  
This section explores the most noteworthy elements of the six themes (Figure 5-1) 
related to management of use as identifying support needed was a key objective 
of this study (3.9). To avoid duplication if a point has been covered (5.3.6, Chapter 
6 and 7), these are signposted. The following section will then discuss how 
identity is central to this management of use.  
 Reasons for use 8.2.1
The first theme focused on reasons for using AAS and although underlying 
motivations will be explored more fully in the next section, it is worth noting here 
that this study found complex and intertwined motivations for use, which aligned 
with current evidence (Kimergård 2015, Bates and McVeigh 2016, Begley et al. 
2017, Richardson and Antonopoulos 2019) (Table 5-2). An anticipated finding was 
that for many the main motivation was to increase muscle and strength, mirroring 
current literature (Sagoe, Andreassen, et al. 2014, Murray et al. 2016, Begley et al. 
2017). However, one of the reported motivations for using AAS was slightly higher 
than expected as other studies have found that increased sex drive or sexual 
function were not highly rated reasons for use (Ip et al. 2011) (5.3.6). The reasons 
for use influenced how AAS use is managed, including: planning, types of 
substances used, dose sizes and preparation. These differed based on individual 
goals, for example, if using AAS as a form of TRT; users talked of taking a continual 
low dose with few ancillary substances compared to those competing (5.3.3.2) 
where often AAS was used in cycles and supra-physiological doses. This influenced 
the type of information and support accessed and wanted for example, 
participants using for TRT wanted acknowledgement of the negative effects of low 
testosterone and access to specialised medical support, whereas those on cycles 
wanted more research into Post Cycle Therapy (PCT), and PCT advice. Moreover, 
in this study, some participant’s motivation changed over time which could lead 
to changes in risks; consequently, support needs to match with the differing 
needs.  
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 Justifications for use and continuing use 8.2.1.1
This study found many long-term AAS-users who despite experiencing negative 
effects, planned to continue using. Justifications of use such as: side-effects were 
minimal and manageable (5.3.3.2), perceptions they engaged in healthy behaviour 
i.e. not drinking and smoking, that unlike other types of illicit substance they did 
not seek to rob people to fund their use, that it does not hurt others and that 
people do not ‘drop dead’ from it, mirrored those in the literature (Boardley et al. 
2014). Such arguments are, of course, valid from the participant’s point of view 
but tend to discount that use can be physically and emotionally harmful. Boardley 
and colleagues (2014) argue that this substance use has become normalised, a 
routine part of the culture and as such users do not have to consciously or morally 
disengage from using. 
This study found that users felt their quality of life had improved through use, 
with users happier, more confident and stating that their new lifestyle helped 
alleviate previous problems such as obesity, body image perception and 
depression, which is similar to other studies (Petrocelli et al. 2008, Smith et al. 
2009, Davies et al. 2011, Walker and Joubert 2011, Kimergård 2015, Joubert and 
Melluish 2016). Feelings associated with using AAS, could reinforce or motivate 
continued use (Smith et al. 2009), as could positive feedback from others. If use 
produces positive side-effects such as greater strength and increased confidence; 
as found in this study and others (Walker and Joubert 2011, Ip et al. 2017), then 
this could reinforce the benefits of use and strengthen their resolve to continue 
their chosen usage. A study of nine AAS-users (aged 18-24) found a potential 
change of motivation when the initial external motivation of wanting to be more 
muscular led to an internal motivation of body image concerns (Harris et al. 2016). 
This study also had a number of participants using as a result of low testosterone 
and AAS-users may return to use to alleviate the potential feelings of dysphoria 
and as a result, loss of libido, lack of energy and possible onset of depression that 
could come with having ASIH (Kanayama and Pope 2018).  
Studies have considered use via the lens of Bandura’s theory of moral thought 
(that is, a self-regulatory process) and action (Boardley and Grix 2014, Boardley et 
al. 2014) and identified that six of the eight social mechanisms to allow for 
immorality were present amongst AAS-users discourse, including advantageous 
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comparison, often comparing use to more ‘harmful’ activities such as heavy 
drinking or smoking (5.3.4.3). Another comparison found in this study was that of 
‘responsible use’ in comparison with less sensible AAS-users (5.3.3.6). This study 
found examples aligned to social mechanisms similar to those suggested by 
Boardley and Grix (2014), such as, moral justification: use allows them to advise 
others (5.3.3.7), and distortion of the consequences: it might not affect me, or 
believing harms are over-exaggerated (5.3.4.2).  
Users in this study saw potential negative social effects from use, for example in 
some countries AAS use put them on the wrong side of the law. Breaking the law 
is not necessarily immoral (Boardley and Grix 2014), and the use was medication 
and not a ‘criminal act’ (5.3.4.1). Justification of use, aligned to moral 
disengagement is the diffusion of responsibility (Boardley and Grix 2014). Within 
this study some participants did appear to displace responsibility, arguing use was 
normal within the body-building world, or in certain gym cultures, but many did 
not, arguing their use was personal choice. Moral justi fication suggests a need to 
justify something that is immoral and although it is helpful to understand 
potential mechanisms for reinforcing use, particularly in countries where AAS is 
banned for personal use, such arguments also feed into the narrative that AAS use 
is in some way immoral and could lead to professionals internalising such 
judgements. This author argues that rather than being judgemental of AAS-users, 
professionals should see users as exercising free will and making rational choices 
(Keane 2003). 
 Effects of AAS use 8.2.2
The effects experienced impacted the management of use in a number of ways. 
Participants changed what and how they used to enhance positive effects or to 
mitigate side-effects, and it was often concerns over long-term side-effects that 
led some to consider stopping use.  
 Positive effects  8.2.2.1
This study highlighted a plethora of positive effects from using AAS which reflects 
previous studies (Rowe et al. 2016, Mey et al. 2018). Users were keen to promote 
the positive physical effects of use and decry the fact that many medical 
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professionals refuse to acknowledge these (5.3.5.3.3). Positive experiences linked 
to increased libido informed people’s decisions to re-start using or continue using 
but with different doses and substances (Chapter 7). The positive effects of AAS 
use were seen as ways of justifying use and the difference in the cases reported 
(768 positives, 148 negatives) emphasises the weighting on the positive effects. 
Moreover, the third most selected motivation for use was ‘positive results 
achieved from using AAS’. A key finding from this study was the narrative around 
the positive benefits that users experienced, that many of these were not purely 
concerned with the physical gains, such as muscle size but instead centred on 
wellbeing, such as being happy or improved self-esteem, which have been linked 
to motivation in other studies (Greenway and Price 2018). Moreover, the 
hyperbolic words and metaphors used to describe feelings when using, for 
example, ‘pumped’, ‘euphoric’ (Figure 5-6) add to the positive emotional feelings 
and such descriptors have been found in other qualitative studies (Smith and 
Stewart 2012). The importance of the positive emotional effects was also 
evidenced by the number of participants that answered ‘improved’ when linking 
to quality of life improvements. The questionnaire did not allow for reasons to be 
given for this; however, from the interviews often the improvements in quality of 
life were aligned to psychological benefits, such as improved confidence and 
being more decisive. This is important as it gives insight into a potential positive 
reinforcement for use of AAS from such effects.  
It is vital to understand that users experience pleasure from using AAS 
(Mulrooney et al. 2019) and this study goes one step further in highlighting the 
perceived positive impact experienced by AAS-users on their wellbeing and 
mental health, as some participants stated that the improvement in quality of life 
was such that they would not wish to return to their old life.  Arguably, the 
prevention-focussed perspective from the medical profession, experienced by 
many participants (5.3.5.3.3) could be because from a medical perspective the 
potentially physical harms seem to take precedent over psychological  benefits. 
Certainly, physical harms are often more easily identified and assessed, when 
compared to the more subjective emotional benefits. Further research into the 
specific improvements in quality of life would be beneficial as this may shed light 
on further support options. It also adds strength to the argument that in order to 
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gain credibility, professionals must acknowledge the benefits of use (Fomiatti et 
al. 2019). 
 Physical side-effects 8.2.2.2
There is little contention within the academic literature, or amongst this study’s 
participants that using AAS does not come without risk. However, that is not true 
of all AAS-users as one study found that over 50% of users thought AAS were not 
harmful to health if used correctly (Alsaeed and Alabkal 2015), and another that 
61% had no knowledge of the sexual problems arising from it (Bahri et al. 2017). 
The perceptions of harm could be dependent on age, culture or risk perception. 
This study found that participants had experienced a wide range of side-effects 
(5.3.2) mirroring those already noted in the literature (Nieschlag and Vorona 
2015, Smit and de Ronde 2018) and included potentially less severe and reversible 
side-effects such as acne, gynecomastia and mood swings to more long-term ones 
such as ASIH. These side-effects did not necessarily lead interviewees to 
discontinue use, and previous studies have shown similar themes, for example 
one study found over 90% of AAS-users planned to continue use despite side-
effects (Ip et al. 2011). Furthermore, Karavolos et al. (2015) concluded that one 
reason for the increase in AAS use, was that AAS was considered safe to use 
(within the online community) and that the side-effects were manageable, 
although they gave no evidence for this directly. In this study side-effects differed 
between participants, which matches previous studies (Richardson and 
Antonopoulos 2019), and users believed that AAS use impacted different 
individuals differently, not a necessarily irrational perspective bearing in mind the 
individual and complex AAS use patterns. Many participants were unconcerned 
about the short-term side-effects of use and felt they were over-exaggerated. 
Some participants talked down the impact of side-effects and felt that they might 
be lucky and not experience the more serious effects of long-term AAS use 
(5.3.2.3). This dissociation and reduction of harm is noted in other studies (Walker 
and Joubert 2011). However, this lack of concern is not necessarily minimalising 
harms as one recent study of 180 AAS-users found no critical health issues from 
side-effects (Smit and de Ronde 2018) and in this study some reported not 
experiencing any side-effects. However, it may also depend on users’ perceptions, 
for example, a large US study of adolescent males found that AAS use was 
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perceived as less risky or harmful when considered easily obtained, if close friends 
used AAS, or if they self-reported low levels of self-esteem, depression or risk-
taking behaviours (Denham 2009).  
This study matches others in that it shows that AAS-users often self-treat side-
effects (Bates and McVeigh 2016, Smit and de Ronde 2018). In this study, of the 
35% of participants who sought specific help for side-effects only 54% (n=25) 
went to see a medical specialist and others have raised concerns that many do not 
seek medical support (Begley et al. 2017). This self-medication for side-effects is 
concerning as the vast majority of AAS-users are not health professionals and 
more often, as with previous studies (3.6 (Harvey et al. 2019), this study found 
users relying on advice from the internet and more experienced AAS-using peers. 
Many users in this study perceived the academic evidence to be unreliable and 
did not match their own frames of reference. This perception could be due to lack 
of resources, legality, or lack of ethicality when it comes to academic research on 
the combinations of substances used and their effects (Smit and de Ronde 2018). 
Therefore, users put their faith in information from longer-term users. The finding 
that the longer people have been using AAS the more likely they were to seek 
help for side-effects (5.3.5.3.2) warrants further investigation and suggests that 
those more experienced although may be more likely to do their own research 
and self-medicate, they may also be experiencing more severe side-effects due to 
long-term use and hence seek support. Self-medication may be effective when it 
comes to reducing risk/harm from short-term side-effects but may not be so 
reliable when it comes to the more serious harms that come with long-term use. 
There appears to be a change in use as user’s age, and in this study, it was older 
users who were more likely to be engaged in continuous low-level use. This 
suggests a change in or different motivation from younger users such as 
maintaining a body aesthetic or self-medicating for low testosterone levels. This 
could be important as this study found that the longer people have been using 
AAS the less likely they are to believe that they could stop using it (5.3.1.3). This 
could suggest that long-term use could increase the likelihood of developing a 
dependency which puts people at increased risk of experiencing physical harms 
(2.2). Therefore, support needs may change as people age. Academics argue for 
more research into the long-term effects of using AAS and there is a need for 
clinical trials to ascertain the risks of sustained AAS use (Kanayama and Pope 
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2018, Smit and de Ronde 2018). This study adds more evidence to support both 
these areas of research.  
 Psychological side-effects 8.2.2.3
This study’s participants experienced a range of negative psychological effects 
(5.3.2.4) with seven people stating their quality of life had worsened. In a study of 
74 AAS-users, Griffiths et al. (2018) found a range of psychological side-effects 
including: impulsivity, sleeplessness, irritability, aggressiveness, relationship 
difficulties, fatigue, and paranoia. This study found all these side-effects except for 
paranoia. Other studies have also noted that individual negative experiences do 
differ and that some experience strong negative emotional reactions (Richardson 
and Antonopoulos 2019). The emotional side-effects, in this study, fell into two 
predominant types: 1. an increase in irritability when on cycle (often this was 
substance-related) and 2. anxiety when coming off-cycle. As with the physical 
side-effects many participants felt it was their responsibility to manage 
psychological side-effects. 
 Aggressive behaviours 8.2.2.3.1
This study found a range of side-effects linked to irritable behaviours and 
psychological side-effects including aggression (Appendix 22, 23), which is 
consistent with other studies (Trenton and Currier 2005, Beaver et al. 2008, 
Jenssen and Johannessen 2015, Lundholm et al. 2015, Piacentino et al. 2015, 
Bates and McVeigh 2016, Begley et al. 2017). However, the results, as with 
previous studies (Petrocelli et al. 2008, Dunn 2015), are inconclusive as the data 
are self-reported and there is no additional objective evidence to suggest the 
behaviours are causal. However, many users noted aggression as a side-effect and 
commented that one specific brand ‘Trenbolone’ caused the most notable 
increases in aggressive behaviours (Appendices 22, 23) and worryingly, one study 
found Trenbolone was one of the two most frequently used substances (Smit and 
de Ronde 2018). Moreover, a Norwegian advice service that was also open to next 
of kin found that, although there was no suggestion that they felt at risk, next of 
kin did report noticing behavioural side-effects of use including loss of empathy, 
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anxiety, depression and aggression (Havnes et al. 2019), which matches those 
found in this study (5.3.2.4).  
The findings showed that some users felt such ideas as ‘roid rage’ were palpably 
untrue, or at least not the whole truth (5.3.2.4, 5.3.4.2 ) and many AAS fora 
articles challenge this perception (Fordham 2014). Other studies have shown that 
users believed that the public has a distorted view of the side-effects (Cohen et al. 
2007) and feel stigmatised because media depictions often focus on stories of 
‘roid rage’ (Maycock and Howat 2005, Griffiths, Murray, and Mond 2016). The 
myth, that AAS use causes rage, is embedded within our western cultural psyche, 
grounded in such cultural icons as the ‘Incredible Hulk’, a hyper-muscular 
superhero with a catch phrase ‘you won’t like me when I am angry’ (Fein 2007) 
and perpetuated in the way AAS use is portrayed in the media with such headlines 
as: ‘My boyfriend did this to me in ‘roid rage attack’’ (Watkins 2015) and reports 
as:  
‘Anabolics addict Raoul Moat shot his ex-girlfriend Samantha Stobbart, 
her new partner Chris Brown and blinded PC David Rathband... Moat, 37, 
described his anger saying: “It’s like the Hulk. It takes over and it’s more 
than anger and it happens when I’m hurt.’ (Myall and O’Boyle 2014) 
An investigation into the correlation between AAS use and aggression (and 
anxiety), considered the two pathways that are thought to be involved in AAS-
induced behavioural disorders and could not identify the molecular mechanisms 
underlying the behavioural alterations following AAS abuse (Bertozzi et al. 2017). 
This is an example where the authors, to emphasise their points, conclude there is 
a need for research as AAS-users can harm others (Bertozzi et al. 2017). There is 
scant evidence in the literature for harm to others with the exception of few 
studies that are not conclusive as to causation (Choi and Pope Jr. 1994, Driessen 
et al. 1996, Seppänen and Eronen 2016).  
This study asked specific questions about users’ thoughts on whether use put 
others at risk and found few felt that their use put others physically at risk, but 
there were other risks such as if they become seriously ill as a side-effect of use. 
One possible explanation for this lack of perceived risks to others could come 
from the wide range of risk management strategies grounded in self -awareness 
used to self-regulate aggressive feelings. We all have different measures of the 
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what constitutes an aggressive feeling and in a sporting context a level of 
‘aggression’ is often seen as desirable although nine participants in this study gave 
‘increase my aggression’ as a reason to use AAS. It is possible that when talking 
about self-regulation of aggression this was not related to AAS use but related to 
their perceived natural levels of aggression. However, Jenssen and Johannessen 
(2015) found both AAS users and contemplators have higher levels of aggression  
compared non-AAS users and they suggest that AAS use could be indicative of an 
aggressive personality profile (Jenssen and Johannessen 2015). Regardless of 
whether AAS-use can increase aggression or if people who use AAS are likely to 
have more aggressive personalities, it is possible that the above-average 
educational levels of participants in this study led to a higher level of self-
awareness related to aggressive tendencies and therefore decided to take action 
to mitigate these.  
A key finding was the concept of taking responsibility for managing emotional 
side-effects (5.3.3.2, 5.3.3.5, 5.3.3.6) and such effects did not absolve users of 
responsibility for their behaviour (Fomiatti et al. 2019). While this could link to a 
desire for being in control, a concept found in traditional views of masculinity 
(McManiman 2001) which is explored in 9.4.4, it is also related to management of 
use.  
A variety of self-regulation tactics were found:  
 Self-awareness - avoidance of certain substances 
 Self-awareness – management feelings 
 Use of other substances (which have calming effects) 
 Meditation  
 Support from others 
The use of such tactics that included meditation and emotional regulation was an 
unexpected finding, and has not been extensively covered in the literature but is 
important, in that such technique and tactics could be something that could be 
incorporated into many harm reduction advice and skills such as meditation could 
be offered by services. Moreover, it is something that could be considered when 
looking at service options that include peer support.  
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 Continuous use versus PCT 8.2.2.4
This study found that 58% of the participants preferred continual use of AAS 
(Table 5-1); either through continued low-level use, or a blast-and-cruise cycle 
compared to the more traditional cycling. Yet previous studies have noted that 
the most typical way to use AAS is in cycles (Rowe et al. 2016, Begley et al. 2017, 
Smit and de Ronde 2018). Normally, PCT is used to help hormone recovery after 
having used supra-physiological amounts of AAS (Griffiths, Henshaw, et al. 2016), 
however, as yet there have been no published empirical quantitative studi es 
investigating this is phenomenon (Griffiths 2019). There was much discussion 
about the efficacy of PCT during interviews and similar to other studies (Griffiths, 
Henshaw, et al. 2016), those advocating PCT wanted access to PCT to help them 
recover. However, several participants had started out doing PCT, but now felt it 
was healthier to continue use but using lower doses of testosterone. For many, 
the reason given for this was not related to physical health, or appearance (i.e. 
fear of losing muscle,) but psychological health, as for some, dropping to low-level 
use meant not having to experience side-effects like anxiety and low libido 
(5.3.2.4.2). Another study found a number of adverse factors motivated the 
continuation of use which included concerns over muscle and strength loss, 
decreased physical ability, decreased attractiveness and loss of respect (Cohen et 
al. 2007) but notably did not include loss of libido or anxiety. However, anxiety 
can be a side-effect of lowered testosterone levels or ASIH (Berglund et al. 2011, 
Kanayama and Pope 2018).  There is a challenge in understanding risks for those 
who have decided on continued low-level use, whether to avoid PCT side-effects 
or as a form of self-prescribed TRT. When used as self-medication for low 
testosterone AAS-users do not see it as harmful, but rather beneficial, with the 
received wisdom being that average testosterone levels used by medical 
professionals are unfair and too generic (5.3.5.3.3, 5.3.2.4.2). Studies have shown 
benefits of TRT as a treatment for low testosterone (Akerman et al. 2017, Moon 
and Park 2019) (Chapter 7). It could be difficult to challenge this perception as the 
efficacy of using PCT has not yet been verified (Smit and de Ronde 2018) and 
there is debate as to the risks versus benefits and efficacy of TRT (Bassil et al. 
2009, Bain 2010, Huo et al. 2016). Consequently, medical professionals may err on 
the side of caution as they do not have confirmation of efficacy and using a 
continual low dose goes against expert advice in the literature as regular long 
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breaks between cycles can help to reduce the side-effects (Rowe et al. 2016). 
However, AAS-users trust the experiences of peers and their own experimental 
experiences. This researcher agrees with others, that access to PCT is a possible 
harm reduction tool (Griffiths, Henshaw, et al. 2016) and should therefore be part 
of any specialist support service. 
 AAS use dependency 8.2.2.5
Post-cycle emotional impacts may further act to strengthen dependence 
mechanisms (Griffiths and Murray 2018). There are three proposed dependence 
routes to AAS: anabolic, hedonistic and androgenic, and in turn the androgenic 
dependence route is related to three negative reinforcement mechanisms: loss of 
libido, fatigue and other hypogonadal symptoms and depression (Kanayama et al. 
2010). Some participants felt that they would be on TRT for the remainder of their 
lives and spoke of their anxiety if this was not available (5.3.1.2, Chapter 7). This 
could in part be explained by the quantitative findings which showed many users 
felt AAS had a positive impact on their quality of life (Figure 5-4). There also 
seemed to be a positive reinforcement as some experienced increases in both 
their libido and sexual function when using AAS. The treatments for the first two 
mechanisms are medication and for the third (depression) anti -depressants are 
suggested and electroconvulsive therapy (Kanayama et al. 2010). Interestingly, 
this study found that participants felt testosterone injections to be more effective 
than prescribed anti-depressants (Chapter 7). 
This study shows that the information needs of many participants focussed on 
safe use and medical support to mitigate side-effects or combat ‘perceived’ low 
testosterone levels, which could link to the age and motivations of this study 
population. Moreover, this study found a high percentage of people on a low-level 
continual dose of testosterone, going against NSP’s guidance (5.3.3.2). NSP advice 
is clear about the need for PCT and that no cycle should be longer than 6-weeks 
(oral) or 12-weeks (injecting) (Campbell and Preston 2017). As this advice is 
contrary to some user’s beliefs and could cause some to reject such services, as 
they do not identify as AAS-users and are self-medicating for TRT, this would only 
reinforce that thinking. Consequently, services need to consider if the types of 
messages they use are potential barriers to people accessing support.  
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 Support for emotional side-effects 8.2.2.6
When considering emotional support needs, there was a small association 
between those who had experienced behavioural changes and/or mood swi ngs 
and the perceived need for emotional support (5.3.6, Table 5-16). This finding 
would seem self-explanatory, as those who were experiencing difficulties 
managing behavioural changes are more likely to suggest there is a need for 
support. Practical support is an important part of harm reduction and in the UK, 
advice on how people might achieve physical gains through dieting and exercise 
regimes is often provided by NSPs (Campbell and Preston 2017), yet arguably little 
is offered to help with the psychological side-effects, and this may be because 
people are reluctant to ask for such help, or acknowledge they might want it. 
Moreover, experiencing mental health problems was the most desirous reason for 
stopping AAS use (Havnes et al. 2019), so this is an area where more support 
might need to be sensitively offered. From this researcher’s perspective, 
regardless of the cause, if AAS-users are experiencing negative emotional 
responses, these should not be ignored as this may increase the likelihood of 
dependence. Consequently, there is a need for services to consider how they 
might offer to support people who experience emotional side-effects.  
 Risk management 8.2.3
In line with previous studies (Cohen et al. 2007) this study found high educational 
levels amongst the cohort, which could suggest a reasonable level of health 
literacy (2.3.1), i.e. an individual’s ability to make sound health decisions in the 
context of everyday life (Kickbusch 2008). Moreover participants seemed to be 
well-informed about the risks of use, as reported elsewhere (Dermota et al. 2013). 
However, just because participants are health literate and have a good knowledge 
of risks, that does not necessarily mean that their behaviour is without harm as 
Jacka et al. (2017, 2020) note they may consider themselves well informed but are 
using internet sources, which could provide potentially misleading or inaccurate 
information. It is also important to note the potential for confirmation bias within 
this population as demonstrated by Meppelink et al. (2019), which found that 
when searching the internet for health information people perceived the belief-
confirming resources as more useful, credible and convincing than information 
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that was inconsistent with their beliefs. As this population makes use of AAS-using 
fora online, which help to build a community of beliefs around AAS use , this could 
impact on health-seeking behaviours as a dominate theme (5.3.5.3.3, 8.2.2.1) is 
the lack of knowledge of medical professionals.  
Participants were often clear about the harms, had strategies for managing side -
effects, and were focused on balancing risks. Arguably, AAS-users are not 
disassociating from harms but are undertaking a risk/benefit analysis and 
concluding that there are greater personal risks to them in not using. To manage 
risks effectively users developed a strong understanding of how their own body 
worked and the impact of the substances on the body (5.3.3.5), which ties in with 
previous studies (Monaghan 2002, Brennan et al. 2019). Participants used a range 
of medications to mitigate for side-effects (5.3.3.2) and this is consistent with 
other studies (Ip et al. 2019). Development of ethnopharmacological knowledge 
can be seen as both a positive and negative. It evidences that this population 
treats their use seriously and is focussed on risk management and harm 
reduction, and could be seen as an empowerment strategy (Brennan et al. 2019). 
However, it could be also seen as a way of justifying how they are responsible and 
different from other types of drug users.  
The distrust of medical professionals could be another reason for self-medication. 
This lack of trust was evidenced through participants’ personal experiences and 
stories from other users in which doctors took a prevention stance, condemned 
all AAS use and were not as knowledgeable as AAS-users (5.3.5.3.3). This lack of 
faith in the knowledge base of the medical profession has been widely reported 
(Pope Jr. et al. 2004, Dunn et al. 2016, Havnes et al. 2019), and numerous 
academics have noted that not only is the medical profession anti -AAS use (Yu et 
al. 2015) but it also doesn’t recognise the efficacy of steroids (Griffiths, Murray, 
Mitchison, et al. 2016), which causes users to question the harms noted by 
medical professionals (Kimergård 2015). However, professionals use evidence-
based advice and there are challenges with effective research in this field, as it is 
predominantly low-level evidence such as observational studies and case reports 
that form the basis of knowledge of side-effects (Smit and de Ronde 2018). 
Consequently, it is not surprising that, in line with other studies (Kimergård 2015), 
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this study found advice from other users being perceived as more reliable (Table 
5-14).  
 Perceptions on and perceptions of AAS use and society 8.2.4
 Stigma  8.2.4.1
This study found actual and perceived stigma attached to using reported by AAS-
users (5.3.4.3) which echoes previous studies (Hanley Santos and Coomber 2017, 
Richardson et al. 2019). One reason for this may be linked to appearance norms as 
one study that specifically asked people for their views on steroid users showed 
non-users often found the associated focus on body-image fake and distasteful 
(Ravn and Coffey 2016). Yet, It was clear from the face-to-face and Skype 
interviews that many of those interviewed did not meet the stereotypical hyper-
muscular form as depicted in the media, although they were more defined than 
perhaps what would be seen as ‘average’ see Figure 9-2 
 
Figure 8-2 Picture of a participant  (Permission granted by participant) 
The narrative surrounding AAS which amplifies side-effects and exacerbates and 
misconstrues aggressive behaviours may mean that people who use are less likely 
to speak out. In this study, participants did not necessarily comprehend why 
activities such as smoking and alcohol consumption which have long-term health 
risks, seemingly carry less stigma, particularly as these can put others ‘passively’ 
at risk. AAS-users also perceived that they face more judgement than people 
undergoing other body modifications (5.3.4.3) such as Botox and breast 
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enhancement, with Society seeing these as medically, socially and even morally 
more acceptable. This contrast between cosmetic enhancers for aesthetic 
enhancement such as Botox being perceived as positive and AAS use as negative, 
is something which has been previously noted in the literature (Mulrooney et al. 
2019). Such body modifications are still predominately the realm of women and 
arguably it is more acceptable for women to care about how they look and as a 
consequence may experience less stigma when they use chemicals for appearance 
enhancement.  
The desire not to be identified with injecting drug users may reflect why many 
users are reluctant to access shared services. It may not just be stigma that is a 
barrier but also fear of consequences. If a key motivation was ‘for my job’ (Table 
5-2), this then might impact on support, for instance in the UK personal AAS use is 
not illegal but for certain professions e.g. police or military, it could have career-
ending consequences, therefore such people are less likely to seek any help 
through ‘official’ channels for fear of it being recorded on medical records This 
could also impact everyday life as one user talked of stories where AAS use 
recorded on medical records impacted a peer’s mortgage insurance (5.3.2.5, 
5.3.5.1, 5.3.4.3). Therefore, this may in part explain why they turn to advice from 
peer networks. A range of elements potentially create stigma, including a 
culmination of media ’roid rage’ stories, economic/social impact of undertaking 
perceived risky behaviours, perceptions of people who use of non-prescribed 
drugs and/or lack of empathy for the reasons behind use e.g. fed by the notion 
that these men want to be unnaturally muscular.  
Whatever the reason for the stigma it is potentially harmful, as this stereotypical 
portrayal could negatively impact professionals as they too, could be influenced 
by cultural and social perceptions and consequently be judgemental.  
Participants expressed concerns about whether this researcher would describe 
them in ways that they considered ‘stereotypical’ (5.3.4.2). Judgements about 
perceptions of substance use are often unconsciously informed by the society in 
which we live, and even researchers can be non-empathetic in their views; for 
example one book on forbidden drugs, covering use of AAS, suggested that the 
harmful side-effects, within which they include grandiose delusions, psychosis and 
reference court cases linking use to the defence of rape, are “a tremendous price 
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to pay for a heartbeat of extra pace, a few more ounces on the squat-thrust, or an 
admiring glance on the bench” (Robson 2005, p.154). This feels judgemental and 
oversimplifies what is fundamentally a more complex matter. Moreover, a recent 
editorial was dismissive of AAS-users suggesting use may be lethal and that users 
are deluding themselves (Smit and de Ronde 2018). This may be the case for some 
but not all, yet Smit and de Ronde (2018) group all AAS-users together. Such 
messages could colour the views and judgements of the reader (whether 
professionals or AAS-users) and partially explain why AAS-users often mistrust not 
just the public but also professional or academic discourse. As users often read 
academic literature (Underwood 2019), there is a need for a balanced perspective 
when addressing such issues in the literature. The prevention approach often 
forms part of the narrative on AAS use in the academic literature, particularly 
from a medical perspective. This will inform medical professionals’ advice and 
guidance and may also explain why there is such a strong perception amongst 
AAS-users that medical professionals will just say stop using (5.3.5.3.3, Chapter 6). 
However, there is a less judgemental perspective in the more harm reduction 
focused academic literature, but these often suggest less orthodox approaches, 
which appear resource intensive and may be unpalatable to governments and are 
often ignored. One of the participants was clear that the prevailing drugs policies 
of: 
‘…the ‘alls’, all drugs are all bad, all the time, for all people, in all 
circumstances.’ (Hugo/USA/53 [TI]) 
was an unhelpful narrative and whilst the prevention narrative focuses on all the 
side-effects of substance use for performance enhancement, there is a disconnect 
with people’s reality which harms the credibility of those promoting such po licies 
(Mey et al. 2018). This narrative sees everyone who uses illicit (or those misusing 
licit substances e.g. alcohol, drugs) in the same light. In line with other studies 
(Monaghan 2002, Simmonds and Coomber 2009, Smith et al. 2009), this study 
found that AAS-users were keen to distance themselves from this narrative, using 
it as a reason for not using NSPs as they are accessed by other substance users. 
Keeping use secret through fear of judgement could influence health-seeking 
behaviours leading people either to lie to medical professionals or not seek help 
when needed. Further discussion on stigma and how it aligns to identity are 
discussed in 8.4.3.  
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 Information and support 8.2.5
This study confirms current knowledge (Chapter 3) around the reliance placed by 
users on the internet and fellow users for advice and support for AAS use (Chapter 
6). The majority of the findings on the themes of support accessed and wanted 
are reported in (Chapter 6), however, due to word limitations the findings on 
trusted information sources are discussed here alongside more detailed 
discussions on peer support, government-led services and targeted support.  
 Trusted information 8.2.5.1
Although there were some small differences in percentages concerning the 
specific type of advice sought, the top two categories remained the same across 
each type of advice: AAS-users and AAS-user fora (Table 5-14). This finding that 
people were more likely to trust information on specialist fora and experienced 
users is in keeping with previous research where concerns have been raised about 
the reliance that AAS-users put on ‘broscience’ and taking advice from the AAS-
using community over professionals (Grogan et al. 2006, Kimergård and McVeigh 
2014a, Hanley Santos and Coomber 2017). Participants in this study noted that 
such information often came from people they trusted and who had experience of 
use, however some noted this was not without risks, as there was a lot of 
incorrect information shared online. This is true as fora are often created for the 
marketing and selling of steroids (Antonopoulos and Hall 2016) and the 
information is often pro-use (Karavolos et al. 2015). Personal lack of knowledge 
about a subject is not necessarily important if the source is deemed trustworthy 
(Marsh and Yang 2018), the authors citing this as an example of why advertisers 
use celebrity endorsements. In this sub-community arguably, there are 
bodybuilders who have attained celebrity status (Bilgrei 2018) and as such are 
deemed trustworthy. However, others felt some celebrities were unreliable 
(5.3.4.3) and added to the stigma. Evidence suggests that people are more likely 
to believe something is true if multiple people are saying it (Komoroski and Rickert 
1992, Marsh and Yang 2018) and many participants, aware of the misinformation 
online looked for agreement from a number of sources including academic studies 
and books to help work out whether a source was credible which could help to 
increase reliability (Chapter 6). Communicating the health concerns around AAS 
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use is complex. A simple message about the immorality of using AAS or that it can 
cause physical health harms is unlikely to impact on the behaviours of many AAS-
users in part due the reinforcement they receive from using within the AAS using 
subculture (Smith et al. 2009). Consequently, there is a need for a wide range of 
different communication channels around using AAS. This study identifies a range 
of communication mechanisms that could be useful  (Chapter 6). 
 Peer support 8.2.5.2
McVeigh and colleagues (2012) argued for better communication of information 
from credible sources through social media, so that users have access to sources 
other than those with vested interests. Based on the findings of this study,  the 
inclusion of academic references in information offered via government-led 
services might carry more weight. Bearing in mind that this study (Chapter 3) 
along with numerous others has found that advice is sought and even preferred 
when it comes from experienced users it is not surprising that many academics 
including this researcher, advocate for public health initiatives to utilise more 
innovative methods of dissemination via peer networks, and be involved in co-
production of harm reduction messages and materials (Bardick et al. 2008, 
Griffiths, Henshaw, et al. 2016, Papangelis et al. 2016, Bates, Tod, et al. 2019, 
Glass et al. 2019, Mulrooney et al. 2019, Salinas et al. 2019).  
It is not just for dissemination of information where peer support could be an 
option. The desire that experienced users have for sharing advice and their 
experiences responsibly (5.3.3.7) could potentially be leveraged, as they appear to 
have a high-level of influence. Moreover, although there are concerns around 
advice from other users, peer support has been something that has been 
advocated and found to be beneficial in other drug using populations (Toseland 
and Hacker 1985, Powell and Perron 2010, Kelch 2014, Treloar et al. 2015, Brown 
et al. 2019). Such sessions could be run by experienced users. While, this 
approach differs from many other peer-led groups in substance use, where peers 
have ceased using, such groups could nonetheless take their model from skills-
based sessions and cover subjects such as making the most from training. It would 
also seem plausible that supporting emotional side-effects is another area where 
experienced peers may be able to offer a valuable service by sharing self-
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management techniques (Table 5-5). However, this is not without its challenges 
such as ensuring that the advice given is evidence-based, does not promote risky 
use and includes discussions on harm reduction. Justifiably, some professionals 
worry that reliance on these experienced users could do more harm than good, 
when they as professionals are more qualified to provide support (Richardson et 
al. 2019) and normalisation of AAS use within a culture could cause AAS-users to 
disassociate from potential harms (Brennan et al. 2017), therefore, whilst 
advocating for peer support, there is a need to ensure that such support is well-
managed and as ‘unbiased’ as possible.  
 Using government provided services 8.2.5.3
One barrier to providing effective support for AAS-users is identifying what 
support people are willing to access. As already discussed in 4.6.1, this population 
is considered hard-to-reach (Smith et al. 2009), with secondary distribution of 
needles common, as 154 participants reported collecting equipment for other 
IPED users (estimated at 639 other people) (Glass et al. 2019). In this study, 98% 
(128/131) of participants injected AAS (Table 5-1); a larger percentage than found 
in other mixed populations e.g. 85% in Begley and colleagues’ (2017) study. 
However, consistent with previous studies (Brennan et al. 2019) injection was 
predominantly self-directed and self-experimentation was used (5.3.3.4). NSPs 
may not be accessed by many IPED users including those utilising oral steroids 
(Glass et al. 2019, van de Ven et al. 2019), however, only five participants in this 
study used just oral steroids (Table 5-1). This study found that accessing NSPs for 
any type of support was limited with just under half of 15/34 UK participants 
accessing needles from NSPs (less for all other types of information/support) with 
only 20/133 participants in total, however some of this will be due to lack of 
access to NSPs in some countries. A key reason given by participants not wanting 
to access advice from NSPs was stigma as participants did not want to be seen as 
users of other illicit substances such as heroin. Ironically, other recreational drug 
users also felt the stigma of the ‘junkie‘ identity (5.3.4.1) and often saw treatment 
services as reinforcing this identity (Radcliffe and Stevens 2008). Therefore, 
arguably, NSPs that also serve other drug-using populations might not be the right 
medium for support.  
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It is noteworthy that a Norwegian service found sexual problems as the most 
commonly reported concern (Havnes et al. 2019) and calls to an anti-doping 
hotline highlighted which side-effects potential AAS-users would be prepared to 
live with and those they would not, finding a potential reason for not using AAS 
was if they might experience problems with genitalia (Christiansen and Bojsen-
Møller 2012). This was also a large concern for participants in this study (Chapter 
7). It is clear there is a need to continue to advocate for a wider range of support 
services for AAS-users. A model of ideal support is discussed more fully in Chapter 
6. Moreover, taking into consideration that several participants spoke of having to 
convince their partners about their use (5.3.4.3), it would be beneficial for 
services to include confidential information and advice services for families and 
friends. There is evidence that free, bespoke, voluntary AAS services are effective 
as one evaluation of a Norwegian AAS information service for AAS-users and next 
of kin found that 98% of users and 100% of the next of kin, found the information 
useful (Havnes et al. 2019).  
There is a need to consider how to engage with the AAS using community outside 
of NSPs (van de Ven et al. 2019) and, as noted the results show that NSPs are 
currently not reaching many of this population. Other studies suggest support 
services could be better placed alongside GP surgeries, linked to pharmacies, be a 
stand-alone service, or attached to gyms (Kimergård and McVeigh 2014a) which 
could increase access and may reduce stigma. The benefits of outreach through 
gyms has been evidenced in other studies (Salinas et al. 2019) and one participant 
in this study noted that sharps bins in the gym were useful (Chapter 6). This seems 
to be a basic harm reduction activity, yet it is understandable that gyms may not 
offer such services for fear of bad publicity and public disapproval. It is important 
to acknowledge the resource pressures on government and local authorities 
which could lead one to question whether people who use AAS should be a 
priority for support services. So, perhaps the answer is not a publicly funded 
solution; perhaps it is a regulated private sector service. However, intervention is 
necessary due to level of harms (Bates, Tod, et al. 2019). Consequently, taking a 
pragmatic approach, it may be helpful to consider how support provisions could 
be resourced.  
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 Targeted support 8.2.5.4
Overall, this thesis supports other research into the need for an individual 
approach to support and care based on assessment of risk, behaviour, health and 
lifestyle (Zahnow et al. 2018). However, this does not mean that certain 
populations should not be targeted with specific information and support and this 
study’s findings point to several key areas for such targeted advice. Firstly, there is 
potentially a need to target preventative interventions at older users, providing 
other options to support them address their reasons for wanting to start or 
restart use for anti-ageing reasons (5.3.1.3). Secondly, Sagoe et al. (2014) 
recommend focussed interventions on people with a range of vulnerabilities and 
those in certain professions such as doormen, male sex workers and sportspeople. 
This study showed that it might be useful to add another occupation to the list: 
personal trainer (5.3.1), as they are potentially influencing others. There is a 
higher prevalence of HIV amongst people who inject IPEDs (Hope et al. 2013), and 
two participants started use after AAS was offered as a treatment for 
counteracting the wasting effects that comes with the disease (5.3.1). Therefore, 
consideration should be given to discussing this issue with people who are 
prescribed AAS to combat HIV wasting.  
Many participants maintained that after weighing up the pros and cons, the risks 
of harms from use were not as detrimental as the short and long-term side-effects 
of stopping use (5.3.3.1). Timing for intervention is crucial and one beneficial 
point to support someone to consider stopping use might be at such a juncture as 
having an adverse outcome as a result of AAS use (Bates, Tod, et al. 2019). 
Perhaps harm reduction initiatives should aim to support people through PCT, but 
also consider different harm reduction methods for those who are using a 
continual low-level dose, which could include referral to medical specialists, and 
an exploration with the participants for their reasons as to why they have adopted 
this strategy. Moreover, finding ways to address the emotional impacts 
experienced coming off-cycle, and techniques to help users manage the low mood 
might reduce harm. This would be particularly useful for those who have mixed 
feelings concerning their continued use yet are unable to envisage a time when 
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they would not be using AAS (9.2.2.5). Although these emotions experienced do 
not affect all participants, it suggests there is a greater need for emotional 
support around AAS use. However, it is unclear from the qualitative data what 
form this should take and what barriers might be in place, therefore a further 
qualitative study is required. 
8.3 Summary 
This section has shown that although there is a range of physical and 
psychological side-effects of AAS use, users often feel that the benefits of using 
outweighs the risks. This study showed that participants who started use for the 
physical benefits continued due to the perceived impact on their positive 
wellbeing. This is important when considering advice and support provision. It has 
shown that AAS-users often have researched their use and have clear strategies 
for managing the risks. When it came to negative psychological effects, although 
these emotions did not affect all participants, it suggests a greater need for 
emotional support around AAS use. It has evidenced that society’s perceptions of 
AAS creates stigma and impacts on help-seeking behaviours. It has highlighted a 
need to change the narrative from prevention to intervention and support, for 
professionals to be non-judgemental and advice to be evidence-based. It has 
considered the need for targeted support, explored the use of peer support and 
need for support for families. The following section will consider underlying 
motivations for AAS use across the life span through the lens of identity.  
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8.4 Identity  
 Introduction 8.4.1
This section explores the second of the two concepts: identity. Findings suggests 
that identity could influence reasons for use and this section uses role theory, in 
particular theories of masculinity to consider underlying motivations for starting, 
continuing or re-starting use. The findings showed that for some participants, 
motivations for use change over time (5.3.1.3), consequently it seeks to apply 
Erikson’s Life Stage Theory (Erikson and Erikson 1997) to illuminate how identity 
can impact across the lifespan and how this may impact motivations for use.  
 Identity as a concept 8.4.2
The findings indicate that the lens of identity could be one way of viewing the 
reasons and underlying motivations for AAS use. Erikson (1968) defines identity in 
adolescence as: 
“The wholeness to be achieved at this stage I have called a sense of  
identity…Individually speaking, identity included, but is more than, the 
sum of the successive identifications of those earlier years when the child 
wanted to be, and often was forced to become, like the people he 
depended on.” (Erikson 1968, p.87) 
Erikson’s definition of identity is psychosocial and multi -dimensional (Schwartz 
2001) and in his prologue to Identity, Youth and Crisis (Erikson 1968) suggests that 
identity covers a multitude of aspects which includes: ‘a unity of personal and 
cultural identity’, an always changing and developing process, ‘a psychohistorical 
perspective’, tied to work and ‘cooperation with others’, ‘manufactured identity’,  
‘sexual identity confusion’ and is ‘always changing and developing’.  Erikson’s 
concept of identity is subjective, compromises of both the conscious and 
unconscious, and represents an individual’s “psychosocial stimulus  value” himself 
and others within their community (Waterman 1988, p.187). It is this definition of 
identity, with its multi-faceted components,  aligned to the values for both oneself 
and significant others that this researcher is using when considering the impact of 
identity on AAS use. This definition incorporates both unconscious and conscious 
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elements of identity, and the idea that an individual’s social and cultural  contexts 
will impact on an individuals’ identity formation (Schachter 2005).  
Identity can provide a structure for an individual to understand who they are, 
provide them with meaning and goals, a sense of free will and control and a sense 
of future coherency between values and beliefs (Adams and Marshall 1996). 
Individuals need to feel significant, which on a personal level concerns self-
agency, but on a group level concerns belonging, with social settings potentially 
influencing the identity formation process (Adams and Marshall 1996). People can 
have multiple dimensions to their identity (Jones and Mcewen 2000) including 
professional, gender, ethnic, religious, sexual orientation, socioeconomic status, 
age, ability (Tatum 2000, Stonewall 2016, Morgan 2017) as well as an incalculable 
range of identities from subcultures including ‘athlete’ (Gustafsson et al. 2018), 
‘bodybuilder’ (Phoenix 2010) ‘drug-user’ (Rødner 2005) and ‘AAS-user’ (Ravn and 
Coffey 2016).  
Identity is often aligned to the roles we play (Biddle 2013). Role theory, developed 
in the 1930’s by sociologists such as Ralph Linton and George Mead, considers an 
individual in the context of the expectations and norms of society e.g. what is the 
traditional role of the father (Biddle 2013), with some roles being due to innate 
circumstances such as what it is ‘to be male’, and others attained such as 
‘bodybuilder’. Role theory proposes that behaviour can relate to socially defined 
positions or expectations (Biddle 1986). This can help to understand the concept 
of the person-in-environment which can be linked to status or the place that 
people have in social settings (Parrish 2014). Consequently, motivations for AAS 
use could link to a desire to meet the expectations of a role. A number of 
motivations for use could link to a participants’ identities, for example gender 
(e.g. look masculine), occupation (e.g. personal trainer) or competitor (e.g. 
bodybuilder). The participants described themselves in a variety of socially 
constructed roles including father, hetero/homosexual male, bodybuilder, 
powerlifter, husband, personal trainer. Some even spoke about these specifically 
in relation to their use: 
‘It may sound strange but sometimes i feel obligated to continue because 
that is how i identify myself. How people know me... Sometimes i think we 
trapped ourselves’. (Tomaz/Belgium/40 [CI]) 
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For some users, identities were clearly in evidence in their answers to a free -text 
question on sexual orientation, either choosing to write about how they saw 
themselves Table 8-1, rather than define themselves by their sexual orientation or 
using specific language to reinforce their masculine identity. 
Table 8-1 Identity: participant self-descriptors   
‘Confident man in his prime’ (Jay/Sweden/27  [q]) 
‘Happy healthy husband and father of three’. (Ivar/Sweden/42 [q]) 
‘Entreprenureal, dedicated, quizical, ambitious and pursuer of truth and education’. 
(Karl/USA/25 [q]) 
‘Married gay male, 53 years old, HIV+ 22 years’ (Hank/USA/53  [q]) 
‘Software engineer, intelligent, psychology grad’ (Niall/Canada/25 [q]) 
‘Tall dark handsome’ (Kris/USA/25  [q]) 
‘I’m a fucking man’ (Troy/USA/28 [q]) 
‘I have a penis’ (Adrian/UK/29 [q]) 
 
The internationalisation of an athletic-ideal plays a prominent role in the 
prediction of muscularity-orientated behaviour (Hoffmann and Warschburger 
2019) and AAS was traditionally the realm of athletes (Evans-Brown and McVeigh 
2008). Being seen as a bodybuilder or athlete can be a part of an identity but may 
not give the whole picture. In the interviews, reflecting on the underlying re asons 
for wanting to build muscle, participants’ motivations to change their physique 
included: achieving sporting goals, overcoming genetic limitations, attaining the 
physique that women wanted, as a response to having contracted HIV, and self -
medication for TRT. Moreover, for some there were motivations linked to self -
identity, e.g. how Hugo saw himself  and wanted to be viewed by others as a Gay 
man (Table 5-7), which relates to the Eriksonian concept of identity being tied to 
value of self and others within the social context. 
Regardless of the initial motivations, use itself has a number of additional benefits 
that could help to reinforce or increase AAS use and in this study although libido 
was not selected as a common motivator it was the most selected benefit of use 
(5.3.2), and TRT was the main reason for use for some participants. There were a 
number of other positive emotional drivers, with over half the participants (53%) 
selecting ‘become happier’ as a motivator. This begs the question “how do they 
define happiness?” It could be that seeing results aligned to their goal made them 
happier. Almost three quarters (74%) felt that using AAS had improved the quality 
of their life. This impact on all aspects of life has been noted in other studies; for 
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example, Latham et al. (2019) found that the “bigger stronger” narrative 
enhanced aspects of AAS-users’ normal lives. If one is using it to rediscover one’s 
youth and one’s libido returns, then it may genuinely improve the user’s quality of 
life. However, if there are potentially deeper psychological reasons linked to an 
identity crisis or a sense of inadequacy then use may be merely palliative.  
 AAS-users’ perception of themselves and the drug-user identity 8.4.3
One facet of identity is tied to the social and cultural context and cooperation 
with others (Erikson 1968), which can come from being part of a group, as people 
have a social need to have a sense of belonging to others, and to feel connected 
(Adams and Marshall 1996). Participants talked of a global AAS-using community 
(5.3.44). Belonging to such a group potentially means adhering to certain cultural 
norms and beliefs. This study showed certain similarities in views within the AAS 
sub-community regarding responsible use (5.3.3.6), seeking to develop an 
ethnopharmacological knowledge (5.3.3.4) and a distrust of medical professions 
(5.3.5.3.3). 
AAS-users were keen to disassociate themselves from ‘traditional drug-users’, 
often labelling them as ‘junkies’ (5.3.4.1) and used reasons such as planning their 
use and maintaining healthy lifestyles. This is consistent with previous studies 
(Smith et al. 2009, Dunn et al. 2014). This distinction between AAS-users and 
recreational drug users centres on the purpose of the drugs used, attitudes 
towards drug use and social and cultural environments of the users (Smith et al. 
2009), and all these points were referenced throughout the interviews. Identity  
may, in part, explain why many AAS-users were keen not to be seen in the same 
light as people who take illicit drugs, as the negative connotations linked to those 
groups was a world away from how they saw themselves, in the context of 
managing risk, taking responsibility and that they saw their use as ‘healthy’  
(5.3.1.3), which is in line with other studies (Bloor et al. 1998). The image of ‘drug 
addict’ did not align with their own self-image and some participants argued, as 
do some experts (Monaghan 2002), that as they are different from other drug 
users (5.3.4) they should be treated differently.  
As an identity, ‘drug-users’ can be viewed differently dependent on culture and 
sub-groups people operate within and some parts of society might see this label 
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as linked to hedonistic behaviours, whereas others might see dissolute or 
delinquent behaviours. This showed that participants associated some types of 
illicit drug-use with criminal behaviour (5.3.4.3), having themselves bought into a 
more stereotypical view of people who use drugs such as heroin. Moreover, some 
AAS-users spoke about other AAS-users in a non-complimentary manner for using 
irresponsibly or abusing AAS, suggesting such people gave AAS use a bad name  
and used labels such as ‘roid heads’ to distance themselves from such users. 
Brennan et al. (2019) note that self-education on all aspects of use was something 
expected by the AAS-using forum members prior to starting use and suggest that 
this type of lay expertise was seen by the group as empowering. This mirrors 
previous studies where AAS-users ‘use’ substances but do not ‘abuse’ them 
(Monaghan 2002). Furthermore, the differentiation between ‘use’ and ‘abuse’, is 
a way for users to differentiate themselves from other steroid users, with abuse 
being perceived as indiscriminate, continuous, over-use, or even unplanned use 
(Bloor et al. 1998). However, in this study, participants no longer saw users who 
used continuously in this light. The differentiation was more subtle; continuous 
use of supra-physiological amounts was considered irresponsible, but dropping to 
a low-level dose, rather than instigating PCT was not.  
The concept of stigma aligned to managing risk has been explored (8.2.4), 
however when considering aspects of identity, it is also worth noting its 
relationship to stigma. There could be an element here of self-stigma, that people 
internalise society’s views of an activity and therefore experience negative 
consequences (Corrigan and Rao 2012) such as a lack of willingness to seek 
support. There is another consideration around accessing information that also 
aligns to identity, that of prestige bias. Prestige bias occurs when people use 
indirect cues from people who are deemed successful within a group or culture 
(Henrich and Gil-White 2001). This can be seen clearly in Peter’s quote (5.3.5.2) 
where he is clear that he seeks information from those who have achieved a level 
of authority and credibility around the subject matter and even looks for credible 
testimonials. Identity is relevant here as it is important for Peter to be seen as 
someone who himself is not irresponsible or lacking in knowledge aligned to his 
AAS use, i.e. he sees himself as responsible AAS-user.  
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This AAS-using identity was one that also changed with the change in motivations 
for use over time, with some using moving from supra-physiological doses or from 
‘blasting and cruising’ to continuous low-level doses of just testosterone (5.3.3.2). 
This could be informed by a revision of their identity i.e. from identifying 
themselves as an AAS-user, to someone who is self-medicating for low 
testosterone and this was articulated by several interviewees (Chapter 7). Identity 
as part of the AAS-using sub-culture, internalising cultural beliefs may lead them 
to distrust medical professionals and therefore less likely to access professional 
support. 
 Gender and identity  8.4.4
One driver for AAS use was changing body shape, the desire to have a 
mesomorphic physique (mesomorphic based on WH Sheldon’s classification of 
body types (Kent 2007)), that is ‘a muscular look’. Participants in this study 
reflected benefits to changing shape and that becoming muscular increased their 
confidence, made them more attractive to women or other men and one person 
referenced gaining ‘more masculine looking facial features’ (Mike/USA/23 [q]). 
Erikson proposed that sex-roles have an impact on identity formation (Erikson 
1968) and men who have internalised the more traditional attitudes around 
masculinity want to be more muscular (McCreary et al. 2005, Frederick et al. 
2017). We are influenced by our culture, background, how we see ourselves, how 
we see the world and our place in it, and can internalise such narratives 
(Franchina and Coco 2018). Furthermore, Christiansen (2019) suggests that men 
gain muscle because physical transformation can change their relationship within 
in their social sphere. Consequently, professionals need to appreciate such 
contextual factors, as the cultural and social processes that impact on physique -
changing behaviours, in order to develop more effective interventions for AAS-
users (Smith et al. 2009). 
The phrase hegemonic masculinity was coined by Connell (1987), and is 
commonly used to refer to the dominant masculine ideals of a culture at a given 
time (Brown 2016). The participants are from western countries, with cultures in 
which the physical ideal of masculinity is embodied by mesomorphic body shape 
which arguably originated with the idea of the Greek warrior heroes (Kanayama et 
al. 2012). In a traditional masculine construct, western society views men as 
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having to be invulnerable, emotionally and physically strong (Trenoweth and 
Lynch 2008) and show stereotypical male characteristics such as “control, 
independence, aggression, competitiveness and strength” (McManiman 2001, 
p.260). The internalisation of the traditional male gender role can play a part in 
men’s desire for an ideal body (Gattario et al. 2015); seeing the gaining of 
muscularity as a gain in masculinity (McCreary et al. 2005). There was a range of 
underlying motivations found concerning people’s desire to modify their physical 
appearance i.e. attain a mesomorphic physique in order to look manly:  
‘…I was proper skinny, so I did want to look like a man really, feel more 
comfortable’ (Lawrie/UK/27 [TI]) 
One theory of masculinity, the concept of masculine contingency (Burkley et al. 
2016), considers the implications of “men staking their self-worth on their sense 
of masculinity” (Isacco and Wade 2017, p.6). This theory suggests that men whose 
self-worth is contingent on a personal sense of masculinity feel increased self-
esteem as a response to positive feedback about their masculinity (Burkley et al. 
2016) which could in part explain why some participants noted an increase in 
quality of life, as they felt better about themselves when embodying the muscular 
ideal. In this study AAS-users raised the idea that current use was driven by social 
media and the prevalence of an ideal male body image; some even admitting that 
they themselves were influenced when younger by film stars (5.3.4). From the 
1980’s there was an increase in the number of overtly muscular male action 
heroes in films, e.g. Arnold Schwarzenegger, who admitted to using AAS (Muscle 
Monster 2015). Since then, muscle-bound heroes have become a prominent 
narrative within western, popular culture e.g. Thor, a superhero God (Roblou 
2012). Such portrayals of masculinity link attractiveness to unrealistic levels of 
muscularity (Murnen and Karazsia 2017) and participants spoke of AAS making 
them feel godlike (Figure 5-6). Worryingly, it is not just Gods who are portrayed in 
this way, Captain America features a story of a man, who through chemical 
enhancement becomes a superhero (Captain America: the first avenger 2011) 
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(Figure 8-3).
 
Figure 8-3  Captain America: Actor transformation (toptenfamous, 2018) 
The change in film star physique is perhaps best exemplified by James Bond’s 
transformation over the decades (Figure 8-4 (Wells 2015)). Identifying with such 
hero figures could mean that some viewers may internalise certain beliefs about 
masculinity (Brown 2016).  
 
In identifying places to share leaflets seeking volunteers for this study, the 
researcher visited local shops selling supplements in Bournemouth and the 
influence of superheroes was evident (Error! Reference source not found.). 
Figure 8-4 James Bond: Muscular transformation 
This figure can be found at the following link: 
https://www.youtube.com/watch?v=JQx1_YDYiB0 
Chris Evans Workout & Body Transformation 1997 - 2018 
(Avengers Infinity War) 
8,364,593 views •28 Mar 2018 
 
Image can be accessed at: 
https://www.telegraph.co.uk/men/active/11822364/Are-action-figures-
giving-boys-body-image-anxiety.html. 
(Wells, 2015) 
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Although the Eriksonian identity theory was 
developed before the rise of social media, its 
emphasis on the social context could be seen as very 
relevant, when considering identity aligned to 
masculinity.  
 
 
 
 
 
181 
 
 
 
The advent of the internet and social media has given 
people 24-hour access to such images literally in the palm of their hand. There has 
been a proliferation of transformation stories (using AAS) such as: the 
transformation of Zyzz 2F3 an ectomorphic teenager into a mesomorph (Peter 2013, 
Underwood 2017), who, even after his death, features in a blog entitled “Gods 
Never Die” (blueslurpee478 2016), living acolytes such as Jon Skywalker 
(Skywalker 2017, Greatest Physiques 2018) and media reports of TV reality stars 
using AAS (Turner 2017). Such people could provide role-models for those aspiring 
to attain a similar physique or level of fame. Social media posts actively target 
men, promoting articles on body transformation tools e.g. Jussim’s (2017) article 
entitled ‘How 11 actors transformed into shredded movie superheroes and 
villains’. This takes the mesomorphic ideal out of the realm of film fantasy to the 
real world, potentially making it appear both desirable and attainable. 
Furthermore, often online images are digitally enhanced (CREDOS 2014) and 
therefore not attainable, and this concern was noted by some participants when 
commenting on risks for young people.  
These concerns are not unreasonable as Social Learning Theory suggests people 
learn from those around us, behaviour can be acquired through imitation of role-
models’ attitudes and patterns of behaviour (Baer and Bandura 1963). The theory 
proposes that patterns learned can be maintained and strengthened by direct 
reinforcement (Baer and Bandura 1963). Today, it is not just in the world of film 
where the mesomorphic body image is celebrated. Computer games have hyper-
mesomorphic characters (Matthews et al. 2016) and playing such characters has 
been shown to impact on increased dissatisfaction with an individual’s body 
image, as men equate masculinity to muscularity (Sylvia et al. 2014). Behaviour 
can be reinforced by positive affirmation, whether this is from how we see 
ourselves or how others see us. The internet has allowed for a wider audience via 
the rise of such platforms as Instagram and FB where people share stories and 
images of their body development. Richardson, Dixon and Kean (2019) perceive 
                                                                 
3
 Real Name: Aziz Serheyevich Shavershian (Body-builder, personal trainer and model) 
Figure 8-5   Incredible Hulk 
statue outside supplements’ 
shop: Own picture 
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that the documenting of body transformations online is only going to become 
more prevalent, suggesting that this will see an increase in appearance-driven 
motivations as people gain social capital from visible virtual admiration received 
via social media platforms.  
 If gaining muscle leads to positive feedback from peers, such positive affirmation 
could serve as an affirmation of the strategies they are using. Tatum (2000, p.10) 
notes that ‘the parts of our identity that do capture our attention are those that 
other people notice, and that reflect back to us.’ Some participants cited feedback 
from peers and positive results as reasons to use (Table 5-2), and previous authors 
have suggested that feelings of invincibility (Figure 5-6) and peer feedback could 
lead to dependent use (Smith et al. 2009). McNeill and Firman’s study (2014) also 
found that the AAS-users’ friends also had a part to play in what is perceived as 
the ideal body shape for a man. Young people have a high-level of heightened 
social sensitivity (Somerville 2013) and this can mean that they may undertake 
risky behaviours, even health risks (Blakemore 2018) in order to avoid being 
excluded or even bullied by peers (5.3.1.2). Considering the pervasiveness of the 
hyper-muscular image in western culture, one area for further research would be 
to examine factors that may encourage or reinforce use e.g. positive effects such 
as social admiration, increased confidence and the subsequent psychological 
positives on self-esteem, confidence and quality of life as one possible 
explanation for dependence comes from reinforcement through social 
conditioning. 
 The AAS-user, masculinity and muscularity 8.4.5
An association has been found between AAS use and distorted body self -image 
(Pipet et al. 2014). Concerns about muscularity may bring an individual to the 
threshold of using AAS (Kanayama, Brower, et al. 2009) which raises misgivings 
about the positive messages on social media highlighting the benefits of steroid 
use. Some men might conclude that this is an effective and safe way to change 
their shape as some AAS-users share images of their ‘ripped’ physiques 
(Richardson et al. 2019). Some participants in this study chose being attractive as 
a motivation to use and some selected being perceived as attractive as a positive 
benefit of use (Figure 5-5, Figure 5-7) linking to other studies which found 
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attracting attention from girls as a reason for use (Smith et al. 2009, McNeill and 
Firman 2014).  
Pressure from mass media can make men feel inadequate about their bodies 
(Barlett et al. 2008, de Vries et al. 2016). Underlying motivations found in this 
study included concerns about being under or overweight (5.3.1.2)and negative 
body talk amongst men focussed on fat and having a muscular physique which 
indirectly effected not only how they viewed their bodies but also their 
expectations of using AAS (Velkoff et al. 2018). Velkoff and colleagues (2018) 
suggested that finding ways to reduce such negative body talk could help to 
mitigate unhealthy behaviours around exercising and eating, potentially reducing 
negative body talk could also mitigate initiation of AAS use. If so, interventions 
should not focus on substance use, but instead start from a young age and 
challenge stereotypes of masculinity. If the ‘ideal male’ body was not associated 
with a muscular frame, this alone may reduce the risk of people using AAS.  
Men who have internalised a muscular ideal of masculinity, but who are not 
naturally mesomorphic, may look to build muscle to feel more masculine (Murnen 
and Karazsia 2017). AAS-user’s masculine identities are influenced by the 
stereotypical presentation of men as muscular in the media and their own father’s 
physical appearance (Smith et al. 2009). Moreover, AAS-user constructs of 
masculinity are linked to muscularity, working hard, not giving up, being physically 
strong, and looking like a man (Walker and Joubert 2011). Reasons for men 
desiring to be more muscular include: to feel stronger, sexier, more confident, 
more attractive to women, healthier, to be better able to defend themselves, be 
better at sports, to be better able to intimidate other males, to feel more 
masculine (Frederick et al. 2007). This connects masculinity to feeling confident, 
and increasing confidence was something that was a motivator for over a third of 
participants in this study (5.3.1). Furthermore, Fomiatti and colleagues (2019) 
argue that exogenous testosterone is perceived to enhance masculine traits such 
as confidence.  
For those who have internalised this hegemonic perspective of masculinity, AAS 
could be a way of achieving congruence between their beliefs on the ideal male 
physique and their own physique. Buchbinder (2010) argued that ideas of 
masculinity are formed in the patriarchal narrative of gender, and whilst it has 
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privileged men, it has nevertheless subjected them to certain pressures. Amongst 
these pressures, as discussed, is a need to look a specific way and one study found 
that when men felt their masculinity was threatened they were more likely to 
create avatars with more defined muscles (Lee-Won et al. 2017). Gender norms 
can impact on men’s physical and mental health as men with a higher conformity 
to masculine norms were likely to have greater muscle dissatisfaction and 
muscularity-oriented disordered eating (Griffiths et al. 2015) and people who 
have muscle dysmorphia (MD) are more likely to use AAS (Pope et al. 2005, 
Murray et al. 2016). An in-depth study related to motivations showed those users 
with a focus on appearance had greater Eating Disorder (ED) and MD 
symptomology, when relating to drive for size, weight and shape, and concluded 
that AAS-users who experience physical appearance concerns are at greater risk 
of physical dysfunction (Griffiths et al. 2018). However, another study found that 
the use of AAS was not precipitated by ideal body image but actually fuelled the 
development of body image problems (Harris et al. 2016). It is clear that cause 
and effect are complex, as potentially MD could be a precursor to AAS use but 
also AAS use in and of itself can cause a preoccupation with body image that can 
then develop into MD. This raises the concern that MD could reinforce the need 
to continue to use. (Rohman 2009).  
Within a western patriarchal culture to be tough and strong is masculine whereas 
softness and weakness are more normally associated feminine characteristics 
(Aro. 2016). As previously noted there are other attributes that align to 
hegemonic masculinity including being in control, independence and being 
intellectually, physically and emotionally strong (Moynihan 1998, O’Neil et al. 
2017, Oliffe et al. 2019). This highlights a potential vulnerability as in this study, 
the side-effects experienced on stopping use such as anxiety, becoming more 
emotional, with one participant referring to this as ‘feeling like girl’ 
(Andrew/UK/25), or loss of libido were deemed less masculine. To avoid such 
unbearable side-effects some continued use e.g. 
‘I've been, been steadily on them for so long, including big doses on and 
off that I am a little afraid that I won’t feel like the man I do now.’ 
(Lewis/USA/37 [TI]) 
Lewis, like several other participants now appears to have a psychological 
dependency on AAS (5.3.3.8). This is not hard to fathom as “the body plays a 
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control role in men’s self-esteem” (Mishkind et al. 1986, p.556) and psychological 
issues such as under confidence or low self-esteem may potentially suggest a 
vulnerability at odds with the masculine characteristics of being strong.  
This targeting of ‘set’ definitions of masculinity is concerning as they are 
potentially unrealistic; the harms of subjecting women to such images are well -
documented (Grabe et al. 2008) and IPED use can be seen as a way for men to 
self-transform as part of this ‘makeover culture’ (Latham et al. 2019). Welchman 
(2000) suggested that the disintegrative forces of the modern world produce a 
threat to identity, leading to a loss of belonging and continuity. Potentially, the 
broadening of gender descriptors, the acceptance of non-binary definitions of 
gender and the rise of female equality might be seen as disintegrative in relation 
to the traditional idea of masculinity and hence the reassertion of the ideal man 
being stronger and more muscular has in part led to rise of the superman trope. 
Whilst there is a preoccupation in society with looking good, winning and the 
mesomorph aesthetic, substances like AAS potentially offer a solution of sorts 
(Rashid 2000), making the connection between some people’s over-emphasis on 
the link between physical appearance and self-worth. Smith et al. (2009) suggest 
that the route to using AAS can be traced back to a person developing their 
identity for what it is to be ‘male’, suggesting that mesomorphic body shaped-
men are seen as more successful and therefore aspirational, and a consequence 
of such social narratives is that young men want to develop their bodies. This in 
turn puts them in environments where IPEDs use is normalised and normalisation 
of use in such a cultures can be a reason for someone to justify use (Smith et al. 
2009). Moreover, this internalisation of masculinity norms may explain why 
aggressiveness was not perceived as a concern when it came to side-effects 
(5.3.2.4, Appendix 23), as anger is considered an acceptable emotion for men to 
express. However, this was also something that men should be able to control, 
another defining male characteristic, and in this study, men talked about their 
strategies for this (Table 5-5, Appendix 22, 23). Considering the pervasiveness of 
the hyper-muscular image in western culture, one area for further research would 
be to examine factors that may encourage or reinforce use e.g. positive effects 
such as social admiration, increased confidence and the subsequent psychological 
positives on self-esteem, confidence and quality of life as one possible 
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explanation for dependence comes from reinforcement through social 
conditioning. 
 Self-medication and masculinity 8.4.6
As hegemonic masculinity encourages a belief in invulnerability, men who have 
internalised this concept may have a lesser concern regarding risk, and may be 
reluctant to seek help (Gannon et al. 2004). Self-medication feeds into the 
aforementioned stereotypical male behaviours around maintaining control and 
independence. When considering research into men’s help-seeking behaviours, 
men are less likely to seek help if they see their problem as aligned to their 
identity, if it is perceived as non-normative and if their social groups promote a 
culture of self-reliance (Addis and Mahalik 2003). When considering AAS-users in 
this context it is feasible to see why some might seek to fix their concerns about 
their libido and low mood through self-medication. However, the self-medication 
hypothesis can be another way of self-rationalising drug use, where substances 
are used to control a range of negative feelings (Khantzian 1997). In a recent 
review for effective interventions for the prevention of AAS use, Bates et al. 
(2019) found that the interventions were often educational and based on the 
concept that people make rational decisions, but the authors argue that when it 
comes to health and behaviour people often do not make rational decisions. 
Arguably, one person’s rational could be another person’s irrational and when it 
comes to weighing up the benefits and costs of AAS use, if a user is doing it for 
reasons aligned to his masculine identity, and perceives that the results have 
increased their happiness, social status or other benefits then perhaps benefits do 
perceivably outweigh costs. It might be beneficial for AAS use interventions to 
include exploration of values and cognitive behavioural therapy (CBT) techniques 
to explore and revaluate internalised masculine schemas (Brady et al. 2019); this 
could be a useful strategy providing care is taken to ensure that such a strategy 
does not do more harm than good and people are supported as the masculine 
schema could be an integral part of their identity.  
Traditionally, emotional problems are treated through anti -depressants, yet this 
study evidenced that men felt low doses of testosterone were more effective than 
anti-depressants (Chapter 7). Another standard treatment is talking therapies, yet 
this study showed that few participants felt they needed this (Table 5-16), and 
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some interviewees suggested there was a need but did it in the context that it 
might be helpful to others. Furthermore, other studies have found that men 
attempting to achieve the ideal body do not seek counselling (Bardick et al. 2008) 
including for depression (Christiansen and Bojsen-Møller 2012). This study has 
shown that a key issue for many AAS-users’ is the actual or perceived effects of 
having low testosterone levels linked to physical and mental wellbeing and other 
studies have shown that participants saw testosterone as amplifying their 
masculinity (Fomiatti et al. 2019). Developing a deeper understanding of the 
wellbeing issues of AAS-users could help to create more effective support systems 
(Moore et al. 2019). Social policy has been mainly informed by the medical 
approach (MacGregor 1999), yet arguably, this approach does not always consider 
the person as a whole and does not always take into account the wider issues 
faced by users.  
Masculinity is associated with control yet depression and anxiety can leave men 
feeling out of control (Wyllie et al. 2012); studies have found poorer wellbeing in 
males exhibiting elevated muscularity-oriented concerns and behaviours (Eik-Nes 
et al. 2018) and they advocate for health professionals to screen for ‘drive for 
muscularity’ on routine assessments, which seems to be a very resource-intensive 
response. The concept that such muscularity-orientated concerns lead to poor 
wellbeing is notable as some participants saw AAS use as a positive medication to 
help improve their wellbeing and studies have found men attempting to attain a 
mesomorphic physique affected by a range of mental health problems (Bardick et 
al. 2008). This adds to the argument that when it comes to men’s wellbeing there 
is a need “to support and encourage coping and help-seeking behaviours amongst 
‘at risk’ men, for example, young men who have strong hegemonic orientation 
towards masculinity” and suggest a need for awareness by mental health nurses 
(Trenoweth and Lynch 2008, p.14). Building on this, there is potentially a need for 
earlier recognition of the potential risk and that this awareness raising be 
broadened to include social workers, teachers and anyone working with young 
men, who are in a position to signpost to relevant support services.  
Traditionally, men have been seen as having “a cavalier attitude” to bodily health 
and avoid or delay seeking help (Wyllie et al. 2012). This view of men not 
seemingly being interested in their health is now being challenged. Oliffe et al. 
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(2019) found wellbeing as a masculine value and noted this was at odds with 
traditional views which suggested men took health risks and that appearing well 
now contributes to masculine capital. Masculinity is associated with a reluctance 
to engage with medical professionals (Wang et al. 2013) and therefore, historically 
just getting men to engage with health services could be problematic. When 
focussing on health-related masculine values men saw looking good as a valuable 
off-shoot of enhancing their wellbeing (Oliffe et al. 2019). If it is the case that men 
are increasingly interested in health-related issues and wellbeing, this would be a 
useful angle to use in supporting men aligned to harm reduction strategies.  
A strong masculine identity could influence why participants did not want to 
access NSPs even for needles, stating that they had enough money to buy them, 
and were indignant at the thought of needing a handout (Chapter 7). This desire 
to pay for support (Chapter 6, Theme 5) speaks of the importance of self-esteem 
and potentially identity, the idea that a man should not rely on others and that 
financial independence is linked to being an adult (Ricci 2019). Their apparent 
willingness to pay for support was seen as a way of taking personal responsibility , 
something they felt differentiated them from other substance users. Moreover, 
offering bespoke support, may not be so controversial if services came with a fee, 
as this study has found that AAS-users are already paying for certain support 
services. However, it could appear morally wrong to separate them in some way 
from other service users of substance use services, but if doing so means that 
many are more likely to access harm reduction services it is worth consideration. 
Costs associated with use need not just be for injecting paraphernalia but could 
also include substances to mitigate side-effects and support to manage emotional 
side-effects. With all the pressures on health services, particularly in countries like 
the UK, where such services are free at the point of access, there is often not 
enough funding for these people who are most vulnerable. Therefore, there is a 
moral case for the public purse not to fund support services for those people who 
use AAS as a recreational choice and that those who can afford to pay for support 
should do so.  
 Masculine identity and testosterone replacement therapy 8.4.7
Evidence suggests that there are differences in age groups as to the type of body 
image men prefer: younger males wanting a lean muscular body and older men 
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focussing on health and lifespan concerns (McNeill and Firman 2014). Could this 
be true for people who use AAS to change their body shape? In this study, some 
of the older participants were focussed on being lean and maintaining their 
muscular physique, suggesting that the perception of appearance norms for 
middle-aged men is changing. The superheroes and action heroes in the movies 
are not necessarily played by young men but by (hyper) muscular middle-aged 
actors such as Daniel Craig, who first starred as James Bond aged 38 Figure 9-4 
and most recently in Spectre aged 47. In this study, a prevailing motivation for 
older men continuing use was wanting to maintain libido (Chapter 7) and side-
effects of ASIH can include depression, loss of libido and erectile dysfunction 
(Pope Jr. et al. 2015). Sexuality, sexual prowess and sexual appetite are essential 
aspects of the construction of masculinity (Trenoweth and Lynch 2008, Marcos et 
al. 2015), and a loss of libido can impact on a man’s notion of his masculinity 
(Chambers et al. 2017). For some there was a desire to overcome the loss of 
virility they experienced; seeing a healthy sex life as more important than 
concerns over long-term health. As well as restoring blood testosterone to normal 
levels, TRT may result in other benefits including: improved sexual desire and 
erectile function, improve energy and mood, reduced total body fat, increased 
lean body mass, mass, bone mineral density and muscle strength (Moon and Park 
2019) and recent evidence has shown that it can have an anti-depressant effect 
via directly promoting neuroplasticity (Walther et al. 2019). As this and other 
studies (Underwood 2019) have shown, AAS-users frequently seek out 
information from scientific articles, and as previously discussed there are many 
articles on TRT as a medication for hypogonadism (Kanayama et al. 2007, Bain 
2010, Pope Jr. et al. 2015, Moon and Park 2019) as well as websites extolling the 
benefits of TRT and a number of high profile (in some cases AAS-using) influencers 
online (Broccardo 2018). Add to this that substances are seen to be a masculine 
way of coping and that men are more likely to self-medicate with drugs to 
manage depression and other unwanted emotions (Wyllie et al. 2012) it follows 
that TRT is seen as a beneficial solution both for libido problems and to maintain a 
lean physique.  
Sex is often a taboo subject and men are often reluctant to discuss such problems 
(Addis and Mahalik 2003), which makes it imperative that these should be tackled 
by professionals. Consequently, information relating to impact on libido and 
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sexual health should be integral to any support and information service.  For one 
participant another justification for use, linked to the notion of masculinity was 
their idea around environmental changes which have the potential to weaken 
masculine characteristics: 
‘As man of 40yrs old a smaller dose is a big immune boost and this stops 
the negative effects of the extremely oestrogenic environment we now live 
in’ (Milton/UK/40 [TI]) 
Although the concept of the oestrogenic environment is beyond the scope of this 
discussion, there is current research in this area, including papers discussing the 
impact of oestrogens from the environment affecting men’s fertility (Akingbemi 
and Hardy 2001) which is widely reported in the media (Gannon et al. 2004). 
Given this population’s familiarity with scientific literature, such concerns may 
further influence their AAS use. 
8.5 Life Stage Theory 
Masculine identity is only one range of theories that could be applied to AAS use. 
Other theories include socioecological frameworks (Bates, Tod, et al. 2019), moral 
justification (Boardley and Grix 2014), planned behaviour (Enaker 2014), 
psychosocial processes, self-medication, objectification and cognitive dissonance 
models as well as theories of deviance and psychological dependence. All these 
theories have a place in explaining the motivations and social context for using 
AAS, however, none of them necessarily focus on the individual’s through -life 
experience. One of the findings from this study was that participants who had 
used for a period of years, had changed how they used as they matured, and 
described the reasons for their use as having evolved, for example, from supra-
physiological doses to a low continual dose of testosterone (5.3.3.2). Moreover, 
some younger participants talked about how they saw their future usage and 
some envisaged a change (5.3.3.8).  
One way in which to consider a person’s life choices and decisions is to view them 
in the context of the whole life cycle, understanding that: 
“to be human is to be on a journey. We live forward from the past; how 
we are in any moment which needs to be understood in the context of a 
before and a next” (Todres et al. 2009, p.72).  
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Especially as: 
“Integrating one’s past, present, and future into a cohesive, unified sense 
of self is a complex task that begins in adolescence and continues for a 
lifetime” (Tatum 2000, p.10).  
Progression through life-stages and exposure to masculinity and muscularity 
norms could play an important part in AAS use across a lifespan (Bates, Tod, et al. 
2019). Erikson’s theory of life-stages (Erikson and Erikson 1997) considered the 
psychosocial perspective to the whole life of the person and suggests that a 
person’s ideas are best understood in relation to their life and social context 
(Welchman 2000). Erikson’s psychosocial development theory is a staged model 
that considers eight development stages (driven by physical and sexual growth) of 
a human aligned to their lifespan (Appendix 24). Erikson believed that each stage 
consisted of a balance between the syntonic (positive) and dystonic (negative) 
elements, and saw the negotiation of this as a challenge that all individuals must 
undertake in order to transition successfully to the next developmental stage  
(Parrish 2014). If for some reason a person does not successfully negotiate a 
stage, then this can potentially impact on the development of the individual; 
example at Table 8-2 (Erikson and Erikson 1997). The model can be used to 
explore the behavioural development of individuals. It is useful to note that each 
stage is not clear cut, that the stages overlap, and Erikson did not stipulate fixed 
ages but did give possible ranges.  
Table 8-2 Stage 5 Erikson's Life Stage negotiation 
Life-stage Psychosocial 
Crisis 
Radius of 
Significant 
Relations 
Basic 
Strengths 
Core-
pathology 
Basic 
Antipathies 
Outcome 
5 
Adolescence 
(12 to 20 
years) 
Identity vs. 
Role 
Confusion 
Peer 
groups and 
Outgroups. 
Models of 
leadership 
Fidelity Repudiation Teens need to develop a 
sense of self, values, 
aspirations and personal 
identity. Success leads to an 
ability to stay true to yourself 
while failure leads to role 
confusion and a weak sense 
of self. 
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In this study, the mean age for starting use was 27 (range 14-57), which is slightly 
older than other studies; for example, mean age: 20-24 years old (Begley et al. 
2017), median first use of AAS: 23 (Smit and de Ronde 2018) and mean age 22 
years (Kanayama and Pope 2018), but is in keeping with other studies in that only 
a small percentage started use in their adolescent years (Sagoe, Andreassen, et al. 
2014). Kanayama and Pope (2018) ascribe initiation as more likely when a person 
is in their twenties as AAS-users have moved away from parental and teacher 
controls and support, so use may go undetected and/or they are less like to 
receive approbation. Many young people use a range of illicit substances, which 
some keep secret from their parents, but others use more openly. At this life-
stage parental influence is usually not as key as that of peer groups, particularly 
around risk (Harris 1995, Somerville 2013, Knoll et al. 2015, Blakemore 2018). 
Therefore, it is less likely that parental knowledge would impact on the decisions 
about substance use, and more likely that peers and role models are more 
influential.  
Motivations for use are varied and complex, with identity underpinning some 
aspects of use and the different life-stages impacting changes in reasons for use 
or risk management. Considering the age ranges of the participants for when they 
started use, participants fell predominantly within three life-stages (stages 5-7). 
When using Erikson’s Life Stage Theory to consider AAS use the motivations 
behind starting use are worth exploring. Stage 5: Identity versus Role Confusion 
Table 8-2, starts at the onset of puberty and goes through to young adulthood. 
This predominantly adolescent stage is driven by a desire to understand oneself in 
relation to the rest of the world, to find an identity, seeking a role that leads to a 
successful path for future life (Erikson and Erikson 1997). It is the struggle 
between the need to stand out and the need to belong, it can lead to 
experimentation and often individuals seek role-models. Successful negotiation of 
this stage comes through a reintegrated sense of self.  
It is here that role theory in relation to what it is to be male, and social learning 
theory (i.e., how I see role models around me behaving), are both relevant. 
Erikson identified that this stage could lead to individuals being influenced by 
certain peer groups to undertake certain behaviours as a way of expressing their 
identity (Parrish 2014). This searching for a sense of an identity could be seen as 
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both a group and an individual journey for it is at this life stage individuals are 
looking to find a sense of belonging and a sense of their own individuality . 
Understanding this innate role of ‘what it is to be a man’ could cause a conflict 
when it comes to negotiating this stage successfully among males who are not 
‘masculine’ as defined by society’s norms. As previously discussed, for some i.e. 
those who have internalised a hegemonic perspective of masculinity, this could 
drive a desire to attain a physique that is deemed to be manly to meet the 
expectations of the male role. If someone has internalised the stereotypical 
masculine mesomorphic image, the attainment of such attributes could lead to 
greater social and self-acceptance. Moreover, once involved in the sub-culture 
ideas on masculine identity could be reinforced by others within the AAS-using 
community as one study found that long-term AAS-users more strongly endorsed 
conventional male roles when compared to non-AAS-users (Kanayama et al. 
2006). 
During stage 5, Erikson (1994, p.156) wrote:  
“It is of great relevance to the young individual’s identity formation that 
he be responded to and be given function and status as a person whose 
gradual growth and transformation make sense to those who begin to 
make sense to him”  
Although Erikson was writing well before the impact of social media, arguably this 
searching for a sense of self is even more pronounced now that it is carried out in 
a virtual world, a world of selfies, where people are seeking instant approval and 
gratification (Gabriel 2014, Bleeker et al. 2016, Sung et al. 2016). Having a 
physique that does not match that of an ideal male could lead to a crisis in 
confidence and self-esteem. AAS use could be a way to help negotiate this ‘crisis’. 
This is not to suggest that use is ego-dystonic, but is perhaps a way to become 
ego-syntonic. When suggesting that a desire to achieve the perfect body aesthetic 
and physicality could lead men into a culture which then reinforces this desire, it 
is useful to consider agency. It may be that during stage 5 an individual had 
formed their sense of identity around a masculine trope but was not able to 
commit fully to that vision until they had the financial and social capital to access 
the resources needed. This relates back to the point made by Kanayama and Pope 
(2018) that it is only once in their twenties that individuals are no longer within 
parental influence and may have financial autonomy. Furthermore, several AAS-
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users talked about starting AAS use when they reached a plateau, when they had 
achieved the most from exercising and believed their genetics was holding them 
back (5.3.1).  
For some an image change may mean successful negotiation and potentially, as 
part of the prevalent makeover culture, it is not a disordered relationship with 
masculinity norms but one that allows transformation to current desired norms 
(Latham et al. 2019). However, for others, it may not be so clear cut and there 
may be other underlying issues, for example: 
‘I noticed that there was something different about me from a very very 
young age… I am going to transform myself into this huge guy, this huge 
physique and that will magically fix all psychological problems… but I 
clung on to that belief, so so, sincerely …I was driven completely by an 
inadequacy on myself …thinking I was a failure as a man, that didn’t live 
up to society’s expectations of being a male… that was the driving force 
behind the whole thing. Which is kind of sad really when you think about it 
…there is so much of an internal battle going on with me right now with 
regards to the steroid use because, it’s revisiting the past, and all the old 
things come up, you know, this hyper-masculinised version of yourself, this 
feminine version of yourself ...there is still an inadequacy, and it’s this 
feeling that I have to somehow, up my game, somehow I have to be more 
masculine’ (Don/UK/39 [TI]) 
This raises the question about congruency, if by looking more masculine one 
becomes more like what they want to be then it may be beneficial for their 
wellbeing, but if one is in a conflict between what they think society believes they 
should be and who they really are then maybe not. Fanaticism is a maladaptation 
for identity versus role confusion, and arguably, in Don’s case  (Appendix 25) his 
AAS use could be an extreme behaviour or reaction to goal attainment. What is 
evident is that Don is using AAS to try to fix an identity which is possibly 
incongruent with who he is (in the questionnaire, he self-described himself as 
gender-fluid), an identity based on his internalisation of others’ views of 
masculinity. However, for some, even if they are using AAS to help them to realise 
that goal, as it is congruent with their own world view then use may be less 
psychologically problematic and aid the successful negotiation of this stage. 
Moreover, it may explain why some users in this study stopped for a period and 
then returned to use in later life (5.3.1.3), which has been found in Havnes and 
colleagues’ (2019) study with no explanation as to why. Arguably, one explanation 
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could be that having used it successfully to resolve a problem once, it is not 
necessarily illogical to do it again, as illustrated by the following quotation: 
‘…muscularity will sometimes give you back something that ageing has 
taken away. And, you know, and so it becomes a coping. Is it an adaptive 
coping, or a maladaptive coping? It depends on who you ask, but it's… a 
little bit of an adaptive coping with the idea of the loss of status and the 
invisibility that comes with aging as a gay man’ (Hugo/USA/53 [TI]) 
Hugo and Don’s experiences, viewed though Erikson’s development model, 
provide an example of how AAS use for one person has led to a potentially 
successful negotiation of a stage whereas for another it has led to a crisis.  
Describing AAS use in terms of adaptive and maladaptive use, although potentially 
a subjective value judgement, could be helpful as several participants talked 
about being comfortable with their use, and carefully managed perceived risk 
(5.3.3.2). Two interview participants who were clearly conflicted about their use 
had noteworthy adverse childhood experiences (5.3.1.2) and adverse childhood 
experiences including: poor relationship with parents, history of mental or 
physical abuse, problems at school, have been overly represented to AAS use 
(Skårberg and Engstrom 2007). It could be that they had not successfully 
negotiated a previous life-stage and as such found it more difficult to negotiate 
subsequent stages. This can result in individuals experiencing problems such as 
impulsivity, psychosomatic conditions, or a sense of inadequacy (Côté and Levine 
1987). Not all men will be affected in the same way by stereotypical images of 
masculinity and there is a need to consider why the muscular portrayals of men in 
the media resonate with some men more than others, inducing them to use AAS 
(Bates, Tod, et al. 2019). There might be something in the life histories of these 
men that makes them more vulnerable to such stereotypes as adverse childhood 
experiences are risk factors for girls developing body image disorders (Vartanian 
et al. 2018). Consequently, more research into this vulnerability would be 
beneficial. 
Table 8-3  Stages 6 and 7: Young and middle adulthood 
Life-stage Psychosocial 
crisis 
Radius of 
significant 
relations 
Basic 
strengths 
Core-
pathology: 
basic 
antipathies 
Outcome 
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6 
Young 
adulthood 
(20 to 40 
years) 
Intimacy vs. 
Isolation 
Partners in 
friendship, sex, 
competition, 
cooperation 
Love Exclusivity Young adults need to form 
intimate, loving relationships with 
other people. Success leads to 
strong relationships, while failure 
results in loneliness and isolation. 
7 
Middle 
adulthood 
(40 to 65 
years)* 
Generativity 
vs. Stagnation 
Divided labour 
and shared 
household 
Care Rejectivity Adults need to create or nurture 
things that will  outlast them, often 
by having children or creating a 
positive change that benefits other 
people. Success leads to feelings of 
usefulness and accomplishment, 
while failure results in shallow 
involvement in the world. 
(Erikson and Erikson 1997)  *age range varies and other scholars have it as young as 34 
(O’Neil 2015) 
Stage 6 (Table 8-3) covers young adulthood and in Eriksonion theory, this is when 
people form intimate relationships, which may lead to having a family. The 
findings show that some participants were concerned about this, which led one to 
have his sperm cryogenically frozen, whereas another stopped using for a time in 
order to start a family (5.3.3). The concepts of protectiveness and a need to fulfil 
the traditional masculine role of provider (O’Neil 2015) are part of the masculine 
stereotype, and some participants, when asked about risks to others, echoed this 
as they saw risks to others, not from behavioural change, but as a result of them 
becoming seriously ill as a result of their use and as a consequence not being able 
to provide for their families (5.3.2.6, 5.3.3.8,). The role of a man traditionally 
centres on taking on the economic responsibility of the family, which could be 
internalised as “I am less of a man If I cannot take care of my family” (O’Neil 2015, 
p.100). This may explain why some participants saw this not just as a risk of  use 
but also raised it as a concern. There are key transition points in a person’s life 
where they enter new spheres of influence, and decision-making could be 
impacted by time and experience (Bates, Tod, et al. 2019). Arguably, as well as 
more concrete changes such as embarking on a new career, the developmental  
stages could impact on how decisions are made, and these too should be 
recognised, for example AAS use to counteract the effects of low testosterone 
levels either as a result of ASIH or resulting from the natural ageing process 
(Chapter 7). At stage 6 there is often a relaxing of gender role standards and a 
need to maintain intimacy (O’Neil 2015). It could be that the desire to maintain 
 
 
197 
 
their libido is part of their negotiation of this stage linked to intimacy and is 
congruent with underlying motivations if aligned to a strong masculine identity. 
Or, if men with an identity aligned to hegemonic masculinity are seeing muscular 
middle-age male role-models as the ideal and norm, it is feasible they have a 
desire to maintain their muscular physique. This could lead to a continuation of 
the adaptive coping used to negotiate stage 5 successfully, and self-medication, in 
the form of TRT, is used to help maintain their masculine identity and the 
successful negotiation of stages 6 or 7 (Table 8-3).  
Some participants were of an age described by Erikson as ‘Middle Adulthood’ 
(Stage 7). Stage 7 entails the concept of generativity versus stagnation, and 
successful negotiation of this stage includes feelings of usefulness and 
accomplishment and creating a positive change that benefits other people (Slater 
2003). It encompasses a wide age span and successful completion of this stage is 
linked to sense of feeling useful and having achieved something. Erikson also 
suggested that this stage was about having created something that might outlast 
a person or benefitted others in a positive way, and there were examples of this 
from participants. For seven interviewees one of the roles that they appear to 
have taken on as a result of using AAS over a number of years was that of 
‘experienced peer’, someone others turned to for advice and this was something 
they relished (5.3.3.7).  
One talked with pride about sharing knowledge through having a written a book 
on AAS and another saw taking part in this study as a way of ‘giving back’ to 
society. It is worth noting that in this study it was the more experienced and 
mature participants who were more focussed on mentoring the younger 
generation of users, and who raised concerns about people, particularly 
youngsters, who did not use responsibly and were influenced by social media 
(5.3.4.2.1). Andreasson and Johansson (2016) also noted this ‘teacher’ role taken 
on by experienced users on fora, who based their advice on personal experiences . 
The passing on of wisdom and advice to inexperienced users serves a valuable 
social need, and could be part of a moral justification of use (Boardley and Grix 
2014). Viewed through the lens of Erikson’s Life Stage Theory this desire to 
mentor and pass on their wisdom could fuel a sense of accomplishment and aid 
the successful negotiation of this stage. 
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There are those who would argue that Erikson’s work was set in the context of his 
own type, as its roots are in Freudian psychology and so is outdated, conservative 
and outmoded (Côté and Levine 1987). It has also been critiqued as being 
reductionist (Amini and Jafari 2012) and male-centric (although this is less likely to 
impact on this study’s population). However, unlike previous models it does not 
focus totally on biological determinism but emphasises the importance of socio-
cultural factors, although, it must be acknowledged that social norms change over 
time. Further criticisms of Erikson’s model focus on its linear staged process, yet 
Erikson does not suggest that once a life-stage has been negotiated, that it could 
not be revisited and renegotiated at a later stage in life. Moreover, the age-bands 
outlined by Erikson should not be seen as set in stone, as socio-cultural changes 
and individuals’ experiences could impact on the development stages. 
Consequently, when considering the psychosocial nature of something such as 
recreational AAS use, such a model is useful as it acknowledges the complexity of 
identity as a concept, is influenced by how someone judges themselves and 
measures up to the perceived judgements of others (Erikson 1994), and considers 
the person across their whole lifespan.  
8.6 Information and support 
 Considering use through a life-stage journey can be a way to look at and identify 
types of support needed. For example Bates and colleagues (2019) note that the 
movement of young people from school into different environments exposes 
them to different societal pressures and they may encounter factors that 
influence their decisions, leading them to argue that interventions may need to 
consider this transitional phase. In this study, several participants shared regret 
around starting use too young (5.3.1.1) and some raised concerns over the 
increase in use by young people (5.3.3.7, 5.3.3.8). A small, but arguably still 
important number of participants stated bullying as a reason for use (Table 5-2) 
and some interviewees talked about experiencing bullying as adolescents 
(5.3.1.2), which mirrors other studies (Davies et al. 2011, Walker and Joubert 
2011). Although the desire to become more muscular may be acted upon when in 
adolescence or later, when a young adult is grappling with identity in relation to 
finding a partner or self-agency, it may be that the desire to become muscular is 
laid down much earlier. Studies show that children’s toys may contribute to 
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cultural expectations around body image, and that an increase in muscularity in 
action toys reflects the ‘ideal’ masculine look for Western cultures (Pope Jr et al. 
1999). Action figures have become hyper-muscular in recent years, and chest size 
has increased considerably from the 34” chest of the first action man dolls 
(Baghurst et al. 2006). There is a possibility that this is impacting preadolescents’ 
views of an ideal body shape for men leading to a sense of inadequacy around 
their physique (Baghurst et al. 2006) and muscularity orientated body 
dissatisfaction has been found in boys as young as six (McLean et al. 2018). 
Moreover, adolescent preoccupation with muscles and body image and body 
checking behaviour are factors for predicting AAS use (Walker et al. 2009, 
Kanayama et al. 2012, Sagoe, Andreassen, et al. 2014, Jenssen and Johannessen 
2015). This suggests a need for professionals when working with young people to 
share positive messages around gender norms and challenge stereotypical 
constructs. 
 Here, evidence shows another key transition, occurring in middle age a change in 
use from supra-physiological doses to continuous low doses. Each person’s 
journey is unique and although categorisation into types can help particularly in 
determining policies and types of services support provision, when it comes to 
supporting users on an individual basis then a pathway approach may be more 
useful. Moreover, as noted adaptive use is a potentially controversial concept, yet 
professionals should still consider what it means for that person if they believe 
that their quality of life has improved due to AAS use as use maybe  ego-syntonic if 
congruent with their expectations. It is likely that prevention messages would not 
be congruent with such beliefs and, are therefore likely to be ignored. 
8.7 Summary identity 
This section has discussed the findings in relation to the aims and objectives of the 
research (3.9) showing how motivations for AAS use can be viewed through the 
lens of identity and particularly masculinity. It evidenced that the impact of social 
media images of ideal masculinity could impact on a person motivation to use AAS 
and that when the desire to become more muscular leads people to use 
potentially harmful substances to facilitate this, then it is important for 
professionals working in this field to understand the drivers and implications. It 
highlighted that the emotional aspect of AAS use, for some, goes deeper than just 
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the physical benefits and helps them attain and maintain a physique and sense of 
wellbeing that is linked to their identity as a man. Consideration was given to 
using Erikson’s Life Stage Theory as a way of helping to understand and explain 
motivations and changes in use over the lifespan. It concluded that understanding 
AAS use across the lifespan was relevant when considering AAS-users’ information 
and support needs. The next section explores the limitations and strengths of the 
study and the researcher’s reflections. 
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8.8 Female Participants Summary 
Our knowledge of female AAS use is limited (1.4, 5.2.1) so to ensure that the 
voices of my two female participants are not lost, the following is a short 
summary of the findings and discussion of two participants who identified as 
female. Table 8-4 gives an overview of some of the differences between two 
reasonably similar female AAS users; both were employed, had college degrees 
(or higher),  and both took part in competitive sports 
Table 8-4 Female Participants 
Demographics** AAS Use 
Ages 40 31 Inject AAS  (n=) 
Number of years using AAS 1 4 Yes 1 
Ethnicity (n=) No 1 
White 1 Has your quality of life improved since using AAS? (n=) 
Other 1 No – stayed the same 2 
Sexual orientation (n=) AAS use pattern (n=) 
Heterosexual  1 Cycling* 2 
Other (pansexual) 1  
Country of residence (n=) 
Australia 1 
UK 1 
*Cycling i.e. using AAS for periods of about 6-12 weeks and then taking a break (Kicman 
2008)  
** as there are only two participants where relevant individual data is included 
 
As the thesis focus on masculine identity a short discussion on comparison with 
other studies looking at female AAS users will be included here. As previously 
noted (para  4.3.14) the majority of AAS users are men due to the motivation to 
increase muscle size (Kanayama, Brower, et al. 2009) with research indicating a 
global prevalence rate for males or 6.4%, and for females, 1.6% (Sagoe 2015).  In a 
study of 12 female AAS-users, female AAS users were more likely to take part in 
competitive sports (Ip et al. 2010, Börjesson et al. 2016). In this study, both 
females exercised for 3 hours a day, with one female participate describing herself 
as a competitive athlete and the other a competitive bodybuilder. Both 
participants used AAS in cycles , one injecting and the other not but only one used 
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PCT.  When it came to motivation for use, both women were motivated by: 
enhancing muscles and strength, for competition and improving endurance and 
stamina which is similar to other female studies (Korkia et al. 1996, Ip et al. 2010). 
However, the older participant also listed a number of other motivations: increase 
confidence, improve appearance, lose weight, increase aggression, overcome 
depression, increase sexual attractiveness, impress my friends and curiosity. The 
women also had different influences to start using, with one stating a close friend 
influenced her, whereas the other cited it was both a personal choice and 
influenced by her coach.  
AAS can affect men and women differently (Onakomaiya and Henderson 2016), 
which is consistent with this study as the side -effects noted by one participant 
were: darkened body hair and a swollen clitoris, although interestingly the 
participant noted that she was not sure if the latter issue was something she was 
unhappy about. These physical side-effects are similar to those found in other 
studies (Ip et al. 2010, Börjesson et al. 2016). However, similar to the men in this 
study one participant experienced depression and unhappiness when coming off 
cycle, whereas other experienced no effects when off-cycle but described feeling 
increased irritability, and jealously whilst using AAS. When it came to asking if 
there was a need for emotional support for people using AAS, one participant 
suggested maybe and the other yes, in the form of counselling. Interestingly, it 
was the participants who had said yes to ‘experiencing’ emotional side-effects 
such as increased ability whilst on-cycle who felt counselling would be useful, not 
the participant who experienced low mood when coming off-cycle, nor did this 
participant use PCT. Both participants selected their quality of life had stayed the  
same, and both reported feeling strong as a positive effect of use, in addition one 
reported increased libido as a positive effect and the other increased feelings of 
confidence and happiness and being proud of her body. Positive physical effects 
for one participant included better mood, better sleep and increased aggression, 
whereas for the other it was around increased in strength, muscle and recovery. 
Both were clear that it was possible to become addicted to AAS use, but that they 
felt they could stop at any time.  
Both participants indicated an awareness of some of the risks of using AASS and 
did not believe their use put others at risk. When it came to support for using 
 
 
203 
 
again there was small differences. Both women accessed AAS forums for advice, 
but one woman also accessed information from websites selling AAS, but only 
trusted the forums, whereas the other had a wider set of sources including 
friends, AAS users, Government information websites and Needle Exchange 
leaflets, but only trusted friends. Moreover, she regularly obtained bloodwork and 
had discussed her use with both a GP, who was helpful and gave non-judgemental 
support and the NE. It is impossible to compare female’s advice seeking behaviour 
with the men’s in general, however these two participants actions, align with the 
men in this study.  The support wanted by the two participants was more 
explanation of health risks, which aligns to previous studies (Grogan et al. 2006) 
and also non-judgemental doctors that will monitors health markers, which was 
also wanted by the men in this study.  
Interviews with eight female weightlifters found that six were influenced by their 
boyfriends to take AAS and reported troublesome family history of substance use 
(Börjesson et al. 2016). Moreover, a web-based survey of 1519 people who used 
strength training, found twelve female AAS users and when compared with 
female non-users, female AAS users were more likely to have qualified for 
substance dependence disorder, have been diagnosed with a psychiatric illness, 
and have a history of sexual and physical abuse (Ip et al. 2010). As women 
experience negative physical effects from using AAS, these studies could suggest 
that women, other than competitive female bodybuilders, who have mental 
health issues or with AAS using male partners may be vulnerable to starting AAS 
use. However, with such a small number of self-selected female AAS users in 
these studies, it is not viable to apply these results to a wider population. Due to 
the potential risks for starting use, and the fact that AAS use effects males and  
females (Onakomaiya and Henderson 2016) differently there is a need for more 
research into female AAS use. 
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8.9 Limitations and strengths  
This section outlines the limitations and strengths of the study. 
8.10 Limitations 
 Study design 8.10.1
There were several limitations to using a mixed-methods approach. An 
anonymous questionnaire did not allow for some of the qualitative answers to be 
explored in more depth, unless the participant volunteered for an interview. The 
amount of qualitative data obtained led to challenges in making sense of all the 
data and required a structured and targeted approach to the analysis. This meant 
that some elements may have been overlooked due to researcher unconscious 
bias (Wheeler 2015, Buetow 2019). As this study was a cross-sectional study by 
design, this meant it was not appropriate for assessing associations, and 
consequently causal relationships between the variables cannot be established 
properly. For the quantitative data the converse was also a challenge, the low 
numbers meant that it was hard to obtain any solid statistical inferences from the 
data, however, Bonferroni’s adjustment (Sedgwick 2014) was applied to give 
some rigour to the quantitative analysis.  
 Questionnaire design 8.10.1.1
Further limitations could be that this study utilised a self-administered 
questionnaire with no other confirmation method used to document AAS use 
among study participants. Many studies on AAS use occasionally had unclear 
questions which potentially gave limitations to the validity of some findings 
(Sagoe and Pallesen 2018). This study incorporated questions on influencers 
regarding use, and information and support but did not take into considerati on 
that one person may have two roles for example doctor and peer, or people who 
said self-taught (for injecting) yet also ticked different types of information 
sources they accessed. This did not impact the validity of the findings but did 
make for less statistical analysis. Moreover, one question covering several options 
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asked participants to identify to which element they were referring, and several 
participants added comments but did not annotate which answer they were 
referring to, which complicated the analysis. For future studies a key learning is 
the need to run a larger pilot as this may highlight such flaws. 
 Sampling frame 8.10.1.2
As it is a secretive population, and use is illegal in many countries (1.4, 4.4.2) and 
although there are global prevalence figures for the numbers of AAS users, it is 
acknowledged that these are likely to be underestimated (1.4). One potential 
effect from not having a defined sampling frame (4.6.1) is that there is no 
guarantee participants are a representative sample of AAS users. All participants 
who answered the questionnaire online and did not complete a paper-based 
version of the survey (with the exception of the three pilot participants) it is 
possible there is bias around the income and educational status as participants 
needed to have internet access and be able to complete a relatively complex 
questionnaire. Moreover, each of the techniques used to col lect the data have 
limitations which are outlined at Table 4-1 Recruitment StrategiesTable 4-1 
and could have impacted on the data collected e.g. that a number of participants 
accessed the survey via link in a closed FB group on low Testosterone may account 
for the number of participants who used continuous low testosterone doses 
rather than being on cycles. 
 Data collection 8.10.2
One of the challenges of using online data collection is that people could choose 
to access the questionnaire more than once and without potentially breaching a 
participant’s anonymity it is not possible to prevent this, however, the length of 
the questionnaire was likely to dissuade many from completing it twice.  
It is important to establish age in a questionnaire (Rodham and Gavin 2006) and 
this was crucial as ethical approval had only been gained for participants over 
eighteen. As this was an anonymous, self-reported study, there was a reliance on 
the integrity of the participant. With a web-based questionnaire there is the 
possibility of hoax responses (Ip et al. 2010). Consequently, there was the 
possibility for false data, including age, to be entered. However, participants were 
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also asked to give length of time using and age starting use, so it was hoped these 
might reduce the likelihood of false data and allowed for cross-checking. There is 
a wider limitation from self-reported data as questions about socially disapproved 
of behaviours relating to drug use may lead to inaccurate data (Harrison 1995). It 
is possible that participants have under-reported the severity of side-effects 
because of shame or fear, or from concerns that reports might increase the 
attention from authorities into steroid use. There are examples of such comments 
on fora related to not using NSPs or admitting to AAS use for fear of increasing 
Government statistics or that it might change the legal situation in the UK 
(Appendix 26). There is also the potential that people willing to talk about their 
experiences are more likely to be pro-use.  
Use of online questionnaires meant that it was difficult to control how widely the 
survey was distributed; therefore, no bar on access dependent on geographical 
location was imposed. This could be a limitation as attitudes to AAS use may differ 
dependent on the legislation and support services in specific countries, which 
means findings should not necessarily be generalised. Moreover, the majority of 
participants in this study resided in countries where use was predominantly illegal 
without prescription which could have impacted the results as discussed in (4.4.2).  
Another limitation, was not having NHS ethics, which meant only non-NHS 
services could be accessed, however, the time needed to get ethics for each 
provider was prohibitive and a key aim of this study was to recruit people away 
from the well-used recruitment methods such as NSPs. Using Instagram was a 
challenge as it was difficult to decide which posts to use to encourage 
engagement of AAS-users but not to promote AAS use. Furthermore, a lot of time 
and effort was spent distributing the questionnaire through a variety of media 
channels and sources. Consequently, it may be helpful for future research, to 
know which channels produced the most results. Therefore, another key learning 
for future studies would be to include a question on where participants saw the 
questionnaire link, to identify the most useful mediums for dissemination of 
similar questionnaires.  
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 Interviews 8.10.2.1
It was notable that the audio-only interviews (e.g. FB chat) were more 
challenging, as unlike Skype there were no visual communication cues. This may 
have led to the researcher missing a communication nuance with incongruences 
between body language and spoken word. It was also harder to build a rapport 
though the typed forms of real-time interview and this lack of rapport could have 
adversely impacted on the participants’ openness. 
8.11 Strengths 
 Study design 8.11.1
There were several benefits of using a mixed-methods approach. First and 
foremost, the use of a literature review (Chapter 3) was helpful in the 
development of the questionnaire, including identifying specific terminology to 
use (3.3). Inclusion of demographic questions enabled comparison with other 
studies, which adds to the strength of the findings. Including free-text questions 
allowed for a bigger pool of qualitative data than would normally be used for a 
purely qualitative study and these also helped inform the semi-structured 
interview questions. Having all interviewees complete the questionnaire, allowed 
the researcher to ask follow-up questions for clarification. Another benefit was 
the ability to re-interrogate the quantitative data, based on some of the themes 
drawn out from the interviews, which targeted the data analysis. The quantitative 
data gave an insight into the specifics of the person’s experience and their AAS 
use, and the qualitative data allowed for a deeper exploration and richer 
understanding of the experiences of the user. Another key strength of the study 
design was running two pilots (4.3.1.2, 4.5.3, 4.7.1). 
 Questionnaire design 8.11.1.1
A key strength of the questionnaire was that the design was influenced and 
reviewed by a wide range of professionals (4.5.3). One way to measure internal 
consistency in a questionnaire is if the participants answer questions in a logical 
way (Ryan et al. 2001) and this was a strength as there were few spurious 
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answers, and those that were there, were often more humorous than spurious 
(Table 8-1). 
 Data collection 8.11.1.2
One strength of collecting data online is that it can reduce errors due to the lack 
of transferring written data on to a computer (Regmi et al. 2017). Another benefit 
of posting online is that it has a wide reach and can easily be shared. A lack of 
geographical boundaries was a strength as it can highlight similarities, such as 
effects of use which are unlikely to differ per location. One of the recruitment 
methods was via a closed FB group which focussed on the issues of having low 
testosterone. This was a fortuitous referral chain (Biernacki and Waldorf 1981), as 
the credibility of the administrator meant that people trusted him, and so were 
happy to participate. However, due to the nature of the group, those participants 
talked about the impact of low testosterone. This is a strength as it highlighted 
the needs of a group of AAS-users for whom this is an issue, however, this is not 
applicable to the whole AAS-using community 
 Interviews 8.11.1.2.1
Another strength was the range of interview methods available to participants 
allowing them different levels of anonymity (4.7.2). As the data is often taken out 
of context when reported there is the potential for it to be misinterpreted, and 
misinterpretation can also occur if the researcher is not part of the same 
community as the participants (Ryan et al. 2001). However, as the interviews were 
semi-structured the researcher was able to ask participants to clarify any points 
that were unclear, which reduced the possibility of misinterpretation. Moreover, 
online tools also instantly allowed the participants to share pertinent website links 
as exemplars of where they sought information and support. As already noted in 
(4.8.24.8.2) there are four components to assess qualitative data, one of which is 
credibility (Lincoln and Guba 1985). Credibility was something that will be a 
challenge to identify prior to the publication of results, however, semi -structured 
interviews did allow for points raised by the early interviewees to be followed up 
in later interviews, to see if views were consistent, and this was often the case. An 
 
 
209 
 
additional strength was that participants were offered, and some accepted, the 
opportunity to review their transcript and amend as desired.  
8.12 Theory and practice  
Reflection is an active and purposeful process of exploration (Gray 2007); it can 
bridge the gap between research and practice (Renganathan 2009), help to 
reduce the risk of research being oppressive and ensure that the researcher’s 
holistic experiences are acknowledged (Ruch 2002). Reflective practice can also 
facilitate a deeper understanding of situations, lead to new discoveries (Gray 
2007) and help to reduce unconscious bias (Buetow 2019). This section shares 
theoretical reflections on the findings linked to practice. From the outset, this 
study has taken a broad psychosocial perspective to AAS use and considers the 
use of typologies of AAS-users in the context of the humanisation of care (Todres 
et al. 2009). It suggests that using a pathway model as a support intervention 
could provide a greater understanding of a person in the context of their use to 
help identify beneficial services. The section also includes some of the 
researcher’s personal reflections on undertaking this study, noting how reflective 
practice influenced elements of the discussion. Finally, it outlines the ways in 
which the data from this study has been disseminated. 
 Typology 8.12.1
One way to help professionals understand users’ differing concerns is to consider 
different ‘types’ of user. Dawson (2001) defined four distinct ‘types’ of AAS-user 
and more recently two further more sophisticated typologies have been 
developed (Christiansen et al. 2016, Zahnow et al. 2018) (2.4 and Appendix 1). 
Zahnow and colleagues (2018) identified a typical pattern of use and associated 
risk behaviours. This study found some participants fitted the types; however, for 
others it was not so clear cut, and some did not fit. For example, in the typologies, 
only the expert type is given credit for accessing scientific articles, but this study 
found this was also true for others, who might more easily fit within the wellbeing 
category. Moreover, some users seemed to have transitioned from one type to 
another and there seemed to be no ‘box’ for users with concerns around virility, 
or who had TRT as a motivation, although potentially ‘rejuvenating’ might fit, 
which could also place them in the wellbeing box. Another example was of one 
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participant, with an extensive enthnopharmacological knowledge, who used AAS 
to improve his wellbeing, yet also admitted an ‘image-related’ aspect to his use, 
thus seeming to straddle two or three types e.g. Hugo (Appendix 25).  
There are pros and cons to trying to create such models. An ideal typography 
cannot describe all the possible approaches to AAS use (Christiansen et al. 2016) 
and Zahnow et al. (2018) noted similarities and differences between theirs and 
Christiansen and colleagues’ (2016) typologies and suggested that although 
typologies are useful for policy-makers, due to the heterogeneous nature of AAS 
use, there is a need for individualised care. Typologies can help professionals to 
offer the right type of support and emphasise that AAS-users are not one 
homogenous group, thereby enabling professionals to provide targeted support 
to subgroup(s). However, there is a need to ensure that assumptions are not 
based on limited information or that everyone falls neatly into a ‘box’.  Even within 
clearly defined typologies there may be differences in the types of support 
needed. Arguably, typologies impose a ‘sort of identity’ on the AAS-user. In trying 
to simplify the complexity, there is the possibility that one label is replaced with 
another. The benefits of the most recent typologies is that they are based 
predominantly on characteristics of use, could help to simplify the complexity for 
professionals and do help to move away from a ‘one-size-fits-all’ mentality, which 
could lead to better identification of avenues for support. However, there is still a 
risk that they may lead professionals to make assumptions and could be harmful if 
used as diagnostic tools. There is a consensus within the literature that it is 
becoming more challenging to identify a typology of user (Salinas et al. 2019). 
Existing AAS typologies do not necessarily consider underlying motivations, 
people fall between groups and move groups, and do not necessarily focus on 
understanding the person in the context of their use. Consequently, it is 
important that at the professional outreach/support level, the focus remains on 
the individual.  
 Person-centred practice 8.12.2
The concept of the humanisation of care is made up of a number of components, 
one of which, ‘personal journey’ (Todres et al. 2009), has already been used to 
justify why Life Stage Theory can be a useful way to consider AAS use (9.11.2.1.1). 
There is another component: ‘uniqueness/homogenisation’ which suggests that 
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humans have a unique self which “can never be reduced to a list of general 
attributes and characteristics” (Todres et al. 2009, p.71). In recent years the 
humanisation of care has been incorporated into training for healthcare 
professionals (Fasanelli et al. 2017, Walker et al. 2017) and a similar philosophy is 
at the heart of social work, that of person-centred practice. Person-centred 
practice has its roots in the work of Carl Rogers (Rogers 2003, 2004) and focuses 
on the importance of non-judgemental, authentic and empathetic professionals 
who treat each person as an individual (Payne 1997). Although not explicitly 
termed ‘person-centred practice’, other academics have suggested taking an 
individual perspective. For example, Richardson & Antonopoulos (2019) suggest a 
need to obtain and understand users' perceptions of AAS and unwanted 
experiences of use, alongside understanding how the cultural dynamics in the 
AAS-using sub-community affect someone’s involvement in AAS use. Havnes and 
colleagues (2019) emphasise a need for individual support focussing on 
psychosocial factors due to the heterogeneous nature of this population and this 
is echoed by others, who also note the importance of exploring underlying 
motivations, risk behaviours and health and lifestyle (Smith et al. 2009, Boardley 
et al. 2014, Griffiths et al. 2018, Zahnow et al. 2018, Bates, Tod, et al. 2019).  
Although Roger’s work focused on their current situation, rather than a client’s 
history of problems, it is arguable that a person’s uniqueness comes from their 
personal experiences and their world view (Simmel 2007). Our world views are 
dependent on a wealth of influences over our lifespan, and each person will 
interpret their experiences differently and use these to construct their own 
reality. To understand someone’s decision to use requires an understanding of 
motivations for use and of how they make sense of the world. For example, as 
argued in 9.4.5, their internalised beliefs on masculinity may impact on suggested 
avenues of support as motivations identified are not clear cut. In this study 
motivations were complex and linked to a sense of identity and psychological 
wellbeing. Therefore, there is a need to consider the individual within the social 
context, not applying a label(s) which can disempower and detract from exploring 
beneath the presenting issue (Dominelli 2002) but instead view the person in the 
context of their history, identity, current circumstances, social context and 
personal motivations.  
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Taking a person-centred approach to AAS use could help to: 
 Evidence how use changes over the lifespan; 
 Explore underlying drivers and current reasons for use; 
 Understand the user in the context of their use; 
 Consider the impact of any adverse childhood experiences; 
 Identify potentially risky behaviours and ways to mitigate risk; 
 Recommend information and support based on individual needs.  
 The AAS-user pathway 8.12.2.1
This study shows that motivations for using AAS can change over the lifespan and 
that some reasons to continue to use can come from deep-rooted beliefs around 
what it is to be masculine (9.4.5), or from learnt behaviours around effective ways 
to solve problems (Chapter 7). Bates and colleagues (2019) suggest a 
socioecological framework for considering AAS use and this study used Eriksonian 
theory to illuminate the changes across the lifespan and suggests a pathway tool 
(Figure 9-6) to explore use across the lifespan, which could be a way to 
encompass all the aspects that would feature within such a framework.  
 
Figure 8-6 AAS use pathway 
 
 
 
213 
 
Moreover, such a tool is explicit in highlighting the potential for the risk of harms 
to increase with long-term use. 
In this study the route into use was individual and personal. For example, two 
people who start with a motivation to start training to gain muscle owing to 
negative experiences from being skinny, will not necessarily follow the same 
pathway of use; while, one user may go it alone and stay focussed on attaining a 
lean, muscular physique, then may be influenced to continue using by the effects 
on libido, another user might become involved with the subculture and start 
down a competitive bodybuilding route. This could lead them to take different 
decisions about how they manage their use. In this study, the choice to use PCT or 
a ‘blast-and-cruise’ strategy was one example of differences in use management 
(5.3.3), which could lead to different side-effects. Taking a person-centred 
approach would help to ensure that the most relevant support options are 
considered. 
 Life Story Work 8.12.2.1.1
The importance of different aspects of our identity matters at different points 
over our lifespan (Tatum 2000), and a potential method for approaching this could 
be using a form of Life Story Work (LSW), which is used in a range of healthcare 
settings including substance use (Etherington 2006, McKeown et al. 2006). AAS-
users may have multiple identities (9.4.3) and LSW is a biographical technique that 
asks people to share their life histories and can help reflection around the 
negotiation of sense of self and identity (Etherington 2006, Ryan and Walker 
2007). LSW can also help professionals uncover previously unidentified 
psychosocial needs, define individual support needs and improve relationships 
between professionals and service users (McKeown et al. 2006). It is a way of 
understanding life experience, and although there is no agreed methodology for 
LSW, using a form of LSW to structure conversations with AAS-users could be a 
way of exploring their AAS use pathway (Figure 9-6). Talking to a person about 
why they chose to start using, being curious about their current motivations, 
getting users to reflect on their life history, identity and exploring thoughts on 
future use could help users open up about individual motivations and worries and 
fears, potentially leading to better identified support services.  
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When suggesting any tool for use within practice, examples can be helpful to 
illustrate how the tool might work. Consequently, Appendix 25 offers four 
sketches of participants’ life stories generated in the data collection process of 
this study. A sketch is a brief outline or description to give essential facts or 
prominent features without giving details (Simpson and Weiner 1989). As each 
pathway is unique the sketches are summaries and extracts from single interviews 
are a way to maintain the voice of the user and authenticity of individual stories 
and illuminate AAS use across the lifespan. The four sketches (Appendix 25) show 
how, taking this approach, professionals can ensure the support options identified 
are led by the individual seeking help. When it comes to prioritising support, it 
could be that support for people who are congruent in their use would be around 
side-effect mitigation and evidence-based information but for those who are 
conflicted, a wider range of support options may be helpful, including talking 
therapies and even looking for prevention over harm reduction.  
As a social worker, I believe that it is important, when using such a tool as LSW, 
for professionals to consider their own role and skills in order to help people 
reflect on their life experiences. To engage in a conversation where someone is 
asked to discuss personal details needs a relationship based on trust and 
empathy, which are skills that can be developed (Norfolk et al. 2007). Trust in a 
relationship can help support change (Dominelli 2004) and maintaining a curious 
approach can enhance this trust and rapport (Mcevoy et al. 2013). A curious 
approach also allows the service user to define their own problems and solutions 
(Teater 2014). Challenges of working in this way include time and resource 
limitations. However, there is a phrase that has come to mind, one that this 
researcher recalls from her previous military career: “time spent in reconnaissance 
is seldom wasted” (Oatts 1959). Here this reconnaissance would be taking the 
time to build a relationship with someone to understand their motivations as 
these may lead to key insights for the most effective types of support.  
8.13 Reflections on academic evidence and policy-making 
Dawson (2001) argued that as AAS use in the UK is not illegal this should empower 
the doctor to treat the patient, and suggested support could include discussing 
the patients aims and giving advice on injections and types of substances. In 2006, 
Grogan and colleagues (2006) stated a need for professionals to work to gain 
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credibility and Dennington et al. (2008) found credibility was given to balanced 
information. Evans-Brown and McVeigh (2008) listed a number of 
recommendations or support for practitioners: the need to recognise the benefits, 
be non-judgemental, appreciate diverse motivations and the need for harm 
reduction advice. Yet these recommendations appear not to have been widely 
followed, except for a small number of specialised services. Since then numerous 
studies have added to knowledge including most recently Richard and 
Antonopolus (2019), Havnes and colleagues (2019), and Underwood (2019) and 
evidence that these recommendations are still relevant today. The findings of this 
study also show that this type of support is wanted but not readily available.  
The way a social problem is defined reflects social policy responses (MacGregor 
1999), thus defining AAS-users as ‘injecting drug users’ focuses on transmission of 
BBVs. Arguably, IPED use is not the same as using drugs such as heroin or cocaine, 
even if linked to psychological issues, because it often carries with it long-term 
goals and could be seen as purposeful. The end of the welfare consensus brought 
with it a change in how policy was informed, moving from technical expertise and 
scientific discourse to include a strong influence from mass media (MacGregor 
1999). This notion, suggested before the widespread use of social media 
platforms, may be more relevant today, and could in part explain why the 
prevailing discourse in the literature is being overlooked, as it does not fit with 
public discourse around drug use. Other reasons for not taking evidence -based 
advice could be cost, lack of political will, as supporting a seemingly deviant 
behaviour would have little public support, that the potential harms are individual 
rather than public health issues or that social norms mean men’s mental health is 
something that has been consistently seen to have been given a lower priority or 
ignored (9.4.6). It could even be that supporting AAS-users is less of a priority as 
substance use is only tackled if there are other issues such as criminal or other 
undesirable social behaviours. When it comes to AAS use and policy, perhaps 
“paternalism and morality tend to take precedence over individual choice” 
(Mulrooney et al. 2019, p.2), which is a position at odds with riskier legal and 
socially acceptable pursuits such as drinking and smoking. Whatever the reason, 
this researcher would argue that this needs to be addressed and support based on 
academic evidence.  
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8.14 Reflections on personal experiences impacting on the 
researcher / research 
As a social worker I come from a perspective of anti-oppressive practice, believing 
that the substance-user is the expert in their own use. I am a feminist and have 
considered how these lenses have meant that I may have viewed masculinity from 
the perspective that the patriarchal nature of our society has negatively impacted 
on men’s view of themselves and their ability to access support. Moreover, it has 
led me to consider how changes in society via social media have seen a rise in 
pressures on men aligned to appearance that have previously been the realm of 
women.  
Monaghan (2002) suggested that if you are part of the same culture as the 
participants you could run the risk that they may make assumptions about your 
knowledge. As an outsider this was not a consideration, however I was concerned 
about personal credibility within this community. Another challenge for me was 
the clash of perspectives between ‘me – the researcher’; purely curious and 
objective, and ‘me - the social worker’; the need to want to offer support and 
solutions. This was particularly evident in one interview, where a participant 
seemed very conflicted in his use. At the end of the interview I felt compelled to 
explore support options with him. This was my social worker persona coming into 
play, and my tendency towards being a rescuer (de Vries 2013). Reflecting on this 
raised my awareness for future interviews, and enabled me to better retain my 
researcher focus, consequently improving my interview technique.  
Qualitative research is an embodied experience and may affect the researcher 
(Dickson-Swift et al. 2009) and I have felt empathy for the stigma faced by this 
sub-community. It has impacted my personal value of authenticity, and I want to 
ensure that I share the participant’s stories honestly. Yet, as a researcher, I need 
to be objective and non-judgemental, honouring their participation, and still raise 
challenging themes. I was affected in part by their ethnopharmological 
knowledge, by their keenness to have a research summary and to partake 
because they felt that more support should be available for people. It has been a 
privilege to share the stories, in a non-judgemental way. I do recognise that 
participant views are biased and subjective, and reflection enabled me to review 
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my work and not let my gratefulness to the interviewees influence concerns about 
being critical in my analysis. They may have their own agenda to ‘minimise harms 
experienced’ and show how controlled or considered or safe they are in their use. 
However, there is still a desire to ensure that my research does not fuel any 
argument that could do this population harm by adding to the stigma and 
mythology. Furthermore, as noted in the limitations in Chapter 7 concerning the 
potential for use of AAS for libido and sexual function to be under-reported, as 
interviewees may have been reluctant to discuss such issues with a female 
interviewer, there also may be other elements of the interviews that might have 
been impacted due to the researcher’s gender and as someone not part of the 
AAS-using community such a downplaying of side-effects. However, alternatively 
as the interviews were confidential participants may have seen them as a safe 
space to share their views, as potentially there was less social pressure on them to 
maintain a certain persona.  
Research interviews can be an intervention (Hutchinson and Wilson 1994) as the 
act of asking a specific question can lead someone to question themselves. 
Several participants reflected on their answers and motivations for use in the light 
of the conversation. It would, therefore, seem relevant to suggest this as an area 
to be considered as part of the support that should be offered; a space where 
people can talk about and reflect on their use. Although people ask questions 
about use within the fora, this is not a place that naturally lends itself to reflective 
conversations and this may be where peer support groups have a place. This also 
led to the development of the AAS use pathway model (Figure 9-6) and 
recommendation of the potential benefit of using LSW.  
One of the challenges faced, possibly not unexpectedly to those who are well 
versed within academic culture, was the forthright stances taken when it comes 
to certain positions or philosophies. I learnt early on that taking a pragmatist 
approach, even though it is well supported and documented, appeared to be 
controversial. Throughout my research journey whether it was in the Transfer 
presentation or getting my literature review published I found myself  coming up 
against polarised views, and the idea that this type of research could only be 
qualitative. This became apparent in the feedback from the peer review of the 
paper (Chapter 7). On one level, the feedback was confidence-inducing as both 
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reviewers felt the paper had something to add to the current body of knowledge, 
however there were elements that made the revisions challenging. The reviewer 
comments themselves came from opposing positions which potentially reflects 
the complexity of undertaking any mixed-methods study. I understand the value 
of having an appropriate methodology but found it hard to understand the 
fixedness of some of those who came from different ideological backgrounds. 
Arguably, this was a good lesson to learn as part of the PGR journey, after all a 
PhD can be considered an apprenticeship of sorts. This led to a realisation that my 
lens was that of an outsider when it came to academia, as a social worker I was 
coming from a different research paradigm and this shed light on why I was 
experiencing confusion. 
8.15 Dissemination 
The dissemination of results is an important aim of research (Lawrence 2006) and 
one way of disseminating information is ensuring contact and building 
relationships with end users (McBride et al. 2008). Consequently, all participants 
and gatekeepers who requested a summary of the study will be provided with 
one. 
8.16 Summary 
This section has explored the researcher’s reflections on the benefits of using 
typologies. It has suggested that although useful, taking a person-centred 
approach might be a more efficacious way of identifying individual support 
needs. Highlighting the importance of considering the person, in the conte nt of 
their whole life experience and suggesting that using a pathway tool aligned to 
LSW, may be a way to facilitate such discussion and help to identify types of 
support services that could best meet the needs of the user. This could allow a 
person to explore the context of their use within their life story related to their 
identity and may lead to a reduction in doses used and possible cessation, if the 
person can find other ways to feel more congruent with their identity. This 
section also shared how reflective practice impacted on the researcher’s journey 
and influenced the research. It concluded with summary of the dissemination 
plans; the next chapter provides the conclusion to the study.  
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 Conclusion Chapter 9
 
This study explored the experiences of AAS-users, particularly in relation to 
understanding the information and support desired. As previously discussed (1.3, 
9.2.5.3), there has been an increase in AAS use, and the current UK support 
provision is focussed on BBV transmission with services provided through NSPs. 
Such provisions may not meet the needs of the current population of AAS-users, 
and this alongside the narrative of harm aligned to AAS use within society could 
be dissuading people from accessing services (2.5). A gap was identified in the 
literature regarding information and support wanted by AAS-users; there was a 
significant amount of data on information and support services, but little that 
explored their preferences (Chapter 3). This current study offers a unique insight 
into both the types of information and support users want and their experiences 
of managing use.  
This study found six themes related to AAS-users’ experiences of use (Figure 5-1). 
A number of motivations were found consistent with those in the literature and 
the study identified that, in some instances, motivations for continuing use 
differed from those for starting use (5.3.1.1). One of the interesting additions that 
this study brings to the literature is a fuller picture into how identity can impact 
AAS use, and an underlying motivation for use could fulfil a need to reinforce a 
specific identity, for example an AAS-user’s decision to use could be influenced by 
their internalisation of society’s perception of what is a ‘real man’ (9.4.4). It 
illuminates the emotional aspect of AAS use, for some showing it goes deeper 
than the physical side-effects and is a way of helping them not just attain and 
maintain a physique but also giving them a sense of wellbeing and symbolising 
their masculine identity (9.2.2.1). It found that an individual’s concept of identity 
could potentially affect how AAS is used and that changes in identity could change 
usage patterns. Additionally, this study highlights that one of the reasons for 
continued use (or in some cases initiation) was not through a desire to body build 
but as a desire to overcome actual or perceived effects of having low testosterone 
levels (5.3.1.3).  
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This study found a range of positive and negative effects of use (5.3.2, 9.2.2). This 
is consistent with current literature, however what is potentially unique about 
these findings is that the majority of participants stated that AAS use had a 
positive impact on their lives. Additionally, this study found that positive effects, 
such as increases in libido became reasons to continue using or restarting use and 
that for many the positive effects outweighed the negative effects (5.3.2). This 
study also found self-reported evidence that AAS use had a strong emotional 
impact with some substances, such as Trenbolone being particularly associated by 
users with increased aggression, and that the emotional effects experienced when 
stopping use were often seen as more detrimental than the negative physical 
effects of using. Another theme explored how AAS-users managed the side-
effects of their use (5.3.3). Participants saw risk management as a vital element of 
using, with many having a strong level of ethnopharmacological knowledge; they 
had often undertaken self-medication for unwanted side-effects and were acutely 
aware of the physical and emotional impact on their bodies from using AAS. A 
unique and unexpected finding was that when it came to the management of the 
emotional side-effects of use, several of the AAS-users reported employing a 
number of techniques for managing these, and also felt that it was their 
responsibility to do so. Although the majority of participants felt there was little 
need for emotional support, there was a number that felt this would be useful, 
and arguably these people are most in need of support. A further key contribution 
from this study highlights the need for support for people who self-medicate to 
mitigate the effects of perceived or actual low testosterone levels. Consequently, 
key to providing support is the need to fully appreciate the perceived benefits 
that people get from using AAS, from both a physical and emotional perspective. 
In addition, support provision should encompass both physical and psychological 
harm reduction. 
This study highlighted the importance of the role played by the AAS-using 
community in providing support (5.3.4) and also that many participants felt the 
public’s perception of AAS-users was unbalanced, biased, and fed by media stories 
about ‘roid’ rage (5.3.4.2, 9.2.4.1). This perception is important as it could impact 
on public health policy and those working within support services. Furthermore, it 
contributes additional data to the evidence base as many users felt medical 
professionals were often judgmental toward their AAS use and took a solely 
 
 
221 
 
preventative focus. This study found that there was an identity aligned to AAS-
users which was very different from that of a ‘traditional’ illicit drug-user (5.3.4), 
and also a somewhat separate one aligned to a ‘self-medicator’ for low 
testosterone. It also highlighted the impact of societal expectations of what an 
‘ideal man’ should look like (9.4.4) and that for some people, internalisation of 
this idea was an underlying motivation for use.  
The findings of this current study are relevant to professionals working with 
people who use AAS. Users predominantly sought information from peers within 
the AAS-using community (5.3.5) as they considered this advice to be trustworthy 
and based on years of experience. This study recommends using a range of 
possible methods of communicating harm minimisation evidence-based 
information with AAS-users (Chapter 6). It was clear from this study that, 
regardless of country few of the participants accessed NSPs or saw these as useful 
services (5.3.5.3.2). Evidence from the study (Chapter 3, 5.3.5.3.3) suggested that 
people wanted to access information and support services but faced several 
barriers. The reason for this was not down to the nature of the services 
themselves, but instead was due to perceived stigma and scepticism of the 
knowledge of professionals around AAS use (9.2.4.1). This also helped to reinforce 
their views on the benefits of self-medication. AAS-users were keen to have 
access to non-judgemental support provided by professionals who understood 
why people choose to use AAS (Chapter 6). It was felt that it was important such 
provision was detached from other services that support people who use illicit 
substances such as opiates, and many were willing to pay for such support (9.2.5). 
This study also includes a recommendation for incorporating peer mentors as part 
of services (9.2.5.2).  
This study has explored two concepts: management of use and identity. These 
were interconnected, however for the most-part identity impacted on how AAS-
users managed their use. It is the first study, to the researcher’s knowledge, to 
apply Erikson’s Life Stage Theory to AAS use (9.5), and in doing so has illuminated 
the importance of understanding the AAS-user in the context of their individual 
life story. This is important as it is clear from this study that motivations for use 
influence the type of information and knowledge sought. In the reflections on the 
study, consideration was given to typologies of AAS use (9.11.1), agreeing that 
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these can be useful to make generalisations for the types of support services 
needed, and perhaps ensure that professionals understand that people use in 
different ways and for different reasons. However, ultimately this report has 
argued for an individualised approach and support needs aligned to facilitate 
engagement, minimise harm and work towards improving quality of life. Life Story 
Work (9.11.2.1.1) was offered as a method for how discussion about a person’s 
journey could help to understand the person in the context of their use and life as 
a whole. A pathways model (Figure 9-6) was also suggested in order to support 
professionals to take a person-centred approach.  
Specific considerations for targeted support were recommended, including certain 
professions, people with HIV and adolescents (9.2.5.4). These specific 
considerations for support should not take away from the concept that 
services/support provision should have the individual at its heart. Understanding 
where the user is on their journey, the motivations for starting use, how they use, 
how they are managing risks and how their motivations may have changed, might 
be a more beneficial way of both identifying information and support needs, and 
help to engage people with services.  
As this is a current study, further areas for research have been highlighted. Firstly, 
research into initiation of use is important. For those who choose to start during 
their adolescent years, AAS use is arguably more harmful (9.2.5.4). Consequently, 
a deeper understanding of the risk and protective factors could help professionals 
identify those potentially at risk and allow early intervention. Secondly, there is a 
need for greater understanding of the emotional impact of use, particularly in 
relation to having perceived or actual low testosterone levels. The research focus 
could identify routes for support and help men to move away from self -
medication (9.4.6, 9.4.7). It would also be useful to have more evidence on the 
barriers to men seeking emotional support. Thirdly, it would be beneficial to 
understand why the longer people use AAS the less likely they are to seek 
support. Fourthly, there is a need to further explore what improvements lead 
users to say that AAS use improves their overall quality of life. Finally, it would be 
beneficial to further understand the changing motivations for use across the 
lifespan. This would enable a greater understanding of long-term use, and 
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methods to more effectively provide targeted support interventions, in particular 
to older users.  
The final chapter of the thesis offers recommendations for practice, policy and 
research derived from this study.  
 
 
224 
 
 Recommendations  Chapter 10
 
10.1 Chapter overview 
This chapter presents a summary of the overall recommendations from the study.  
10.2 Introduction 
The intention of the research was to propose concrete recommendations for 
professionals on the basis of stated needs. The aim of this research was to gain an 
understanding of AAS use from the perspective of the user and to explore how 
motivations may impact on information and support requirements to effectively 
support AAS-users (3.9). Therefore, the recommendations are presented under 
the following areas: practice, policy and research. 
10.3 Recommendations for practice 
 Information and support 10.3.1
A key recommendation is that there should be appropriate information and 
support available for people who use AAS. There should be an individual person-
centred approach to support based on assessment of: motivations for use, risk, 
behaviour, health and lifestyle (0, 8.12.2). Support should include a range of 
services including substance, blood and other panel tests, supply of injecting 
paraphernalia, harm reduction advice, and PCT (8.2.2.4). Chapter 6 outlines the 
suggested services for specialist IPED/AAS clinics. Specifics of this support could 
also include clear advice on a range on healthy lifestyle choices, including diet 
(nutrition) and exercise, information aligned to wellbeing and men’s health issues 
(5.3.6, 8.2.2.6), and self-medication of side-effects (5.3.3, 8.2.3).  
For this support to be effective it needs to take a psycho-social perspective and 
not be purely based on the medical model, with professionals encouraged to talk 
to users about their history of AAS use, including initiation, their current use and 
any worries and fears for the future (8.12.2). Moreover, professionals should start 
with the concept that users are experts in their own use and use this as a 
framework to take time to explore the motivations for use. This would allow for 
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exploration of alternative evidence-based options, as user’s patterns of use are 
related to motivations (8.2.2.4) and users openly seek out evidence-based advice 
(0 and Chapter 6). Interventions such as Life Story Work may be a way to help 
understand users’ experiences in the context of their life pathway of use 
(8.12.2.1). Support for AAS-users should be tailored to their needs and include 
consideration of use as self-medication for low testosterone (Chapter 7, 8.4.6). 
A further recommendation for support is a need for emotional support services 
such as counselling and group support. Professionals who offer support to AAS-
users should talk frankly to users about sex (Chapter 7, 8.6), the need to monitor 
behavioural changes and how to effectively manage emotional side-effects 
(8.2.2.6). Moreover, specialist one-to-one support should be available for those 
conflicted about their motivation for use (8.5, 8.12.2.1.1). Consideration should 
also be given to providing group and peer support (8.2.5.2). This could include 
groups led by a professional around beliefs and values linked to concepts of 
masculinity and negative self-talk/body talk, and peer-led support, which could 
include sharing nutritional and exercise advice, risk management, mindfulness 
and mood management. Within all support services, professionals offering 
support need to have a clear understanding of the benefits, be non-judgemental 
(8.2.5.1) and acknowledge (where applicable) the depth of ‘specialised’ 
knowledge of the AAS-users (0). Although there is a need for specialised support 
services, consideration should be given to where these are situated. It may be 
that such support services should be placed alongside GP surgeries, linked to 
pharmacies, within gyms or stand-alone and not attached to traditional drug-
using services (8.2.5.3). Options should also be given to allow people to pay for 
specialist services (5.3.4.1, Chapter 6, 8.4.6). There should also be services that 
provide confidential information for families and support for next of kin services 
(0). 
 Communication channels 10.3.1.1
Recommendations for a range of communication channels and methods for the 
provision of information and support are in Chapter 6. Support for AAS use needs 
to be targeted through already established communication channels for this 
community, for example via online specialist fora and gyms. Information should 
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be evidence-based and where possible have academic references (8.2.5.1). 
Information should also be targeted at personal trainers, those prescribed with 
AAS as a result of contracting HIV, and those using for anti -ageing reasons 
(8.2.5.4, 8.4.7). 
 Wider professional services 10.3.2
It is not just those who work in specialised services who should have an 
awareness of AAS use. A key recommendation from this study is that any 
professional working with adolescent/young men, particularly those with adverse 
childhood experiences, which includes nurses, doctors, social workers, youth 
workers, mental health practitioners, sexual health clinic workers, teachers, sports 
coaches, support workers, should have a base-level understanding of AAS use 
(8.4.6). This knowledge should include: risks of starting use, motivations for use, 
potential harms to self and support services (8.2.5.4, 8.6), and should have a 
balanced non-judgemental perspective when addressing the issues (Chapter 6). 
Professionals working with children should aim to address issues of masculinity 
and challenge stereotypes as a desire to change one’s appearance to align with 
having absorbed the physical manifestation of the hegemonic ideal as part of the 
male identity could be a reason to initiate use (8.2.5.4, 8.4.4). Here schools, 
colleges and universities (and other institutions accessed by young people) are 
encouraged to have conversations about such issues as hegemonic masculinity, 
gender stereotypes and the impact of internalisation of media ideals versus 
realistic norms (8.4.4). 
10.4 Recommendations for policy 
Policy should predominantly take a harm reduction focus as a prevention message 
creates barriers (8.2.5.3, 8.13). Moreover, the issue of self-phlebotomy and blood 
donations should be noted as a cause for concern and addressed (Chapter 6). 
10.5 Recommendations for research 
In order to assist professionals in information provision and to help them meet 
AAS-users’ needs, it would be useful to undertake more detailed research into 
predictors for initiating use, including: adverse childhood experiences, the impact 
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of social media and peer pressure on AAS use, and why some men are more 
affected by media influences such as hegemonic masculinity than others (8.4.5). It 
may also be beneficial to gain more data on the protective factors against 
initiating use. Moreover, a deeper understanding of the effects of low 
testosterone on men entering middle age may shed light on why men choose to 
use AAS to maintain their libido (Chapter 7), the motivations for changes in use 
across the lifespan and implications for treatment (8.6). Additionally, more 
research is required into the emotional and psychological side-effects of specific 
substances, for example Trenbolone, to more effectively advise those 
experiencing emotional side-effects (8.2.2.6). At present, there is scant 
information in the literature on the underlying perceptions aligned to quality of 
life improvements (Figure 5-4) and also risks of sustained-long-term use of 
testosterone, therefore these would also be useful areas for further research. It 
would also be beneficial to the investigate reasons for and potential mechanisms 
to overcome those barriers to implementing recommendations from research into 
policy and practice (8.13). Finally, there is need for research into the risks and 
management strategies for women who use AAS (Chapter 6, 8.8).  
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Appendix 1  Typology of AAS users 
Taken from Zahnow et al. (2018). 
 
 
Features of Christiansen et al. (2016) steroid user typologies and the four clusters. 
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Appendix 2 Scoping review search strategy (PICO)  
 
To identify the most effective search strategy, key words and number of word 
groupings were tested to select articles on AAS. The final search strategy used is 
below.  
 
   Questions and Search algorithms 
 
  
What type of support (if any) do people who use AAS 
want? 
PI(CO) 
 
What support is available for people (recreational?) who 
use non-prescriptive Anabolic Androgenic Steroids 
Population 
 
anabolic androgenic OR designer N3 steroid* OR recreat* 
steroid* OR anabolic steroid* OR anabolic drug* OR 
Synthe* testosterone OR "Synthe* testosterone" OR "non 
prescript*" steroid* OR non-prescript* steroid* OR "non-
medic*" steroid* OR “non prescri*” N2 steroid* OR non-
prescri* N2 steroid* OR “non medic*” N2 steroid* OR non-
medic* N2 steroid* OR performance N3 enhanc* drug* or 
image N3 enhanc* drug* or appearance N3 enhanc* drug* 
or muscle N3 enhanc* drug* OR muscle N3 develop* drug* 
or performance N3 develop*drug* OR doping N3 steroid* 
Intervention 
AND 
Support or advice or help or aid or barrier* or information 
or guidance or intervention* or "needle exchange* or 
program*" 
(to clarify 
population) NOT 
animal* OR mice OR rats OR "guinea pig*" OR 
spectrometry OR bovine 
 AND In English language 
 AND peer reviewed 
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Appendix 3 Testing of word groups for search 
strategy 
Steroid* or AAS or performance N3 enhanc* or image N3 enhanc* or appearance N3 enhanc* or 
muscle N3 enhanc*  or designer or "Synthe* testosterone"  
WITH: anabolic* or androgen* or recreational* or drug* or substance* or *use* or non prescri* or 
"non-prescri*" or non-medic* or "non-medic*" 
WITH: Qualitative or "focus group*" or Forum* or phenomenology or interview* or audiorecording 
or thematic or "grounded theory" or attitude or them* or "semi-structured" or semistructured or 
unstructured or informal or "in-depth" or indepth or "face-to-face" or s tructured or guide or guides 
or narrat* or ethnograph* or "field work" or "key informant" or discussion* or fieldwork  
More focused - Facet 1 
anabolic androgenic  OR designer drug* OR recreat* drug* OR recreat* s teroid* OR anabolic 
s teroid* OR anabolic drug* OR Synthe* testosterone OR "Synthe* testosterone" OR "non 
prescript*" s teroid* OR non-prescript* s teroid* OR "non-medic*" steroid* OR “non prescri*” N2 
steroid* OR non-prescri* N2 s teroid* OR “non medic*” N2 s teroid* OR non-medic* N2 s teroid* OR  
performance N3 enhanc* drug* or image N3 enhanc* drug* or appearance N3 enhanc* drug* or 
muscle N3 enhanc* drug*  OR muscle N3 develop* drug* or performance N3 develop*drug*  
More focused -  Facet 2 
performance N3 enhanc* drug* or image N3 enhanc* drug or appearance N3 enhanc* drug or 
muscle N3 enhanc* drug OR Gym OR muscle N3 develop* or performance N3 develop* or 
performance N3 increas*or muscle N3 increas* 
or motiv*OR muscle dysmorphia 
Limit 
Qual itative or "focus group*" or Forum* or phenomenology or interview* or audiorecording or 
thematic or "grounded theory" or attitude or them* or "semi-structured" or semistructured or 
unstructured or informal or "in-depth" or indepth or "face-to-face" or s tructured or guide or guides 
or narrat* or ethnograph* or "field work" or "key informant" or discussion* or fieldwork  
More broad - Facet 1 
des igner drug* OR recreat* drug* OR recreat* s teroid* OR anabolic s teroid* OR anabolic drug* OR 
Synthe* testosterone OR "Synthe* testosterone" OR "non prescript*" steroid* OR non -prescript* 
s teroid* OR "non-medic*" steroid* OR non-medic* N2 s teroid*   
More broad - Facet 2 
Perform* or image* or appear* or muscle* or increas* 
More broad -  Facet 3 
Use or using:  Motiv* or 
Androgen* N3 Steroid* OR performance N3 enhanc* OR image N3 enhanc* OR appearance N3 
enhanc* or muscle N3 enhanc*  OR designer OR "Synthe* testosterone" OR doping anabolic* OR 
doping androgen* OR recreational doping OR anabolic androgenic  OR designer androgen* OR 
recreat* s teroid* OR anabolic steroid* OR anabolic drug* OR Synthe* testosterone OR "Synthe* 
testosterone" OR "non prescript*" steroid* OR non-prescript* steroid* OR "non-medic*" steroid* 
OR “non prescri*” N2 s teroid* OR non-prescri* N2 s teroid* OR “non medic*” N2 s teroid* OR non-
medic* N2 s teroid* 
Androgen* OR performance N3 enhanc* OR image N3 enhanc* OR appearance N3 enhanc* or 
muscle N3 enhanc* OR doping anabolic* OR doping androgen* OR recreational doping OR anabolic 
androgenic  OR designer androgen* OR recreat* OR  anabolic* OR Synthe* testosterone OR 
"Synthe* testosterone" OR "non prescript*"  OR non-prescript* OR "non-medic*"  OR “non prescri*” 
OR non-prescri* OR “non medic*” OR non-medic*  OR "Synthe* testosterone" 
Drug* or steroid*  
Support or advice or help or a id or barrier* or information or guidance or intervention* or "needle 
exchange*"  
anabolic androgenic  OR designer N3 s teroid* OR recreat* s teroid* OR anabolic s teroid* OR anabolic 
drug* OR Synthe* testosterone OR "Synthe* testosterone" OR "non prescript*" s teroid* OR non-
prescript* s teroid* OR "non-medic*" s teroid* OR “non prescri*” N2 s teroid* OR non-prescri* N2 
steroid* OR “non medic*” N2 s teroid* OR non-medic* N2 s teroid* OR performance N3 enhanc* 
drug* or image N3 enhanc* drug* or appearance N3 enhanc* drug* or muscle N3 enhanc* drug*  
OR muscle N3 develop* drug* or performance N3 develop*drug*  OR doping 
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Synonyms for AAS Combined With  
Steroid* or AAS or performance N3 enhanc* or image N3 enhanc* 
or appearance N3 enhanc* or muscle N3 enhanc*  or designer or 
"Synthe* testosterone" 
anabolic* or 
androgen* or 
recreational* or drug* 
or substance* or 
*use* or non prescri* 
or "non-prescri*" or 
non-medic* or "non-
medic*" 
A 
anabolic androgenic  OR designer drug* OR recreat* drug* OR 
recreat* steroid* OR anabolic steroid* OR anabolic drug* OR 
Synthe* testosterone OR "Synthe* testosterone" OR "non 
prescript*" steroid* OR non-prescript* steroid* OR "non-medic*" 
steroid* OR “non prescri*” N2 steroid* OR non-prescri* N2 
steroid* OR “non medic*” N2 steroid* OR non-medic* N2 steroid* 
OR  
performance N3 
enhanc* drug* or 
image N3 enhanc* 
drug* or appearance 
N3 enhanc* drug* or 
muscle N3 enhanc* 
drug*  OR muscle N3 
develop* drug* or 
performance N3 
develop*drug*  
B 
designer drug* OR recreat* drug* OR recreat* steroid* OR anabolic 
steroid* OR anabolic drug* OR Synthe* testosterone OR "Synthe* 
testosterone" OR "non prescript*" steroid* OR non-prescript* 
steroid* OR "non-medic*" steroid* OR non-medic* N2 steroid*   
 c 
Perform* or image* or appear* or muscle* or increas*  d 
Androgen* N3 Steroid* OR performance N3 enhanc* OR image N3 
enhanc* OR appearance N3 enhanc* or muscle N3 enhanc*  OR 
designer OR "Synthe* testosterone" OR doping anabolic* OR doping 
androgen* OR recreational doping OR anabolic androgenic  OR 
designer androgen* OR recreat* steroid* OR anabolic steroid* OR 
anabolic drug* OR Synthe* testosterone OR "Synthe* testosterone" 
OR "non prescript*" steroid* OR non-prescript* steroid* OR "non-
medic*" steroid* OR “non prescri*” N2 steroid* OR non-prescri* N2 
steroid* OR “non medic*” N2 steroid* OR non-medic* N2 steroid* 
 e 
Androgen* OR performance N3 enhanc* OR image N3 enhanc* OR 
appearance N3 enhanc* or muscle N3 enhanc* OR doping anabolic* 
OR doping androgen* OR recreational doping OR anabolic 
androgenic  OR designer androgen* OR recreat* OR  anabolic* OR 
Synthe* testosterone OR "Synthe* testosterone" OR "non 
prescript*"  OR non-prescript* OR "non-medic*"  OR “non prescri*” 
OR non-prescri* OR “non medic*” OR non-medic*  OR "Synthe* 
testosterone" 
 f 
anabolic androgenic  OR designer N3 steroid* OR recreat* steroid* 
OR anabolic steroid* OR anabolic drug* OR Synthe* testosterone 
OR "Synthe* testosterone" OR "non prescript*" steroid* OR non-
prescript* steroid* OR "non-medic*" steroid* OR “non prescri*” N2 
steroid* OR non-prescri* N2 steroid* OR “non medic*” N2 
steroid* OR non-medic* N2 steroid* OR performance N3 enhanc* 
drug* or image N3 enhanc* drug* or appearance N3 enhanc* drug* 
or muscle N3 enhanc* drug*  OR muscle N3 develop* drug* or 
performance N3 develop*drug*  OR doping 
 g 
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Appendix 4  Data extraction form and example of 
quality review by supervisor 
Information requirements for data extraction for SLR 
Record number (to uniquely identify study): 
General information  Participant characteristics   
Researcher performing data 
extraction 
 Number of participants  
Date of data extraction  Age range:  
Identification features of the 
study: 
 Gender recorded:  
Record number (to uniquely 
identify study): 
 No. Male:  
Author:  No. of females:  
Year:  Ethnicity:  
Article title:  Socio-economic status:  
Citation:   Co-morbidities:   
Type of publication (e.g. journal 
article, conference abstract):  
 Use of other substances:  
Country of origin:  Groups defined AAS users v Non-AAS users 
(Types of users):  
 
Source of funding:  Demographics described:  
Study characteristics  Inclusion/Exclusion criteria reported:  
Aim/objectives of the study:  Length of time using AAS:  
Study inclusion and exclusion 
criteria:  
 Age started using AAS:  
Recruitment procedures used:    Findings:  
Setting: Gym, Needle Exchange 
Clinics:  
 Sources of Information (Y/N)  
Methodology clear:  Type of Information (list what and how 
accessed) 
 
Paper-based Questionnaires:  Sources of support (Y/N)  
Online questionnaires:  Type of Support (list what and how accessed)  
Face to Face interviews:    
Outcome data/results    
Researcher’s Bias:    
Author’s conclusions:    
Decisions:    
Name of second reviewer:    
Agreement with Reviewer:    
Should study be included?    
Reason for exclusion:    
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Example of quality review by supervisor 
Data Extraction Table 
Record Number  11 16 10 
Identification 
features of 
study 
Citation Grogan, S., Shepherd, S., Evans, 
R., Wright, S., and Hunter, G., 
2006. Experiences of Anabolic 
Steroid Use: In-depth Interviews 
with Men and Women Body 
Builders. Journal of Health 
Psychology [online], 11 (6), 845.  
Iversen, J., Topp, L., Wand, H., and 
Maher, L., 2013. Are people who 
inject performance and image-
enhancing drugs an increasing 
population of Needle and Syringe 
Program attendees? Drug & Alcohol 
Review [online], 32 (2), 205–207.  
Griffiths, S., Henshaw, R., McKay, F. H., 
and Dunn, M., 2016. Post-cycle therapy 
for performance and image enhancing 
drug users: A qualitative investigation. 
Performance Enhancement & Health 
[online].  
  References review: no. of 
articles identified 
 0  0  0 
  Type of publication Journal article Journal article Journal article 
  Country of Origin UK Australia Australia 
  Source of funding   Australian Government Department 
of Health and Ageing. 
  
General 
Information 
Researcher OH OH OH 
Date 23.8.17 23.8.17 22.8.17 
Participant 
Characteristics 
Number of participants  11 2395 26 
Age range: 20-39   21-62 
Gender recorded: y   yes 
No. Male: 5   24 
No. of females: 6   2 
Ethnicity: n   n 
Socio-economic status: n     
Co-morbidities:        
Use of other substances:       
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Groups defined AAS users v 
Non-AAS users (Types of 
users):  
AAS users Comparison with non-injectors of 
PIEDs 
PIED users 
Demographics described: n   Location, age, gender 
Inclusion/Exclusion criteria 
reported: 
    yes: non-prescribed PIED use 
Length of time using AAS: y     
Age started using AAS: ?     
Study 
characteristics 
Aim/objectives of the study: to investigate anabolic steroid 
users’ experiences of, and 
motivations for, use.  
Are people who inject performance 
and image-enhancing drugs an 
increasing population of Needle and 
Syringe Program attendees? 
to understand issues related to post-cycle 
therapy (PCT) among a sample of 
performance and image enhancing drugs 
(PIED) users in Australia. 
  Study inclusion and exclusion 
criteria:  
      
  PED/AAS or other AAS PIEDS PIED 
  Recruitment procedures 
used:   
The women were contacted 
through ‘snowball sampling’ from 
an initial contact known by the 
fifth author. Two of the male 
interviewees were known to the 
first author. The other four men 
volunteered to take part in the 
study responding to a request by 
the second author.  
The ANSPS is a national cross-
sectional sero-survey conducted 
annually at ~50 NSP services. 
Consent- ing NSP attendees complete 
a brief self-administered 
questionnaire and provide a capillary 
blood sample for human 
immunodeficiency virus (HIV) and 
hepatitis C (HCV) antibody testing. 
personal contacts, advertisements posted 
on Internet discussion boards, and 
snowball sampling 
  Setting: Gym, Needle 
Exchange Clinics:  
Gym NSPs   
  Methodology clear: semi-structured interviews y   
  Notes Recruitment process l imited, no 
inclusion/exclusion criteria 
National survey Response rate 41%   
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  Validity considered       
  Qualitative or Quantitative qualitative Quantitative   
  Paper-based Questionnaires:       
  Online questionnaires:       
  Online Forum data reviewed       
  Face to Face interviews: y   y 
Findings: Sources of Information (Y/N) y n n 
Type of Information (l ist what 
and how accessed) 
research via books, internet & 
trusted information sources: lack 
of faith in GP 
n n 
Sources of support (Y/N)   y y 
Ideal information or support     access to medical support for PCT 
Type of Support (l ist what 
and how accessed) 
  where they got hold of needles  PCT 
Outcome 
data/results 
Statistical techniques / 
measurements used 
thematic analysis clearly outlined thematic analysis 
Researcher’s Bias:       
Study limitations noted     yes 
Author’s conclusions: Support from within the body 
building community is necessary to 
enable the development of 
realistic and credible health 
promotion strategies for use with 
this group, and for the 
development of viable prevention 
programmes. 
provision of specialist training to 
existing NSP services or the 
establishment of state-wide specialist 
services, similar to that operating in 
Victoria, may be warranted. NSP 
services must continue to engage 
with PIEDs injectors to provide sterile 
injecting equipment 
PCT is one way in which PIED users 
attempt not only to maximise 
  Include/Exclude Include Exclude Include 
  Notes Re include/exclude   No numbers, focus on injecting (PIED 
not AAS) data not on support needed 
But the focus is on post-cycle therapy to 
reduce impact of being off cycle not on 
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or information support (as PCT needs drugs) 
Decisions Second reviewer: Margarete Margarete Edwin 
  Agreement with Reviewer: agree agree yes 
  Should study be included? Include exclude yes, the following authors' comment is 
tell ing: "Steroids were seen as easier to 
access than PCT; as such, participants 
tended to continue to use steroids rather 
than taper down their use, leading to 
health concerns." 
  Reason for exclusion: small, but seemingly very relevant 
study--  congruent with your 
study's focus 
interesting, but unclear about actual 
numbers used, and focus solely on IV 
usage isn't congruent with your 
study-- 
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Appendix 5 Methodological quality appraisal tool – 
Quantitative studies 
 
 
1  
Sampling method: Was it representative of the population 
intended in the study?  
A. Non-probability sampling (including: purposive, quota, 
convenience and snowball sampling)  
B. Probability sampling (including: simple random, systematic, 
stratified g, cluster, two-stage and multi-stage sampling)  
 
 
0 
 
1  
2  Was a response rate mentioned within the study? (Respond 
no if response rate is below 60)  
A. No  
B. Yes  
C. Not applicable 
 
 
0 
1  
3  Was the data collection tools used valid and reliable?  
A. No  
B. Yes  
 
0 
1  
4  Was it a primary or secondary data source?  
A. Primary data source  
B. Secondary data source (survey, not designed for the 
purpose)  
 
1 
0  
5   Were the statistical methods appropriate for the study 
design? 
A. Yes 
B. No 
 
1 
0  
6  Was data on information and/or support for AAS use 
recorded within the study?  
A. No  
B. Yes 
 
 
0 
1  
Scoring: Total score divided by total number of items multiplied by 100  
Methodological Appraisal Score  
Bad * Satisfactory ** Good 
*** 
0 – 
33 %  
34 – 66 %  67 – 
100 %  
 
Adapted from Davids and Roman’s (2014) Quantitative Review Methodology: 
Appraisal Score: 67–100%  ***, 34 – 66% **, 0 – 33% *     
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Appendix 6 Appraisal of mixed-methods paper 
Paper reviewed: (Dennington et al. 2008) 
 
1  
Sampling method: Was it representative of the population intended in the 
study?  
A. Non-probability sampling (including: purposive, quota, convenience and 
snowball sampling)  
B. Probability sampling (including: simple random, systematic, stratified g, 
cluster, two-stage and multi -stage sampling)  
 
 
0  
2  Was a response rate mentioned within the study? (Respond no if response rate 
is below 60)  
A. No  
B. Yes  
C. Not applicable 
 
 
Not 
applicable 
3  Was the data collection tools used valid and reliable?  
A. No  
B. Yes  
 
1  
4  Was it a primary or secondary data source?  
A. Primary data source  
B. Secondary data source (survey, not designed for the purpose)  
 
1 
 
5   Were the statistical methods appropriate for the study design? 
C. Yes 
D. No 
 
1 
 
6  Was data on information and/or support for AAS use recorded within the 
study?  
A. No  
B. Yes 
 
 
1  
Scoring: Total score divided by total number of items multiplied by 100  
Methodological Appraisal Score  
Bad * Satisfactory ** Good *** 
0 – 33 %  34 – 66 %  67 – 100 %    (80%) 
Adapted from Davids and Roman’s (2014) Quantitative Review Methodology 
(Appendix XX): Appraisal Score: 67–100%  ***, 34 – 66% **, 0 – 33% *   
Quant: *** and Qual: *** 
 
Mixed methods  (Pluye et al. 2011) 
 5.1. Is the mixed methods research design relevant to address the qualitative and 
quantitative research questions (or objectives), or the qualitative and quantitative aspects 
of the mixed methods question (or objective)?  Yes *** 
 5.2. Is the integration of qualitative and quantitative data (or results*) relevant to 
address the research question (objective)? Yes, but results were not integrated ** 
 5.3. Is appropriate consideration given to the limitations associated with this 
integration, e.g., the divergence of qualitative and quantitative data (or results*) in a 
triangulation design? 
 Can’t tell  – data not integrated  
 Criteria for the qualitative component (1.1 to 1.4), and appropriate criteria for the 
quantitative component (2.1 to 2.4, or 3.1 to 3.4, or 4.1 to 4.4), must be also applied. 
 *These two items are not considered as double-barrelled items since in mixed 
methods research, (1) there may be research questions (quantitative research) or research 
objectives (qualitative research), and (2) data may be integrated, and/or qualitative 
findings and quantitative results can be integrated. 
 Overall, **  
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Appendix 7 PROSPERO International prospective 
register of systematic reviews  
 
Review title and timescale 
Review title 
Give the working title of the review. This must be in English. Ideally it should state succinctly the 
interventions or exposures being reviewed and the associated health or social problem being 
addressed in the review. 
Support for people who use Anabolic Androgenic Steroids: an investigation into what they want 
and what they currently access  
 
Original language title 
 
For reviews in languages other than English, this field should be used to enter the title in the 
language of the review. This will be displayed together with the English language title. 
 
Anticipated or actual start date 
Give the date when the systematic review commenced, or is expected to  commence. 03/07/2017 
 
Anticipated completion date 
Give the date by which the review is  expected to be completed. 03/10/2017 
 
Stage of review at time of this submission 
Indicate the stage of progress of the review by ticking the relevant boxes. Reviews that have 
progressed beyond the point of completing data extraction at the time of initial registration are not  
eligible for inclusion in PROSPERO. This field should be updated when any amendments are 
made to a published record. 
The review has not yet started × 
 
Review stage Started Completed 
Preliminary searches Yes Yes 
Piloting of the study selection process  Yes Yes 
Formal screening of search results against eligibility criteria No No 
Data extraction No No 
Risk of bias (quality) assessment No No 
Data analysis 
 
Provide any other relevant information about the stage of the review 
here. 
No No 
 
Review team details 
Named contact 
The named contact acts as the guarantor for the accuracy of the information presented in the 
register record. Orlanda Harvey 
 
Named contact email 
Enter the electronic mail address of the named contact. harveyo@bournemouth.ac.uk 
 
Named contact address 
Enter the full postal address for the named contact. 
Bournemouth House 17-19 Christchurch Road Bournemouth BH1 3LH UK 
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Named contact phone number 
Enter the telephone number for the named contact, including international dialing code. 01202 
967435 
Organisational affiliation of the review 
Full title of the organisational affiliations for this review, and website address if available. This 
field may be completed as 'None' if the review is not affiliated to any organisation.None 
 
Website address: 
 
Review team members and their organisational affiliations  
Give the title, first name and last name of all members of the team working directly on the review. 
Give the organisational affiliations of each member of the review team. 
 
Title First name Last name Affiliation 
Mrs Orlanda Harvey Bournemouth 
University 
Dr Margarete Parrish Bournemouth 
University 
Professor Edwin van Teijlingen Bournemouth 
University 
Dr Steve Keen Bournemouth 
University 
 
Funding sources/sponsors 
Give details of the individuals, organizations, groups or other legal entities who take responsibility 
for initiating, managing, sponsoring and/or financing the review. Any unique identification 
numbers assigned to the review by the individuals or bodies listed should be included. 
Bournemouth University as part of PhD Studentship 
 
Conflicts of interest 
List any conditions that could lead to actual or perceived undue influence on judgements 
concerning the main topic investigated in the review. 
Are there any actual or potential conflicts of interest? None known 
 
Collaborators 
Give the name, affiliation and role of any individuals or organisations who are working on the 
review but who are not listed as review team members. 
Title First name Last name Organisation details 
Review methods 
 
Review question(s) 
State the question(s) to be addressed / review objectives. Please complete a separate box for each 
question. 
1. What support and information do people using non-prescriptive Anabolic Androgenic 
Steroids (AAS) for recreational purposes  access? 
 
2. What support and information do people using non-prescriptive AAS for recreational 
purposes say they want? 
 
Searches 
Give details of the sources to be searched, and any restrictions (e.g. language or publication 
period). The full search strategy is not required, but may be supplied as a link or attachment. 
 
A three step search strategy will be carried out in an iterative manner: 1) An initial search will be 
carried out in the EBSCO database using the term AAS. This will be followed by an analysis of 
key text words contained in the title and abstract and the index terms used to describe the article in 
order to broaden search terms. 2) The identified keywords and index terms will then be used across 
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included databases. 3) The reference lists of included articles will be scanned to identify any 
potentially relevant articles not picked up through the database search. The following databases 
will be included: Academic Search Complete, British Library EthOS, Business Source Complete, 
CINAHL Complete, Communication Science, Hospitality and Tourism complete, Directory of 
Open Access Journals, Environment Complete, Education Source, Emerald Insight, IEEE 
XPLORE Digital Library, J-Stage, JSTOR Journals, Information Science & Technology Abstracts, 
MEDLINE Complete, Supplemental Index, SciELO, GreenFILE, SocIndex with Full text, 
SwePub, Complementary Index, SportDiscus with full text, PsycINFO, ScienceDirect, 
Communication abstracts, Teacher reference Center, and ERIC. The PROSPERO database and 
Cochrane Library database will also be searched for on-going reviews. Key terms developed in the 
context of review inclusion criteria relating to anabolic androgenic steroids, information, and 
support. There will be no geographical or date restrictions, however publications were limited to 
those studies in English (due to a lack of resources for translation), which have been peer 
reviewed. 
 
URL to search strategy 
If you have one, give the link to your search strategy here. Alternatively you can e-mail this to 
PROSPERO and we will store and link to it. 
 
I give permission for this file to be made publicly available No 
 
Condition or domain being studied 
Give a short description of the disease, condition or healthcare domain being studied. This could 
include health and wellbeing outcomes. 
The use of AAS has historical roots in enhancing performance in sports, however in recent years 
they are increasingly used by the general population (particularly male gym users) for their 
anabolic effects (Bojsen-Møller and Christiansen 2010, Nutt 2012). Research over the last twenty 
years has demonstrated that the use of AAS can be detrimental to a person’s physical and 
emotional wellbeing (Jones et al. 2011, McVeigh et al. 2012). Social Workers often work with the 
most vulnerable in society and have a role in helping people to identify the types of sup port 
available to them to help minimise harm. The review aims to investigate the support that people 
who use AAS for recreational (non-competitive) purposes access and also identify the types of 
information and support people who use AAS want. This review will identify and synthesise the 
available evidence on the support for people using AAS. 
 
Participants/population 
Give summary criteria for the participants or populations being studied by the review. The 
preferred format includes details of both inclusion and exclusion criteria. 
Studies including populations such as recreational AAS users, non-competitive AAS-using 
bodybuilders and, AAS users accessing drug services will be eligible for inclusion. The review 
will include evidence on all individuals who use AAS including occasional and long-term users. 
 
Intervention(s), exposure(s) 
Give full and clear descriptions of the nature of the interventions or the exposures to be reviewed  
Any support (information or intervention) designed to support people who use mu scle enhancing 
substances will be considered for inclusion. This will include support and information offered by 
local authorities, government, internet, peers, gyms and drugs services. Excluded will be any 
intervention given by professionals to professional athletes. 
 
Comparator(s)/control 
Where relevant, give details of the alternatives against which the main subject/topic of the review 
will be compared (e.g. another intervention or a non-exposed control group). 
Any alternative support or no support comparisons. 
 
Types of study to be included 
Give details of the study designs to be included in the review. If there are no restrictions on the 
types of study design eligible for inclusion, this should be stated. 
Any studies with a clearly defined set of objectives and pre-defined eligibility criteria will be 
considered for inclusion. This may include: Studies that report on findings which use quantitative 
methods (data collection and analysis) and studies which include qualitative questions on types of 
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information and support sought out by people who use AAS. 
 
Context 
Give summary details of the setting and other relevant characteristics which help define the 
inclusion or exclusion criteria. 
Studies that seek information from participants who use non-prescribed AAS recreationally. 
Inclusion • Studies including populations such as recreational AAS users, non -competitive AAS-
using bodybuilders and weightlifters and, AAS users accessing drug services will be eligible for 
inclusion. • Qualitative and quantitative data • Articles where participants have been asked about 
where they access support, advice and information to help them manage their substance use. o Any 
AAS-user information on support (information, advice, service or intervention) designed to 
support people who use muscle enhancing substances will be considered for inclusion. This could 
include support and information offered by local authorities, GPs, internet, peers, gyms and drugs 
services. Exclusion criteria: • Articles not in English • Articles not peer-reviewed • Studies on 
wider drugs prevention interventions • Specific medical interventions i.e. efficacy of treatments for 
side effects • Studies involving participants who compete professionally. • Prevention strategies o 
Studies that focus on prevention of AAS use amongst school athletes were excluded from this 
study, as the aims focused on education and the prevention of AAS use within the sporting context 
rather than focussing on and working with people who used AAS, with recreational motivations. • 
Any study that focuses on competitive sports/athletes or (high) school athletes 
 
Primary outcome(s) 
Give the most important outcomes. 
 
Qualitative and Quantitative studies: Outcomes related to insights, views, perspectives etc. of 
people who use AAS about on the support and information they require. Qualitative and 
Quantitative studies: Studies that identify which support and information AAS users’ access.  
 
Give information on timing and effect measures, as appropriate. 
 
Secondary outcomes 
List any additional outcomes that will be addressed. If there are no secondary outcomes enter 
None. None 
Give information on timing and effect measures, as appropriate. 
 
Data extraction (selection and coding) 
Give the procedure for selecting studies for the review and extracting data, including the number 
of researchers involved and how discrepancies will be resolved. List the data to be extracted. 
Data will be extracted from articles included in the review into a pre-designed form which will be 
piloted and amended as appropriate. The initial data extraction will be the same for all selected 
papers which will gather the demographic information from the paper as well as research design. 
 
Risk of bias (quality) assessment 
State whether and how risk of bias will be assessed, how the quality of individual studies will be 
assessed, and whether and how this will influence the planned synthesis. 
The pre-designed extraction form will be reviewed by EvT. The first researcher (OH) will screen 
articles for eligibility based on their title and abstracts to exclude articles outside the scope of this 
systematic review; full text articles will be sourced if there is any uncertainty. SK undertook a 10% 
review of articles screened out by title and a 20% of those screened out by abstract. Poten tially 
relevant articles will undergo a full text screen and 30% will be crossed checked (10% by SK, 10% 
by MP and 10% by EvT) and consensus will be sought where there is ambiguity. The first 
researcher (OH) will then extract the data with MP, SK and EvT independently checking 30% of 
the extraction forms for accuracy. Disagreements which may arise will be resolved by discussion 
and a third opinion will be sought from an independent researcher where there is discrepancy. The 
quality of the selected papers will be reviewed using the relevant CASP (Critical Appraisal Skills 
Programme) checklist. 
 
Strategy for data synthesis 
Give the planned general approach to be used, for example whether the data to be used will be 
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aggregate or at the level of individual participants, and whether a quantitative or narrative 
(descriptive) synthesis is planned. Where appropriate a brief outline of analytic approach should be 
given. 
 
The results of data extraction and quality assessment will be presented in structured tables and as a 
narrative summary. Thematic analysis will be used to synthesise the data from any qualitative 
studies and where possible identifying high order themes to offer a summary of findings. Due to 
the high possibility that there will be a lack of heterogeneity between the studies a narrative 
synthesis will be carried out of the quantitative studies. If possible, the findings from both the 
qualitative and quantitative analysis will then be synthesised to give and overall picture for a 
picture of how the current support available matches the wishes of people who use AAS. 
 
Analysis of subgroups or subsets  
Give any planned exploration of subgroups or subsets within the review. ‘None planned’ is a valid 
response if no subgroup analyses are planned. 
None planned 
 
Review general information 
 
Type and method of review 
Select the type of review and the review method from the drop down list. Systematic review 
 
General interest 
 
LanguageSelect the language(s) in which the review is being written and will be made available, 
from the drop down list. Use the control key to select more than one language. 
English 
 
Will a summary/abstract be made available in English? Yes 
Country 
Select the country in which the review is being carried out from the drop down list. For mu lti-
national collaborations select all the countries involved. Use the control key to select more than 
one country. 
United Kingdom 
 
Other registration details  
Give the name of any organisation where the systematic review title or protocol is registered 
together with any unique identification number assigned. If extracted data will be stored and made 
available through a repository such as the Systematic Review Data Repository (SRDR), details and 
a link should be included here. 
 
Reference and/or URL for published protocol 
Give the citation for the published protocol, if there is one. 
Give the link to the published protocol, if there is one. This may be to an external site or to a 
protocol deposited with CRD in pdf format. 
 
I give permission for this file to be made publicly available Yes 
 
Dissemination plans 
Give brief details of plans for communicating essential messages from the review to the 
appropriate audiences. The review will be submitted to an academic journal on completion  
 
Do you intend to publish the review on completion? Yes 
 
Keywords 
Give words or phrases that best describe the review. (One word per box, create a new box for each 
term) Anabolic Androgenic Steroid Use, support, information, advice. Substance-related disorders 
 
Details of any existing review of the same topic by the same authors  
 283  
Give details of earlier versions of the systematic review if an update of an existing review is being 
registered, including full bibliographic reference if possible. 
 
Current review status 
Review status should be updated when the review is completed and when it is published. Ongoing 
 
Any additional information 
Provide any further information the review team consider relevant to the registration of the review. 
 
Details of final report/publication(s)This field should be left empty until details of the 
completed review are available. Give the full citation for the final report or publication of the 
systematic review. 
Give the URL where available 
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Appendix 9  Social Work and AAS article 
Harvey, O., 2019. ‘Shades of Grey’: The Ethics of Social Work 
Practice in Relation to Un-prescribed Anabolic Androgenic Steroid 
Use. Practice: Social Work in Action, 31 (4), 239-258. 
 
See: https://eprints.bournemouth.ac.uk/31664/ 
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Appendix 10 Participant information sheet 
and research questionnaire 
 
My name is Orlanda Harvey and I am seeking your help in relation to a research study on 
why people choose to use Anabolic Androgenic Steroids (AAS) 
I am a researcher from Bournemouth University and I am conducting research on this 
subject, so that we can better understand the reasons why people use AAS, as well  as 
what sorts of information and support AAS users currently have, or wish they had. 
All  details and information collected through the research will  be completely confidential 
and anonymised, and no individual will be identifiable. Before you decide whether to 
answer the questionnaire, please take time to read the following information and discuss 
with others, should you wish. You can also contact me directly should you have any 
questions.  
Participants: To take part in the study, you must be 18 years or older, and use, or have 
recently used, AAS (within the last 6 months). 
 
Purpose: The study aims to explore people’s first-hand experiences of using AAS, compare 
these experiences with information available from academic studies, and understand 
what types of support people who use AAS would like. This will  help to identify and 
understand the types of support and information that people who use AAS are most l ikely 
to want and use.  
 
The questionnaire will  take approximately 15 minutes to complete, as it covers  a wide 
range of issues.  The questionnaire features several questions where the answers are ‘free 
text’ boxes, as we would like to give you the opportunity to share your thoughts and 
opinions. Please be as open and detailed as you can and would like when answering any 
question. The more honest you are the more helpful and meaningful the data will  be. 
 
Benefits: Whilst there are no immediate benefits for those people participating in the 
project, it is hoped that this work will  lead to a broader understandi ng of the support that 
AAS users would value. Being involved in the research does mean giving up a l ittle time to 
fi l l  in the questionnaire. However, you do not have to give any information you do not 
wish to, and no questions relate to the purchase of AAS.  
Confidentiality: Only I, and my supervisory team, will  be able to access the study data. 
Anonymised data collected in this study may be used in future reports, such as academic 
journals and conference presentations. However, all  details are anonymous and no 
individual will be identifiable through such publication of data. For the protection of 
yourself and the researchers conducting this study, this research has been reviewed and 
approved in l ine with Bournemouth University’s research ethics code of practice.   
Withdrawal: You can withdraw at any time.  Please note that to withdraw you would only 
need to close the browser page (if completing online) or not return the questionnaire to 
the researcher.  However, once you have completed and submitted the questionnaire, we 
are not able to remove your anonymised responses from the study. 
Thank you for taking the time to read this. If you have any questions regarding this 
research, please feel free to contact me using the information below. There is also an 
opportunity at the end of the questionnaire for you to consider taking part in further 
research. Please return in a sealed envelope to: O Harvey:  Rm 202, Royal London House, 
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Christchurch Road, Bournemouth. BH1 3LT (or you can email to: 
harveyo@bournemouth.ac.uk) 
Your participation in this research study will  make a valuable contribution to our 
understanding of AAS use and the potential for future support for AAS users, so I do hope 
that you decide to take part.  
Contact Information:  Researcher: Orlanda Harvey: harveyo@bournemouth.ac.uk; tel: 
01202 967435 
Supervisor:  Dr M. Parrish, Email: 
mparrish@bournemouth.ac.uk 
If you have a concern about any aspect of this study and wish to complain, please contact: 
Prof V. Hundley, Deputy Dean for Research & Professional Practice: Faculty of Health and 
Social Care, Bournemouth University by email to 
researchgovernance@bournemouth.ac.uk    
 
By completing this questionnaire, it is assumed that you have given full 
informed consent. 
 
1. At what age did you start using AAS?  
 
 
2. For how many years have you used AAS? 
 
 
3. How many hours on average do you exercise / workout a day?  
 
 
 
(Please tick) Yes No 
4. Do you take part in competitive sports?   
5. Do you use other supplements and drugs in conjunction with using AAS?   
5a. If yes, what do you use them for? 
 
 
6. Do you use Human Growth Hormone (HGH)?                           Please tick one box 
only 
Yes No, and never intend 
to 
No, but I am considering using HGH 
 
7. How would you best describe your AAS use pattern?             Please tick one box 
only 
Use in 8-12 
week 
cycles, 
with off-
cycle, or 
post-cycle 
therapy  
Continual 
low-level 
use with 
topping up 
when 
desired  
Other If you selected Other, please describe:  
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8. It is suggested that there are a wide range of reasons for using AAS, and 
many people have more than one. Please tick all of the reasons that are 
relevant to your use 
For my Job  Improve my 
appearance 
 Enhance my muscles or 
strength 
 
Become 
happier 
 Increase my 
aggression  
 Increase my sexual 
attractiveness  
 
For personal 
security  
 Increase my 
confidence 
 A celebrity I respect uses AAS  
For competition  In preparation 
for crime  
 Recommended by my 
coach/trainer  
 
Prevent injury  Increase my sex 
drive  
 Conceal the use of other illicit 
drugs 
 
Overcome 
depression 
 Help me stop 
being bullied 
 An elite sportsperson I respect 
uses AAS 
 
Curiosity  Impress my 
friends 
 Positive results I achieve from 
using AAS 
 
Become brave  Improve 
endurance or 
stamina 
 Frustration, I’ve not achieved 
the desired results from 
exercise 
 
Lose weight  My friends use 
AAS  
 My work colleagues use AAS   
Transitioning 
gender 
 A family member 
uses AAS 
 Positive results that others 
achieved who used AAS 
 
Improve fitness   My partner uses 
AAS 
 Other  
If you selected 
Other, please 
describe: 
 
 
9. Who (if anyone) has helped you to decide to start using AAS to achieve your 
goals? Tick all that apply 
A fellow gym user  A brother or sister (or 
step)  
 Parent or step-
parent 
 
Another family 
member 
 A close friend  My personal trainer 
/ coach  
 
Purely my own 
decision 
 Other  My Partner  
If you selected 
Other, please 
describe:  
 
 
 
10. What do you see as the benefits to you of using AAS? 
 
 
11. What, if any, do you see as the risks to you of using AAS?  
 
12. Do you see your AAS use as putting others at risk?                                                      
(Please tick one only)                       
Yes Maybe No 
12a. Please describe in what ways (if any) your use of using AAS puts others at 
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risk 
 
 
It is suggested that a wide range of unintended side effects result from using 
AAS, and people’s experiences of these are varied.  
13. Please list any positive side effects you have experienced:  
 
14. Please list any negative or unwanted side effects you have experienced: 
 
15. Have you ever sought help for any side effects of AAS use?                                   
(Please tick one only) 
Yes No 
If yes, please answer the following questions… (if not please go to question 16) 
15a. What did you 
seek help for?  
 
15b. Where did you 
seek help from? 
 
15c. Was the help 
effective?  
Yes      No             (if no, why not) 
 
15d. Did you tell the 
person(s) you 
sought help from 
that you used AAS? 
Yes     No              (if no, why not?) 
 
 
15e. Did you feel 
that the person(s) 
you sought 
treatment from 
were helpful? 
Yes      No             (If yes, what did they do that was 
helpful?) 
 
 
16.  Do you inject AAS? (Please tick 
one) 
Yes: No: 
 
If yes, please answer question 17, if no please go to question 18:  
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17.  If yes, where do you get your needles from?   
Please tick all of the reasons that are relevant to your use? 
Needle exchange  Pharmacy  My doctor  
Friends  Family  Work colleagues  
Gym goers  AAS users  Websites that sell AAS   
AAS supplier  My partner  Other  
If you selected 
Other, please 
specify: 
 
17a. Who taught 
you how to 
inject AAS?  
 
 
 
18.  What type of support 
do you feel should be 
available for people using 
AAS?  
 
Please complete the grid: Please tick all those that are applicable to you.  
 19. Where 
do you get 
your 
advice 
from 
concernin
g the most 
effective 
types of 
AAS to 
use? 
20. Wh
o do 
you 
trust to 
give you 
advice 
on AAS? 
21. Where 
do you get 
your 
advice 
from 
concernin
g the risks 
of AAS 
use? 
22. Where 
do you get 
your 
advice 
from 
concernin
g cycling 
and 
stacking of 
AAS? 
23.  Who
, if 
anyone 
do you 
discuss 
your 
AAS use 
with? 
Needle 
Exchange 
     
Pharmacy      
My Doctor      
My partner      
Friends      
Family      
Work 
colleagues 
     
Gym goers      
AAS users      
Website: 
Health / 
Governmen
t sponsored  
     
Websites 
selling AAS 
     
AAS-user 
forums 
     
AAS users 
You-Tube 
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videos 
AAS 
supplier 
     
Other      
If other: 
please state 
     
 
24. Do you feel you could stop using AAS at any time if you chose 
to do so? (Please tick) 
Yes No 
24a. If no, why not? 
25. Would you consider accessing any type of professional 
support that would assist you to stop using AAS?                       
(Please tick) 
Yes No 
25a. If yes, what types of support would you consider accessing? 
 
  
 
26. Do you ever get mood swings that you relate directly to your AAS use?                       
(Please tick one) 
Yes No 
26a. If you selected yes, please describe 
27. Do your ever experience changes in your behaviour that you link directly to 
your AAS use? (Please tick one ) 
Yes No 
27a. If you selected yes, please describe 
 
28. It is suggested that there may be a range of positive emotions (feelings) 
from using AAS, and that people’s experiences of these are varied: Please tick 
the ones (if any) that you have experienced? 
 Yes  No  Yes No 
Increase in my libido 
(desire to have sex) 
  Feeling strong   
Feeling unconquerable   Feeling happier    
Feeling high    Feeling proud of 
my body  
  
Increase in confidence    Feeling brave   
Feeling pumped   Euphoria   
If you have other positive 
feelings, please describe 
them here 
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29.  It is suggested that there may be a range of negative emotions (feelings) 
from using AAS, and that people’s experiences of these are varied. Please 
consider each of the ones listed below and tick the box that is most applicable 
to your AAS use experience. 
 Strongly 
Agree 
Agree Not 
sure 
Disagree Strongly 
Disagree 
My irritability has increased      
I have become quick to anger      
My jealousy (in relationships) 
has increased 
     
I have hit someone      
My libido (sex drive) has 
increased 
     
I lose my temper more often      
My aggressive feelings have 
increased 
     
I get into fights more often      
I am more tired      
I have some loss of sexual 
function 
     
If you have other negative 
feelings, please add them 
here 
 
29a. If you have experienced 
any of these feelings, please 
describe how you manage 
them? 
 
30. Some suggest that there are a range of emotions (feelings) from stopping 
using AAS (or in post-cycle therapy), and that people’s experiences of these are 
varied. Please tick the ones (if any) that you have experienced? 
 Yes  No  Yes No 
Low mood   Become 
anxious 
  
Unhappiness   Relief    
Reduction in my confidence   Fear   
If you have other feelings, 
please add them here 
 
30a. If you have experienced 
any of these feelings, please 
describe how you manage 
them? 
 
31.  Have you ever acted on any feelings of aggression because of your AAS 
use?                (Please tick one) 
Yes No 
31a. If you selected yes, please describe 
32.  Do you believe that there should be support for the emotional impact of 
using AAS?     (Please tick one) 
Yes No Maybe Don’t know 
32a. If yes, what support do you think would be helpful? 
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33.  Do you believe it is possible to become addicted to using AAS? (Please tick 
one) 
Yes No Other 
If you selected Other, please explain 
34.  Since using AAS, which of the following statements is true for you? (Please 
tick one) 
My quality of life has improved  
My quality of life has stayed the same  
My quality of life has got worse  
 
35.  If you have any other comments that you would like to make about your own 
AAS use, or AAS use in general, please add them here: 
 
Demographic Information: And finally, to help me clarify your answers 
statistically for the purposes of the research, there are a few questions about 
yourself 
In which country do you live?   
For UK residents, please state which county in 
the UK  
 
How old are you (in years)?  
To which ethnic group do you belong?  
With what gender do you identify?  
 
Please tick which of the following you consider yourself to be? 
Recreational exerciser  Competitive 
bodybuilder 
 Personal 
trainer 
 
Competitive weightlifter  Competitive 
athlete 
 Other  
If you selected Other, 
please specify’  
 
 
Are you?    (Please tick one) 
A student  Unemployed  Self-
employed 
 
Retired  Employed  Other  
If you selected Other, please 
specify 
 
Which is the highest level of education do you have?  (Please tick one) 
Primary 
Education 
 Secondary 
Education  
 College or University  
What is your Sexual Orientation?                                                                               
(Please tick one) 
Straight/Heterosexual  Gay  Prefer to self-describe  
Self-description:   
 
I confirm that I am 18 years of age or older - please circle:    Yes  No 
AAS Use: I currently use AAS (or have used within the last 6 months) – please 
circle:     Yes    No 
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Opportunity to take part in further research   
Would you be interested in taking part in a more in-depth follow up 
(anonymous) interview about your experiences of AAS use? (Please tick one) 
Yes No 
If yes, which would be your preferred method for such an interview?   (Please 
tick all that apply) 
In person: one to one interview (Bournemouth and Poole area)   
In person: as part of a focus group (Bournemouth and Poole area)   
Via live chat (online)  
On Skype  
On the telephone  
No preference  
Other: please specify 
If you are interested in being invited to take part in an interview, please leave 
your contact details: 
Name you would prefer to be known by:  
Contact details: 
 (Please give your preferred contact details e.g. phone number/email 
address/twitter) 
By leaving your contact details you are expressing an interest in being 
interviewed and are not committed to doing so.  
 
Would you like a summary of the findings?  (Please tick one) 
Yes No 
If yes, please enter your email address here: 
 
Leaving your contact information will not affect your confidentiality as any 
contact information will only be used for the purpose of contacting you to arrange 
an interview by the named researcher (Orlanda Harvey) and will not be recorded 
as part of the research data. All personal data relating to this study will be held for 
30 months from the date of publication of the research. BU will hold the 
information we collect about you in hard copy in a secure location and on a BU 
password protected secure network where held electronically. Except where it 
has been anonymised, we will restrict access to your personal data to those 
individuals who have a legitimate reason to access it for the purpose or purposes 
for which it is held by us.  
Thank you very much for taking the time to complete the questionnaire.   
Should you have any further questions, please do not hesitate to contact me on:  
Orlanda Harvey: harveyo@bournemouth.ac.uk -  Twitter: @arrowandthesong  
Should you wish to find out further information on AAS use, the following website 
has a wealth of useful information, advice and support: 
http://ipedinfo.co.uk/contact.html and this one has more information on the 
topic: https://humanenhancementdrugs.com/ 
Confidentiality Confirmation: The study data will only be accessible by researcher 
and her supervisory team. Anonymised data collected in this study may be used in 
future reports such as academic journal and conference presentations. No 
individual will be identifiable through such publication of data.   
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Appendix 11 Questionnaire design: References for 
options used in the questionnaire 
Survey Question Data: Options References/Sources 
Motivations:  Occupational, improved appearance, 
aggression, enhanced muscle or strength, personal 
security, psychological well -being (including boosting 
self-esteem or confidence) or satisfaction, sexual 
attraction, physiological recovery or injury prevention, 
overcoming depression, curiosity, trainers’ approval, 
family influence, media influence, peer influence, use 
of AAS as a sport or social norm and for sporting or 
competitive activities frustration as not achieved the 
desired results from exercise. Because my friends use 
AAS, Because my work colleagues use AAS, Because a 
family member uses AAS to get fitter, to improve 
endurance or stamina, in preparation for crime, 
concealing concomitant substance use and becoming 
brave. increase in sex drive and to lose fat were also 
motivations for use 
(Petrocelli  et al. 2008, 
Petersson et al. 2010, Sagoe, 
Molde, et al. 2014, McVeigh et 
al. 2015, Hanley Santos and 
Coomber 2017) 
Support Provision: Needle Exchange, Pharmacy, My 
Doctor, My partner, Friends, Family, Work colleagues, 
Gym goers, AAS users, Website: Health / Government 
sponsored, Websites sell ing AAS, AAS-user forums, AAS 
users, You-Tube videos, AAS supplier 
(Kimergård and McVeigh 
2014b, 2014a, Dunn et al. 2016, 
Griffiths, Henshaw, et al. 2016, 
Rowe et al. 2016, Hanley Santos 
and Coomber 2017, Tighe et al. 
2017, Zahnow et al. 2017, 
Greenway and Price 2018) 
Positive Effects: Increase in my libido (desire to have 
sex), Feeling strong, Feeling unconquerable, Feeling 
happier, Feeling high, Feeling proud of my body, 
Increase in confidence, Feeling brave, Feeling pumped, 
Euphoria 
(Petrocelli  et al. 2008, 
Petersson et al. 2010, Sagoe, 
Andreassen, et al. 2014, 
Greenway and Price 2018) 
Negative Effects: Increase irritability, quick to anger, 
increase in jealousy (in relationships),  hit someone, 
increase in l ibido (sex drive), lose my temper more 
often, increase in aggressive feelings, get into fights 
more often, increase in tiredness, some loss of sexual 
function  
(Petrocelli  et al. 2008, Skårberg 
et al. 2008, Petersson et al. 
2010, McVeigh et al. 2015, 
Greenway and Price 2018) 
PCT side-effects: Low mood, Become anxious, 
Unhappiness, Relief, Reduction in my confidence, Fear  
(Piacentino et al. 2015, 
Griffiths, Henshaw, et al. 2016, 
Greenway and Price 2018) 
Type of user: Recreational exerciser, Competitive 
bodybuilder, Personal trainer, Competitive weightlifter, 
Competitive athlete  
(Ager 2015) 
Quality of life:  Since using AAS, which of the following 
statements is true for you?  (Please tick one) 
My quality of l ife has improved 
My quality of l ife has stayed the same 
My quality of l ife has got worse 
Adapted from: 17. How has 
your l ifestyle or quality of l ife 
changed since you have been 
using steroids?  (Ager 2015) 
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Appendix 12 Summary of distribution contacts for 
questionnaire 
 
UK Services 
 Service  Service  
1 Aberdeen Steroid Clinic 14 NECA STEP Harm Reduction Service 
2 Bolton Harm Reduction Service  15 One Recovery Staffordshire: addiction 
Dependency Solutions 
3 Bournemouth Addaction 16 PACT NOW EDAS 
4 Bristol Drugs Project (BDP)  17 Project 6  
5 Bucks One recovery:  The OASIS 
Partnership  
18 Smart Muscle -Turning Point 
6 CHOICES Chelmsford 19 Somerset Drug & Alcohol Service 
(SDAS)  
7 DHI Warmley 20 Southampton Drug & Alcohol 
Recovery Service (SDARS)  
8 Guernsey Drug Concern 21 The Juice Bar 
9 Harbour Community Access Safer 
Injecting Service  
22 Turning point 
10 Harm Minimisation at the Pump 
Clinic 
23 WDP (www.wdp.org.uk) 
11 IRiS Sandwell  24 North Westminster Drug & Alcohol 
Service  
12 KIKIT Pathways to Recovery  25 Weymouth and Dorset 
13 Middlesbrough 26 Welsh Centre for Action on 
Dependency and Addiction  
 
American, Canadian, Ireland and Australian Support Services - Offered 
help 
Organisation 
The Exchange Anchor Point, AK http://homernews.com/homer-news/2017-02-
23/grant-helps-make-syringe-exchange-program-viable 
Generations Project Alameda, CA | Tri City Health Center - http//www.tri-
cityhealth.org/ 
ACONhealth - https//www.acon.org.au/about-acon//#-acon-sydney 
Drugs Outreach Worker Kilkenny 
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Summary of overall distribution of questionnaire to targeted populations 
Communication 
Tool 
Targeted Populations Number 
Contacte
d 
Number of 
Shares 
Known* 
Other known sharing of 
information or 
acknowledgement of post 
Email or Phone UK Support Services for 
people who use 
recreational drugs 
76 26  
Email Overseas Organisations 
(USA, Canada, Ireland, 
Australia, New Zealand)  
Support Services for 
people who use 
recreational drugs 
72 4  
Email UK Gyms (Pro muscle) 46 1  
Email Muscle Forum Admins 32  5 allowed Forum posts: 
(see Appendix XX for 
interaction example) 
In person Shops sell ing Supplements  2 2  
Via personal 
friends with  
member ship 
of pro-muscle 
gyms 
Local gyms:  2 2  
LinkedIn  Personal contacts 
messaged 
213 40  
Facebook Personal contacts directly 
messaged 
117 29  
Facebook Posted on personal FB 
page 
  7 people re-posted 
Facebook Messaged closed AAS / 
Testosterone groups to 
see if they would share 
 2  
Twitter People directly tweeted 
to using @.... and asking 
them to share 
questionnaire l ink 
306  37 (retweets) 
 
Twitter Unsolicited retweets by 
Twitter users 
 23 
Instagram Instagram Users   98 likes in total for 
posts, and  
65 followers on the 
basis of the posts. 
Youtube Presentation and link to 
study posted 
  22 views 
*it is possible people shared the survey without confirming or replying that they 
were sharing it  
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Appendix 13 Summary of promotion and distribution 
channels for the questionnaire  
Business card flyer 
This image is the business card sized flyer that was distributed to NSPs and local shops.  
 
Figure 0-1 Flyer 
Social media platforms: Twitter and Instagram 
Figure 0-2 is the tweet that was pinned to the researcher’s Twitter profile and shared via 
Instagram, FB and Twitter. A number of hashtags were used (Table 0-1) and Google 
translate was used to translate the post into a number of languages to share on twitter 
(Table 0-2). A presentation as created for Youtube to promote the study (Figure 0-3). It 
was also posted on Reddit (Figure 0-4). 
Figure 0-2 Social media promotion  
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Table 0-1  Hashtags used on Twitter and Instagram 
Hashtages Used on Twitter 
#anabola steroider  #muskel  #spieren #músculos #esteroides #bodybuilding  
#steroïden #culturismo #steroidy #mięśnie #kulturystyka #lamusculation #stéroïdes 
#muscles #Muskeln #бодибилдинг #стероиды #мышцы #músculos #esteróides 
#steroidi #Muscoli #lihakset #steroidit #kehonrakennus #筋  #ステロイド  # steroidler 
#steroider #muskel #spieren #músculos #стероиды #мышцы #músculos #esteróides 
#steroidi #Muscoli #lihakset #steroidit #kehonrakennus #steroid anabolik 
#steroidanabolik #анабалічныястэроіды #bodybuilding #anabolskesteroider  
#muscle #muscles #muscleworship #bodybuilder #bodybuilding #biceps #abs #pecs 
#posing #pumped #flex #steroids #shredded #ripped #physique #enhancement #roids 
#gym #actor #sculpting #roids #gains #harmmin #support #IPED #bodyimage 
#enhancement #muscleworship #beard #abs #posing #flexing  
Instagram: Instagram hashtags  
#aesthetic #ripped #roids #gym #gymlife #steroids #muscle #powerbodybuilding 
#strength #physique #fitness #actor #power #fitfam #sculpting #workout #gymrat 
#gains #bodybuilding #bodybeautiful #workout #instafit Use Anabolic steroids: Share 
your experiences: link in my Bio - https://goo.gl/w8N5A1 
 
Table 0-2 Languages used for posts 
Language: Tweet translated into via Google Translate  
Russian Bulgarian 
Spanish Finnish 
Polish German 
Lithuanian Norwegian 
Hungarian Swedish 
Greek Icelandic 
Danish French 
 
YouTube and Reddit 
 
 
 
 
 
Figure 0-3 Screenshot of Youtube 
post 
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A formal request was emailed to ask if the study could be posted on muscle forums 
(Table 0-3) and Figure 0-7 is an example of one that was posted once permission was 
granted. This post was shared on the forums and posts did receive a few comments 
(Figures 0-5 and 0-6). 
Table 0-3  Muscle Forums 
Muscle Forums: – Agreed to allow Survey to be posted 
UK-Muscle.co.uk  
Tmuscle.co.uk 
Muscle Talk https://www.muscletalk.co.uk/Testosterone-Other-Steroids-f10.aspx 
Forum.bodybuilding.nl 
https://thinksteroids.com/community/threads/please-assist-aas-survey.134390001/ 
 
  
  
Figure 0-4 Screenshot of Reddit/forum request post 
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Figures 6 and 7:  
The following page is the poster that was sent to NSPs, gyms and handed out to shops and 
friends alongside the questionnaire (see Appendix 12 for distribution).  
Figure 0-5 screenshot of forum interaction 
Figure 0-7  Screenshot 2  
of forum post 
Figure 0-6  Screenshot 1 of forum 
interaction 
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Appendix 14 Email invitation to participate in a research 
 307  
Project interview, Participant information and agreement 
forms 
 
Dear XXX,  
Thank you very much for expressing an interest in being interviewed as part 
in a research project about the use of Anabolic Androgenic Steroids.  
This email is to invite you to take part in an interview to share your experiences 
of using Anabolic Androgenic Steroids and offers you important information 
regarding the study.  
Just to confirm, in order to be eligible to take part in the study potential 
participants must be 18 years or older and using, or have recently used Anabolic 
Androgenic Steroids (AAS) within the last 6 months.   
The research involves a 30 - 45 minute interview, and seeks to gain an insight 
into your experiences of using AAS with a particular focus on understanding the 
barriers to seeking support and types of support AAS users want. By participating 
in the interviews you will be helping professionals to understand AAS use from a 
user’s perspective and also give a clearer picture of the type of support and 
information that people who use AAS would like to access  
The interview is designed to be conversational and you are not compelled to give 
an answer to each question, should you choose not to do so. Interviews can be 
carried out at a variety of times and locations to suit your preference. NB: 
(potential participants were asked their preference on the questionnaire – 
dependent on their preference will depend on which of the following information 
is entered here: 
Either 
In your expression of interest for taking part in an interview, you suggested that 
you would prefer a telephone (online) interview.   
Or  
In you expression of interest for taking part in an interview, you suggested that 
you would prefer face-to-face interview. There are several options available to 
you: Bournemouth University (Talbot or Lansdowne Campuses) or XXX (again this 
will depend on location of participant – it is envisaged this could be a local Needle 
Exchange Office).  
Confidentiality: In helping us by being interviewed it is important for you to 
understand that all the information that you provide will be treated with the 
strictest of confidence and all data will be completely anonymous when it is 
analysed. The study data will only be accessible by researcher and her 
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supervisory team. Anonymised data collected in this study may be used in future 
reports such as academic journals and conference presentations. However, no 
individual will be identifiable through such publication of data. The research 
process and its findings are subject to ethical guidelines set out by Bournemouth 
University. 
Finally, I feel it is important to state that your participation in this research study 
will make a highly valuable contribution to our understanding of AAS use and the 
potential future safety of other AAS users, so I do hope that you decide to take 
part. 
Thank you for taking the time to read this.  
If you are still willing to take part in an interview, I would be grateful if you would 
contact me, and we can arrange a suitable time and place.  
Best wishes 
Orlanda 
Orlanda Harvey 
PhD Student (Research) 
Faculty of Health and Social Sciences, Bournemouth University 
Interest: Anabolic- Androgenic Steroid Use and Social Work 
Office: 01202 967435 
Twitter @arrowandthesong 
If you have a concern about any aspect of this study and wish you complain, 
please contact: 
Deputy Dean for Research & Professional Practice, Bournemouth University, Tel: 
+44 1202 965206, Email:  researchgovernance@bournemouth.ac.uk 
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Participant Information Sheet – Interviews 
 
My name is Orlanda Harvey and I am seeking your help in relation to a research 
study on why people choose to use Anabolic Androgenic Steroids (AAS) 
I am a researcher from Bournemouth University and I am conducting research on 
this subject, so that we can better understand the reasons why people use AAS, 
as well as what sorts of information and support AAS users currently have, or 
wish they had. 
All details and information collected through the research will be completely 
confidential and anonymised, and no individual will be identifiable. Before you 
decide whether to take part in the interview, please take time to read the 
following information and discuss with others, should you wish. You can also 
contact me directly should you have any questions.  
Participants: To take part in the study, you must be 18 years or older, and use, 
or have recently used, AAS (within the last 6 months). 
 
Purpose: The study aims to explore people’s first-hand experiences of using AAS, 
compare these experiences, and understand what types of support people who 
use AAS would like. This will help to identify and understand the types of support 
and information that people who use AAS are most likely to want and use.  
 
The interview will take between 30 and 45 minutes to complete, as it covers a 
wide range of issues.  Please be as open and detailed as you can and would like 
when answering any question. The more honest you are the more helpful and 
meaningful the data will be. If you do not wish to answer any question, you may 
choose not to do so.  
 
Benefits: Whilst there are no immediate benefits for those people participating 
in the project, it is hoped that this work will lead to a broader understanding of 
the support that AAS users would value. Being involved in the research does 
mean giving up the time to take part in the interview. However, you do not have 
to give any information you do not wish to, and no questions relate to the 
purchase of AAS.  
Confidentiality: Only I, and my supervisory team, will be able to access the study 
data. Anonymised data collected in this study may be used in future reports, 
such as academic journals and conference presentations. However, all details are 
anonymous and no individual will be identifiable through such publication of 
data. For the protection of yourself and the researchers conducting this study, 
this research has been reviewed and approved in line with Bournemouth 
University’s research ethics code of practice.  No questions will be asked about 
the purchase or supply of AAS. This is a confidential interview and information is 
being used for research purposes only, However, should, at any time during the 
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interview,  information be shared that would lead to you or another person 
being at significant risk of imminent harm, then the researcher has a duty to 
break confidentially.  
Interview Recording: Will I be recorded? 
If you chose to take part in the interview the conversations will be audio 
recorded and used for analysis within the study. All recordings will be 
anonymised and kept on a password protected secure server and stored at 
Bournemouth University for a minimum of 5 years.  
Withdrawal: You can stop and withdraw from the interview at any time.  Please 
note that to withdraw you would only need to tell the researcher that you wish 
to withdraw.  However, once you have completed the interview and the data 
analysed, we are not able to remove your anonymised responses from the study. 
 
Personal Data: All personal data relating to this study will be held for 30 months 
from the date of publication of the research. BU will hold the information we 
collect about you in hard copy in a secure location and on a BU password 
protected secure network where held electronically. Except where it has been 
anonymised, we will restrict access to your personal data to those individuals 
who have a legitimate reason to access it for the purpose or purposes for which 
it is held by us.  
Contact Information: Leaving your contact information will not affect your 
anonymity or confidentiality as any contact information will only be used for the 
purpose of contacting you to share the results by the named researchers 
(Orlanda Harvey/Margarete Parrish) and will not be recorded as part of the 
research data.  
Should you have any further questions, please do not hesitate to contact me on:  
Orlanda Harvey: harveyo@bournemouth.ac.uk - Twitter: @arrowandthesong  
 
Should you wish to find out further information on AAS use, the following 
website has a wealth of useful information, advice and support: 
http://ipedinfo.co.uk/contact.html and this one has more information on the topic: 
https://humanenhancementdrugs.com/ 
Thank you for taking the time to read this. If you have any questions regarding 
this research, please feel free to contact me using the information below.  
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Your participation in this research study will make a valuable contribution to our 
understanding of AAS use and the potential for future support for AAS users, so I 
do hope that you decide to take part.  
Contact Information: Researcher: Orlanda Harvey: harveyo@bournemouth.ac.uk; 
tel: 01202 967435 
Supervisor:  Dr M. Parrish, Email: 
mparrish@bournemouth.ac.uk 
 
If you have a concern about any aspect of this study and wish to complain, please 
contact: 
Prof V. Hundley, Deputy Dean for Research & Professional Practice: Faculty of 
Health and Social Care, Bournemouth University by email to 
researchgovernance@bournemouth.ac.uk    
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Participant Agreement Form - Interview 
Title of project: A Mixed Methods Study into Anabolic Androgenic Steroid (AAS) Use – 
The voice of the recreational AAS user 
Name, position and contact details of researcher: Orlanda Harvey: 
harveyo@bournemouth.ac.uk 
Name, position and contact details of supervisor: Dr Margarete Parrish:  Senior 
Lecturer Mparrish@bournemouth.ac.uk  Address: Bournemouth University, 
Bournemouth House, 19 Christchurch Road, Bournemouth. BH1 3LH 
 
I have read and understood the participant information sheet (ref 4 PI 
sheet_interviews approved) for the above research project.  
Please Initial here 
I confirm that I have had the opportunity to ask questions.  
I understand that my participation is voluntary.  
I understand that I am free to withdraw up to the point where the data are 
processed and become anonymous, so my identity cannot be determined  
 
I am 18 years of age or over  
I am currently using, (or within the last 6 months have used) AAS  
I have given my full consent to being interviewed about my experiences of 
using AAS 
 
During the interview, I am free to withdraw without giving reason and without 
there being any negative consequences.  
 
Should I not wish to answer any particular question(s), I am free to decline.    
I give permission for the members of the research team (the researcher and 
her Supervisors) to have access to my anonymised responses.  
 
I understand that my name will not be linked with the research materials, and I  
will not be identified or identifiable in the outputs that result from the 
research.   
 
I understand taking part in the research will include being recorded (audio) but 
that these recordings will be deleted once transcribed. 
 
I agree to take part in the above research project.  
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Date     _______________                            Signature/initial 
____________________________          
Name of Researcher                               Date                              Signature 
Orlanda Harvey 
This form should be signed and dated by all parties after the participant receives a copy 
of the participant information sheet and any other written information provided to the 
participants. A copy of the signed and dated participant agreement form should be kept 
with the project’s main documents which must be kept in a secure location.  
Would you like a summary of the findings?                                                              (Please tick one) 
Yes No 
If yes, please enter your email address here: 
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Appendix 15 Format and qualitative questions for one-
to-one interviews  
 
Standardised Introduction: 
My name is Orlanda Harvey and I am a postgraduate researcher from Bournemouth 
Universality and will be interviewing you today. Thank you for agreeing to take  part in 
this interview. The interview will take about 30 – 45 mins and consist of a series of 
questions, some of which have been pre-written and some which will be asked on the 
basis of your answers. The research seeks to gain an insight into your experiences of 
using AAS and also on understanding the barriers to seeking support and types of 
support AAS users want. This is a confidential interview and information is being used 
for research purposes only, However, should, at any time during the interview,  
information be shared that would lead to you or another person being at significant risk 
of imminent harm, then the researcher has a duty to break confidentially.  
The interview is designed to be conversational and you are not compelled to give an 
answer to each question, should you choose not to do so. The interview will also be 
recorded (with your permission). You may withdraw from this interview at any time and 
the data will be destroyed. All the information that you provide will be treated with the 
strictest of confidence and all data will be completely anonymous when it is analysed.  
At the end of the interview, should you wish it, information can be provided on where to 
seek further support and advice.  
Can I please confirm that you have a copy of the participant information sheet and have 
signed the participant agreement form?  
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Question Outline: 
Theme 1: Motivations for use 
 Could you please tell me why you decided to use AAS? 
o How old where you when you starting using AAS? 
o Follow up question around the motivations - (any underlying motivations) – 
dependent on answer given 
 What do you see as the hardest time you have been through in your life?  
o Follow up question around how this links to decision to use AAS (if relevant)  
 How has AAS use impacted on your life? 
Theme 2: AAS use 
 What are the good points/ not so good points of using AAS for you? 
o Follow up question around any behavioural changes mentioned or issued 
raised 
 Has your use of AAS impacted on your relationships with others? 
Theme 3: Support 
 Where do you go for support and advice on using AAS? 
o Has this changed from when you started? 
For each type of support or source of advice mentioned:  
o How reliable (helpful) do you find this support?  
 What type of support and advice do you think should be available to people who use 
AAS? 
o Dependent on answers, further question on why they think there 
should/shouldn’t be support and the types of support? 
 
 Is there anything else you would like to share about your experiences with using AAS 
use? 
Standardised conclusion:  
Thank you for taking part in this study, by doing so you have made a highly valuable 
contribution to our understanding of AAS use and the potential future safety of other 
AAS users. These are my contact details (hand over business card); please do not 
hesitate to contact me should you have any further questions, or if you would like a 
summary of the report. Just to confirm this interview is completed confidential and the 
data will be anonymised.  
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Appendix 16 Extract from transcript (two pages) 
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Appendix 17 Sample of development of codes and 
themes 
 Initial Codes – coded on the transcripts 
 Data then entered into NVivo and recoded 
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Development of themes 
  
Fourth iteration of coding 
framework 
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Appendix 18 Data cleansing of questionnaire: Summary 
of actions taken  
Question Action Example Participant responses Resolution 
3. Number 
of hours per 
day 
exercised 
Averaged 
out answers 
(26 recoded) 
14. 2-3 2.5 
20. 3 times/w- Missing (-9)  
91. 1 and a half to 2 hours  1.7 
Not all  respondents will  exercise every day – in some cases 
unable to determine hours per day (so were coded as 
missing) 
In which 
country do 
you live? 
Standardised 
Country 
Names 
U.K., United Kingdom, England, 
Scotland, Wales 
UK 
America, United States, US USA 
Note: 93. Poland England now Canada 
(and removed county as London) 
Canada 
In which 
county do 
you live? 
Counties 
grouped to 
regions of 
England 
If no region (or region outside England) 
used the country that makes up the 
Union 
Wales 
Scotland 
NI 
What age 
did you start 
using AAS 
Recoded 
erroneous 
answers 
Age stated as 21333, 240 Missing 
Number of 
years using 
AAS 
Recoded 
erroneous 
answers 
Number of years 200 
 
Missing 
With which 
gender do 
you 
identify? 
Standardised 
term for 
gender 
Man, M, Malr, I'm a fucking man, I have 
a penis 
Male 
7. f Female 
Ethnicity? Recoded 
into set 
groups: 
standardised 
and groups 
terms  
Caucasian, white dude, White, non-
Latino, white Christian, Human :) 
(interviewed in person – so white 
British), Caucasian Australian British 
decent 
White 
Ethnic swede, Sweden/European (with 
roots in Europe), Caucasian European, 
just... an average Dutch guy :), Slav, 
(Mediterranean/Caucasian), Viking, 
Easturopen katolic 
White European 
Latino Hispanic 
WB White British 
Indian Asian 
Asian/European, Half Indonesian, Half 
Dutch, Middle Eastern (Caucasian), 
White British and Arab mixed, South 
Asian), Asian & white), British Pakistani 
Mixed Race 
American, None, Maori  Other/Unknown 
Greek, Mediterranean, 
Italian/Canadian, Dane 
European 
Education 
Level 
Those 
coded: Other 
recoded 
dependent 
on self-
RVT RDCS   former cardiovascular 
sonographer, Those with Masters 
degrees, MSW, NVQ 3/4 
Electricotechnical Engineering, NVQ6 
Construction Management, Registered 
 College or 
university 
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Question Action Example Participant responses Resolution 
description investment advisor.  Series 7, 73, 65, 66 
etc, about to finish my masters in 
geological engineering 
Some high school  Secondary 
Education 
 
Employment 
status 
Standardised 
answers 
Other: no description given Other: 
Suck. Car accident, Other: no 
description given 
Left as Other 
employed on sick leave Employed 
Q10.b Who 
taught you 
to inject 
Standardised 
answers – 
changed to 
multi 
question 
Google, online Internet 
Physician, former nurse, a nurse friend, 
close friend with medical training, 
studying chiropractic and is a qualified 
phlebotomist. - NB: if word friend used 
also coded friend 
Medical 
professional 
 
Youtube, Internet tutorial, Online 
tutorial, instructional video 
Online videos 
Myself, self, self/medical training, me, 
researched it myself, i 'm a goddamn 
doctor- If mentioned medical training 
also coded other 
Self-taught 
My dad, my father, family member, i  
am not in able: provide my wife 
Family 
 
medical journals, medical textbooks 
and public health leaflets contained 
within injecting equipment sports 
packs 
Books 
 
a friend who use to compete, friends, 
best friend, One of my first boyfriends. 
Training partners, myself. Other AAS 
users, Fellow gym user 
Friend or Peer 
 
Safe injecting with worker NSP 
Strength coach Coach 
Q9 Seeking 
help for 
support 
Changed No 
to yes 
Stated no but then gave answers given 
to follow on questions about the help 
received 
Yes 
Q10-a-12/13 
Where do 
you get your 
needles 
from? 
Re-
categorising: 
Other  
Added 2 categories based on Other 
responses and recoded:  
1. General online stores such as ebay,  
2. 2. online stores that sell  medical 
supplies 
 
Q 12 – 16 
(9,13) - 
Advice 
sought: 
Re-coding Repetition error in questions on 
support AAS users appears twice – 
checked each respondent for each 
question and ensured if Y ticked in first 
instance 
Removed 
second column 
NB: if a participant ticked both yes and No then the answer was recoded to yes 
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Appendix 19 Interview Summary and demographics of interviewees 
Interview Summary (UK) 
Participant pseudonym Country  Method Chosen Transcript Actions**  Supervisor check 
Isaac UK Skype video call  A B (Y)  
Milton UK In person A  ST 
Andrew UK Telephone A  EVT 
Harry UK Telephone A B (Y) C   
Peter UK Telephone A   
Del UK In person A  MiP 
Han UK Telephone A EvT 
Alvin UK Skype video call A   
Clinton UK What’s App typed chat (Synchronous) A   
Powel UK Google Hangouts call A   
Don UK Skype video call A  MIP 
Lawrie UK In person A   
Robert UK Skype call A   
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Interview Summary (Overseas) 
 Participant pseudonym Country Method Chosen Transcript Actions Supervisor check 
Joel USA What’s App call A  B (Y)  
Asi USA Skype video call A   
Hugo USA Skype video call A B (Y) EvT 
Theo Denmark FB Messenger call A  B (Y) ST 
Lewis USA What’s App call A   
Lee USA Google Hangouts call  A B (Y)  
Tomaz Belgium  FB Messenger typed chat (Synchronous) A B (Y)  
Lev Canada  Skype call A ST 
Johan Hong Kong Skype video call A B (Y) C  
Paul USA Skype call A B (Y) C MiP 
* used to maintain confidentiality ** Transcript Actions: A: sent offer email to read B: received Y/N reply and sent if said yes to review, C: received comments 
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Demographics of interviewees
Case 
ID 
Interview 
method 
Country of 
Residence 
Age Gender~ 
 
 
Ethnic 
Group 
 
 
How would you describe yourself: 
Other: added (self-description)  
Which is 
the highest 
level of 
education 
do you 
have?* 
Employed 
Other (self-
description) 
Sexual 
Orientation 
 
 
Andrew  Telephone UK 25 M white Competitive bodybuilder College Self-employed H 
Harry  Telephone UK 52 M white Recreational Exerciser College Employed H 
Peter  Telephone UK 24 M white Recreational Exerciser / Other (Personal 
Trainer) 
College Self-employed H 
Alvin  Skype UK 36 M white Competitive Athlete College Self-employed H 
Clinton What’ App 
chat 
UK 20 M white Recreational Exerciser College Employed / 
Student 
H 
Isaac  Skype UK 42 M white Recreational Exerciser College Student H 
Don  Skype UK 39 GF white Recreational Exerciser College Student P 
Del  In person UK 35 M mixed Recreational Exerciser College Employed H 
Han  Telephone UK 42 M white Other (Damaged goods) Secondary Other 
(Unemployable) 
H 
Asi  Skype USA 28 M white Recreational Exerciser / Aspiring 
competitive athlete 
College Employed B 
Hugo  Skype USA 53 M white Recreational Exerciser College Self-employed Gay 
Powel  Google 
Hangouts 
Call  
USA 34 M white Personal Trainer College Self-employed H 
Lewis  What’s App 
chat 
USA 37 M white Personal Trainer College Employed H 
Lee  Google 
Hangouts 
USA 43 M white Competitive bodybuilder /Personal 
Trainer 
College Employed H 
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Case 
ID 
Interview 
method 
Country of 
Residence 
Age Gender~ 
 
 
Ethnic 
Group 
 
 
How would you describe yourself: 
Other: added (self-description)  
Which is 
the highest 
level of 
education 
do you 
have?* 
Employed 
Other (self-
description) 
Sexual 
Orientation 
 
 
video 
Joel  What’s app 
call  
USA 34 M hispanic Recreational Exerciser Secondary Employed H 
Paul  Skype call  USA 29 M white Personal Trainer College Employed H 
Lev  Skype  Canada 32 M white Recreational Exerciser / Other (Before 
competitive athlete now just my own 
personal health and appearance) 
College Employed H 
Theo  Messenger 
call  
Denmark 30 M white Other (Fat guy trying to lose weight) College Student H 
Tomaz  Messenger 
chat 
Belgium 40 M white Competitive bodybuilder College Employed H 
Johan  Skype Hong Kong 36 M white Competitive bodybuilder College Employed H 
Lawrie  In person UK 27 M white Competitive Athlete College Self-employed H 
Robert  Skype Spain 34 M white Recreational Exerciser College Employed H 
Milton  In person UK 40 M white Competitive Athlete Secondary Retired H 
*College = College or university, secondary = Secondary Education ~ M= Male, GF= Gender fluid  H = Heterosexual, P = Pansexual, B = Bisexual
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Appendix 20 AAS use and the potential for 
addiction 
Participants thoughts on the addictive qualities of using AAS 
‘whilst steroids may not be physically addicting, I do think there's a mental 
aspect to them because …they don't only make your body feel stronger and 
more capable. But when your body's like that your mind is better, …you feel 
healthy and everything's good in your head. So, it's definitely, most assuredly a 
combination of both, like if I was to all of a sudden couldn't have them. I have no 
doubt that I in some way, shape or form, it would probably put me into a bit of a 
depression.’ (Lewis/USA/37) 
 
 ‘oh you tasted it. So now I want to carry on because you're going so easily and 
so nice and the feeling on it is completely different than someone exercise 
without. It is that dopamine released in your brain you might not know it but it's 
there. So, later on when you want to stop, it's still there, …you’re missing that 
kick I would say or I would call that. …and that's why it's like a vicious circle 
everyone and they get up to that and then it is hard to come off.’ 
(Lev/Canada/32) 
 
‘it is easy to go forwards but it is not very easy to go backwards. And there would 
be the fact that I’d done so much research into the positives, long-term of 
maintaining a  decent level, that it, psychologically it would blow me, because I 
would be like, shit I’m all those things, that I decided and took the risk to 
mitigate are now going to hit me full force and there is nothing I can do about it. 
So, one way or another I would have to find a way to stay on.’ (Robert/Spain/34) 
 
‘I would say that it's a very hard ride to get off of. Once you feel the benefits and 
gains from using them, it's hard to not want to take them. I guess they aren't 
addictive, but they can be very gripping!’ (Clinton/UK/20)  
 
‘physique changing is as much an addiction as it is to the drug’ (Don/UK/39) 
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Appendix 21 Benefits of using AAS – Summary of 
questionnaire data 
 Benefits of using AAS* Tally 
Increased (faster) Strength, power “Significantly improved gains in strength, much 
more than what training and diet achieve alone,” 
43 
Faster muscle building capabilities, increased muscle, increase size, maintain muscle 
mass while calorie restricted, Sparing muscle while burning fat 
42 
Increased Sex drive, improved sex life, libido, sexual benefits, positive effects in the 
bedroom 
26 
Recovery, healing properties, less injuries, control over my own body (especially 
regarding injuries), “Less injuries and more recovery firstly and allowing me to train 
more”, Better regeneration 
25 
Confidence, improved confidence and outlook on life 19 
Work harder the next day, more stamina, easier gains, endurance, better results from 
exercise, Greater results, enabling me to workout harder and longer, thus gaining 
better results, feel better in the gym, easier to train more often, workouts get more 
intense and productive, Achieve higher results, ie breaking pr's, Faster progress on my 
fitness goals, Able to continue to progress when lifting weights  “feeling amazing in and 
outside of the gym” 
18 
Improved mood, less depression, positive mood, mood enhancement, improved mental 
health 
14 
Fat loss/harder to put on fat, faster weight loss, fat burning, my fat body wants to be 
fat. Its hormones fight me every step of the way. My will power alone is not enough 
12 
Personal, image acceptance in a world that is so appearance based, I have the desired 
appearance, Appearance, better physical attractiveness, “My physical appearence 
mostly and the effect you gain from that. The more I grow and the more I get ripped, 
the more I walk around confidently and I think it improves my overall confidence and 
hapiness.” 
11 
Increased, improved performance, faster results, over all better performance in all 
aspects of life. 
10 
More aesthetic body, body transformation, improved physique, Healthier look, Better 
looking body, A look to the physique that couldnt be achieved naturally, Improvements 
in physique; better physical appearance and condition, look amazing 
10 
Feeling of wellbeing, feeling better, Increased wellness, “AAS can be used to promote 
health, longevity, and wellness” 
9 
Improved health, better overall health reducing the risk of Diabetes, and other obesity 
related conditions, overall boost to health 
8 
Increased sex-appeal, attractiveness, Increased attraction from the opposite sex, 
attract more women, “Not the main reason but I have noticed increased attention from 
females whilst I was single at the time.“, More sexually attractive to females 
6 
Anti-aging, slowing of the age process, You feel much younger 6 
More energy 5 
Quality of life, I enjoy my life more due to AAS 5 
Growth, definition, Body composition, helped change my body shape 5 
Hyperbolic word descriptors: Awesomeness, everything, Get jacked as fuck 4 
Improved physical appearance 4 
Happier 3 
More mentally stable, stabilised moods, stable mood 3 
Less pain, less aches and pains 3 
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 Benefits of using AAS* Tally 
More alert, Increased focus, more focused more determinaded 3 
Up my low-test level, A steady high normal Testosterone level, Stable but elevated T 
levels are an advantage to me 
3 
Increased lean body mass, Less loss of lean mass dieting 2 
Increase in overall fitness 2 
Improved Joints, Therapeutic effect on joints with increased sinovial fluid and greater 
collagen uptake 
2 
Improved metabolism 2 
Reduced Stress, enhanced ability to deal with stress 2 
Increased mental performance, Improved cognition 2 
Rock-hard erections, improved sexual performance, acquire super boners 2 
Self esteem 2 
A hobby, “gave me something to train and focus on at a difficult time in my life.” 2 
Social admiration, big = respect 2 
‘Fighting HIV wasting’, ‘Survived 34 years of HIV.  Look better than HIV negative people 
my age’ 
2 
‘I think what looks like permanent muscle from usage will play a part in helping me 
move my salary up faster in the future too’, ‘I'm a doorman so using them benefits my 
job too’ 
2 
Weight gain 2 
Increased protein retention, better protein synthesis 2 
Helps with my damaged body, 1 
I feel more in touch with my emotions, which probably sounds strange, but is most 
likely attributed to fluctuations in hormones such as estrogen.  I still regard it as a 
benefit 
1 
Helps me stay alive 1 
More competitive in my sport 1 
Improves motivation 1 
Increased aggression 1 
Increased trust and reverence from people 1 
A sense of self satisfaction that allows me to now focus more on what I’m passionate 
about than trying to look good for society 
1 
Longevity in weight training 1 
Increased tendon strength, increased bone density 1 
Less likely to lose size while dieting hard. 1 
Healthy lifestyle 1 
I came back to be a better version of myself by giving a chance 1 
Intimidation 1 
Feeling normal again 1 
Developing my understanding of AAS using my body as my own guide  1 
Keeping my hormonal levels balanced 1 
Increase IGF 1 
Reduces insulin sensitivity 1 
Preventing sarcopenia while getting older 1 
Improved sleep 1 
Immune boost during the winter 1 
Play an endurance heavy sport without sacrificing muscle 1 
* Benefits have been grouped together and some specific quotes have been used to 
illustrate certain elements and to keep the user’s own words to keep their ‘voice’   
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Appendix 22 Questionnaire comments referencing 
aggressive behaviours and management 
 
Answers to the following questions all elicited answers concerning aggressive 
behaviours, which are summarised in the Table below. 
Q. Risks of using AAS  
Q. Negative or unwanted side-effects you have experienced of using AAS 
Q. If you selected ye, you get mood swings, please describe:  
Q. If you selected yes, you experience behavioural changes, please describe: 
Q. If you have other negative feelings, please describe:  
Q. If you have experienced any of these feelings, please describe how you manage 
them? 
Q. If you selected yes, I have acted on feelings of aggression, please describe what 
happened? 
Behavioural Changes Aggression: from Questionnaires (self-report) 
 from use of oral AAS I will often get a very focused and aggressive mood 
swing  
 Short tempered, less caring, more selfish, relationship deterioration  
 Very bad tempered and intolerant of those around me 
 no care of others around me. 
 Playing rugby, far more fights  
 more aggro easier  
 more aggressive and more forward person 
 One time I yelled at my sister.  
 Increased motivation and aggressiveness. 
 When I took trenbolone it made me more angry but I quickly stopped 
using and the aggression decreased. 
 increased aggression (<- deserves it's own text box), relationship 
problems   
 I shouted at someone because I was irritable... Because my E2 was high.  
 Angry over the simple issues 
 More aggressive in a positive way. More assertive.  
 Certain compounds cause great aggression like Trenbolone so I no longer 
use that steroid. 
 Loss of control ( mania ) alone deep feeling of frustration 
 Anger  
 Arguments Snapping at people  
 Become aggressive in the gym and keep lifting until exhausted. 
 agression  
 phychosis 
 violence in material things 
 increased aggression  
 I’ve also noticed cardiac and psychological issues after usage and 
cessation of Tren E, anger and difficulty controlling mood.   
  Constant persistent anger, cold mechanical mildly sociopathic affect 
towards people    
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Behavioural Changes Aggression: from Questionnaires (self-report) 
 Angrier now after Tren, getting better, persisted for at least 3-6 months. 
Feel bad looking back at how I acted.      
 Aggressive tendencies that I can control  
 I do notice my temperament may be a little shorter fused at times, 
especially with certain substances. 
 If If testosterone is at a supraphysiological level your aggression and 
dominance can come out as well 
 They give me higher aggression and a shorter fuse  
 Just feel irritable more  
 Just more on edge  
 Very mild increase in temper. Have to be mindful of it 
 quicker to anger 
 getting angry faster 
 I hacked my ex's facebook to check if she'd been with someone else - 
which she had 
 I experience aggression and anger at doses of testosterone higher than 
1000mg a week of long esters. 
 Tren has caused heightened aggression.  
 Some verbal arguments when using Tren.  
 I’ve become more mature so my AAS effect on my irritability has gone 
down however it’s not related to the drug.  
 Temper  
 Rage  
 Hitting out   
 Irritation and frustration. 
 Quicker to anger. 
 Sudden irritation  
 More impulsive 
 I lost my temper while driving the car  
 Easily irritable sometimes  a explosive  behavior but thi is really rare   
 Not crazy bipolar mood swings.. but if you mad about something it makes 
you pissed.  
 Ehh. Yes and no. I mean I’m more straight forward and blunt while on aas 
 More agressive  
 Angry over small things 
 Slightly agitated more easily, never more aggressive  
 Short fuse,  
 Maybe short tempered. But have complete control of myself as to 
whether i act on aggression.    
 aggression 
 irritability  
 I get irritated alot easyer but it's not a problem.  
 pronounced aggression (particularly with trenbolone) 
 Trenbolone makes me very short tempered, aggressive and my mind is 
filled with viscious and violent thoughts. However, in company with other 
people, they cannot tell as I am so adept at internalising these feelings 
 Increased impulsivity and risk taking   
 Got very angry in traffic once 
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Behavioural Changes Aggression: from Questionnaires (self-report) 
 Im always on. I cant imagine the increased aggression hasnt affected my 
behavior 
 I get irritated easier 
 I get mad quicker  
 Anger  
 Rage, MOre aggresive 
 I quit my job i start yelling and screaming because of a small fight 
 Sometimes I can be a little more impatient 
 very easily irritable  
 less emotional /(cold )   
 get in to argument with my partner over stupid little things  with time and 
yeras this become easily contoble drinking lots of melisa and other herbal 
tea to help with my mood swings 
 I’m gettin aggressive very easy or I have bad mood without a reason   Also 
some of the thing which never have any whay to piss me off they do  
 Again aggressive very focused sometimes rude and very easy going in to 
the conflict  
 I was on noght out and some guys was laughing from me or my miss and I 
nearly broke them fingers but normally I would never do that  
 I can get angry on levels that are crazy, and since i am mental stable 
understand that i feel angry without no reason, so just stay patient until it 
goes away.. it's the hormone instability at that moment that makes me 
feel angry even though i had nothing that troubled me or made me angry 
 Mood Swings, Bad mood, being angry / mad it's the most common things  
 Had a fight with my girlfriend. I was about to slap her when i understood 
what i was about to do and said to myself "immediately calm the fuck 
down. you are not THAT type of a faggot person" 
 Apologized and asked her a minute to calm down myself before we 
continue the argument.  
 Some (few) anabolic steroids may cause irritability or anxiety, although 
the effect in my experience is mild, simply makes things like getting 
stressed out while stuck in traffic more noticeable 
 roid rage, false sense of security 
 can be on top of the world then feel angry over the smallest thing  
 losing temper and its escalated into a fight  
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Appendix 23 Self-reported effects of using Trenbolone 
This study did not seek to find out the individual effects of  specific brands or types of 
AAS however, one substance ‘Trenbolone’ did stand out as something that could have 
very beneficial effects but was also particularly problematic to use, in relation to 
unwanted behavioural side effects. 
Use Quotation 
Effects 
on 
Cycle  
‘compounds cause behavioural changes l ike Trenbolone so I no longer use that 
steroid’ (Nick/USA/50) 
‘Tren has caused heightened aggression. If estrogen [sic] spikes I can get moody 
but knowing my dosages and blood levels I can actually manage moods more’ 
(Rod/Australia/39) 
‘Trenbolone makes me very short tempered, aggressive and my mind is fi l led 
with viscious [sic] and violent thoughts’ (Don/UK/39) 
‘that is the one compound that does make me raise an eyebrow, but just 
because of the people that have come back to me after using it, and said, that I 
can’t ever use that again, I went crazy’  (Robert/Spain/34) 
‘I never got on with Trenbolone. Trenbolone was one steroid that did make me 
irritable and did make me agitated.’ (Isaac/UK/42) 
‘I did use one compound: trenbolone, for a while and I had every negative side 
effect with it imaginable with that; I had shortness of breath, I had flushing, I had 
night sweats, I had quick, quick to enrage.’ (Hugo/USA/53) 
it made me so indifferent about l ike my relationship with the people around me. 
It's l ike it was almost l ike a sense of arrogance that no one else really mattered 
around me’ (Peter/UK/24) 
‘I'm running Tren right now, and you know I get the full  nightmares, I get the 
extreme sweats, the insomnia is pretty bad... I don't forget a single bit of the, the 
terror of the nightmare.’ (Lewis/USA/37) 
‘Tren is not the best drug to take, …I am not emotional but Tren’s not a good 
drug if you are not very in control of your impulses and your emotions and I am 
on Tren right now but very small doses of it because I've taken it before, and like 
man it just, it just makes you so depressed for no reason... I'm terrified of getting 
fat again... so that's why I l ike doing Tren so much, because it, it just sucks 
everything down really well …I don't know if I'm gonna keep doing it because 
…I'm not empathetic to stuff... I don't l ike the person that I am, when I'm doing 
it.’ (Joel/USA/34) 
‘I am on trenbolone and that could cause, actually that could ca use problems 
right now. Definitely it's easier to get angry and Yeah, lose control that’s for sure. 
Especially on trenbolone because that's a very specific compound, lots of friends 
and guys at the gym would say the same thing’ (Lev/Canada/32) 
‘I used it for a period of around eight weeks and I didn't get any sort of 
heightened aggression which some people find I didn't you know I got night 
sweats, it reduced the amount of sleep I needed it seemed and but it made me 
so indifferent about l ike my relationship with the people around me. It's l ike it 
was almost l ike a sense of arrogance that no one else really mattered around 
me’ (Peter,24,UK) 
‘I am having occasionally l ight night sweats, occasionally, sl ight er acid reflux, but 
no problem at all. It is very easy…um, with the Tren, I noticed initially a slight 
increase in irritability when I am driving, so you know, swearing at other drivers, 
you know, in my head sometimes, but that has passed now’ (Del/35/UK)  
‘Very low mood after using trenabol’ (Grant/UK/29) 
After a 
Cycle 
‘First cycle, off Tren I was very insecure’ (Jason/UK/40) 
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Appendix 24 Erikson’s Life Stage Theory  
Stage Psycho-
social crisis 
Radius of 
significant 
relations 
Basic 
strengths 
Core-pathology basic 
antipathies 
1: Infancy 
(birth to 18 
months) 
Trust vs. 
Mistrust 
Maternal 
person 
Hope Withdrawal  
Outcome Children develop a sense of trust when caregivers provide reliability, care, and 
affection (Hope). A lack of this will  lead to mistrust. 
2: Early 
childhood (18 
months to 3 
years) 
Autonomy 
vs. Shame 
and Doubt 
Parental 
persons 
Will  Compulsion 
Outcome Children need to develop a sense of personal control over physical skills and a 
sense of independence. Exploration of environment.  Success leads to feelings 
of autonomy, failure results in feelings of shame and doubt. 
3: Preschool 
(3 to 5 years) 
Initiative vs. 
Guilt 
Basic family Purpose Inhibition 
Outcome Children need to begin asserting control and power over the environment. 
Success in this stage leads to a sense of purpose. Children who try to exert too 
much power experience disapproval, resulting in a sense of guilt. 
4: School age 
(5 to 12 years) 
Industry vs. 
Inferiority 
Neighbourhoo
d, School  
Competence Inertia 
Outcome Children need to cope with new social and academic demands. Success leads to 
a sense of competence, while failure results in feelings of inferiority. 
5: 
Adolescence 
(12 to 20 
years) 
Identity vs. 
Role 
Confusion 
Peer groups 
and 
Outgroups. 
Models of 
leadership 
Fidelity Repudiation 
Outcome Teens need to develop a sense of self, values, aspirations and personal identity. 
Success leads to an ability to stay true to yourself, while failure leads to role 
confusion and a weak sense of self. 
6: Young 
adulthood (20 
to 40 years) 
Intimacy vs. 
Isolation 
Partners in 
friendship, sex, 
competition, 
cooperation 
Love Exclusivity 
Outcome Young adults need to form intimate, loving relationships with other people. 
Success leads to strong relationships, while failure results in loneliness and 
isolation. 
7: Middle 
adulthood (40 
to 65 years) 
Generativit
y vs. 
Stagnation 
Divided labor 
and shared 
household 
Care Rejectivity 
Outcome Adults need to create or nurture things that will  outlast them, often by having 
children or creating a positive change that benefits other people. Suc cess leads 
to feelings of usefulness and accomplishment, while failure results in shallow 
involvement in the world. 
8: Maturity 
(late adult) 
(65 to death) 
Ego 
Integrity vs. 
Despair 
Mankind, ‘My 
Kind’ 
Wisdom Disdain 
Outcome Older adults need to look back on life and feel a sense of fulfi lment. Success at 
this stage leads to feelings of wisdom, while failure results in regret, bitterness, 
and despair. 
Erikson’s Stages of Development adapted from Erikson and Erikson (1997) 
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Appendix 25 Sketches to illuminate the differing 
AAS use pathway  
 
The first two sketches consider two people (Hugo, and Asi,) who appear 
comfortable in their use, and the second two (Don, and Lewis,) who are more 
conflicted about their use. It is acknowledged that as these are only sketches the 
life stories are incomplete.  
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 Hugo's (USA/53) story (Table 1) 
 
Motivations: Improve my appearance, increase my confidence, enhance my muscles or 
strength, become happier, increase my sexual attractiveness, positive results I achieved 
from using AAS, increase my sex drive, my friends use AAS, impress my friends, improv e 
endurance or stamina.  
Hugo is gay, contracted HIV as a young man and was prescribed AAS by a doctor to help 
combat the wasting side effects of HIV. His reasons for using have changed over time and 
he saw many benefits for using AAS. These benefits outweigh the risks for Hugo, and he 
did not suggest any confliction with use. 
 ‘For me, it's a combination of the medical, originally for wasting syndrome. And then 
lately to me, it's been about the medical in the sense of healthy aging because of 
testosterone replacement and then, the recreational… There's a medical side where I'm 
interested in …testosterone replacement therapy for middle aged man with hypogonadal 
symptoms ...and then there is, I guess, I'm sheepish to admit it. I think it's the, there is a 
cosmetic and cultural side because I think … gay men fetishize muscularity it's just pretty, 
it’s not universal, but it's darn close to it. And there's a prestige with that… I realized the 
critics if they heard me… would say, Oh, H will you get off your high horse, come on, 
dude, you're doing this because you’re vain, you want to be muscular and you want to be 
admired for being muscular... And I understand that because there's an element of that, 
…there's a certain kind of positive narcissistic benefit to somebody saying, you know, …I 
can have a little bit of social currency, …there comes a time walking on the street in a gay 
neighbourhood where, you know, you pass somebody, and you know, you do a double 
take, and I, you know, you can't circle the date on the calendar, but there comes a time I 
think, in the life of gay men when they don't get that anymore… it's that gay, middle aged 
men’s invisibility and you know, sometimes I mean, a Bentley or a Rolls Royce will do it to 
but you know, muscularity will sometimes give you back something that aging has taken 
away. And, you know, and so it becomes a coping. Is it an adaptive coping, or a 
maladaptive coping? It depends on who you ask, but it's, you know, it's, to me, it's a little 
bit of an adaptive coping with the idea of the loss of status and the invisibility that comes 
with aging as a gay man. Now, with, you know, naturally just gradually getting a little 
more silver in my hair and stuff like that, you know, instead of being the blonde twink 
from the university that got into the gay bars without an ID now I’m the daddy. You know, 
it's like the grey hair and the beard and, and muscular’.  
Hugo selected a range of both physical and psychological motivations for using AAS and 
talked about his experiences as an older gay man, noting a positive consequence of having 
been prescribed AAS to combat his wasting syndrome, and the impact on his social life. 
There is evidence that gay men are more likely to report higher levels of internalisation of 
male ideals and body image concerns compared to heterosexual men (Strübel and Petrie 
2019) and also at higher risk of AAS use (Blashill and Safren 2014). However, for Hugo his 
own risk/benefit analysis highlighted that he did not see his use as problematic, that it 
impacted positively on his quality of life and the risks outweighed the potential costs. 
Moreover, he had clear strategies for managing risks. Understanding that Hugo’s use 
started through prescription steroids, that his use is now continuous and low-level, and 
that he now sees his use as both having physical and social advantages and linked to his 
identity as a gay man, could help professionals to consider the approach to take. It is likely 
that a preventative approach would not be accepted but that a more harm minimisation 
focus would be something he would engage with.   
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 Asi's (USA/28) story (Table2) 
 
Motivations to use: Improve my appearance, increase my aggression, enhance my muscles 
or strength, become happier, prevent injury, curiosity, positive results I achieved from 
using AAS, increase my sex drive, improve endurance or stamina, other (hormone 
replacement therapy). 
Asi had been working out in the gym since being a teenager and starting using AAS in his 
mid-twenties. He had used recreational drugs previously, and said initially that AAS was a 
line he did not want to cross. However, he noticed his progress in the gym was not as fast 
as others and was curious about how AAS might make him ‘bigger, faster and stronger’. 
He reported that part of what influenced his decision was that he  had got tested and 
found that he had low testosterone levels. He described himself as an all or nothing kind 
of person, and he did a lot of research first. He listed the benefits of using, which included: 
symptoms of low testosterone no longer present, increased strength, ability to gain 
muscle and rid fat and higher libido. He said he felt more in touch with his emotions and 
described the risks and felt these could be mitigated by responsible use. He stated that his 
quality of life since using AAS has improved: 
“it feels more normal for me to have I sort of more sustained sex drive and that is just 
with testosterone replacement dose but it's just, it's kind of hard to put down in words 
but just an overall more, a better feeling of wellness I guess so I have more of a sort of 
energy feeling , I guess. Yeah almost like a confidence in a way, I guess” 
Asi had few concerns about his use, side-effects experienced were minimal and envisaged 
a potential change in use on the future. When it came to information and support, Asi 
reported that he did a lot of evidence-based research and got his bloodwork done 
privately and regularly. Asi said he chose not to seek help from a doctor as he felt their 
knowledge in this area was low. Asi reported one potential concern: sel f-phlebotomy. He 
felt there was need to support people who wanted to use phlebotomy as a way to 
mitigate harms. When considering future usage, Asi felt that other priorities might mean 
that he would not be able to sustain the fitness regime he has now, but that he would still 
want a TRT dose. (Asi/USA/28) 
This insight into Asi’s journey is useful as it highlighted a complex range of motivations for 
use are both physical and psychological and that Asi‘s high sex drive is important to him. 
Asi’s decision-making showed that any support offered that focussed on prevention was 
not something that would be acceptable as he was already of the mind-set that he will 
need to use low levels of testosterone in the future. However, as he took an evidence-
based approach to use, he may be open to support aligned to harm minimisation. Notably, 
Asi said he had not experienced any particularly problematic side-effects yet in the 
questionnaire he listed a number of side-effects which were a direct result of use, (which 
he was self-medicating for), and others that he had previously but that AAS use had 
exacerbated including a risk of sleep apnoea. He also said that he was receiving treatment 
for lower jaw growth potentially as a result of using Human Growth Hormone (HGH), 
which is also a high-risk behaviour (Evans-Brown and McVeigh 2009). Consequently, 
building a trusting relationship with Asi could be vital; as although he does his research, he 
appears to be still taking risks and downplaying some of his side-effects. 
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 Don's (UK/39) story (Table 3)
 
Motivation: Increase my confidence, enhance my muscles or strength, become happier, overcome 
depression, help me stop being bullied, frustration: I’ve not achieved the desired results from 
exercise, become brave. Don starting using AAS in a drive to change his appearance, to build muscle 
to become more ‘manly’: ‘I felt well I  am going to take a really practical approach to this and I 
thought I am going to, I am going to transform myself into this huge guy, this huge physique and 
that will  magically fix all psychological problems’.  
Don used supra-physiological doses of AAS, and spoke of having a plan for his use, and having done 
his research. Don was conflicted in his use; he liked the aesthetic changes but did not feel 
comfortable using and felt that this was potentially an unhealthy way of coping to overcome a 
sense of inadequacy. He felt his desire to use stemmed from his childhood experiences and the 
internationalisation of his beliefs around masculinity. Don's mother had a history of mental health 
problems, Don said his father could be very frightening and he had a ‘very abusive, very traumatic 
childhood’. This had caused a major conflict for him around identity, which he described as having 
led to a number of psychological problems including diagnoses of anxiety and depression, and a 
tendency to use a range of substances to self-medicate. Don saw his choice to use AAS as a practical 
solution to fixing his issues around identity which years of counselling could not help. However, he 
was aware AAS use may not be a solution, particularly as he was also experimenting with an alter 
ego who was female: ‘there is so much of an internal battle going on with me right now with 
regards to the steroid use because, it’s revisiting the past, and all  the old things come up, you know, 
this hyper-masculinised version of yourself, this feminine version of yourself, ...there is sti l l an 
inadequacy’. Don’s methods of procuring AAS also put in a very risky situation. Don reported he had 
taken a break but was considering starting use again: 
‘It's a battle - I only recently ran a 12 week cycle for the first time in over 3 years. I was completely 
AAS free but that nagging inadequacy I feel in myself, my sense of lack of power and confidence 
overrides my logical brain. I justify it by minimising doses, compounds and cycles. At 39 years of age 
and having been in and out of psychotherapy for 15 years, I feel I need to train with AAS and 
practice jujitsu to gain a sense of power I never had in childhood due to an abusive, neglectful 
mother with BPD with narcissistic and histrionic traits. My father was a weak male role model who 
failed to defend me from my mother. I am desperate to feel some amount of normal power and 
control.’ 
There were a few participants with adverse childhood experiences such as bullying and parental 
abuse, and for some this led to an uneasy relationship with use. Don’s story exemplifies this. Don is 
clearly conflicted in his use, he has sought help from doctors, NSPs and counsellors, yet when 
seeking such help much of Don’s history would not be evident. For Don standard harm minimisation 
advice may not be enough. Don’s life story suggests that counselling has also not been successful, as 
he has had negative experiences working with a counsellor. His history is further complicated by his 
use of a range of illicit substances and identity issues. His desire to self-medicate with AAS use does 
not seem to sit well with him as although he saw it as a solution, he kept questioning it. Don’s wider 
problems impacted on his decision-making and his risk-taking, and this made him not just vulnerable 
to self-medicating and t getting caught up in the darker side of AAS use putting him on the wrong 
side of the law. Understanding Don in the context of his life history is essential to offering him the 
widest possible range of support options and may even include CBT, mentoring or other forms of 
one-to-one support in fact a detailed plan incorporating a range of different options may be 
beneficial.  
Field note from interview: Don stated in the questionnaire he was gender-fluid. He interviewed in his 
male persona, but his avatar was a female persona and he talked of going to University in his female 
persona as liberating.  
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Lewis's (USA/37) story (Table 4) 
 
Motivations: Improve my appearance, enhance my muscles or strength, positive results I 
achieved from using AAS, improve endurance or stamina, improve fitness.  Lewis had been 
training in martial arts since the age of 7, took up wrestling at 15, had an abusive, 
aggressive father and was given AAS by coaches at the age of 15. Lewis described a 
traumatic childhood history:  
 
‘I was really poor, I was ….constantly and physically abused as a kid. It was just a really, 
really shitty childhood ... my dad was a bit of a mean bastard… he raised me like you would 
raise a fighting Pitbull. You know, he wanted, he purposely raised me to be mean and 
aggressive and to fight every chance... So, so fighting and everything just came really 
naturally, my whole life. Up until now until I became a father and a husband and all that, I 
mean, fighting was just a constant occurrence or confrontation.’ Although he did not 
directly link this to his AAS use, his introduction to AAS was though his high-school wrestling 
coaches. He had a history of mental health issues, and these were exacerbated by some of 
the steroids: ‘I already have some mental health issues, so that and I already suffer f rom 
night terrors. Um. So that that exacerbates like, night terrors’.  
 
Lewis talked about starting young and how using affected him: ‘I was a kid so, honestly, 
dumping, in retrospect, dumping that kind of hormone into an already hormonal body. It 
kind of messed up my, my mental state to be honest… I was always on edge, not like roid 
rage or anything. But, you know, I was already a teenager dealing with being a teenager so 
it kind of exacerbated all your natural teenage angst and issues at the time’.  
 
Lewis was fearful of stopping use: ‘I'm not gonna lie to you it's uh I have this fear that if I 
stopped training and since the PEDs do help me train, I have this fear that I'm just going to 
fall apart because a couple times when I’ve injured myself and haven't  been able to train 
for a while, my my joints start to hurt, I don't feel as good, I start eating like shit, so I have 
this fear that if I can't lift or train that I'm just gonna like break apart like Humpty Dumpty, 
kind of thing and I again I'm not gonna lie, you know at this point I've been, been steadily 
on them for so long, including big doses on and off that I am a little afraid that I won’t feel 
like the man I do now.’ 
 
Use has also changed for Lewis ‘I don't PCT these days. …I just go from high doses  into my 
TRT doses’. He saw himself blasting and cruising going forward, but eventually saw a time 
where he would purely be using a TRT dose. He was aware of the risks of use and the need 
for evidence-based information: ‘for me, it was just all about the truth, the good or bad, 
good and bad, because yes, this shit isn’t 100% safe, even for a 38-year-old man with 
experience. I'm not stupid about that. I know that no matter what, it's a science experiment 
I'm doing on my body and there's always potential for error’. 
 
Lewis is concerned about the psychological effects of stopping use, but comfortable with 
how he is using now, feeling he is using responsibly, and is not looking to stop. Reflecting on 
his life story it is possible to see how, for Lewis, his use has become potentially problematic, 
and is linked to his internalisation of what it is to be a man. There is a need to help him 
reflect on side-effects of the compounds he is using and ways to reduce harm. Here too a 
possible discussion about supporting his mental health and fears for the future could be 
beneficial. There is the potential to discuss other ways to see how he could get more from 
his training whilst minimising AAS use.   
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Appendix 26 Excerpt from a forum discussion on UK 
needle exchange programmes 
 
Lloyds Pharmacy Steroid Needle Pack  - Started by Anonymous, April 19, 2015 
(Anonymous 2015) 
 My source told me lloyds dont give steroid needle packs anymore? (Greens 
and blues) Do they? If not, where can I get some?  
 
Further comments from other members:  
 Don't get a pack - just go to any chemist that does needle exhange and tell 
them what you want. Personally I prefer the specialised places as they will let me take 
loads. Like boxes of stuff. Best experience was in Norwich where my partner is from. A 
really good service there. Went in and asked me what I wanted. I said I didn't want to 
clear them out - so she showed me just how much stuff they had! This was in a 
hospital though. Even gave the stuff out in tesco carrier bags, which i think is a nice 
touch rather than the black plastic bags which scream I've got needles to anyone in 
the know. The women was lovely. 
 Buy them online. 
 Chances are it's now moved to your local boots or superdrug store chap 
 why do all you clowns still use needle exhanges , its costs a couple of quid for 
them where do you think the gov gets its statistics from for increased usage ???? it will 
be all well and good when you can done for having one dbol tab !! 
 I may be totally wrong - but I think they get funding on the amount of stuff 
they give out. So in a strange way I think you are supporting them by getting stuff 
from them.  MENTION=47330]kuju[/MENTION] can you confirm this? Pretty much yes 
- they need to demonstrate a need for teh service to justify its existence. .and given 
that steroid users are (in a lot of places) the majority of needle exchange clients - it's 
important to support them. That said - pharmacies will give fixed packs out, which 
vary wildly from area to area. Specialist needle exchanges will take a pick and mix 
approach, can give you more advice, possibly run health checks and in a lot of areas 
now..are running steroid user specific clinics, often outside normal hours.  
 Well........until last year I was responsible for collecting those statistics across 
a large chunk of the north west. I was also Chair of the National Needle Exchange 
Forum. So speaking based on that experience...... The majority of the government's 
statistics actually come from the British Crime Survey (an inherently flawed thing..). 
But regardless; the government was aware of all this 2011 when they asked the ACMD 
to look at anabolic steroids and provide recommendations. We were also involved in 
that. The net result was the ACMD stating there was no need to change the law; which 
teh government were happy to accept. Yes that may change one day but we'll fight 
against it. Given the slowly changing face of drug prohibition generally; I think it's 
getting increasingly less likely it'll get worse. Needle exchanges provide advice around 
injecting, sterile equipment, a place to dispose of used kit safely, they can provide 
confidential treatment for injection site issues such as abscesses..no judgements..no 
informing your GP. Some of them provide expert advice around diet and training, more 
advanced health checks such as bloodwork etc etc. It's a completely confidential 
health service...why wouldn't you engage with it? 
 If steroids became illegal now, it'd be so stupid.  
 when ever i drop my sharps bins off at needle exchange i just tell them its for 
B12 injections, sisters ex was insulin user and they split up, someone chucked it in the 
lane round back of my house, used them for skag, basically anything to avoid bumping 
up the statistics on gear use and bringing it to the medias attention we got a nice little 
number going on over in the UK at the moment, dont want it to end up like the states. 
